Angiotensinâ€“Neprilysin Inhibition versus Enalapril in

New England Journal of Medicine
371, 993-1004
DOI: 10.1056/nejmoa1409077

Citation Report

#	Article	IF	Citations
1	Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase. Cellular and Molecular Life Sciences, 2005, 62, 599-605.	2.4	13
2	Spanish Implantable Cardioverter-defibrillator Registry. Ninth Official Report of the Spanish Society of Cardiology Electrophysiology and Arrhythmias Section (2012). Revista Espanola De Cardiologia (English Ed), 2013, 66, 881-893.	0.4	25
3	Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	3
7	Neprilysin Inhibition for Heart Failure. New England Journal of Medicine, 2014, 371, 2335-2337.	13.9	43
8	Natriuretic peptides and cardio-renal disease. International Journal of Cardiology, 2014, 176, 630-639.	0.8	102
9	How will 2014 European Society of Cardiology Congress influence our daily practice?. Anatolian Journal of Cardiology, 2014, 14, 669-673.	0.4	0
10	Insuffisance cardiaque. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2014, 2014, 38-39.	0.0	0
11	Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. International Journal of Cardiology, 2014, 177, 731-733.	0.8	19
12	The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide. Canadian Journal of Cardiology, 2014, 30, S442-S454.	0.8	14
13	Recent Developments in Cardiovascular Stem Cells. Circulation Research, 2014, 115, e71-8.	2.0	29
14	Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGMâ€HF, CONFIRMâ€HF, SIGNIFY, atrial fibrillation, betaâ€blockers and heart failure, and vagal stimulation in heart failure. ESC Heart Failure, 2014, 1, 82-86.	1.4	5
15	Modern Drug Development. JAMA - Journal of the American Medical Association, 2014, 312, 2619.	3.8	5
16	PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?. Global Cardiology Science & Practice, 2014, 2014, 34.	0.3	3
17	The ACC Looks to Balance Emerging Science and Clinical Practice Guideline Development. Journal of the American College of Cardiology, 2014, 64, 2061-2063.	1.2	0
18	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2014 (August 30 â€“ September 3, 2014, Barcelona, Spain). Revista Espanola De Cardiologia (English Ed), 2014, 67, 912.e1-912.e10.	0.4	0
19	LCZ696â€"a PARADIGM shift in treatment for heart failure. Nature Reviews Cardiology, 2014, 11, 618-618.	6.1	2
20	Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure. JACC: Heart Failure, 2014, 2, 663-670.	1.9	129
21	Resumen de estudios clÃnicos presentados en el Congreso de 2014 de la Sociedad Europea de CardiologÃa (30 de agosto-3 de septiembre de 2014, Barcelona, EspaÃ±a). Revista Espanola De Cardiologia, 2014, 67, 912.e1-912.e10.	0.6	5

#	Article	IF	Citations
22	Neprilysin Inhibition â€" A Novel Therapy for Heart Failure. New England Journal of Medicine, 2014, 371, 1062-1064.	13.9	45
23	European Society of Cardiology (ESC) Congress Report From Barcelona 2014. Circulation Journal, 2014, 78, 2610-2618.	0.7	6
25	Over, Under, or Just Right? How do we interpret ICD utilization in the modern era?. Indian Pacing and Electrophysiology Journal, 2015, 15, 15-19.	0.3	0
27	Natriuretic peptides in the cross-talk of human cardiovascular and metabolic regulation. Journal of Hypertension, 2015, 33, 1139-1141.	0.3	2
28	Review of the top 5 cardiology studies of 2013-14. Canadian Pharmacists Journal, 2015, 148, 349-354.	0.4	3
29	Plasma levels of natriuretic peptides and development of chronic kidney disease. BMC Nephrology, 2015, 16, 171.	0.8	16
30	The appropriate dose of angiotensinâ€convertingâ€enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?. ESC Heart Failure, 2015, 2, 103-105.	1.4	8
31	Global variation in clinical profile, management, and postâ€discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the <scp>ASTRONAUT</scp> trial. European Journal of Heart Failure, 2015, 17, 591-600.	2.9	58
32	<scp>BNP</scp> in heart failure: even leucocytes cannot escape its influence. European Journal of Heart Failure, 2015, 17, 536-538.	2.9	2
33	The Aliskiren Trial to Minimize <scp>OutcomeS</scp> in Patients with <scp>HEart</scp> failure trial (<scp>ATMOSPHERE</scp>): revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure, 2015, 17, 1075-1083.	2.9	18
34	Effect of Cardiac Resynchronization Therapy on Inflammation in Congestive Heart Failure: A Review. Scandinavian Journal of Immunology, 2015, 82, 191-198.	1.3	7
35	Current Challenges in the Management of Heart Failure. Circulation Journal, 2015, 79, 948-953.	0.7	25
36	Natriuretic Peptides and Cardiometabolic Health. Circulation Journal, 2015, 79, 1647-1655.	0.7	73
37	Pharmacological treatment of left ventricular remodeling: recent trial results. Clinical Investigation, 2015, 5, 767-776.	0.0	1
38	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clinical Science, 2015, 130, 57-77.	1.8	208
40	LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure. BMC Pharmacology & Toxicology, 2015, 16, A1-A104.	1.0	4
41	How to Do More With Less. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 460-462.	0.9	3
42	Update of treatment in chronic heart failure. Medicina ClÃnica (English Edition), 2015, 145, 545-550.	0.1	1

#	Article	IF	Citations
43	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
45	Highlights from the British Society for Heart Failure 17th annual autumn meeting: â€œyesterday's problems, today's solutionsâ€. Future Cardiology, 2015, 11, 261-265.	0.5	0
46	Strategies to Reduce Heart Failure Hospitalizations and Readmissions: How Low Can We Go?. Cardiovascular Innovations and Applications, 2015, 1, .	0.1	0
47	Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy, 2015, 35, 823-837.	1.2	23
48	Wnt Signaling in Cardiac Disease. , 2015, 5, 1183-1209.		43
49	Geographic differences in heart failure trials. European Journal of Heart Failure, 2015, 17, 893-905.	2.9	64
50	Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?. European Journal of Heart Failure, 2015, 17, 875-878.	2.9	14
51	Clinical trials update from the European Society of Cardiologyâ€“Heart Failure meeting 2015: <scp>AUGMENTâ€HF</scp>, <scp>TITRATION</scp>, <scp>STOPâ€HF</scp>, <scp>HARMONIZE</scp>, <scp>LION HEART</scp>, <scp>MOODâ€HF</scp>, and reninâ€“angiotensin inhibitors in patients with heart and renal failure. European Journal of Heart Failure, 2015, 17, 979-983.	2.9	15
52	Hyperkalaemia in heart failure: binding the patient to improved treatment?. European Journal of Heart Failure, 2015, 17, 997-999.	2.9	7
53	Innovative devices for advanced heart failure. Current Opinion in Cardiology, 2015, 30, 267-276.	0.8	2
54	Chronic heart failure. Current Opinion in Cardiology, 2015, 30, 344-353.	0.8	4
55	Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. Journal of Hypertension, 2015, 33, 1458-1464.	0.3	34
56	Sacubitril/Valsartan. Hospital Pharmacy, 2015, 50, 1025-1036.	0.4	7
57	Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World Journal of Cardiology, 2015, 7, 808.	0.5	35
58	Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy. Review of Diabetic Studies, 2015, 12, 13-28.	0.5	24
59	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. Italian Journal of Medicine, 2015, 3, 309.	0.2	1
60	Oral pharmacological treatment of congestive heart failure. Journal of the Korean Medical Association, 2015, 58, 237.	0.1	0
61	Water, Electrolytes, and Acidâ€“Base Balance. , 2015, , 701-713.		2

#	Article	IF	Citations
62	PARADIGM-HF Trial and its Important Clinical Meanings. Journal of Cardiovascular Diseases & Diagnosis, 2015, 03, .	0.0	0
63	Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians. Hospital Pharmacy, 2015, 50, 454-459.	0.4	9
64	5th BSH Heart Failure Nurse Study Day. British Journal of Cardiac Nursing, 2015, 10, 249-252.	0.0	0
66	C-type natriuretic peptide prevents angiotensin II-induced cardiac remodelling and dysfunction. BMC Pharmacology & Toxicology, 2015, 16, .	1.0	0
67	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vascular Health and Risk Management, 2015, 11, 283.	1.0	17
68	Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thrombosis and Haemostasis, 2015, 114, 70-77.	1.8	13
69	Fluid Management In Patients With Chronic Heart Failure. Cardiac Failure Review, 2015, 1, 90.	1.2	56
70	Next Generation ARBs. International Heart Journal, 2015, 56, 585-586.	0.5	1
71	Addition of a Nitric Oxide Donor to an Angiotensin II Type 1 Receptor Blocker May Cancel Its Blood Pressure-Lowering Effects. International Heart Journal, 2015, 56, 656-660.	0.5	4
72	Recent advances in treatment of heart failure. F1000Research, 2015, 4, 1475.	0.8	11
73	LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. American Journal of Hypertension, 2015, 28, 1409-1417.	1.0	60
74	Cardiorenal protection during chronic reninâ€“angiotensinâ€“aldosterone system suppression: evidences and caveats. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 126-131.	1.4	13
75	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 2015, 36, 1990-1997.	1.0	335
76	Association between reninâ€“angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. European Heart Journal, 2015, 36, 2318-2326.	1.0	83
77	Left Ventricular Assist Devices. Journal of the American College of Cardiology, 2015, 65, 2542-2555.	1.2	218
79	Annual Congress of the European Society of Cardiology: Aug 30â€“Sept 3 2014; Barcelona, Spain. American Journal of Cardiovascular Drugs, 2015, 15, 69-72.	1.0	0
80	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
81	Prevention of PKG1Î± oxidation augments cardioprotection in the stressed heart. Journal of Clinical Investigation, 2015, 125, 2468-2472.	3.9	64

#	Article	IF	Citations
82	Cardiac endotheliumâ€“myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. European Heart Journal, 2015, 36, 2050-2060.	1.0	126
83	Heart failure: key points and recent developments in management. The Prescriber, 2015, 26, 25-31.	0.1	2
84	What is the need for another new journal?. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 74-75.	1.4	0
85	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. European Journal of Heart Failure, 2015, 17, 1066-1074.	2.9	85
86	Design of Major Randomized Trials. Journal of the American College of Cardiology, 2015, 66, 2757-2766.	1.2	56
87	Considerations for initial therapy in the treatment of acute heart failure. Critical Care, 2015, 19, 399.	2.5	14
89	Statistical Controversies in ReportingÂofÂClinical Trials. Journal of the American College of Cardiology, 2015, 66, 2648-2662.	1.2	72
90	Estimating the Long-Term Treatment Benefits of Sacubitrilâ€“Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290.	13.9	92
92	Cardiac Adrenergic Nervous System and Left Ventricular Remodeling. American Journal of the Medical Sciences, 2015, 350, 321-326.	0.4	8
94	Challenging Issues in Clinical Trial Design. Journal of the American College of Cardiology, 2015, 66, 2886-2898.	1.2	52
95	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	13.9	790
97	Coenzyme Q10 to treat and prevent heart disease. British Journal of Cardiac Nursing, 2015, 10, 382-387.	0.0	1
99	Concentraciones plasmÃ¡ticas de neprilisina: Â¿unÂnuevo marcador pronÃ³stico enÂlaÂinsuficiencia cardiaca?. Revista Espanola De Cardiologia, 2015, 68, 1053-1055.	0.6	5
100	Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. Journal of the American Heart Association, 2015, 4, e002423.	1.6	115
101	Vasopeptidase Inhibition Corrects the Structure and Function of the Small Arteries in Experimental Renal Insufficiency. Journal of Vascular Research, 2015, 52, 94-102.	0.6	2
102	Heart failure with preserved ejection fraction: Refocusing on diastole. International Journal of Cardiology, 2015, 179, 430-440.	0.8	91
103	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Canadian Journal of Cardiology, 2015, 31, 3-16.	0.8	96
104	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552

#	Article	IF	Citations
105	Unwinding the Interaction of Natriuretic Peptides andÂNeprilysinâˆ—. Journal of the American College of Cardiology, 2015, 65, 666-667.	1.2	10
107	Angiotensin receptor-neprilysin inhibitors in heart failure: a shifting paradigm. Evidence-Based Medicine, 2015, 20, 61-61.	0.6	0
108	Novel RAAS agonists and antagonists: clinical applications and controversies. Nature Reviews Endocrinology, 2015, 11, 242-252.	4.3	126
109	LCZ696: too good to be true?. European Heart Journal, 2015, 36, 410-412.	1.0	10
110	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. Journal of the Chinese Medical Association, 2015, 78, 1-47.	0.6	183
111	Critical insights into the beneficial and protective actions of the kallikreinâ€“kinin system. Vascular Pharmacology, 2015, 64, 1-10.	1.0	27
112	The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology, 2015, 12, 220-229.	6.1	238
113	Surviving the gauntlet: Modern challenges in cardiovascular drug approval and implementation. American Heart Journal, 2015, 169, 191-193.	1.2	0
114	Heart failure: the cardiovascular epidemic of the 21st century. European Heart Journal, 2015, 36, 395-397.	1.0	33
115	Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis. European Journal of Clinical Investigation, 2015, 45, 274-287.	1.7	29
116	Suppression of neutrophil superoxide generation by <scp>BNP</scp> is attenuated in acute heart failure: a case for â€˜<scp>BNP</scp> resistanceâ€™. European Journal of Heart Failure, 2015, 17, 475-483.	2.9	11
117	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	1.0	80
118	Therapeutic Adjustments in Stage D Heart Failure: Challenges and Strategies. Current Heart Failure Reports, 2015, 12, 15-23.	1.3	3
119	Guidelines for Translational Research in Heart Failure. Journal of Cardiovascular Translational Research, 2015, 8, 3-22.	1.1	28
120	Mixed results for heart failure therapies. Nature Reviews Cardiology, 2015, 12, 73-75.	6.1	3
121	The Basis of Translational Physiology: From Molecules to Humans, a Wide Arc of Scientific Inquiry. Physiology, 2015, 30, 4-5.	1.6	0
122	Evaluating the safety and efficacy of sodium-restricted/Dietary Approaches to Stop Hypertension diet after acute decompensated heart failure hospitalization: Design and rationale for the Geriatric OUt of hospital Randomized MEal Trial in Heart Failure (GOURMET-HF). American Heart Journal, 2015, 169, 342-348.e4.	1.2	15
123	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Archives of Toxicology, 2015, 89, 1401-1438.	1.9	492

#	Article	IF	Citations
124	Prospective Comparison of ARNi With ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF). Circulation, 2015, 131, 11-12.	1.6	11
126	Patient-Reported Outcomes in Heart Failure: Existing Measures and Future Uses. Current Heart Failure Reports, 2015, 12, 236-246.	1.3	24
128	Heart Failure Management: Continuing to Fail or Signs of Success?. Cardiovascular Drugs and Therapy, 2015, 29, 5-6.	1.3	4
129	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. Canadian Journal of Cardiology, 2015, 31, 1282-1292.	0.8	10
130	Site selection for heart failure clinical trials in the USA. Heart Failure Reviews, 2015, 20, 375-383.	1.7	13
131	Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 510-517.	2.9	153
132	Brain natriuretic peptide is able to stimulate cardiac progenitor cell proliferation and differentiation in murine hearts after birth. Basic Research in Cardiology, 2015, 110, 455.	2.5	27
133	New Approaches in the Treatment of Hypertension. Circulation Research, 2015, 116, 1074-1095.	2.0	233
134	The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure. Journal of the American College of Cardiology, 2015, 65, 1029-1041.	1.2	133
135	â€˜Hearts and mindsâ€™: association, causation and implication of cognitive impairment in heart failure. Alzheimer's Research and Therapy, 2015, 7, 22.	3.0	73
136	ActualizaciÃ³n 2014 en cardiologÃa clÃnica, cardiologÃa geriÃ¡trica e insuficiencia cardiaca y trasplante. Revista Espanola De Cardiologia, 2015, 68, 317-323.	0.6	6
137	Vagal nerve stimulation for heart failure: new pieces to the puzzle?. European Journal of Heart Failure, 2015, 17, 125-127.	2.9	9
138	Advances in pediatric heart failure and treatments. Progress in Pediatric Cardiology, 2015, 39, 33-36.	0.2	0
139	Cardio-renal protection through reninâ€“angiotensinâ€“aldosterone system inhibition: current knowledge and new perspectives. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 132-133.	1.4	3
140	Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. International Journal of Cardiology, 2015, 196, 61-69.	0.8	22
141	Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene, 2015, 569, 1-6.	1.0	160
142	Small molecule and peptide therapies for chronic heart failure: a patent review (2011 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 1175-1190.	2.4	5
143	Contemporary Drug Development in Heart Failure. Circulation: Heart Failure, 2015, 8, 826-831.	1.6	34

#	Article	IF	Citations
144	Neprilysin in Heart Failure. JACC: Heart Failure, 2015, 3, 637-640.	1.9	23
145	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly InhibitÂCirculating Neprilysin Activity inÂHeartÂFailure. JACC: Heart Failure, 2015, 3, 629-636.	1.9	72
146	Sildenafil Does Not Prevent Heart Hypertrophy and Fibrosis Induced by Cardiomyocyte Angiotensin II Type 1 Receptor Signaling. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 406-416.	1.3	14
147	Fellow-Initiated Clinical Trials. Journal of the American College of Cardiology, 2015, 66, 324-327.	1.2	5
148	Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues. European Heart Journal, 2015, 36, 2279-2280.	1.0	4
149	Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure. Heart Failure Clinics, 2015, 11, 499-506.	1.0	28
150	Falling Cardiovascular Mortality in HeartÂFailure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	1.9	36
151	Cyclic Nucleotide Signalling in Kidney Fibrosis. International Journal of Molecular Sciences, 2015, 16, 2320-2351.	1.8	45
152	What Physicians Need to Know About Renal Function in Outpatients with Heart Failure. Cardiology, 2015, 131, 130-138.	0.6	16
153	Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?. European Journal of Heart Failure, 2015, 17, 468-471.	2.9	19
154	Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via coapplication of a neutral endopeptidase 24.11 inhibitor. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L563-L568.	1.3	13
155	Why is heart failure so important in the 21st century?. European Journal of Heart Failure, 2015, 17, 122-124.	2.9	15
156	Clinical characteristics and outcomes of patients with angina and heart failure in the <scp>CHARM</scp> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 257	2.9	17
158	Breakthroughs in internal and respiratory medicine. Lancet Respiratory Medicine,the, 2015, 3, 600-602.	5.2	1
159	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. Journal of Cardiac Failure, 2015, 21, 741-750.	0.7	28
160	Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure. Annals of Pharmacotherapy, 2015, 49, 1237-1251.	0.9	17
162	Second episode of near-fatal angioedema in a patient treated with everolimus. Annals of Allergy, Asthma and Immunology, 2015, 115, 152-153.	0.5	5
163	Team-Based Care for Outpatients with Heart Failure. Heart Failure Clinics, 2015, 11, 379-405.	1.0	26

#	Article	IF	Citations
164	Therapeutic developments in the therapy of heart failure: lessons to be learned: Figure 1. European Heart Journal, 2015, 36, 1952-1954.	1.0	3
165	Racial Differences in NatriureticÂPeptideÂLevels. JACC: Heart Failure, 2015, 3, 513-519.	1.9	72
166	Future care planning: a first step to palliative care for all patients with advanced heart disease. Heart, 2015, 101, 1002-1007.	1.2	31
168	The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. Human Gene Therapy, 2015, 26, 293-304.	1.4	33
169	Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. European Heart Journal, 2015, 36, 902-905.	1.0	61
170	<scp>REPORTâ€HF</scp>: the unique blend of global heart failure registry and longitudinal cohort study. European Journal of Heart Failure, 2015, 17, 472-474.	2.9	3
171	Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	0
172	Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 241-246.	1.0	19
173	Biomarkers in Acute Heart Failure. Revista Espanola De Cardiologia (English Ed), 2015, 68, 514-525.	0.4	21
174	LCZ696 (Angiotensinâ€“Neprilysin Inhibition). Journal of Pharmacy Practice, 2015, 28, 137-145.	0.5	8
175	The year in cardiology: heart failure 2014. European Heart Journal, 2015, 36, 421-424.	1.0	3
176	Biomarcadores en la insuficiencia cardiaca aguda. Revista Espanola De Cardiologia, 2015, 68, 514-525.	0.6	29
177	Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. International Journal of Cardiology, 2015, 186, 104-105.	0.8	29
178	Considerations for DrugÂDevelopment forÂHeart Failure. Journal of the American College of Cardiology, 2015, 65, 1060-1061.	1.2	1
179	Multicenter trials, guidelines, and uncertainties â€" Do we know as much as we think we do?. International Journal of Cardiology, 2015, 187, 600-603.	0.8	8
180	Hop, Skip, and Jump. JACC: Heart Failure, 2015, 3, 273-274.	1.9	2
181	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. International Journal of Cardiology, 2015, 189, 6-11.	0.8	17
182	Cardiovascular Drug Development. Journal of the American College of Cardiology, 2015, 65, 1567-1582.	1.2	168

#	Article	IF	Citations
183	New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?. Current Hypertension Reports, 2015, 17, 557.	1.5	28
184	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. Journal of the American College of Cardiology, 2015, 65, 1668-1682.	1.2	116
185	Natriuretic Peptides as a Novel Target in Resistant Hypertension. Current Hypertension Reports, 2015, 17, 18.	1.5	6
186	LCZ696: The Next Step in Improving RAS Inhibition?. Current Hypertension Reports, 2015, 17, 37.	1.5	7
187	Creation of clinically relevant model of chronic heart failure: Application of multi-modality imaging to define physiology. Journal of Nuclear Cardiology, 2015, 22, 673-676.	1.4	0
189	Cardiac Actions of Atrial Natriuretic Peptide. Circulation Research, 2015, 116, 1278-1280.	2.0	21
190	Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Medicine, 2015, 13, 35.	2.3	23
191	Molecular Targets in the Treatment of Cardiac Hypertrophy. , 2015, , 343-371.		11
192	CoQ₁₀ Function and Role in Heart Failure and Ischemic Heart Disease. Annual Review of Nutrition, 2015, 35, 175-213.	4.3	52
193	Baroreflex Activation Therapy for the Treatment of Heart Failure With a ReducedÂEjection Fraction. JACC: Heart Failure, 2015, 3, 487-496.	1.9	204
194	A big-hearted molecule. Nature, 2015, 519, 416-417.	13.7	13
195	Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. European Heart Journal, 2015, 36, 1967-1973.	1.0	87
196	An update on heart failure and peripheral arterial disease. European Heart Journal, 2015, 36, 885-887.	1.0	3
197	Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. European Journal of Heart Failure, 2015, 17, 242-247.	2.9	105
198	Update on management of heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2015, 30, 173-178.	0.8	6
199	Redox-sensitive mechanisms underlying vascular dysfunction in heart failure. Free Radical Research, 2015, 49, 721-742.	1.5	10
200	Update for 2014 on Clinical Cardiology, Geriatric Cardiology, and Heart Failure and Transplantation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 317-323.	0.4	5
201	LCZ696: a new paradigm for the treatment of heart failure?. Expert Opinion on Pharmacotherapy, 2015, 16, 435-446.	0.9	30

#	Article	IF	Citations
202	Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature, 2015, 519, 472-476.	13.7	274
203	Drug therapies in older adults (part 2). Clinical Medicine, 2015, 15, 155-159.	0.8	5
204	A Review of the Key Clinical Trials of 2014. Cardiology and Therapy, 2015, 4, 5-23.	1.1	8
205	Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. British Journal of Clinical Pharmacology, 2015, 80, 389-402.	1.1	312
206	Role of the Renin-Angiotensin-Aldosterone System in the Management of Neonatal Heart Failure. NeoReviews, 2015, 16, e575-e585.	0.4	2
207	New medical therapies for heart failure. Nature Reviews Cardiology, 2015, 12, 730-740.	6.1	43
208	Combined Angiotensin Receptor/Neprilysin Inhibitors: A Review of the New Paradigm in the Management of Chronic Heart Failure. Clinical Therapeutics, 2015, 37, 2199-2205.	1.1	18
210	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opinion on Pharmacotherapy, 2015, 16, 2283-2292.	0.9	26
211	LCZ696 (Sacubitril/Valsartan). Journal of the American College of Cardiology, 2015, 66, 2072-2074.	1.2	14
212	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	1.2	118
213	An Emerging Role of Natriuretic Peptides. Mayo Clinic Proceedings, 2015, 90, 1666-1678.	1.4	16
214	Synthesis of a Precursor to Sacubitril Using Enabling Technologies. Organic Letters, 2015, 17, 5436-5439.	2.4	34
215	The Role of Neprilysin Inhibitors in Cardiovascular Disease. Current Heart Failure Reports, 2015, 12, 389-394.	1.3	16
216	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1075-1084.	0.4	23
217	Gaps and Resemblances in Current Heart Failure Guidelines. Heart Failure Clinics, 2015, 11, 529-541.	1.0	1
218	Angioedema induced by cardiovascular drugs: new players join old friends. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1196-1200.	2.7	44
219	Molecular Screen Identifies Cardiac Myosinâ€“Binding Protein-C as a Protein Kinase G-Iî± Substrate. Circulation: Heart Failure, 2015, 8, 1115-1122.	1.6	31
220	Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2015, 24, 1571-1596.	1.9	12

#	Article	IF	Citations
222	Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1053-1055.	0.4	5
223	Fifteen Years. New England Journal of Medicine, 2015, 373, 1774-1775.	13.9	6
224	Unraveling N-Terminal Proâ€"B-Type Natriuretic Peptide: Another Piece to a Very Complex Puzzle in Heart Failure Patients. Clinical Chemistry, 2015, 61, 1016-1018.	1.5	23
225	The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Review of Cardiovascular Therapy, 2015, 13, 1017-1030.	0.6	37
226	Neprilysin. JACC: Heart Failure, 2015, 3, 645-646.	1.9	6
227	Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. Kidney International, 2015, 88, 109-120.	2.6	43
228	Nâ€terminal proâ€Bâ€type natriuretic peptide and the risk of stroke and transient ischaemic attack: the Rotterdam Study. European Journal of Neurology, 2015, 22, 695-701.	1.7	14
229	Prognostic Value and Kinetics of SolubleÂNeprilysin in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 641-644.	1.9	44
230	Hospitalized Heart Failure in the United States. Heart Failure Clinics, 2015, 11, 591-601.	1.0	3
231	Of stiff and weak ventricles. European Heart Journal, 2015, 36, 2545-2547.	1.0	0
232	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. Current Atherosclerosis Reports, 2015, 17, 64.	2.0	15
233	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 777-785.	1.9	19
234	Chronobiology and Pharmacologic Modulation of the Reninâ€"Angiotensinâ€"Aldosterone System in Dogs: What Have We Learned?. Reviews of Physiology, Biochemistry and Pharmacology, 2015, 169, 43-69.	0.9	28
235	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.	1.0	187
236	Fundamentals of Clinical Trials. , 2015, , .		603
237	LCZ696, The Need for an Indication in Arterial Hypertension. American Journal of Hypertension, 2015, 28, 1403-1404.	1.0	2
238	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. Current Heart Failure Reports, 2015, 12, 318-327.	1.3	10
239	Cardiorenal syndrome. Hong Kong Journal of Nephrology, 2015, 17, 36-45.	0.0	0

#	Article	IF	Citations
240	In-hospital management of acute heart failure: Practical recommendations and future perspectives. International Journal of Cardiology, 2015, 201, 231-236.	0.8	31
241	Inherited cardiomyopathiesâ€"Novel therapies. , 2015, 155, 36-48.		14
242	Hard-Wired Bias. Mayo Clinic Proceedings, 2015, 90, 1171-1175.	1.4	35
245	Recent Developments in Heart Failure. Circulation Research, 2015, 117, e58-63.	2.0	60
246	Natriuretic Peptides as Therapy for Heart Failure â€“ Unfulfilled Promise?. Journal of Cardiac Failure, 2015, 21, 865-867.	0.7	1
247	Proâ€"Atrial Natriuretic Peptide. JACC: Heart Failure, 2015, 3, 715-723.	1.9	29
248	Novel Interventional Therapies to Modulate the Autonomic Tone in HeartÂFailure. JACC: Heart Failure, 2015, 3, 786-802.	1.9	46
249	INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocrine Connections, 2015, 4, R25-R36.	0.8	30
251	Management of Heart Failure With Preserved Ejection Fraction: A Review. Clinical Therapeutics, 2015, 37, 2186-2198.	1.1	30
252	Making Sense of Statistics in ClinicalÂTrialÂReports. Journal of the American College of Cardiology, 2015, 66, 2536-2549.	1.2	57
253	Hypogammaglobulinemia and impaired antibody response in a child with chromosome 2p15-16.1 microdeletion syndrome. Annals of Allergy, Asthma and Immunology, 2015, 115, 153-155.	0.5	3
254	Heart Failure: A Major Management Challenge With Encouraging Recent Progress. Clinical Therapeutics, 2015, 37, 2182-2185.	1.1	1
255	The Globalization of HeartÂFailure Research. JACC: Heart Failure, 2015, 3, 657-658.	1.9	4
256	Improving outcomes in heart failure: a personal perspective. European Heart Journal, 2015, 36, 3467-3470.	1.0	41
258	Understanding Heart Failure. Cardiac Electrophysiology Clinics, 2015, 7, 557-575.	0.7	20
259	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	3.8	288
260	Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones:biomarkers or mediators. Clinica Chimica Acta, 2015, 443, 3-8.	0.5	30
261	The war against heart failure: the Lancet lecture. Lancet, The, 2015, 385, 812-824.	6.3	646

#	Article	IF	Citations
262	Neprilysin inhibitors preserve renal function in heart failure. International Journal of Cardiology, 2015, 179, 329-330.	0.8	27
263	â€˜Cutting-edgeâ€™ medicines vs. affordable quality health care?. British Journal of Cardiac Nursing, 2016, 11, 370-371.	0.0	0
264	Heart failure: updated guidelines and an expanding trajectory. British Journal of Cardiac Nursing, 2016, 11, 318-319.	0.0	0
265	Improving Patient Outcomes With Oral Heart Failure Medications. Home Healthcare Now, 2016, 34, 242-253.	0.1	2
266	Cardiovascular pharmacotherapyâ€”2015 was a good year. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 209-211.	1.4	0
267	Primary Prevention of Sudden Cardiac Death in Patients with Heart Failure: How Effective is Current Pharmacologic Therapy?. Cardiovascular Pharmacology: Open Access, 2016, 5, .	0.1	1
268	Beneficial Effects of Combined AT₁ Receptor/Neprilysin Inhibition (ARNI) Versus AT₁ Receptor Blockade Alone in the Diabetic Eye. , 2016, 57, 6722.		9
269	Identification of disturbed pathways in heart failure based on Gibbs sampling and pathway enrichment analysis. Genetics and Molecular Research, 2016, 15, .	0.3	6
270	Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?. Cardiac Failure Review, 2016, 2, 47.	1.2	5
271	Cardiac rehabilitation in patients with pacemakers and implantable cardioverter defibrillators. Monaldi Archives for Chest Disease, 2016, 86, 756.	0.3	28
273	A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure. Current Cardiology Reviews, 2016, 12, 311-317.	0.6	2
274	Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventionsâ€”A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	1.9	10
275	Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. Journal of Diabetes Research, 2016, 2016, 1-17.	1.0	69
276	Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure. Cardiology Research and Practice, 2016, 2016, 1-12.	0.5	66
277	Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide?. Stem Cells International, 2016, 2016, 1-18.	1.2	15
278	Hyperkalemia in heart failure patients: current challenges and future prospects. Research Reports in Clinical Cardiology, 2016, , 1.	0.2	2
279	Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arquivos Brasileiros De Cardiologia, 2016, 106, 62-9.	0.3	233
280	Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Therapeutics and Clinical Risk Management, 2016, 12, 887.	0.9	16

#	Article	IF	Citations
281	Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure. Frontiers in Cardiovascular Medicine, 2016, 3, 37.	1.1	12
282	The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function. BMC Research Notes, 2016, 9, 440.	0.6	13
283	Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?. Arquivos Brasileiros De Cardiologia, 2016, 106, 77-9.	0.3	2
284	Heart Failure: Diagnosis, Management and Utilization. Journal of Clinical Medicine, 2016, 5, 62.	1.0	249
285	Crucial Role of miR-433 in Regulating Cardiac Fibrosis. Theranostics, 2016, 6, 2068-2083.	4.6	134
286	The Mechanism of Action of LCZ696. Cardiac Failure Review, 2016, 2, 40.	1.2	38
287	Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Design, Development and Therapy, 2016, 10, 1627.	2.0	16
288	Treatment of Heart Failure With Reduced Ejection Fractionâ€"Recent Developments. American Journal of Therapeutics, 2016, 23, e531-e549.	0.5	1
289	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement. Pediatric Critical Care Medicine, 2016, 17, S20-S34.	0.2	18
290	Epigenetic regulation in heart failure. Current Opinion in Cardiology, 2016, 31, 255-265.	0.8	39
291	In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 424-431.	0.7	21
292	Characterization of Relaxant Responses to Natriuretic Peptides in the Human Microcirculation In Vitro and InÂVivo. Microcirculation, 2016, 23, 438-446.	1.0	14
293	Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. Journal of Cardiovascular Medicine, 2016, 17, 701-706.	0.6	4
294	Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Failure Reviews, 2016, 21, 645-660.	1.7	64
295	Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. International Journal of Cardiology, 2016, 221, 198-204.	0.8	5
296	Can 2 Pills a Day Keep Readmission Away?. Journal of the American College of Cardiology, 2016, 68, 249-251.	1.2	3
297	Putting Together the Pieces of the Natriuretic Peptide Puzzle â^—. JACC: Heart Failure, 2016, 4, 670-673.	1.9	5
298	Angiotensin-receptor-neprilysin inhibition. Nurs Crit Care (Ambler), 2016, 11, 5-8.	0.3	0

#	Article	IF	Citations
299	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2016, 22, 659-669.	0.7	59
300	Serum neprilysin and recurrent hospitalizations after acute heart failure. International Journal of Cardiology, 2016, 220, 742-744.	0.8	12
301	Natriuretic peptide-guided management in heart failure. Journal of Cardiovascular Medicine, 2016, 17, 556-568.	0.6	35
302	Heart failureâ€"potential new targets for therapy. British Medical Bulletin, 2016, 119, 99-110.	2.7	24
303	Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation. Cardiovascular Research, 2016, 111, 142-153.	1.8	26
304	Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials. Proteomics, 2016, 16, 894-905.	1.3	10
305	Development and validation of a reliable and rapid LCâ€MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Biomedical Chromatography, 2016, 30, 1467-1475.	0.8	29
306	Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment. European Journal of Heart Failure, 2016, 18, 442-444.	2.9	10
307	Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock, 2016, 46, 239-248.	1.0	259
308	Vascular Complications of Diabetes. Circulation Research, 2016, 118, 1771-1785.	2.0	262
309	Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 2016, 37, 3167-3174.	1.0	114
310	Growth Regulation of Cardiomyocytes: Control of Cell Size and Its Role in Cardiac Hypertrophy. , 2016, , 167-189.		0
311	Efficacy of Sacubitril/Valsartan Relative toÂa Prior Decompensation. JACC: Heart Failure, 2016, 4, 816-822.	1.9	84
312	Beta-blockers in COPD: time for reappraisal. European Respiratory Journal, 2016, 48, 880-888.	3.1	60
313	Adding insult to injury: heart failure andÂincident cancer. European Journal of Heart Failure, 2016, 18, 267-268.	2.9	4
314	Entresto (sacubitril/valsartan). Practical Diabetes, 2016, 33, 178-179.	0.1	0
315	Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies. Journal of Cardiovascular Pharmacology, 2016, 68, 183-190.	0.8	3
316	Contemporary clinical trial updates in heart failure. Current Opinion in Cardiology, 2016, 31, 349-355.	0.8	1

#	Article	IF	Citations
317	Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits. International Journal of Clinical Practice, 2016, 70, 537-553.	0.8	8
318	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. Journal of Cardiac Failure, 2016, 22, 753-760.	0.7	141
319	End of the Road for Vagus Nerve Stimulation? â^—. Journal of the American College of Cardiology, 2016, 68, 159-160.	1.2	1
320	Vagus nerve stimulation: state of the art of stimulation and recording strategies to address autonomic function neuromodulation. Journal of Neural Engineering, 2016, 13, 041002.	1.8	74
321	Sacubitril/Valsartan. Cardiology in Review, 2016, 24, 41-47.	0.6	15
322	Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications. Archiv Der Pharmazie, 2016, 349, 399-409.	2.1	9
323	Outcome improvement of patients with heart failure and reduced ejection fraction: has it ended in the new millennium?. European Journal of Heart Failure, 2016, 18, 512-513.	2.9	1
324	Betaâ€blocker, angiotensinâ€converting enzyme inhibitor/angiotensin receptor blocker, nitrateâ€hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (<scp>BANDAID</scp>²): an evidenceâ€based mnemonic for the treatment of systolic heart failure. Internal Medicine Journal, 2016, 46, 653-662.	0.5	14
325	Sacubitril/valsartan for chronic heart failure: its future potential. The Prescriber, 2016, 27, 26-34.	0.1	2
326	Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1119-1125.	0.4	10
327	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. Handbook of Experimental Pharmacology, 2016, 243, 79-108.	0.9	7
328	An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). Postgraduate Medical Journal, 2016, 92, 726-734.	0.9	8
329	Sacubitril/Valsartan (LCZ696) in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 133-165.	0.9	31
330	Innovative Therapeutics. JACC Basic To Translational Science, 2016, 1, 557-567.	1.9	45
332	The Kidney and Electrolytes Imbalances in Heart Failure. , 2016, , 549-571.		0
333	Understanding acute heart failure: pathophysiology and diagnosis. European Heart Journal Supplements, 2016, 18, G11-G18.	0.0	32
334	Heart failure: an historical perspective. European Heart Journal Supplements, 2016, 18, G3-G10.	0.0	19
336	ESC Heart Failure: a new journal aims to broaden heart failure views. European Journal of Heart Failure, 2016, 18, 1415-1419.	2.9	0

#	Article	IF	Citations
338	Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 2912-2914.	1.2	24
339	The Three-Decade Long Journey in Heart Failure Drug Development. Handbook of Experimental Pharmacology, 2016, 243, 1-14.	0.9	12
340	Circulating Long Noncoding RNAs in Personalized Medicine. Journal of the American College of Cardiology, 2016, 68, 2914-2916.	1.2	22
341	Natriuretic Peptides, 6-Min Walk Test, andÂQuality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. Journal of the American College of Cardiology, 2016, 68, 2690-2707.	1.2	83
342	Heart failure â€“ whatâ€™s new and whatâ€™s changed?. Clinical Medicine, 2016, 16, s37-s42.	0.8	4
344	Fine Tuning Adenylyl Cyclase as a (Gene)ÂTherapy for Heart Failure. JACC Basic To Translational Science, 2016, 1, 630-632.	1.9	1
345	Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction in Sweden. Value in Health, 2016, 19, A650-A651.	0.1	1
346	Comentarios a la guÃa ESC 2016 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2016, 69, 1119-1125.	0.6	22
347	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0
348	Evolving Concepts on the Basic Mechanisms of Heart Failure. , 2016, , 15-31.		0
349	Reninâ€“angiotensinâ€“aldosterone system blockade in chronic kidney disease: current strategies and a look ahead. Internal and Emergency Medicine, 2016, 11, 627-635.	1.0	28
350	Troponin in Cardiovascular Disease Prevention: Updates and Future Direction. Current Atherosclerosis Reports, 2016, 18, 12.	2.0	28
351	Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart FailureÂWith ReducedÂEjection Fraction. JACC: Heart Failure, 2016, 4, 392-402.	1.9	106
352	Molecular Physiology of Membrane Guanylyl Cyclase Receptors. Physiological Reviews, 2016, 96, 751-804.	13.1	291
353	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	1.2	283
354	Is There a Need for â€œBias Policeâ€•in Industry-Sponsored Research?. Mayo Clinic Proceedings, 2016, 91, 120-121.	1.4	3
355	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016, 134, e282-93.	1.6	494
356	The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials. Kidney International Reports, 2016, 1, 43-56.	0.4	17

#	Article	IF	Citations
357	Plasma Corin as a Predictor of Cardiovascular Events in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 664-669.	1.9	34
358	Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancingin vivoandex vivoactions. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 98-105.	1.4	26
359	Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 106-107.	1.4	7
360	Direct cellular reprogramming: the hopes and the hurdles. European Journal of Heart Failure, 2016, 18, 157-159.	2.9	4
361	Brain Natriuretic Peptide Treatment andÂHeartÂFailure Prevention. JACC: Heart Failure, 2016, 4, 548-550.	1.9	3
362	Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. European Journal of Clinical Pharmacology, 2016, 72, 917-924.	0.8	20
363	Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. Journal of Molecular and Cellular Cardiology, 2016, 97, 106-113.	0.9	31
364	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488.	1.2	549
365	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
366	Neural modulation for hypertension and heart failure. International Journal of Cardiology, 2016, 214, 320-330.	0.8	15
367	The metabolic vascular syndrome - guide to an individualized treatment. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 5-17.	2.6	29
368	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. New England Journal of Medicine, 2016, 374, 1521-1532.	13.9	204
369	Global cardiovascular protection in chronic kidney disease. Nature Reviews Cardiology, 2016, 13, 603-608.	6.1	36
370	Soluble neprilysin retains catalytic activity in heart failure. Journal of Heart and Lung Transplantation, 2016, 35, 684-685.	0.3	23
371	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. European Heart Journal, 2016, 37, 3135-3140.	1.0	23
372	Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated â€˜Anticipation Medicineâ€™ for Zero Cardiovascular Event. Progress in Cardiovascular Diseases, 2016, 59, 262-281.	1.6	116
373	Novel insight into the dangerous connection between diabetes and heart failure. Herz, 2016, 41, 201-207.	0.4	12
374	Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension. Current Hypertension Reports, 2016, 18, 39.	1.5	30

#	Article	IF	Citations
375	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. Canadian Journal of Cardiology, 2016, 32, S15-S34.	0.8	9
376	Unbelievable Folly of Clinical Trials in Heart Failure. Circulation: Heart Failure, 2016, 9, e002837.	1.6	21
377	The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure. International Journal of Cardiology, 2016, 212, 187-189.	0.8	9
378	Pharmacologic and Endovascular Reversal of Left Ventricular Remodeling. Journal of Cardiac Failure, 2016, 22, 829-839.	0.7	16
379	Evolution of natriuretic peptides testing in heart failure â€" Impact of novel therapies. Clinical Biochemistry, 2016, 49, 643-644.	0.8	0
380	NICE approves innovative treatment for moderate to severe heart failure. BMJ, The, 2016, 353, i2402.	3.0	3
381	Drug discovery in reninâ€"angiotensin system intervention: past and future. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 118-125.	1.0	23
382	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262.	1.6	142
383	Are We Really in Love With OldÂTherapies?. JACC: Heart Failure, 2016, 4, 415-416.	1.9	3
384	Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. JACC: Heart Failure, 2016, 4, 403-408.	1.9	18
385	B-Type Natriuretic Peptide Testing in the Era of Neprilysin Inhibition: Are the Winds of Change Blowing?. Clinical Chemistry, 2016, 62, 663-665.	1.5	7
386	Potential new drug treatments for congestive heart failure. Expert Opinion on Investigational Drugs, 2016, 25, 811-826.	1.9	15
387	Neprilysin Inhibition in the TimeÂofÂPrecision Medicine â^—. JACC: Heart Failure, 2016, 4, 409-414.	1.9	9
388	Cardiac remodelling and RAS inhibition. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 162-171.	1.0	96
389	Bradykinin: Inflammatory Product of the Coagulation System. Clinical Reviews in Allergy and Immunology, 2016, 51, 152-161.	2.9	85
390	Heart Failure Therapies for End-Stage Chemotherapyâ€"Induced Cardiomyopathy. Journal of Cardiac Failure, 2016, 22, 439-448.	0.7	31
392	Heart Failure in Older Adults. Canadian Journal of Cardiology, 2016, 32, 1140-1147.	0.8	99
394	Attenuated atrial natriuretic peptide-mediated lipolysis in subcutaneous adipocytes of obese typeÂ2 diabetic men. Clinical Science, 2016, 130, 1105-1114.	1.8	19

#	Article	IF	Citations
395	Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. American Journal of Human Genetics, 2016, 99, 607-623.	2.6	47
396	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	12
397	The Primary Outcome Is Positive â€" Is That Good Enough?. New England Journal of Medicine, 2016, 375, 971-979.	13.9	112
398	Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptorâ€"neprilysin inhibition compared with AT1 receptor blockade alone. Clinical Science, 2016, 130, 1209-1220.	1.8	38
399	Troponin-Guided Heart Failure Therapy: Are We There Yet?. Current Emergency and Hospital Medicine Reports, 2016, 4, 200-205.	0.6	0
400	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. American Heart Journal, 2016, 182, 80-88.	1.2	142
401	Localization of corin and atrial natriuretic peptide expression in human renal segments. Clinical Science, 2016, 130, 1655-1664.	1.8	26
402	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic To Translational Science, 2016, 1, 301-308.	1.9	24
403	Neprilisina: indicaciones, expectativas y retos. Revista Espanola De Cardiologia, 2016, 69, 647-649.	0.6	8
404	Heterogeneity across one disease, two drugs, three trials, and four guidelines: are we further ahead?. European Journal of Heart Failure, 2016, 18, 1244-1247.	2.9	0
405	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
406	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	1.2	86
407	Bâ€Type Natriuretic Peptide Modulates Pulmonary Vein Arrhythmogenesis: A Novel Potential Contributor to the Genesis of Atrial Tachyarrhythmia in Heart Failure. Journal of Cardiovascular Electrophysiology, 2016, 27, 1462-1471.	0.8	9
408	The patient with left ventricular systolic dysfunction now and in the future. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 516-522.	0.2	3
409	Current treatment of heart failure with reduction of left ventricular ejection fraction. Expert Review of Clinical Pharmacology, 2016, 9, 1619-1631.	1.3	6
410	B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics. Revista Clínica Espanõla, 2016, 216, 393-398.	0.3	2
411	Cardiovascular pharmacotherapy. International Journal of Cardiology, 2016, 224, 412-415.	0.8	0
412	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Current Diabetes Reports, 2016, 16, 116.	1.7	40

#	Article	IF	Citations
413	Chronic congestive heart failure â€" a new therapeutic choice. Cmaj, 2016, 188, 1137-1138.	0.9	0
414	European drug market entries 2015 with new mechanisms of action. Clinical Medicine, 2016, 16, 475-480.	0.8	2
415	Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- IIIâ€"rationale, trial design and baseline data. Nephrology Dialysis Transplantation, 2017, 32, gfw321.	0.4	24
416	Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H404-H414.	1.5	58
417	The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines. Journal of Cardiac Failure, 2016, 22, 726-730.	0.7	11
418	A Test in Context: Neprilysin. Journal of the American College of Cardiology, 2016, 68, 639-653.	1.2	197
419	Unlocking the Therapeutic Potential of Apelin. Hypertension, 2016, 68, 307-309.	1.3	11
420	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2016, 18, 1228-1234.	2.9	173
421	Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?. International Journal of Cardiology, 2016, 219, 111-114.	0.8	20
422	Acute decompensated heart failure (ADHF): A comprehensive contemporary review on preventing early readmissions and postdischarge death. International Journal of Cardiology, 2016, 223, 1035-1044.	0.8	25
423	A Janus-Faced Role for Atrial Natriuretic Peptide in Myocardial Infarction?. Circulation Research, 2016, 119, 181-183.	2.0	0
424	Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the <scp>USA</scp>. European Journal of Heart Failure, 2016, 18, 1211-1219.	2.9	27
425	Pharmacology of heart failure: From basic science to novel therapies. , 2016, 166, 136-149.		18
426	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 89-93.	2.9	43
427	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a doubleâ€blind, randomized comparison of two uptitration regimens. European Journal of Heart Failure, 2016, 18, 1193-1202.	2.9	180
428	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
429	Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. Journal of Clinical Pharmacology, 2016, 56, 78-86.	1.0	34
431	Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (<scp>LCZ</scp>696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovascular Therapeutics, 2016, 34, 191-198.	1.1	67

#	Article	IF	Citations
432	Abnormal Pulsatile Hemodynamics in Hypertensive Patients With Normalized 24â€Hour Ambulatory Blood Pressure by Combination Therapy of Three or More Antihypertensive Agents. Journal of Clinical Hypertension, 2016, 18, 281-289.	1.0	5
433	Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 119-127.	0.7	13
434	<scp>LCZ</scp>696 (Valsartan/Sacubitril) â€“ A Possible New Treatment for Hypertension and Heart Failure. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 14-22.	1.2	29
435	Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy. Pharmacotherapy, 2016, 36, 955-970.	1.2	8
436	Globalization of heart failure trials: no turning back on this paradigm. European Heart Journal, 2016, 37, 3175-3177.	1.0	4
437	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
438	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
439	The ICD in Heart Failure â€” Time for a Rethink?. New England Journal of Medicine, 2016, 375, 1283-1284.	13.9	36
440	Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nature Reviews Nephrology, 2016, 12, 610-623.	4.1	422
441	Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. Circulation: Heart Failure, 2016, 9, .	1.6	42
442	Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience. International Journal of Cardiology, 2016, 223, 781-784.	0.8	9
443	Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. Future Cardiology, 2016, 12, 573-584.	0.5	11
444	Interventional Therapies for Secondary and Essential Hypertension. Updates in Hypertension and Cardiovascular Protection, 2016, , .	0.1	2
445	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Journal of the American College of Cardiology, 2016, 68, 2425-2436.	1.2	271
446	NT-proBNP. Journal of the American College of Cardiology, 2016, 68, 2437-2439.	1.2	69
447	Medical Treatment of Aortic Stenosis. Circulation, 2016, 134, 1766-1784.	1.6	113
448	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Circulation, 2016, 134, 1785-1787.	1.6	35
449	Why to Replace an ACEÂorÂARB With an ARB/Neprilysin Inhibitor?. Journal of the American College of Cardiology, 2016, 68, 2390-2391.	1.2	0

#	Article	IF	Citations
450	What constitutes optimal neurohumoral antagonism in chronic heart failure?. Heart, 2016, 102, 1922-1932.	1.2	3
451	Multigram scale, chiron-based synthesis of sacubitril. Tetrahedron Letters, 2016, 57, 5928-5930.	0.7	5
452	Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure. Circulation, 2016, 134, 1664-1678.	1.6	34
454	Report of the American Heart Association (AHA) Scientific Sessions 2015, Orlando. Circulation Journal, 2016, 80, 51-57.	0.7	7
455	Novel Therapies for Heart Failureã€€â€“ Where Do They Stand? â€“. Circulation Journal, 2016, 80, 1882-1891.	0.7	24
456	2016 ESC and ACC/AHA/HFSA heart failure guideline update â€" what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628.	6.1	38
457	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQq0 0 0 rgBT /Overlock 10 T Therapy. Circulation: Heart Failure, 2016, 9, .	1.6	83
458	Angiotensin Receptor-Neprilysin InhibitionÂin Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2016, 4, 823-825.	1.9	2
459	Neprilysin: Indications, Expectations, and Challenges. Revista Espanola De Cardiologia (English Ed), 2016, 69, 647-649.	0.4	7
460	Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. International Journal of Cardiology, 2016, 224, 191-198.	0.8	37
461	Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: a case report. Perfusion (United Kingdom), 2016, 31, 699-702.	0.5	1
462	Angiotensin Neprilysin Inhibition for Patients With Heart Failure. JAMA Cardiology, 2016, 1, 971.	3.0	17
463	A Gordian knot: disentangling comorbidities in heart failure. European Journal of Heart Failure, 2016, 18, 759-761.	2.9	1
464	Updates on Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 718.	3.0	127
465	The Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides. ChemBioChem, 2016, 17, 1495-1498.	1.3	57
466	Combined neprilysin and reninâ€"angiotensin system inhibition in heart failure with reduced ejection fraction: a metaâ€anâ€alysis. European Journal of Heart Failure, 2016, 18, 1238-1243.	2.9	56
467	Influence of Sacubitril/Valsartan (LCZ696)ÂonÂ30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology, 2016, 68, 241-248.	1.2	101
468	MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure. Expert Opinion on Therapeutic Targets, 2016, 20, 1287-1300.	1.5	12

#	Article	IF	Citations
470	How robust are clinical trials in heart failure?. European Heart Journal, 2017, 38, ehw427.	1.0	49
471	The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016, 102, 1342-1347.	1.2	139
472	Cost-Effectiveness of Sacubitrilâ€“Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2016, 165, 681.	2.0	63
473	Sacubitrilâ€“Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It?. Annals of Internal Medicine, 2016, 165, 735.	2.0	19
475	Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration. Cardiovascular Drugs and Therapy, 2016, 30, 623-633.	1.3	10
477	From ARB to ARNI in Cardiovascular Control. Current Hypertension Reports, 2016, 18, 86.	1.5	12
478	Heart Failure With Preserved EjectionÂFraction andÂAtrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	1.2	292
479	Evolving therapies for the management of chronic and acute decompensated heart failure. American Journal of Health-System Pharmacy, 2016, 73, 1745-1754.	0.5	3
481	Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?. Progress in Cardiovascular Diseases, 2016, 59, 253-261.	1.6	38
482	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2016, 18, 127.	1.3	5
483	Structure of neprilysin in complex with the active metabolite of sacubitril. Scientific Reports, 2016, 6, 27909.	1.6	39
485	Angiotensin-Neprilysin Inhibition as a Paradigm for All?. Current Cardiology Reports, 2016, 18, 115.	1.3	9
486	<scp>PARADIGMâ€HF</scp>: does dose matter?. European Journal of Heart Failure, 2016, 18, 1235-1237.	2.9	4
487	October 2016 at a glance: treatment of heart failure. European Journal of Heart Failure, 2016, 18, 1209-1210.	2.9	0
488	Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. Scientific Reports, 2016, 6, 33678.	1.6	70
489	Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 2016, 7, 278-290.	1.1	35
490	Global left atrial failure in heart failure. European Journal of Heart Failure, 2016, 18, 1307-1320.	2.9	104
491	Effect of age and sex on efficacy and tolerability of Î² blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855.	3.0	95

#	Article	IF	Citations
492	Natriuretic peptides revisited. Journal of Cardiovascular Medicine, 2016, 17, 840-842.	0.6	2
493	Striking the Right Balance in Heart Failure. Annals of Internal Medicine, 2016, 164, 125.	2.0	3
494	Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open, 2016, 6, e014010.	0.8	14
495	What Can Geriatrics Teach Cardiology?. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	0
498	The realâ€world evidence of heart failure: findings from 41 413 patients of the <scp>ARNO</scp> database. European Journal of Heart Failure, 2016, 18, 402-410.	2.9	120
499	A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2016, 18, 716-726.	2.9	149
500	Neprilysin and Natriuretic Peptide Regulation in Heart Failure. Current Heart Failure Reports, 2016, 13, 151-157.	1.3	31
502	Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. European Journal of Clinical Pharmacology, 2016, 72, 1065-1073.	0.8	31
505	Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. Cardiovascular Research, 2016, 111, 154-162.	1.8	52
506	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	1.9	48
507	The Future of Heart Failure Diagnosis, Therapy, and Management. Circulation, 2016, 133, 2671-2686.	1.6	75
508	Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Current Atherosclerosis Reports, 2016, 18, 48.	2.0	10
509	Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. JAMA Cardiology, 2016, 1, 714.	3.0	89
510	Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition. Hypertension Research, 2016, 39, 753-755.	1.5	0
511	The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line. Hypertension Research, 2016, 39, 758-763.	1.5	16
512	Potent influence of obesity on suppression of plasma B-type natriuretic peptide levels in patients with acute heart failure: An approach using covariance structure analysis. International Journal of Cardiology, 2016, 215, 283-290.	0.8	20
513	Editorial Commentary: Curbing the rising tide of heart failure costs: Novel drugs and their place in the continuum of care. Trends in Cardiovascular Medicine, 2016, 26, 493-494.	2.3	0
514	â€œFibroblastâ€•pharmacotherapy â€" Advancing the next generation of therapeutics for clinical cardiology. Journal of Molecular and Cellular Cardiology, 2016, 94, 176-179.	0.9	2

#	Article	IF	Citations
515	Stem cells for the treatment of heart failure. Current Research in Translational Medicine, 2016, 64, 97-106.	1.2	36
516	Pharmacologic Trends of Heart Failure. , 2016, , .		0
517	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circulation: Heart Failure, 2016, 9, .	1.6	52
518	Novel MicroRNA Regulators of Atrial Natriuretic Peptide Production. Molecular and Cellular Biology, 2016, 36, 1977-1987.	1.1	20
520	A Review of the Key Clinical Trials of 2015: Results and Implications. Cardiology and Therapy, 2016, 5, 109-132.	1.1	6
521	Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. European Journal of Heart Failure, 2016, 18, 433-441.	2.9	22
522	A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. Journal of Clinical Pharmacology, 2016, 56, 936-947.	1.0	6
523	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2016, 1, 666.	3.0	130
524	Precision medicine in cardiology. Nature Reviews Cardiology, 2016, 13, 591-602.	6.1	183
525	Insulinâ€like growth factor 1 prevents diastolic and systolic dysfunction associated with cardiomyopathy and preserves adrenergic sensitivity. Acta Physiologica, 2016, 216, 421-434.	1.8	16
526	Pharmacokinetic drugâ€“drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Clinical Pharmacology in Drug Development, 2016, 5, 27-39.	0.8	21
527	Risk Related to Preâ€“Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	260
528	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 59-64.	1.3	7
529	Can Nitrite AMP _k Up Sirt -ainty to Treat Heart Failure With Preserved Ejection Fraction?. Circulation, 2016, 133, 692-694.	1.6	3
530	Emerging Therapies for Acute and Chronic Heart Failure. Journal of Pharmacy Practice, 2016, 29, 46-57.	0.5	2
531	Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies. Current Diabetes Reports, 2016, 16, 11.	1.7	28
532	Focus on renal congestion in heart failure. CKJ: Clinical Kidney Journal, 2016, 9, 39-47.	1.4	77
533	Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. CardioRenal Medicine, 2016, 6, 83-98.	0.7	442

#	Article	IF	Citations
534	New Targets in the Drug Treatment of Heart Failure. Drugs, 2016, 76, 187-201.	4.9	2
535	Valsartan/Sacubitril for Heart Failure. JAMA - Journal of the American Medical Association, 2016, 315, 25.	3.8	38
536	Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandatedÂtreatment guidelines and the real-world clinicalÂarena. Kidney International Supplements, 2016, 6, 20-28.	4.6	49
537	Cardiac Myosin Activators for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 67, 1456-1458.	1.2	6
538	Potassium homeostasis and dyskalemias: theÂrespective roles of renal, extrarenal, and gutÂsensors in potassium handling. Kidney International Supplements, 2016, 6, 7-15.	4.6	13
539	Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metabolism and Disposition, 2016, 44, 554-559.	1.7	54
540	Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. BMC Cardiovascular Disorders, 2016, 16, 39.	0.7	13
541	Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies. Regenerative Medicine, 2016, 11, 225-227.	0.8	13
542	Mending the Broken Heart: A Neprilysin Inhibitor for Heart Failure. Journal for Nurse Practitioners, 2016, 12, e111-e114.	0.4	1
543	The effect of LCZ696 (sacubitril/valsartan) on amyloidâ€Î² concentrations in cerebrospinal fluid in healthy subjects. British Journal of Clinical Pharmacology, 2016, 81, 878-890.	1.1	89
544	<scp>LCZ</scp>696, a Firstâ€inâ€Class Angiotensin Receptorâ€Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension. Journal of Clinical Hypertension, 2016, 18, 308-314.	1.0	39
545	Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction. Drugs, 2016, 76, 387-396.	4.9	24
546	Utility of Patient-Reported Outcome Instruments in Heart Failure. JACC: Heart Failure, 2016, 4, 165-175.	1.9	120
547	Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure. Expert Review of Clinical Pharmacology, 2016, 9, 513-523.	1.3	7
548	When Sweet Turns Salty. Journal of the American College of Cardiology, 2016, 67, 813-816.	1.2	6
549	The Prevention of Hospital Readmissions in Heart Failure. Progress in Cardiovascular Diseases, 2016, 58, 379-385.	1.6	179
550	A New Mechanism of Action in Heart Failure. Journal of Pharmacy Technology, 2016, 32, 116-124.	0.5	2
551	Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter. Clinical Chemistry, 2016, 62, 617-622.	1.5	37

#	Article	IF	Citations
552	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Failure Reviews, 2016, 21, 95-102.	1.7	55
553	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 2016, 209, 310-316.	0.8	22
554	Novel biomarkers and therapies in cardiorenal syndrome. Current Opinion in Pharmacology, 2016, 27, 56-61.	1.7	10
555	Assessing quality-of-life outcomes in cardiovascular clinical research. Nature Reviews Cardiology, 2016, 13, 286-308.	6.1	40
556	Hypertension â€“ state of the art 2015. Clinical Medicine, 2016, 16, 52-54.	0.8	4
557	Heart failure â€“ what the general physician needs to know. Clinical Medicine, 2016, 16, 25-33.	0.8	1
558	Stroke and Heart Failure: Clinical Features, Access to Care, and Outcomes. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1048-1056.	0.7	16
559	In Replyâ€"Is There a Need for â€œBias Policeâ€•in Industry-Sponsored Research?. Mayo Clinic Proceedings, 2016, 91, 121.	1.4	0
560	Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. American Journal of Medicine, 2016, 129, 560-567.	0.6	55
561	New Management Strategies in Heart Failure. Circulation Research, 2016, 118, 480-495.	2.0	37
562	Benefits of strict blood-pressure lowering in hypertension. Nature Reviews Cardiology, 2016, 13, 125-126.	6.1	10
563	The PARADIGM of Influenza Vaccination inÂHeart Failure Patients âˆ—. JACC: Heart Failure, 2016, 4, 159-161.	1.9	5
564	New and old agents in the management of diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2016, 25, 232-239.	1.0	31
566	From CONSENSUS to SAVE: The Early Development of Inhibition of the Renin-Angiotensin System in the Treatment of Chronic Heart Failure. Journal of Cardiac Failure, 2016, 22, 395-398.	0.7	7
567	Trials and Tribulations. Journal of Cardiac Failure, 2016, 22, 180-181.	0.7	3
568	Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation, 2016, 133, 1115-1124.	1.6	173
569	Ivabradine for the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy, 2016, 14, 553-561.	0.6	5
570	â€œNihilismâ€•of chronic heart failure therapy in children and why effective therapy is withheld. European Journal of Pediatrics, 2016, 175, 445-455.	1.3	39

#	Article	IF	Citations
571	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002744.	1.6	130
572	Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration. International Journal of Cardiology, 2016, 209, 291-295.	0.8	41
573	Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure: TableÂ1. European Heart Journal, 2016, 37, 745-746.	1.0	4
574	Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. Expert Review of Cardiovascular Therapy, 2016, 14, 703-711.	0.6	6
575	Heart Failure With Preserved Ejection Fraction. Current Problems in Cardiology, 2016, 41, 145-188.	1.1	107
576	A new approach to treatment of acute heart failure. Journal of Cardiology, 2016, 67, 395-398.	0.8	14
577	New medications for heart failure. Trends in Cardiovascular Medicine, 2016, 26, 485-492.	2.3	26
578	B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics. Revista Clinica Espanola, 2016, 216, 393-398.	0.2	9
579	Cardiometabolic crosstalk in obesity-associated arterial hypertension. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 19-28.	2.6	15
581	Angioedema with renin angiotensin system drugs and neutral endopeptidase inhibitors. Journal of the American Society of Hypertension, 2016, 10, 387-389.	2.3	6
582	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. Heart, 2016, 102, 320-330.	1.2	29
583	Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies. Hypertension, 2016, 67, 309-315.	1.3	33
584	Sacubitril-Valsartan for the Treatment of Heart Failure. JAMA Internal Medicine, 2016, 176, 249.	2.6	26
585	LXRÎ± improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. Diabetologia, 2016, 59, 634-643.	2.9	33
586	Cardiomyocyte Ca²⁺ dynamics: clinical perspectives. Scandinavian Cardiovascular Journal, 2016, 50, 65-77.	0.4	11
587	Influenza Vaccination in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158.	1.9	112
588	Reninâ€“angiotensinâ€“aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. International Journal of Cardiology, 2016, 205, 65-71.	0.8	23
589	B-Type Natriuretic Peptide as a Therapeutic Strategy: Opportunities and Pitfalls. Cardiology, 2016, 133, 119-121.	0.6	0

#	Article	IF	Citations
590	Sacubitril/valsartan (LCZ696) for the treatment of heart failure. Expert Review of Cardiovascular Therapy, 2016, 14, 145-153.	0.6	18
591	Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation. Heart, 2016, 102, 397-406.	1.2	56
592	Clinical management of dilated cardiomyopathy: current knowledge and future perspectives. Expert Review of Cardiovascular Therapy, 2016, 14, 137-140.	0.6	20
593	The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. International Journal of Cardiology, 2016, 203, 279-281.	0.8	64
594	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
595	Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 321-328.	0.4	23
596	Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 109-116.	0.6	19
597	Dietary Micronutrient Intake and Micronutrient Status in Patients With Chronic Stable Heart Failure. Journal of Cardiovascular Nursing, 2017, 32, 148-155.	0.6	24
598	Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 407-416.	0.6	12
599	Assessment of Drugâ€“Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 309-318.	0.6	16
600	New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction. Journal of Pharmacy Practice, 2017, 30, 541-548.	0.5	0
601	Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. International Journal of Cardiology, 2017, 226, 132-135.	0.8	7
602	Angiotensin receptorâ€“neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. International Journal of Cardiology, 2017, 226, 136-140.	0.8	10
603	Role of Neprilysin Inhibitors in Heart Failure. American Journal of Therapeutics, 2017, 24, e737-e743.	0.5	4
604	The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgraduate Medical Journal, 2017, 93, 29-37.	0.9	48
605	Short Stay Management of Acute Heart Failure. Contemporary Cardiology, 2017, , .	0.0	0
606	Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Journal of Cardiology, 2017, 70, 225-231.	0.8	36
607	Phosphodiesterase 2 as a Therapeutic Target for Heart Failure. Circulation Research, 2017, 120, 13-16.	2.0	0

#	Article	IF	Citations
608	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. Archives of Cardiovascular Diseases, 2017, 110, 1-6.	0.7	2
609	Cardioâ€Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. Clinical Pharmacology and Therapeutics, 2017, 101, 481-490.	2.3	24
610	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor. Circulation: Heart Failure, 2017, 10, .	1.6	79
611	Heart failure guidelines: Whatâ€™s new?. Trends in Cardiovascular Medicine, 2017, 27, 316-323.	2.3	8
612	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	178
613	Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model. Journal of Pharmaceutical Sciences, 2017, 106, 1439-1451.	1.6	18
614	Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension. Hypertension, 2017, 69, 411-420.	1.3	157
615	Sacubitril/valsartan in chronic heart failure with reduced ejection fraction: a guide to its use. Drugs and Therapy Perspectives, 2017, 33, 1-7.	0.3	2
617	Cyclic nucleotide imaging and cardiovascular disease. , 2017, 175, 107-115.		16
618	Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Current Heart Failure Reports, 2017, 14, 106-116.	1.3	16
620	Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly?. European Journal of Heart Failure, 2017, 19, 549-551.	2.9	1
621	Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clinical Research in Cardiology, 2017, 106, 501-513.	1.5	38
622	Neprilysin Inhibitors in Cardiovascular Disease. Current Cardiology Reports, 2017, 19, 16.	1.3	3
623	The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 447-457.	1.0	32
624	Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatrics and Neonatology, 2017, 58, 303-312.	0.3	69
625	Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. American Journal of Medicine, 2017, 130, 635-639.	0.6	9
626	Potential Expanded Indications for Neprilysin Inhibitors. Current Heart Failure Reports, 2017, 14, 134-145.	1.3	26
627	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2017, 19, 12.	1.5	38

#	Article	IF	Citations
628	What proportion of patients with chronic heart failure are eligible for sacubitrilâ€“valsartan?. European Journal of Heart Failure, 2017, 19, 768-778.	2.9	64
629	Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Medicine, 2017, 9, 20.	3.6	114
630	Editorial commentary: Guidelines for the treatment of chronic heart failure. Trends in Cardiovascular Medicine, 2017, 27, 324-325.	2.3	1
631	New pharmacological approaches in heart failure therapy: developments and possibilities. Future Cardiology, 2017, 13, 173-188.	0.5	0
632	Dilated cardiomyopathy. Lancet, The, 2017, 390, 400-414.	6.3	445
633	Outpatient Emergencies. Medical Clinics of North America, 2017, 101, 507-519.	1.1	4
634	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. Expert Review of Clinical Pharmacology, 2017, 10, 517-534.	1.3	4
635	Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs. JACC Basic To Translational Science, 2017, 2, 1-12.	1.9	34
636	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Current Heart Failure Reports, 2017, 14, 59-70.	1.3	72
637	Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge. Pharmacotherapy, 2017, 37, 645-656.	1.2	6
638	Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. Current Emergency and Hospital Medicine Reports, 2017, 5, 47-55.	0.6	0
639	Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. Handbook of Experimental Pharmacology, 2017, 243, 537-560.	0.9	8
641	Cost-Effectiveness of Sacubitrilâ€“Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2017, 166, 607.	2.0	5
642	Cost-Effectiveness of Sacubitrilâ€“Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2017, 166, 606.	2.0	0
643	Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics, 2017, 56, 1461-1478.	1.6	41
644	Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study. Journal of Cardiovascular Pharmacology, 2017, 69, 374-381.	0.8	36
645	Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2017, 23, 464-475.	0.7	255
646	Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. Journal of Hypertension, 2017, 35, 877-885.	0.3	42

#	Article	IF	Citations
647	Limitations of Sacubitril/Valsartan in the Management of Heart Failure. American Journal of Therapeutics, 2017, 24, e234-e239.	0.5	21
648	Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?. Biomedicine and Pharmacotherapy, 2017, 90, 752-759.	2.5	28
649	Contemporary Approaches to Patients with Heart Failure. Cardiology Clinics, 2017, 35, 261-271.	0.9	19
650	B-type natriuretic peptide increases cortisol and catecholamine concentrations in healthy subjects. Journal of Applied Physiology, 2017, 122, 1249-1254.	1.2	6
651	Optical control of a receptor-linked guanylyl cyclase using a photoswitchable peptidic hormone. Chemical Science, 2017, 8, 4644-4653.	3.7	23
652	Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its longâ€term side effects. Cardiovascular Therapeutics, 2017, 35, e12272.	1.1	20
653	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 399-407.	1.9	31
654	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. American Heart Journal, 2017, 189, 177-183.	1.2	43
655	Achieving a Maximally Tolerated Î²-Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	1.2	41
656	Molecular remodeling of the renin-angiotensin system after kidney transplantation. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2017, 18, 147032031770523.	1.0	8
657	Relevance of Heart Failure in Prevention, Treatment and Prognosis of Ischemic Stroke. Neurology International Open, 2017, 1, E61-E64.	0.4	1
658	Sacubitrilâ€“Valsartan for Heart Failure: From Devil's Advocate to Evidence-Based Medicine. American Journal of Therapeutics, 2017, 24, e109-e110.	0.5	4
659	Prognostic Implications of Moderate AorticÂStenosis in Patients With LeftÂVentricular SystolicÂDysfunction. Journal of the American College of Cardiology, 2017, 69, 2383-2392.	1.2	122
660	Detection of High-sensitivity Troponin T in Patients With Cardiovascular Risk. Response. Revista Espanola De Cardiologia (English Ed), 2017, 70, 616.	0.4	0
661	The Role of Emerging Risk Factors in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 28.	2.0	43
662	Navigating Choices Among a Sea ofÂComorbidities â^—. Journal of the American College of Cardiology, 2017, 69, 2380-2382.	1.2	0
663	Sacubitrilâ€“Valsartan in Heart Failure. Annals of Internal Medicine, 2017, 166, 681.	2.0	0
664	Targets for Heart Failure With Preserved Ejection Fraction. Clinical Pharmacology and Therapeutics, 2017, 102, 228-237.	2.3	17

#	Article	IF	Citations
665	Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 610-615.	2.0	19
666	Vasopressin and Vasopressin Antagonists in Heart Failure. Handbook of Experimental Pharmacology, 2017, 243, 307-328.	0.9	9
667	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e1054-e1091.	1.6	417
668	Heart failure. Lancet, The, 2017, 390, 1981-1995.	6.3	483
669	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of Cardiac Failure, 2017, 23, 628-651.	0.7	531
670	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161.	1.6	2,130
671	Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). Current Heart Failure Reports, 2017, 14, 187-196.	1.3	5
672	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803.	1.2	2,256
673	Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models. Advanced Healthcare Materials, 2017, 6, 1600571.	3.9	25
674	Elucidating the Origin of Long Residence Time Binding for Inhibitors of the Metalloprotease Thermolysin. ACS Chemical Biology, 2017, 12, 225-233.	1.6	14
675	Influence of atrial fibrillation on postâ€discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <scp>ASTRONAUT</scp> trial. European Journal of Heart Failure, 2017, 19, 552-562.	2.9	23
676	Selecting heart failure patients for metabolic interventions. Expert Review of Molecular Diagnostics, 2017, 17, 141-152.	1.5	5
677	Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet, The, 2017, 389, 1831-1840.	6.3	44
678	Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. Future Cardiology, 2017, 13, 103-115.	0.5	1
679	Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 528-537.	1.9	52
680	Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction. European Heart Journal, 2017, 38, 1144-1146.	1.0	7
681	LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2017, 108, 138-148.	0.9	103
682	Firstâ€inâ€Class Composite Angiotensin Receptorâ€“Neprilysin Inhibitors (ARNI) in Practice. Clinical Pharmacology and Therapeutics, 2017, 102, 265-268.	2.3	4

#	Article	IF	Citations
683	Lessons in Bridge-Building: A Multidisciplinary Approach to Heart Failure Care. Journal of Cardiac Failure, 2017, 23, 574-575.	0.7	4
684	Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 50.	0.4	3
685	Heart failure, post-hospital mortality and renal function in Tanzania: A prospective cohort study. International Journal of Cardiology, 2017, 243, 311-317.	0.8	14
686	Is there a place for a dual angiotensin receptor-neprilysin inhibitor in the treatment of hypertension?. Journal of Hypertension, 2017, 35, 726-728.	0.3	0
687	Serelaxin in the Treatment of Acute Heart Failure in the Emergency Department. Current Emergency and Hospital Medicine Reports, 2017, 5, 68-75.	0.6	0
688	BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?. European Heart Journal, 2017, 38, 2374-2376.	1.0	6
689	Should recommendations for clinical use be restricted to patients who were enrolled in a pivotal clinical trial?. European Journal of Heart Failure, 2017, 19, 779-781.	2.9	1
690	June 2017 at a glance: biomarkers and medical treatment. European Journal of Heart Failure, 2017, 19, 699-700.	2.9	0
691	Medical and Device Options for Patients with End-Stage Heart Failure. , 2017, , 1-9.		0
692	The Future of Heart Transplantation. , 2017, , 237-248.		0
693	Angiotensin Receptorâ€“Neprilysin Inhibition. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 356-364.	1.0	5
694	Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. Annales De Biologie Clinique, 2017, 75, 259-267.	0.2	3
695	Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry. Clinical Cardiology, 2017, 40, 907-913.	0.7	13
697	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. Heart Failure Reviews, 2017, 22, 641-655.	1.7	19
698	Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline. Drug Discovery Today, 2017, 22, 1598-1603.	3.2	17
699	Management of heart failure in the elderly. Current Opinion in Cardiology, 2017, 32, 217-223.	0.8	10
700	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. Circulation, 2017, 135, 2077-2080.	1.6	28
701	Integrating electronic health records into the study of heart failure: promises and pitfalls. European Journal of Heart Failure, 2017, 19, 1128-1130.	2.9	8

#	Article	IF	Citations
702	Future drug discovery in renin-angiotensin-aldosterone system intervention. Expert Opinion on Drug Discovery, 2017, 12, 1-22.	2.5	26
703	From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring. Archives of Cardiovascular Diseases, 2017, 110, 413-419.	0.7	12
704	Surgical Revascularization in Older Adults with Ischemic Cardiomyopathy. Heart Failure Clinics, 2017, 13, 571-580.	1.0	5
705	Multidisciplinary Heart Failure Clinics Are Associated With Lower Heart Failure Hospitalization and Mortality: Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2017, 33, 1237-1244.	0.8	72
706	Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. Journal of the American Society of Hypertension, 2017, 11, 461-468.	2.3	14
707	Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDAÂApproval. JACC: Heart Failure, 2017, 5, 460-463.	1.9	12
708	Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacological Research, 2017, 125, 57-71.	3.1	96
709	The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. European Journal of Heart Failure, 2017, 19, 1401-1409.	2.9	39
711	Diagnosis and Management of Heart Failure in Older Adults. Heart Failure Clinics, 2017, 13, 427-444.	1.0	13
712	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. Heart Failure Clinics, 2017, 13, 467-483.	1.0	3
713	Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan. JAMA Cardiology, 2017, 2, 818.	3.0	2
714	Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. European Heart Journal, 2017, 38, 1872-1882.	1.0	126
715	Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Metaâ€Analysis of Randomized Controlled Trials. Journal of Cardiovascular Electrophysiology, 2017, 28, 538-543.	0.8	23
716	An NPPB Promoter Polymorphism Associated With Elevated Nâ€Terminal proâ€Bâ€Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. Journal of the American Heart Association, 2017, 6, .	1.6	42
717	Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 115-126.	1.0	53
718	Devices for management of sudden cardiac death: Successes, challenges and perspectives. International Journal of Cardiology, 2017, 237, 34-37.	0.8	13
719	Selection of the Best of 2016 in Clinical Cardiology: Therapeutic Novelties. Revista Espanola De Cardiologia (English Ed), 2017, 70, 123-124.	0.4	0
720	Diagnostic and Prognostic Value of CMR T 1 -Mapping in Patients With Heart Failure and Preserved Ejection Fraction. Revista Espanola De Cardiologia (English Ed), 2017, 70, 848-855.	0.4	6

#	Article	IF	Citations
721	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 924-932.	0.4	12
722	SelecciÃ³n de lo mejor del aÃ±o 2016 en cardiologÃa clÃnica. Novedades terapÃ©uticas. Revista Espanola De Cardiologia, 2017, 70, 123-124.	0.6	0
724	Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. European Journal of Heart Failure, 2017, 19, 710-717.	2.9	116
725	The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-Î² concentrations and clearance in the cynomolgus monkey. Toxicology and Applied Pharmacology, 2017, 323, 53-65.	1.3	29
726	Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Failure Reviews, 2017, 22, 263-277.	1.7	18
727	Hypertension up to date: SPRINT to SPYRAL. Clinical Research in Cardiology, 2017, 106, 475-484.	1.5	18
728	The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. , 2017, 178, 67-82.		2
729	Double Vision. JACC: Heart Failure, 2017, 5, 232-235.	1.9	9
730	Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. Current Heart Failure Reports, 2017, 14, 30-39.	1.3	6
731	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 305-309.	1.9	101
732	New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. Expert Opinion on Pharmacotherapy, 2017, 18, 645-655.	0.9	12
733	Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. European Heart Journal, 2017, 38, 1738-1746.	1.0	74
734	Cardiopulmonary Exercise Test as a Tool to Choose Therapy in Heart Failure. Annals of the American Thoracic Society, 2017, 14, S67-S73.	1.5	7
735	Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF. Heart Failure Reviews, 2017, 22, 279-288.	1.7	11
736	Gender differences in the effects of cardiovascular drugs. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 163-182.	1.4	204
737	Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. Expert Opinion on Investigational Drugs, 2017, 26, 651-659.	1.9	11
738	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. European Journal of Heart Failure, 2017, 19, 1615-1623.	2.9	149
739	Major developments in the 2016 European guidelines for heart failure. Revista Clínica Espanõla, 2017, 217, 405-409.	0.3	1

#	Article	IF	Citations
740	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	1.0	160
741	A review of the current management of acute and chronic heart failure in the context of ischemic heart disease. Continuing Cardiology Education, 2017, 3, 30-36.	0.4	0
742	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	2.9	17
743	Should Nonischemic CRT Candidates Receive CRT-P or CRT-D? â^—. Journal of the American College of Cardiology, 2017, 69, 1679-1682.	1.2	12
744	Clinical Guide to Heart Transplantation. , 2017, , .		8
745	Current Pharmacological Therapies in Heart Failure Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 107-114.	1.0	21
746	The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 23.	2.0	33
747	Expression of neprilysin in periodontitis-affected gingival tissues. Archives of Oral Biology, 2017, 79, 35-41.	0.8	6
748	Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise?. Hypertension Research, 2017, 40, 439-440.	1.5	2
749	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	1.2	32
750	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 333-340.	5.5	258
751	Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. Clinical Science, 2017, 131, 553-566.	1.8	17
752	Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?. Lancet Diabetes and Endocrinology,the, 2017, 5, 314-315.	5.5	9
753	An overview of current treatments in heart failure. British Journal of Cardiac Nursing, 2017, 12, 120-127.	0.0	2
754	A Change of Heart: the New Era of Heart Failure Management. Current Emergency and Hospital Medicine Reports, 2017, 5, 21-27.	0.6	0
755	Cardio-Renal Syndrome: A double edged sword. Disease-a-Month, 2017, 63, 92-100.	0.4	8
756	Outcome Measures in HFpEF Trials. Journal of the American College of Cardiology, 2017, 69, 1358-1359.	1.2	0
757	New Developments in Cardiac Regeneration. Heart Lung and Circulation, 2017, 26, 316-322.	0.2	14

#	Article	IF	Citations
758	Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a populationâ€based linked electronic health record cohort study in 2.1 million people. European Journal of Heart Failure, 2017, 19, 1119-1127.	2.9	101
759	Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease. Clinical Chemistry, 2017, 63, 108-115.	1.5	46
760	Natriuretic Peptides and Analytical Barriers. Clinical Chemistry, 2017, 63, 50-58.	1.5	34
761	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clinical Chemistry, 2017, 63, 211-222.	1.5	41
762	The year in cardiology 2016: heart failure. European Heart Journal, 2017, 38, ehw638.	1.0	1
763	Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia, 2017, 60, 701-708.	2.9	53
764	ICD Implantation in Patients with Nonischemic Heart Failure. New England Journal of Medicine, 2017, 376, 89-92.	13.9	7
765	An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. Value in Health, 2017, 20, 388-396.	0.1	29
766	Criteria for use of composite end points for competing risksâ€"a systematic survey of the literature with recommendations. Journal of Clinical Epidemiology, 2017, 82, 4-11.	2.4	31
767	Long-term neprilysin inhibition â€" implications for ARNIs. Nature Reviews Cardiology, 2017, 14, 171-186.	6.1	111
768	Silent disease progression in clinically stable heart failure. European Journal of Heart Failure, 2017, 19, 469-478.	2.9	49
769	Angiotensin II Receptorâ€"Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats. Journal of the American Heart Association, 2017, 6, .	1.6	30
770	Regenerating the human heart: direct reprogramming strategies and their current limitations. Basic Research in Cardiology, 2017, 112, 68.	2.5	38
772	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 1875-1886.	1.2	198
773	(Re)Discovering the Neurohormonal and Hemodynamic Duality of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 1887-1889.	1.2	9
774	Role of Cardiac Magnetic Resonance inÂtheÂDiagnosis and Prognosis ofÂNonischemicÂCardiomyopathy. JACC: Cardiovascular Imaging, 2017, 10, 1180-1193.	2.3	189
775	Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond. Current Heart Failure Reports, 2017, 14, 498-506.	1.3	6
777	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Advances in Experimental Medicine and Biology, 2017, 1067, 197-217.	0.8	44

#	Article	IF	Citations
778	Neprilysin Inhibition and the Treatment of Heart Failure. Cardiology in Review, 2017, 25, 315-320.	0.6	1
779	Novel Therapies for Acute Decompensated Heart Failure. , 2017, , 177-189.		0
780	Who Would Be Branded With Failure?. Circulation, 2017, 136, 1359-1361.	1.6	2
781	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	1.6	53
782	Pharmacotherapy Choice Is Associated with 2-Year Mortality for Patients with Heart Failure and Reduced Ejection Fraction. Advances in Therapy, 2017, 34, 2345-2359.	1.3	6
783	Renal Sympathetic Denervation ProtectsÂthe Failing Heart Via Inhibition ofÂNeprilysinÂActivity in the Kidney. Journal of the American College of Cardiology, 2017, 70, 2139-2153.	1.2	69
784	The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	1.2	43
785	Neprilysin and Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2154-2156.	1.2	4
786	Sustained Activation of Guanylate Cyclase-A with TDT, a Natriuretic Peptide Derivative, Exhibits Cardiorenal Protection in Dahl Salt-Sensitive Hypertensive Rats. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 402-410.	1.3	5
787	The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. European Heart Journal, 2017, 38, 3308-3317.	1.0	112
789	Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension. European Heart Journal, 2017, 38, 3318-3320.	1.0	11
790	Effect of Natriuretic Peptideâ€"Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	3.8	386
791	The potential role and rationale for treatment of heart failure with sodiumâ€"glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	2.9	139
792	Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice. Progress in Cardiovascular Diseases, 2017, 60, 187-197.	1.6	14
793	Heart failure with reduced ejection fraction. Nature Reviews Disease Primers, 2017, 3, 17058.	18.1	136
794	New issues on measurement of B-type natriuretic peptides. Clinical Chemistry and Laboratory Medicine, 2017, 56, 32-39.	1.4	20
795	Mechanisms contributing to cardiac remodelling. Clinical Science, 2017, 131, 2319-2345.	1.8	132
796	Cardiac Computed Tomography Angiographic Findings as Predictors of Late Heart Failure in an Asymptomatic Diabetic Cohort: An 8-Year Prospective Follow-Up Study. Cardiology, 2017, 138, 218-227.	0.6	5

#	Article	IF	Citations
797	Using biomarkers to guide heart failure management. Expert Review of Cardiovascular Therapy, 2017, 15, 729-741.	0.6	12
798	Sacubitril/valsartan: um importante avanÃ§o no puzzle terapÃªutico da insuficiÃªncia cardÃaca. Revista Portuguesa De Cardiologia, 2017, 36, 655-668.	0.2	17
799	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. European Journal of Heart Failure, 2017, 19, 1551-1553.	2.9	10
800	Pharmacologic Management for Heart Failure and Emerging Therapies. Current Cardiology Reports, 2017, 19, 94.	1.3	9
801	Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC: Heart Failure, 2017, 5, 688-689.	1.9	3
802	Reply. JACC: Heart Failure, 2017, 5, 689.	1.9	1
803	Pediatric Cardiomyopathies. Circulation Research, 2017, 121, 855-873.	2.0	207
804	WITHDRAWN Ventricular Arrhythmias in Non-ischemic Cardiomyopathy. Journal of Arrhythmia, 2017, , .	0.5	1
805	Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?. European Journal of Heart Failure, 2017, 19, 1648-1650.	2.9	4
806	Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.	0.8	19
807	The Initial Evaluation and Management of a Patient with Heart Failure. Current Cardiology Reports, 2017, 19, 103.	1.3	1
808	Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 655-668.	0.2	6
809	The management of diagnosed heart failure in older people in primary care. Maturitas, 2017, 106, 26-30.	1.0	7
810	Reducing the Global Burden of Cardiovascular Disease, Part 2. Circulation Research, 2017, 121, 695-710.	2.0	256
811	Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	20
812	Profiling B-Type Natriuretic Peptide Cleavage Peptidoforms in Human Plasma by Capillary Electrophoresis with Electrospray Ionization Mass Spectrometry. Journal of Proteome Research, 2017, 16, 4515-4522.	1.8	14
813	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	0.8	503
815	Cardiac Palliative Medicine. Current Heart Failure Reports, 2017, 14, 428-433.	1.3	8

#	Article	IF	Citations
816	Long-term management of end-stage heart failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 153-166.	1.7	22
817	Clinical Effectiveness of Hydralazineâ€“Isosorbide Dinitrate in African-American Patients With HeartÂFailure. JACC: Heart Failure, 2017, 5, 632-639.	1.9	17
818	Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health, 2017, 20, 1260-1269.	0.1	32
819	DetecciÃ³n de troponina T ultrasensible en pacientes con riesgo cardiovascular. Respuesta. Revista Espanola De Cardiologia, 2017, 70, 616.	0.6	0
820	Navigating the Future of Cardiovascular Drug Developmentâ€”Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovascular Drugs and Therapy, 2017, 31, 445-458.	1.3	8
821	Is an Admission for Decompensated Heart Failure Inevitable?. Progress in Cardiovascular Diseases, 2017, 60, 171-177.	1.6	9
822	Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results. Journal of the American Board of Family Medicine, 2017, 30, 556-557.	0.8	6
823	Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium. American Heart Journal, 2017, 190, 76-85.	1.2	16
827	Heart failure in patients with kidney disease. Heart, 2017, 103, 1848-1853.	1.2	132
828	Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2017, 120, 1166-1170.	0.7	6
829	PDE3 inhibition by C-type natriuretic peptide-induced cGMP enhances cAMP-mediated signaling in both non-failing and failing hearts. European Journal of Pharmacology, 2017, 812, 174-183.	1.7	28
830	Answer to Dr. Eyuboglu. International Journal of Cardiology, 2017, 235, 188.	0.8	0
831	The Transition From Hypertension toÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 543-551.	1.9	305
832	Principales novedades de las guÃas europeas de insuficiencia cardiaca del 2016. Revista Clinica Espanola, 2017, 217, 405-409.	0.2	4
835	Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress. Biomedicine and Pharmacotherapy, 2017, 93, 1343-1357.	2.5	62
837	Elevated Admission Potassium Levels and 1-Year and 10-Year Mortality Among Patients With Heart Failure. American Journal of the Medical Sciences, 2017, 354, 268-277.	0.4	7
838	Marketing masked as clinical research. The Phase IIIB studies and other sample cases. European Journal of Internal Medicine, 2017, 44, e16-e17.	1.0	0
839	Kyoto Congestive Heart Failure (KCHF) study: rationale and design. ESC Heart Failure, 2017, 4, 216-223.	1.4	39

#	Article	IF	Citations
840	Heart failure â€“ whatâ€™s new and whatâ€™s changed?. Clinical Medicine, 2017, 17, 341-346.	0.8	1
841	Comparative analysis of the factors associated with citation and media coverage of clinical research. Scientometrics, 2017, 112, 1271-1283.	1.6	8
842	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. Current Heart Failure Reports, 2017, 14, 203-209.	1.3	3
843	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	1.2	95
844	The Paradox in Demonstrating Hydralazine-Nitrate Efficacy. JACC: Heart Failure, 2017, 5, 640-641.	1.9	0
845	Realâ€world dosing of evidenceâ€based medications for heart failure: embracing guideline recommendations and clinical judgement. European Journal of Heart Failure, 2017, 19, 1424-1426.	2.9	9
846	Goldilocks Dilemma of Dose Titration in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	2
847	Usefulness of Released Cardiac Myosin Binding Protein-C as a Predictor of Cardiovascular Events. American Journal of Cardiology, 2017, 120, 1501-1507.	0.7	6
848	Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dualâ€acting angiotensin receptorâ€neprilysin inhibitor. Pharmacology Research and Perspectives, 2017, 5, e00336.	1.1	32
849	Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development. Journal of Cardiac Failure, 2017, 23, 697-699.	0.7	6
850	Antihypertensive Drugs. Side Effects of Drugs Annual, 2017, 39, 183-187.	0.6	1
851	Gene therapy for hypertension. Expert Opinion on Biological Therapy, 2017, 17, 1345-1361.	1.4	4
852	Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure, 2017, 10, .	1.6	150
853	2017 Lucian Award. Circulation Research, 2017, 121, 1312-1315.	2.0	1
854	Smooth Muscle Phenotypic Diversity. Advances in Pharmacology, 2017, 78, 383-415.	1.2	5
855	Heart Failure and Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 709-723.	0.7	21
856	Role of Payers in the Development of Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2017, 70, 2822-2830.	1.2	5
857	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	1.6	53

#	Article	IF	Citations
858	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	38
859	Heart Failure and Kidney Disease. Advances in Experimental Medicine and Biology, 2017, 1067, 219-238.	0.8	20
862	Long-Term Outcomes of AcuteÂHeartÂFailure. Journal of the American College of Cardiology, 2017, 70, 2487-2489.	1.2	11
863	Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500.	1.2	114
865	MiocardiopatÃas (II). Formas dilatadas. Medicine, 2017, 12, 2561-2572.	0.0	0
866	The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy. Advances in Experimental Medicine and Biology, 2017, 1000, 103-129.	0.8	19
867	Improving heart failure patient outcomes utilizing guideline-directed therapy. Nurse Practitioner, 2017, 42, 3-14.	0.2	5
868	Emerging roles for pharmacists in performance-based risk-sharing arrangements. American Journal of Health-System Pharmacy, 2017, 74, 1007-1012.	0.5	3
869	Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	1.9	238
870	Challenges in the Development of Novel Cardiovascular Therapies. Clinical Pharmacology and Therapeutics, 2017, 102, 194-196.	2.3	6
871	Clinical trials in acute heart failure: beginning of the end or end of the beginning?. European Journal of Heart Failure, 2017, 19, 1358-1360.	2.9	5
873	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. American Heart Journal, 2017, 191, 75-81.	1.2	31
874	Resolution of Cheyne-Stokes Respiration after Treatment of Heart Failure with Sacubitril/Valsartan: A First Case Report. Cardiology, 2017, 137, 96-99.	0.6	11
875	Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure. Current Medical Research and Opinion, 2017, 33, 2027-2038.	0.9	3
876	Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (â‰¥65 Years) With Systolic Hypertension. American Journal of Hypertension, 2017, 30, 1163-1169.	1.0	49
877	Rationales and choices for the treatment of patients with NYHA class II heart failure. Postgraduate Medicine, 2017, 129, 619-631.	0.9	3
878	Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology and Allergy Clinics of North America, 2017, 37, 483-495.	0.7	35
879	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	13.9	355

#	Article	IF	Citations
880	Antihyperglycemic agents and cardiovascular outcomes. Current Opinion in Cardiology, 2017, 32, 642-650.	0.8	2
881	Synthetic Modification within the â€œRPRLâ€•Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation. Journal of Medicinal Chemistry, 2017, 60, 6408-6427.	2.9	35
882	Sacubitril/valsartan: beyond natriuretic peptides. Heart, 2017, 103, 1569-1577.	1.2	72
883	Treatment of Hyperkalemia in Heart Failure. Current Heart Failure Reports, 2017, 14, 266-274.	1.3	16
884	Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. Npj Systems Biology and Applications, 2017, 3, 12.	1.4	96
886	Urinary neprilysin in the critically ill patient. BMC Nephrology, 2017, 18, 172.	0.8	14
887	Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Current Cardiology Reports, 2017, 19, 71.	1.3	147
888	Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Current Heart Failure Reports, 2017, 14, 338-349.	1.3	67
889	Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations. British Journal of General Practice, 2017, 67, 326-327.	0.7	18
890	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. International Journal of Cardiology, 2017, 244, 229-234.	0.8	113
891	Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. Cardiology, 2017, 136, 192-203.	0.6	16
892	New and old roles of the peripheral and brain reninâ€“angiotensinâ€“aldosterone system (RAAS): Focus on cardiovascular and neurological diseases. International Journal of Cardiology, 2017, 227, 734-742.	0.8	53
893	Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction. Circulation Research, 2017, 120, 120-132.	2.0	55
894	Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. JAMA Cardiology, 2017, 2, 86.	3.0	1
895	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2017, 2, 79.	3.0	143
897	Reducing Readmissions among Heart Failure Patients Discharged to Home Health Care: Effectiveness of Early and Intensive Nursing Services and Early Physician Followâ€Up. Health Services Research, 2017, 52, 1445-1472.	1.0	77
898	Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease. Circulation, 2017, 135, 566-577.	1.6	231
899	Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertension Research, 2017, 40, 472-476.	1.5	29

#	Article	IF	Citations
900	Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. European Journal of Heart Failure, 2017, 19, 167-176.	2.9	91
901	Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. Annual Review of Pharmacology and Toxicology, 2017, 57, 455-479.	4.2	79
902	Fibers for hearts: A critical review on electrospinning for cardiac tissue engineering. Acta Biomaterialia, 2017, 48, 20-40.	4.1	230
903	Heart failure 2016: still more questions than answers. International Journal of Cardiology, 2017, 227, 766-777.	0.8	15
904	Gene therapy for heart failure. Trends in Cardiovascular Medicine, 2017, 27, 216-222.	2.3	22
905	Acute myocardial infarction. Lancet, The, 2017, 389, 197-210.	6.3	869
906	Cardiac molecular imaging to track left ventricular remodeling in heart failure. Journal of Nuclear Cardiology, 2017, 24, 574-590.	1.4	10
907	Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. Clinical Pharmacology and Therapeutics, 2017, 101, 254-263.	2.3	89
908	Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends in Cardiovascular Medicine, 2017, 27, 123-133.	2.3	117
909	Targeting vasoactive peptides for managing calcific aortic valve disease. Annals of Medicine, 2017, 49, 63-74.	1.5	14
910	Heart failure outcomes in clinical trials of glucoseâ€lowering agents in patients with diabetes. European Journal of Heart Failure, 2017, 19, 43-53.	2.9	91
911	Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients. Journal of Heart and Lung Transplantation, 2017, 36, 355-365.	0.3	14
912	Heart Failure Therapy in 2016. Annals of Pharmacotherapy, 2017, 51, 79-82.	0.9	3
913	Neurohormonal activation in heart failure with reduced ejection fraction. Nature Reviews Cardiology, 2017, 14, 30-38.	6.1	359
914	Neprilysin Inhibitors: Emerging Therapy for Heart Failure. Annual Review of Medicine, 2017, 68, 41-49.	5.0	16
915	Newer drugs for heart failure: hype or hope?. Expert Opinion on Investigational Drugs, 2017, 26, 5-7.	1.9	1
916	Are diuretic additives fit for uncontrolled hypertensive patients receiving telmisartan and amlodipine treatment?. Hypertension Research, 2017, 40, 346-347.	1.5	0
917	Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.	2.9	95

#	Article	IF	Citations
918	Understanding Heart Failure. Heart Failure Clinics, 2017, 13, 1-19.	1.0	45
919	Rationale for and design of the <scp>TRUEâ€AHF</scp> trial: the effects of ularitide on the shortâ€term clinical course and longâ€term mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	2.9	31
920	Effect of left ventricular systolic dysfunction on secondary medical prevention and clinical outcome in stable coronary artery disease patients. Archives of Cardiovascular Diseases, 2017, 110, 35-41.	0.7	4
921	Cardioprotective Effects of LCZ696Â(Sacubitril/Valsartan) After ExperimentalÂAcuteÂMyocardial Infarction. JACC Basic To Translational Science, 2017, 2, 655-668.	1.9	63
922	NT-proBNP and Myocardial Fibrosis. Journal of the American College of Cardiology, 2017, 70, 3110-3112.	1.2	6
923	Sacubitril/Valsartan in an Elderly Patient with Heart Failure: A Case Report. Cardiology, 2017, 138, 3-6.	0.6	10
924	Sacubitril/Valsartan in Clinical Practice: A Report of 2 Cases. Cardiology, 2017, 138, 7-10.	0.6	4
925	Pharmacological Management of a Heart Failure Patient with Severe Obesity. Cardiology, 2017, 138, 11-12.	0.6	1
926	Sacubitril/Valsartan: Effect on Walking Test and Physical Capability. Cardiology, 2017, 138, 17-20.	0.6	12
927	Overcoming the Declining Trends inÂInnovation and Investment in Cardiovascular Therapeutics. JACC Basic To Translational Science, 2017, 2, 613-625.	1.9	20
928	Sacubitril/Valsartan in â€œField Practiceâ€•Patients with Advanced Heart Failure: A Monocentric Italian Experience. Cardiology, 2017, 138, 13-16.	0.6	6
929	Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. European Heart Journal Supplements, 2017, 19, C22-C28.	0.0	7
930	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2017, , .	1.5	2
931	Sacubitril/Valsartan in Clinical Practice: The Italian Experience. Cardiology, 2017, 138, 1-2.	0.6	4
932	Management of a Multicomorbid Patient with Heart Failure. Cardiology, 2017, 138, 21-23.	0.6	3
933	Margaret McCartney: Only data can say if new is better. BMJ: British Medical Journal, 2017, 357, j2191.	2.4	0
934	Controversies in hypertension management: target blood pressure, renal nerve ablation, ARNIs, and NSAIDs medication. European Heart Journal, 2017, 38, 3245-3248.	1.0	0
935	Aetiology, diagnosis and management of heart failure in infants and children. SA Heart Journal, 2017, 14, .	0.0	0

#	Article	IF	Citations
936	Entresto in heart failure. NursePrescribing, 2017, 15, 605-611.	0.1	0
937	ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: PRACTICAL ASPECTS AND DISCUSSION ISSUES OF RATIONAL PHARMACOTHERAPY. Rational Pharmacotherapy in Cardiology, 2017, 13, 856-862.	0.3	0
938	Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure. , 0, , .		0
939	B-type natriuretic peptide-guided treatment for heart failure: is the GUIDE-IT trail the end of the road?. Journal of Xiangya Medicine, 0, 2, 77-77.	0.2	0
940	The need to apply the best therapy in heart failure â€“ the era after PARADIGM-HF. Archives of Medical Science, 2017, 5, 1244-1248.	0.4	0
941	The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Archives of Medical Science, 2017, 5, 1207-1216.	0.4	26
942	Pharmacological update: New drugs in cardiac practice: A critical appraisal. Annals of Cardiac Anaesthesia, 2017, 20, 49.	0.3	4
943	Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 369-382.	1.0	18
944	Atrial Natriuretic Peptideã€€â€• Old But New Therapeutic in Cardiovascular Diseases â€•. Circulation Journal, 2017, 81, 913-919.	0.7	23
945	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. BioMed Research International, 2017, 2017, 1-15.	0.9	1
946	The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy. Case Reports in Cardiology, 2017, 2017, 1-4.	0.1	2
947	Current Therapeutic Options for Heart Failure in Elderly Patients. BioMed Research International, 2017, 2017, 1-11.	0.9	13
948	Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence. Disease Markers, 2017, 2017, 1-9.	0.6	19
950	The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. International Journal of COPD, 2017, Volume 12, 1325-1337.	0.9	40
951	Novel approaches for treating hypertension. F1000Research, 2017, 6, 80.	0.8	5
952	Improvement in Exercise Capacity by Exercise Training Associated With Favorable Clinical Outcomes in Advanced Heart Failure With High B-Type Natriuretic Peptide Level. Circulation Journal, 2017, 81, 1307-1314.	0.7	10
953	Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial. BMC Cardiovascular Disorders, 2017, 17, 274.	0.7	23
954	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circulation Journal, 2017, 47, 555.	0.7	56

#	Article	IF	Citations
955	Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target. Cardiovascular Pharmacology: Open Access, 2017, 06, .	0.1	7
957	Cardiac Natriuretic Peptides. , 2017, , 3-39.		1
958	EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. Rational Pharmacotherapy in Cardiology, 2017, 13, 370-377.	0.3	1
959	Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC). Korean Circulation Journal, 2017, 47, 543.	0.7	24
960	New pharmacological and technological management strategies in heart failure. Vascular Health and Risk Management, 2017, Volume 13, 111-121.	1.0	4
961	Chronic heart failure. Australian Prescriber, 2017, 40, 128-136.	0.5	17
962	Renin Angiotensin Aldosterone System and Heart Function. , 2017, , 229-248.		0
963	Neurohormonal Blockade in Heart Failure. Cardiac Failure Review, 2017, 03, 19.	1.2	53
964	Impact on Patient Care: The 2016 European Heart Failure Guidelines. European Cardiology Review, 2017, 12, 78.	0.7	0
965	Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis. World Journal of Cardiology, 2017, 9, 182.	0.5	12
966	Treatments for Heart Failure. , 2017, , 628-662.		2
967	Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials. Cardiovascular Diagnosis and Therapy, 2017, 7, 397-404.	0.7	14
968	Role of circulating factors in cardiac aging. Journal of Thoracic Disease, 2017, 9, S17-S29.	0.6	14
969	The challenge of co-existent moderate aortic stenosis and left ventricular systolic impairment. Journal of Thoracic Disease, 2017, 9, 3560-3563.	0.6	0
970	Moderate aortic valve stenosis in patients with left ventricular systolic dysfunctionâ€"insights on prognosis and the potential role of early aortic valve replacement. Journal of Thoracic Disease, 2017, 9, 3590-3593.	0.6	3
971	Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic. American Journal of Cardiovascular Drugs, 2018, 18, 143-151.	1.0	13
973	Approaching Regulatory Approval of Cardiovascular Regenerative Therapy. Circulation Research, 2018, 122, 552-554.	2.0	0
975	Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. British Journal of Clinical Pharmacology, 2018, 84, 1072-1074.	1.1	6

#	Article	IF	Citations
976	Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction. Clinical Cardiology, 2018, 41, 752-757.	0.7	4
977	Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry. International Journal of Cardiology, 2018, 257, 168-176.	0.8	10
978	Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Failure, 2018, 5, 275-283.	1.4	52
979	Impact of sacubitrilâ€“valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTOâ€SAS study design. ESC Heart Failure, 2018, 5, 222-230.	1.4	19
980	The role of angiotensin receptorâ€“neprilysin inhibitors in cardiovascular diseaseâ€”existing evidence, knowledge gaps, and future directions. European Journal of Heart Failure, 2018, 20, 963-972.	2.9	35
981	Management of Heart Failure in Advancing CKD: Core Curriculum 2018. American Journal of Kidney Diseases, 2018, 72, 284-295.	2.1	50
984	The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. Current Heart Failure Reports, 2018, 15, 37-43.	1.3	29
985	Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. Contemporary Clinical Trials, 2018, 66, 45-50.	0.8	7
986	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. Current Heart Failure Reports, 2018, 15, 44-52.	1.3	12
987	The heart failure burden of type 2 diabetes mellitusâ€”a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323.	1.7	41
989	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
990	The role of bradykinin receptor type 2 in spontaneous extravasation in mice skin: implications for nonâ€allergic angioâ€oedema. British Journal of Pharmacology, 2018, 175, 1607-1620.	2.7	7
991	Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction. ESC Heart Failure, 2018, 5, 211-221.	1.4	36
993	Treatment of Heart Failure with Preserved Ejection Fraction. Advances in Experimental Medicine and Biology, 2018, 1067, 67-87.	0.8	39
994	Combined Angiotensin Receptorâ€“Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. Journal of the American Heart Association, 2018, 7, .	1.6	38
995	Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. American Heart Journal, 2018, 199, 176-177.	1.2	0
996	Hypertension Canadaâ€™s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
997	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Canadian Journal of Cardiology, 2018, 34, 632-643.	0.8	56

#	Article	IF	Citations
998	Heart failure and inhibition of renin-angiotensin-aldosteron system. Cor Et Vasa, 2018, 60, e263-e273.	0.1	2
999	Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor. Indian Heart Journal, 2018, 70, S102-S110.	0.2	22
1001	Cardiac risk in non-cardiac surgery: A review. Trends in Anaesthesia and Critical Care, 2018, 21, 6-12.	0.4	1
1002	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 547-554.	5.5	124
1003	Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 45.	0.4	5
1004	Cardiac cachexia: addressing the challenge. British Journal of Cardiac Nursing, 2018, 13, 30-34.	0.0	1
1005	DASH Score and Subsequent Risk of Coronary Artery Disease: The Findings From Million Veteran Program. Journal of the American Heart Association, 2018, 7, .	1.6	32
1006	Treatment of Diabetes in People With Heart Failure. Canadian Journal of Diabetes, 2018, 42, S196-S200.	0.4	24
1007	Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery. Diabetes, Obesity and Metabolism, 2018, 20, 2029-2033.	2.2	30
1008	Serious adverse drug reactions with sacubitril/valsartan EntrestoÂ®: a French pharmacovigilance survey. European Journal of Clinical Pharmacology, 2018, 74, 983-984.	0.8	6
1009	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. Current Cardiology Reports, 2018, 20, 39.	1.3	27
1010	Real-world management of heart failure in the Netherlands. Netherlands Heart Journal, 2018, 26, 240-241.	0.3	0
1011	Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups. Scandinavian Cardiovascular Journal, 2018, 52, 205-210.	0.4	8
1012	Improvement in clinical outcomes of patients with heart failure and active cocaine use after Î²â€blocker therapy. Clinical Cardiology, 2018, 41, 465-469.	0.7	6
1013	Novel heart failure biomarkers: why do we fail to exploit their potential?. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 246-263.	2.7	67
1014	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498.	3.0	84
1015	Augmentation of glucagonâ€like peptideâ€1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. European Journal of Heart Failure, 2018, 20, 973-977.	2.9	26
1016	Costâ€Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States. Pharmacotherapy, 2018, 38, 520-530.	1.2	21

#	Article	IF	Citations
1017	Heart Failure and Pulmonary Hypertension. , 2018, , 193-227.		1
1018	A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan. Canadian Journal of Cardiology, 2018, 34, 1089.e1-1089.e3.	0.8	3
1019	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. Clinical Medicine, 2018, 18, 138-145.	0.8	11
1020	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. International Journal of Cardiology, 2018, 260, 82-87.	0.8	20
1021	Prevalence of P wave dispersion and interatrial block in patients with systolic heart failure and their relationship with functional status, hospitalization and one year mortality. Egyptian Heart Journal, 2018, 70, 181-187.	0.4	11
1022	Catheter ablation of atrial fibrillation in heart failure with reduced ejection fraction. Journal of Cardiovascular Electrophysiology, 2018, 29, 1049-1058.	0.8	11
1023	Leptin-Aldosterone-Neprilysin Axis. Circulation, 2018, 137, 1614-1631.	1.6	163
1024	New Dimensions in Palliative Care Cardiology. Canadian Journal of Cardiology, 2018, 34, 914-924.	0.8	10
1025	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	1.9	272
1026	Balancing decisions in mechanical circulatory support: It's all in the timing. Journal of Heart and Lung Transplantation, 2018, 37, 694-695.	0.3	0
1027	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. Circulation: Heart Failure, 2018, 11, e004745.	1.6	55
1028	Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgraduate Medicine, 2018, 130, 308-316.	0.9	18
1029	Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. Circulation: Heart Failure, 2018, 11, e004302.	1.6	68
1030	Application and impact of run-in studies. Journal of General Internal Medicine, 2018, 33, 759-763.	1.3	17
1031	From Molecules to Markets. Circulation: Heart Failure, 2018, 11, e004815.	1.6	3
1032	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). American Heart Journal, 2018, 199, 130-136.	1.2	71
1033	CABG or PCI for Diabetic Patients WithÂLeft Ventricular Dysfunction. Journal of the American College of Cardiology, 2018, 71, 828-831.	1.2	1
1034	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. International Journal of Cardiology, 2018, 254, 215-221.	0.8	19

#	Article	IF	Citations
1035	Predicting the future after acute myocardial infarction: A gaze into the crystal ball of gene expression profile. International Journal of Cardiology, 2018, 254, 47-48.	0.8	1
1036	B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1500-1506.	0.6	2
1037	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. European Heart Journal, 2018, 39, 2255-2262.	1.0	45
1038	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	0.8	41
1039	Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney. European Journal of Pharmacology, 2018, 824, 128-132.	1.7	6
1040	Natriuretic peptides. D'oÃ¹ venons-nous? Que sommes-nous? OÃ¹ allons-nous?. International Journal of Cardiology, 2018, 254, 256-257.	0.8	2
1041	Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?. Cardiology in Review, 2018, 26, 196-200.	0.6	5
1042	The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Current Cardiology Reports, 2018, 20, 5.	1.3	39
1043	The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure. Heart Failure Reviews, 2018, 23, 291-302.	1.7	27
1044	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	2.9	118
1045	Drug treatment of heart failure in the elderly. Herz, 2018, 43, 207-213.	0.4	16
1046	The clinical relevance of drugâ€“drug interaction between co-trimoxazole and sacubitril/valsartan treatment in a heart failure patient: a case report and overview of mechanisms and management in clinical practice. Clinical Research in Cardiology, 2018, 107, 524-526.	1.5	2
1047	Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 351-355.	1.0	10
1048	Ventricular Arrhythmic Storm after Initiating Sacubitril/Valsartan. Cardiology, 2018, 139, 119-123.	0.6	14
1049	Eligibility of sacubitrilâ€“valsartan in a realâ€world heart failure population: a communityâ€based singleâ€centre study. ESC Heart Failure, 2018, 5, 337-343.	1.4	48
1050	Evolving Role of Natriuretic Peptides from Diagnostic Tool to Therapeutic Modality. Advances in Experimental Medicine and Biology, 2018, 1067, 109-131.	0.8	11
1051	Reninâ€“angiotensin system inhibitionâ€”it's been a long but fruitful journey. European Journal of Heart Failure, 2018, 20, 687-688.	2.9	0
1052	Heart Failure. Primary Care - Clinics in Office Practice, 2018, 45, 63-79.	0.7	1

#	Article	IF	Citations
1053	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2018, 20, 760-768.	2.9	62
1054	Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure. Heart Failure Reviews, 2018, 23, 507-516.	1.7	4
1055	Monitoring Biomarkers in Patients Receiving Neprilysin Inhibitors. Current Emergency and Hospital Medicine Reports, 2018, 6, 8-16.	0.6	4
1056	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. American Heart Journal, 2018, 200, 134-140.	1.2	8
1057	Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling. Circulation Research, 2018, 122, 319-336.	2.0	81
1058	Who needs an implantable cardioverterâ€defibrillator? Controversies and opportunities after DANISH. European Journal of Heart Failure, 2018, 20, 413-416.	2.9	10
1059	Improving Heart Failure Therapeutics Development in the United States. Journal of the American College of Cardiology, 2018, 71, 443-453.	1.2	40
1061	Effect of glucose-lowering therapies on heart failure. Nature Reviews Cardiology, 2018, 15, 282-291.	6.1	45
1062	Can available mathematical models predict serum digoxin levels in Thai patients?. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 377-384.	0.7	2
1063	Innovative spectrophotometric methods for simultaneous estimation of the novel two-drug combination: Sacubitril/Valsartan through two manipulation approaches and a comparative statistical study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 193, 365-374.	2.0	13
1064	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 2018, 104, 1006-1013.	1.2	50
1065	Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Failure, 2018, 5, 249-256.	1.4	20
1066	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. European Journal of Heart Failure, 2018, 20, 199-215.	2.9	128
1067	Profound Vasoplegia During Sacubitril/Valsartan Treatment After Heart Transplantation. Canadian Journal of Cardiology, 2018, 34, 343.e5-343.e7.	0.8	14
1068	Vitamin D as a Modifiable Risk Factor for Incident Heart Failure in Atrial Fibrillation. JACC: Heart Failure, 2018, 6, 85-86.	1.9	4
1069	Paradigms and PARAGON-HF. JACC: Heart Failure, 2018, 6, 86.	1.9	1
1072	A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. Clinical Pharmacology and Therapeutics, 2018, 104, 546-552.	2.3	29
1073	Chronic Management of Patients with Left Ventricular Assist Devices. , 2018, , 145-159.		0

#	Article	IF	Citations
1075	Sacubitril/valsartan instead of reninâ€angiotensin system inhibition alone: A step forward in resistant hypertension. Journal of Clinical Hypertension, 2018, 20, 65-68.	1.0	9
1076	Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management. European Journal of Heart Failure, 2018, 20, 433-435.	2.9	16
1077	<scp>PARADIGM</scp>â€<scp>HF</scp> Trial: Secondary Analyses Address Unanswered Questions. Pharmacotherapy, 2018, 38, 284-298.	1.2	9
1078	2017 ACC Expert Consensus Decision Pathway for Optimization of HeartÂFailure Treatment: Answers to 10ÂPivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	1.2	235
1079	Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal, 2018, 198, 145-151.	1.2	60
1080	Effect of the angiotensin receptorâ€“neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. British Journal of Clinical Pharmacology, 2018, 84, 926-936.	1.1	13
1081	LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. Journal of Cardiac Failure, 2018, 24, 266-275.	0.7	71
1082	Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?. Journal of Cardiac Failure, 2018, 24, 109-111.	0.7	5
1083	Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study. European Journal of Internal Medicine, 2018, 51, 53-60.	1.0	7
1084	Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?. Clinical Pharmacology and Therapeutics, 2018, 103, 802-814.	2.3	6
1085	Neurohormonal Imbalance: A Neglected Problemâ€”And Potential Therapeutic Targetâ€”In Acute Heart Failure. Current Problems in Cardiology, 2018, 43, 294-304.	1.1	9
1086	Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. American Heart Journal, 2018, 197, 43-52.	1.2	27
1087	Patient experience in clinical trials: results of a survey. European Journal of Heart Failure, 2018, 20, 612-614.	2.9	2
1088	Negotiating renal dysfunction when treating patients with heart failure. Expert Review of Cardiovascular Therapy, 2018, 16, 113-122.	0.6	7
1089	Sudden cardiac death following admission for acute heart failure: adding insult to injury. European Journal of Heart Failure, 2018, 20, 533-535.	2.9	3
1090	Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database). American Journal of Cardiology, 2018, 121, 725-730.	0.7	9
1091	Clinically relevant results from cardiovascular outcome trials. Nature Reviews Endocrinology, 2018, 14, 67-68.	4.3	1
1092	Recent advances in heart failure. Current Opinion in Cardiology, 2018, 33, 249-256.	0.8	15

#	Article	IF	Citations
1093	The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin. European Heart Journal, 2018, 39, 1794-1798.	1.0	27
1094	Chronic heart failure - Impact of the condition on patients and the healthcare system in the Czech Republic: A retrospective cost-of-illness analysis. Cor Et Vasa, 2018, 60, e224-e233.	0.1	4
1095	Nocturnal Hypertension. Hypertension, 2018, 71, 997-1009.	1.3	178
1096	Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. BMJ: British Medical Journal, 2018, 360, j5748.	2.4	62
1097	Whatâ€™s new in cardiorenal syndrome?. Intensive Care Medicine, 2018, 44, 908-910.	3.9	6
1098	Ventricular arrhythmias in nonischemic cardiomyopathy. Journal of Arrhythmia, 2018, 34, 336-346.	0.5	14
1099	The Effects of Tranilast on Cardiomyopathy in Becker Muscular Dystrophy Requires Profound Cardiac and Neurologic Evaluations. Internal Medicine, 2018, 57, 2099-2099.	0.3	1
1100	Future pharmacological therapy in hypertension. Current Opinion in Cardiology, 2018, 33, 408-415.	0.8	12
1101	A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. Pharmacogenomics, 2018, 19, 599-612.	0.6	10
1103	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. Postgraduate Medicine, 2018, 130, 299-307.	0.9	15
1105	Expanded algorithm for managing patients with acute decompensated heart failure. Heart Failure Reviews, 2018, 23, 597-607.	1.7	6
1106	Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 135-139.	1.0	0
1107	Combination Therapy of Renin Angiotensin System Inhibitors and Î²-Blockers in Patients with Heart Failure. Advances in Experimental Medicine and Biology, 2018, 1067, 17-30.	0.8	7
1108	Cardiovascular and Metabolic Heterogeneity of Obesity. Circulation, 2018, 137, 1391-1406.	1.6	493
1109	Neprilysin Inhibition: What We Know and What We Don't Know. Journal of Cardiac Failure, 2018, 24, 276-277.	0.7	2
1110	Recent major advances in cardiovascular pharmacotherapy. European Journal of Clinical Pharmacology, 2018, 74, 853-862.	0.8	4
1111	Innovation in Heart Failure Treatment. JACC: Heart Failure, 2018, 6, 401-409.	1.9	34
1112	Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 28.	0.4	13

#	Article	IF	Citations
1113	Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. Advances in Clinical Chemistry, 2018, 85, 1-30.	1.8	25
1114	Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. International Journal of Cardiology, 2018, 261, 130-133.	0.8	6
1115	Cardiac unloading by LVAD support differentially influences components of the cGMPâ€“PKG signaling pathway in ischemic and dilated cardiomyopathy. Heart and Vessels, 2018, 33, 948-957.	0.5	7
1116	The Current Focus of Heart Failure Clinical Trials. Journal of Cardiac Failure, 2018, 24, 321-329.	0.7	4
1117	Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines. Drugs, 2018, 78, 567-576.	4.9	7
1118	Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. International Journal of Cardiology, 2018, 258, 192-198.	0.8	48
1119	New Innovations in Treatment and Monitoring of Heart Failure With Guidelines on the Use of Sacubitril/Valsartan and Ivabradine. American Journal of Therapeutics, 2018, 25, e92-e103.	0.5	0
1120	Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor. American Journal of Therapeutics, 2018, 25, e508-e509.	0.5	3
1121	Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition. Xenobiotica, 2018, 48, 300-313.	0.5	24
1122	Evaluation of Pharmacokinetic and Pharmacodynamic Drugâ€“Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mildâ€toâ€Moderate Hypertension. Clinical Pharmacology and Therapeutics, 2018, 103, 468-476.	2.3	5
1124	Should All Heart Failure Patients Be Treated With Sacubitril/Valsartan?. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 98-98.	1.0	0
1125	Advances in Cardiovascular Health in Women over the Past Decade: Guideline Recommendations for Practice. Journal of Women's Health, 2018, 27, 128-139.	1.5	11
1126	Emerging Therapies for Congestive Heart Failure. Clinical Pharmacology and Therapeutics, 2018, 103, 77-87.	2.3	8
1127	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239
1128	Neurohormonal targets in the treatment of pediatric heart failure. Progress in Pediatric Cardiology, 2018, 49, 2-8.	0.2	0
1129	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. European Journal of Cardio-thoracic Surgery, 2018, 53, 5-33.	0.6	292
1130	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641.	2.9	33
1131	What will be the impact of sacubitril/valsartan in clinical practice?. Journal of Cardiovascular Medicine, 2018, 19, e88-e90.	0.6	2

#	Article	IF	Citations
1132	Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. Journal of Medical Economics, 2018, 21, 174-181.	1.0	24
1134	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the EfficacyÂand Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104.	1.9	141
1135	Use of sacubitril/valsartan in acute decompensated heart failure: a case report. ESC Heart Failure, 2018, 5, 184-188.	1.4	7
1136	Inverse Association Between Myocardial B-Type Natriuretic Peptide Release and Functional Capacity in Healthy Humans. Heart Lung and Circulation, 2018, 27, 995-1003.	0.2	3
1137	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	1.4	21
1138	Barcelona Bioâ€HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. European Journal of Heart Failure, 2018, 20, 938-940.	2.9	20
1139	The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure â€“ an Update. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 9-18.	1.2	17
1140	Ventricular Tachycardia in Patients With Dilated Cardiomyopathy. , 2018, , 820-828.		0
1141	Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death. , 2018, , 1084-1091.		0
1142	Response by Dr Packer to the Letter of Dr Blankfield. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 99-100.	1.0	0
1143	Extending survival by reducing sudden death with implantable cardioverterâ€defibrillators: a challenging clinical issue in nonâ€ischaemic and ischaemic cardiomyopathies. European Journal of Heart Failure, 2018, 20, 420-426.	2.9	9
1144	Transition from angiotensin-converting enzyme inhibitor/angiotensin-II-receptor-blocker to sacubitril/valsartan in chronic heart failure patients: Initial experiences in clinical practice. Cor Et Vasa, 2018, 60, e209-e214.	0.1	1
1145	Newer hormonal pharmacotherapies for heart failure. Expert Review of Endocrinology and Metabolism, 2018, 13, 35-49.	1.2	1
1146	Natriuretic Peptide Deficiencyâ€"When There Is Too Little of a Good Thing. JAMA Cardiology, 2018, 3, 7.	3.0	20
1147	Predicting Survival in Patients With Heart Failure With an Implantable Cardioverter Defibrillator: The Heart Failure Meta-Score. Journal of Cardiac Failure, 2018, 24, 735-745.	0.7	17
1148	Early benefits of sacubitril/valsartan: Hype or hope. International Journal of Cardiology, 2018, 252, 140-141.	0.8	1
1149	Natriuretic Peptides in Heart Failure. Heart Failure Clinics, 2018, 14, 13-25.	1.0	88
1150	Do we still need ICDs if we have ARNi?. Heart Rhythm, 2018, 15, 403-404.	0.3	4

#	Article	IF	Citations
1151	Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension. Hypertension, 2018, 71, 70-77.	1.3	29
1152	N -Terminal B-type Natriuretic Peptide in Heart Failure. Heart Failure Clinics, 2018, 14, 27-39.	1.0	45
1153	Role of the sodiumâ€hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 800-811.	2.2	10
1155	Rationale and design of <scp>TRANSITION</scp>: a randomized trial of preâ€discharge vs. postâ€discharge initiation of sacubitril/valsartan. ESC Heart Failure, 2018, 5, 327-336.	1.4	42
1156	Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study. International Journal of Cardiology, 2018, 252, 136-139.	0.8	44
1157	Management protocols for chronic heart failure in India. Indian Heart Journal, 2018, 70, 105-127.	0.2	27
1158	The Diuretic Potential of Sacubitril/Valsartan: A Tale of 2 Patients. Journal of Cardiovascular Nursing, 2018, 33, 104-110.	0.6	8
1159	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	2.9	35
1160	Contribution of cardiac and extraâ€cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 2018, 20, 504-510.	2.9	52
1161	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 2018, 104, 144-150.	1.2	61
1162	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. Clinical Chemistry, 2018, 64, 597-608.	1.5	52
1163	Novel avenues for drug discovery in diabetic kidney disease. Expert Opinion on Drug Discovery, 2018, 13, 65-74.	2.5	15
1164	Impact of systolic blood pressure on the safety and tolerability of initiating and upâ€titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 2018, 20, 491-500.	2.9	59
1165	Diagnosis and Treatment of Heart Failure for Inpatient Providers. , 2018, , 3-21.		2
1166	Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm, 2018, 15, 395-402.	0.3	138
1167	Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart, 2018, 104, 230-236.	1.2	26
1168	NICE: treating symptomatic chronic heart failure with reduced ejection fraction. British Journal of Cardiac Nursing, 2018, 13, 436-437.	0.0	0
1169	Real-Word Evidence of Improvement in Quality-of-Life Score, New York Heart Association Class and Tolerability of Valsartan/Sacubitril in Patients with Heart Failure. Heart Lung and Circulation, 2018, 27, S124.	0.2	0

#	Article	IF	Citations
1170	APPROACHES TO PERSONALIZED THERAPY. Rational Pharmacotherapy in Cardiology, 2018, 14, 418-424.	0.3	2
1171	Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?. Cardiovascular Diagnosis and Therapy, 2018, 8, 549-551.	0.7	0
1172	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. Journal of Thoracic Disease, 2018, 10, S4282-S4295.	0.6	69
1173	Myocardial Cell Signaling During the Transition to Heart Failure. , 2018, 9, 75-125.		12
1174	EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION. Rational Pharmacotherapy in Cardiology, 2018, 14, 210-216.	0.3	2
1175	Sacubitril/valsartan: a cardiovascular drug with pluripotential actions. Cardiovascular Diagnosis and Therapy, 2018, 8, 543-548.	0.7	5
1176	Refractory Angina. , 2018, , 412-431.		3
1177	Left and Right Ventricular Remodeling. , 2018, , 171-185.		1
1178	OBSOLETE: Ischemic Cardiomyopathy. , 2018, , .		0
1179	Advanced heart failure: Where do we stand?. Hellenic Journal of Cardiology, 2018, 59, 303-305.	0.4	9
1180	A new educational program in heart failure drug development. Journal of Cardiovascular Medicine, 2018, 19, 411-421.	0.6	8
1181	Bin-CE: A comprehensive web application to decide upon the best set of outcomes to be combined in a binary composite endpoint. PLoS ONE, 2018, 13, e0209000.	1.1	2
1182	Accuracy of B-natriuretic peptide for the diagnosis of decompensated heart failure in muscular dystrophies patients with chronic respiratory failure. Neurology International, 2018, 10, 7917.	1.3	3
1183	Effects of rhBNP on Elderly Emergency Patients with Acute Heart Failure. Archives of Medicine, 2018, 10, .	0.2	0
1184	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S72-S81.	1.0	77
1185	Medicamenteuze behandeling van hartfalen. Bijblijven (Amsterdam, Netherlands), 2018, 34, 465-475.	0.0	0
1186	New trends in drug treatment of heart failure in old age. Geriatric Care, 2018, 4, .	0.2	1
1189	Atrial Natriuretic Factor and the Family of Natriuretic Peptides. , 2018, , 569-580.		0

#	Article	IF	Citations
1190	Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment. Drugs in Context, 2018, 7, 1-7.	1.0	10
1191	OBSOLETE: Practical Guide to Evidence-Based Management of Heart Failure in the Outpatient Setting. , 2018, , .		0
1192	OBSOLETE: Management and Care of Older Cardiac Patients. , 2018, , .		0
1193	OBSOLETE: Left and Right Ventricular Remodeling. , 2018, , .		0
1194	OBSOLETE: Biomarkers in Heart Failure, Use of. , 2018, , .		0
1195	OBSOLETE: Neurohormonal Blockade. , 2018, , .		0
1196	Rare Case of Advanced Non-Tropical, Isolated Right Ventricular Endomyocardial Fibrosis. Heart Lung and Circulation, 2018, 27, S124.	0.2	0
1198	Cardiac Magnetic Resonance Imaging for Long-Term Prognosis in Heart Failure. Circulation: Cardiovascular Imaging, 2018, 11, e008264.	1.3	2
1199	Sacubitril/Valsartan Averts AdverseÂPost-Infarction Ventricular RemodelingÂand Preserves SystolicÂFunction in Rabbits. Journal of the American College of Cardiology, 2018, 72, 2342-2356.	1.2	63
1200	Angiotensin Receptor-Neprilysin Inhibitors Emerge as Potential Treatment for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 2357-2359.	1.2	4
1201	Who Benefits From a Defibrillatorâ€"Balancing the Risk of Sudden Versus Non-sudden Death. Current Heart Failure Reports, 2018, 15, 376-389.	1.3	5
1202	Spanish Implantable Cardioverter-defibrillator Registry. 14th Official Report of the Spanish Society of Cardiology Electrophysiology and Arrhythmias Section (2017). Revista Espanola De Cardiologia (English Ed), 2018, 71, 1047-1058.	0.4	3
1203	Echocardiography in Heart Failure. , 2018, , 126-141.		0
1204	Renal Denervation Halts Left Ventricular Remodeling and Dysfunction in HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 2622-2624.	1.2	6
1205	Coronary Microvascular Disease Pathogenic Mechanisms and TherapeuticÂOptions. Journal of the American College of Cardiology, 2018, 72, 2625-2641.	1.2	405
1207	Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure. JAMA Cardiology, 2018, 3, 1232.	3.0	12
1208	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226.	3.0	38
1209	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 1160.	3.0	57

#	Article	IF	Citations
1210	Hyperkalaemia in Heart Failureâ€"Pathophysiology, Implications and Therapeutic Perspectives. Current Heart Failure Reports, 2018, 15, 390-397.	1.3	10
1212	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. IJC Heart and Vasculature, 2018, 21, 80-86.	0.6	4
1213	PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS. Rational Pharmacotherapy in Cardiology, 2018, 14, 167-175.	0.3	2
1214	Registro EspaÃ±ol de Desfibrilador AutomÃ¡tico Implantable. XIV Informe Oficial de la SecciÃ³n de ElectrofisiologÃa y Arritmias de la Sociedad EspaÃ±ola de CardiologÃa (2017). Revista Espanola De Cardiologia, 2018, 71, 1047-1058.	0.6	16
1215	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. Frontiers in Cardiovascular Medicine, 2018, 5, 178.	1.1	21
1216	Innovative Strategies in Heart Failure: Present and Future. Archives of Medical Research, 2018, 49, 558-567.	1.5	2
1218	Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. Journal of Comparative Effectiveness Research, 2018, 7, 1073-1082.	0.6	1
1219	GLPâ€1 Is a Coronary Artery Vasodilator in Humans. Journal of the American Heart Association, 2018, 7, e010321.	1.6	16
1220	Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, doubleâ€blind, 8â€week study. Journal of Clinical Hypertension, 2019, 21, 67-76.	1.0	39
1221	Neprilysin Inhibitors and Bradykinin. Frontiers in Medicine, 2018, 5, 257.	1.2	51
1222	Post hoc analyses of SHIFT and PARADIGMâ€HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: â€œSafety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trialâ€•by Bocchi et al.. ESC Heart Failure, 2018, 5, 1069-1071.	1.4	15
1223	Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?. Cardiovascular Drugs and Therapy, 2018, 32, 633-635.	1.3	10
1224	Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients. Journal of Cardiovascular Medicine, 2018, 19, 597-605.	0.6	14
1225	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.3	2,129
1226	Sex Differences in the Management of Advanced Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 88.	0.4	14
1227	Sacubitril/Valsartan. Heart Failure Clinics, 2018, 14, 479-491.	1.0	1
1228	Neprilysin inhibition promotes corneal wound healing. Scientific Reports, 2018, 8, 14385.	1.6	5
1229	PHARMACOTHERAPY OF HEART FAILURE. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 78.	0.3	2

#	Article	IF	Citations
1230	In-Hospital Initiation of Guideline-Directed Heart Failure Pharmacotherapy to Improve Long-Term Patient Adherence and Outcomes. Critical Care Nurse, 2018, 38, 16-24.	0.5	2
1231	Treatment of heart failure with preserved ejection fraction. Monaldi Archives for Chest Disease, 2018, 88, 951.	0.3	0
1232	Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus. European Journal of Heart Failure, 2018, 20, 1649-1652.	2.9	11
1233	Cardiovascular disease and COPD: dangerous liaisons?. European Respiratory Review, 2018, 27, 180057.	3.0	187
1234	Management of advanced heart failure: a review. Expert Review of Cardiovascular Therapy, 2018, 16, 775-794.	0.6	6
1235	Cognitive Deficit in Heart Failure Patients. JACC: Heart Failure, 2018, 6, 888-889.	1.9	0
1236	Extracorporeal Isolated Ultrafiltration for Management of Congestion in Heart Failure and Cardiorenal Syndrome. Advances in Chronic Kidney Disease, 2018, 25, 434-442.	0.6	4
1237	Home-Delivered Meals Postdischarge From Heart Failure Hospitalization. Circulation: Heart Failure, 2018, 11, e004886.	1.6	81
1238	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
1239	Treatment of heart failure in the elderly: Which drugs are essential and which should be avoided. Monaldi Archives for Chest Disease, 2018, 88, 948.	0.3	0
1240	Echo- and B-Type Natriuretic Peptide-Guided Follow-Up versus Symptom-Guided Follow-Up: Comparison of the Outcome in Ambulatory Heart Failure Patients. Cardiology Research and Practice, 2018, 2018, 1-8.	0.5	13
1241	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. Circulation: Heart Failure, 2018, 11, e005400.	1.6	36
1242	Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease. Circulation, 2018, 138, 1515-1518.	1.6	9
1243	The expanding role of implantable devices to monitor heart failure and pulmonary hypertension. Nature Reviews Cardiology, 2018, 15, 770-779.	6.1	22
1244	Practical Guide to Evidence-Based Management of Heart Failure in the Outpatient Setting. , 2018, , 125-142.		0
1245	Managing the Economic Challenges in the Treatment of Heart Failure. Progress in Cardiovascular Diseases, 2018, 61, 476-483.	1.6	4
1246	A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. Journal of Cardiac Failure, 2018, 24, 773-782.	0.7	18
1247	Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ: British Medical Journal, 2018, 363, k4209.	2.4	138

#	Article	IF	Citations
1248	Whatâ€™s new in heart failure therapy 2018?â€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 921-930.	0.5	8
1249	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation, 2018, 138, 1039-1053.	1.6	24
1250	Troponinâ€ levels as a potential prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction: Who will benefit most?. Clinical Cardiology, 2018, 41, 1548-1554.	0.7	6
1251	Growth differentiation factorâ€15 reveals the dark side of heart failure. European Journal of Heart Failure, 2018, 20, 1710-1712.	2.9	2
1252	Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs in Context, 2018, 7, 1-10.	1.0	41
1253	Combined angiotensin receptor and neprilysin inhibition therapy for heart failure. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 35-37.	0.1	0
1254	Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure. Current Heart Failure Reports, 2018, 15, 368-375.	1.3	12
1256	PARALLEL-HFâ€€â€• A Paradigm Shift for Heart Failure Treatment in Japan? â€•. Circulation Journal, 2018, 82, 2479-2480.	0.7	1
1257	Sacubitril/valsartan: from a large clinical trial to clinical practice. Journal of Cardiovascular Medicine, 2018, 19, 473-479.	0.6	8
1258	Chronic heart failure: epidemiology, investigation and management. Medicine, 2018, 46, 594-600.	0.2	7
1259	Reduced ejection fraction heart failure – new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments. Clinical Interventions in Aging, 2018, Volume 13, 651-656.	1.3	12
1260	Gender Differences in Ischemic Cardiomyopathy. Current Atherosclerosis Reports, 2018, 20, 50.	2.0	21
1261	Sex differences in ischemic heart disease and heart failure biomarkers. Biology of Sex Differences, 2018, 9, 43.	1.8	35
1262	Growth differentiation factorâ€15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2018, 20, 1701-1709.	2.9	56
1263	Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group?. IJC Heart and Vasculature, 2018, 21, 1-6.	0.6	18
1264	It Is Not Taboo: Addressing Sexual Function in Adults with Congenital Heart Disease. Current Cardiology Reports, 2018, 20, 93.	1.3	9
1265	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics, 2018, 36, 1463-1473.	1.7	14
1266	Resistant Hypertension. , 2018, , 398-408.		1

#	Article	IF	Citations
1267	Targeting Calpain for Heart FailureÂTherapy. JACC Basic To Translational Science, 2018, 3, 503-517.	1.9	41
1268	GPCR-autoantibodies in chronic heart failure. Frontiers in Bioscience - Landmark, 2018, 23, 2065-2081.	3.0	13
1269	Possible Enzymatic Downregulation of the Natriuretic Peptide System in Patients with Reduced Systolic Function and Heart Failure: A Pilot Study. BioMed Research International, 2018, 2018, 1-6.	0.9	22
1270	Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1426-1428.	2.2	1
1271	Novel ¹⁸F-Labeled PET Imaging Agent FV45 Targeting the Reninâ€“Angiotensin System. ACS Omega, 2018, 3, 10460-10470.	1.6	11
1272	The Barcelona Bio-HF Calculator. JACC: Heart Failure, 2018, 6, 808-810.	1.9	4
1273	Drugs for heart failure and arrhythmias. Medicine, 2018, 46, 652-657.	0.2	0
1274	Biomarkers and Heart Failure. , 0, , .		0
1275	Comments on GUIDE-IT, a randomized study of natriuretic peptide-guided therapy in high-risk patients with heart failure and reduced ejection fraction. Journal of Laboratory and Precision Medicine, 2018, 3, 10-10.	1.1	0
1276	The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea. Clinical Drug Investigation, 2018, 38, 727-736.	1.1	7
1277	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial. JACC: Heart Failure, 2018, 6, 517-526.	1.9	59
1278	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	1.9	94
1279	Health Status Disparities by Sex, Race/Ethnicity,Âand Socioeconomic Status in Outpatients With Heart Failure. JACC: Heart Failure, 2018, 6, 465-473.	1.9	65
1280	Excessive Adiposity and Metabolic Dysfunction Relate to Reduced Natriuretic Peptide During RAAS Activation in HIV. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1558-1565.	1.8	10
1281	Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. International Journal of Cardiology, 2018, 264, 118-123.	0.8	27
1282	The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovascular Therapeutics, 2018, 36, e12435.	1.1	132
1283	Sacubitril/valsartan: Can haemodynamic monitoring help with up-take?. International Journal of Cardiology, 2018, 271, 202-203.	0.8	0
1284	Sacubitril-valsartan in the real world: From theory to clinical practice. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 497-498.	0.2	2

#	Article	IF	Citations
1285	Pro: continuous positive airway pressure and cardiovascular prevention. European Respiratory Journal, 2018, 51, 1702400.	3.1	25
1286	Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes. Journal of the American Heart Association, 2018, 7, .	1.6	46
1287	Hyperkalemia in Heart Failure: Probably Not Oâ€œKâ€• Journal of the American Heart Association, 2018, 7, .	1.6	10
1288	Current drug therapy for heart failure with reduced ejection fraction. Herz, 2018, 43, 383-391.	0.4	7
1289	An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction. Advances in Therapy, 2018, 35, 785-795.	1.3	28
1290	Highlights from the British Society for Heart Failure 20th Annual Autumn Meeting: three decades of heart failure. Future Cardiology, 2018, 14, 203-206.	0.5	0
1291	Is the PARADIGM-HF cohort representative of the real-world heart failure patient population?. Revista Portuguesa De Cardiologia, 2018, 37, 491-496.	0.2	14
1292	Uso do Sacubitril/Valsartan no Â«mundo realÂ»: da teoria Ã prÃ¡tica clÃnica. Revista Portuguesa De Cardiologia, 2018, 37, 497-498.	0.2	3
1293	Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them. European Journal of Heart Failure, 2018, 20, 1335-1337.	2.9	2
1294	Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. American Journal of Cardiovascular Drugs, 2018, 18, 473-482.	1.0	7
1295	Heart Failure: Influence of Drug Interventions on Vessels. , 2018, , 575-588.		0
1296	Implantable cardioverterâ€defibrillators in heart failure patients with reduced ejection fraction and diabetes. European Journal of Heart Failure, 2018, 20, 1031-1038.	2.9	24
1297	Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. American Journal of Cardiovascular Drugs, 2018, 18, 333-345.	1.0	12
1299	Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA. Europace, 2018, 20, 1882-1897.	0.7	27
1300	Biomarkers in Heart Failure, Use of. , 2018, , 293-302.		0
1301	Catheter ablation of atrial fibrillation with heart failure: An updated meta-analysis of randomized trials. International Journal of Cardiology, 2018, 269, 170-173.	0.8	23
1302	Chronic Heart Failure. Deutsches Ärzteblatt International, 2018, 115, 124-130.	0.6	22
1303	Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk. Hypertension, 2018, 72, 270-276.	1.3	51

#	Article	IF	Citations
1304	Ischemic Cardiomyopathy. , 2018, , 145-154.		1
1305	Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone. Diabetes, 2018, 67, 1616-1626.	0.3	24
1306	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2018, 6, CD012721.	1.5	56
1307	Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors. Current Heart Failure Reports, 2018, 15, 270-279.	1.3	0
1308	Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP. Nature Communications, 2018, 9, 2446.	5.8	52
1309	Is the PARADIGM-HF cohort representative of the real-world heart failure patient population?. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 491-496.	0.2	4
1310	Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock. Case Reports in Cardiology, 2018, 2018, 1-3.	0.1	4
1311	Evidence-Based Approach in Translational Dental Research. , 2018, , 81-101.		5
1313	Heart Failure in Adult Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2018, , .	0.2	0
1314	Combination drug therapy in heart failure: greater than the sum of its parts. European Journal of Heart Failure, 2018, 20, 1323-1325.	2.9	3
1315	Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. American Journal of Cardiovascular Drugs, 2018, 18, 405-413.	1.0	24
1316	Use of Vasodilators in Heart Failure. , 2018, , 523-537.		0
1317	Outpatient Monitoring and Self-Care. , 2018, , 755-772.		7
1318	The Cardiac Natriuretic Peptide System. , 2018, , 163-171.		1
1319	Renal effects of sacubitril/valsartan in patients with diabetes. Lancet Diabetes and Endocrinology,the, 2018, 6, 519-521.	5.5	4
1320	Sex, drugs, and heart failure: a sexâ€sensitive review of the evidence base behind current heart failure clinical guidelines. ESC Heart Failure, 2018, 5, 745-754.	1.4	36
1321	Heart Failure. Annals of Internal Medicine, 2018, 168, ITC81-ITC96.	2.0	11
1322	Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. BMJ Open, 2018, 8, e021108.	0.8	32

#	Article	IF	Citations
1323	Cardiorenal Syndromes. , 2018, , 33-51.		0
1324	New antihypertensive medications and clinical implications. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2018, 32, 223-235.	1.7	7
1325	The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports. BMC Cardiovascular Disorders, 2018, 18, 155.	0.7	5
1326	Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. International Journal of Cardiology, 2018, 271, 169-173.	0.8	19
1327	The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. European Heart Journal, 2018, 39, 3464-3471.	1.0	14
1328	Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes. American Journal of Physiology - Renal Physiology, 2018, 315, F263-F274.	1.3	47
1329	Heart Failure and Frailty in the Community-Living Elderly Population: What the UFO Study Will Tell Us. Frontiers in Physiology, 2018, 9, 347.	1.3	5
1330	Commentary: Central-acting therapeutics alleviate respiratory weakness caused by heart failureâ€“induced ventilatory overdrive. Frontiers in Physiology, 2018, 9, 554.	1.3	1
1331	Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review. Frontiers in Physiology, 2018, 9, 692.	1.3	49
1332	Renin Angiotensin Aldosterone System Blockers. , 2018, , 230-241.		1
1333	Preparation, Characterization, and Formulation Development of Drugâ€“Drug Protic Ionic Liquids of Diphenhydramine with Ibuprofen and Naproxen. Molecular Pharmaceutics, 2018, 15, 4190-4201.	2.3	40
1334	Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obesity Reviews, 2018, 19, 1189-1204.	3.1	44
1335	A medicine for tall, white, blond-haired and blue-eyed, middle-aged, physically active, rich males?. European Journal of Preventive Cardiology, 2018, 25, 1152-1155.	0.8	2
1336	Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fractionã€€â€• Baseline Characteristics and Treatment of PARALLEL-HF Trial â€•. Circulation Journal, 2018, 82, 2575-2583.	0.7	16
1337	Sex Differences in Heart Failure. Advances in Experimental Medicine and Biology, 2018, 1065, 529-544.	0.8	43
1338	Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany. Pharmacoeconomics, 2018, 36, 1285-1296.	1.7	24
1339	Sacubitrilâ€“valsartan in heart failure and multimorbidity patients. ESC Heart Failure, 2018, 5, 956-959.	1.4	21
1340	Sex Differences in the Coronary System. Advances in Experimental Medicine and Biology, 2018, 1065, 257-278.	0.8	42

#	Article	IF	Citations
1341	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. Medical Journal of Australia, 2018, 209, 363-369.	0.8	31
1342	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung and Circulation, 2018, 27, 1123-1208.	0.2	262
1343	Current State of Pediatric Heart Failure. Children, 2018, 5, 88.	0.6	31
1344	Working together to achieve better outcomes for patients with heart failure. Primary Health Care, 2018, 28, 35-41.	0.0	2
1345	Acute Decompensated Heart Failure. , 2018, , 233-240.		0
1346	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	1.6	117
1347	Natriuretic Peptides and Normal Body FluidÂRegulation. , 2018, 8, 1211-1249.		30
1348	Sacubitril/Valsartan: potential treatment for paediatric heart failure. Cardiology in the Young, 2018, 28, 1077-1081.	0.4	4
1349	Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology. International Journal of Molecular Sciences, 2018, 19, 424.	1.8	90
1350	cGMP Signaling and Vascular Smooth Muscle Cell Plasticity. Journal of Cardiovascular Development and Disease, 2018, 5, 20.	0.8	33
1351	HeartLogic Multisensor Algorithm Identifies Patients During Periods of Significantly Increased Risk of Heart Failure Events. Circulation: Heart Failure, 2018, 11, e004669.	1.6	73
1352	CSI position statement on management of heart failure in India. Indian Heart Journal, 2018, 70, S1-S72.	0.2	18
1353	Diagnostic concordance between NT-proBNP and BNP for suspected heart failure. Clinical Biochemistry, 2018, 59, 50-55.	0.8	37
1354	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation, 2018, 138, 1505-1514.	1.6	145
1355	Reduction of Insulin Requirement After Starting Treatment With Sacubitril/Valsartan in a Patient with Diabetes Treated With Continuous Subcutaneous Insulin Infusion (CSII): A case report. Journal of Diabetes Science and Technology, 2018, 12, 1254-1255.	1.3	8
1356	Effects of Ivabradine on Hemodynamic and Functional Parameters in Left Ventricular Systolic Dysfunction: a Systematic Review and Meta-analysis. Journal of General Internal Medicine, 2018, 33, 1561-1570.	1.3	7
1357	Obstacles to mineralocorticoid receptor antagonists in a communityâ€based heart failure population. Cardiovascular Therapeutics, 2018, 36, e12459.	1.1	13
1358	A validated RP-HPLC method for the determination of rosuvastatin in presence of sacubitril/valsartan in rat plasma: Application to in vivo evaluation of OATP-mediated drug interaction potential between rosuvastatin and sacubitril/valsartan. Microchemical Journal, 2018, 143, 31-38.	2.3	10

#	Article	IF	Citations
1359	Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7428-E7437.	3.3	33
1360	Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. Journal of Biological Engineering, 2018, 12, 2.	2.0	108
1361	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 11, e004446.	1.6	58
1362	Device therapy in heart failure with reduced ejection fractionâ€"cardiac resynchronization therapy and more. Herz, 2018, 43, 415-422.	0.4	10
1363	Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Journal of Cardiac Failure, 2018, 24, 533-536.	0.7	14
1364	New Insights in Peripartum Cardiomyopathy. Obstetrics and Gynecology Clinics of North America, 2018, 45, 281-298.	0.7	3
1366	Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF). American Heart Journal, 2018, 205, 87-96.	1.2	11
1367	Established and Emerging Roles of Biomarkers in Heart Failure. Circulation Research, 2018, 123, 614-629.	2.0	200
1368	Management of Heart Failure in Adult Congenital Heart Disease. Progress in Cardiovascular Diseases, 2018, 61, 308-313.	1.6	10
1369	Exosomes: Basic Biology and Technological Advancements Suggesting Their Potential as Ischemic Heart Disease Therapeutics. Frontiers in Physiology, 2018, 9, 1159.	1.3	41
1370	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
1371	Mechanisms and treatment of heart failure in diabetes. Practical Diabetes, 2018, 35, 117.	0.1	0
1372	Novel Medical Treatments for Hypertension and Related Comorbidities. Current Hypertension Reports, 2018, 20, 90.	1.5	12
1373	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	1.2	199
1374	Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. New England Journal of Medicine, 2018, 379, 2297-2306.	13.9	1,276
1375	Chronic heart failure: Role of the GP in management. Family Medicine and Community Health, 2018, 6, 3-9.	0.6	1
1376	Neurohormonal Blockade. , 2018, , 459-476.		0
1377	Current challenges in managing comorbid heart failure and COPD. Expert Review of Cardiovascular Therapy, 2018, 16, 653-673.	0.6	30

#	Article	IF	Citations
1378	Electrical manipulation of the failing heart. Heart Failure Reviews, 2018, 23, 885-896.	1.7	2
1379	Cardiovascular Pharmacology. , 2018, , 132-166.		0
1380	A prospective, randomized, doubleâ€blind, placeboâ€controlled pilot study of sacubitril/valsartan (<scp>E</scp>ntresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. Journal of Veterinary Internal Medicine, 2018, 32, 1555-1563.	0.6	6
1381	Sacubitril valsartan for chronic heart failure: a practical context. British Journal of Cardiac Nursing, 2018, 13, 394-399.	0.0	0
1382	Gender medicine in dilated cardiomyopathy: pride and prejudice. European Journal of Heart Failure, 2018, 20, 1401-1403.	2.9	4
1383	Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?. Circulation, 2018, 138, 551-553.	1.6	39
1384	Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease. Current Heart Failure Reports, 2018, 15, 307-314.	1.3	12
1385	Therapeutic approaches for cardiac regeneration and repair. Nature Reviews Cardiology, 2018, 15, 585-600.	6.1	268
1386	Characteristics and Treatments of Patients Enrolled in the CHAMPâ€HF Registry Compared With Patients Enrolled in the PARADIGMâ€HF Trial. Journal of the American Heart Association, 2018, 7, .	1.6	26
1387	Role of Aldosterone Receptor Antagonists in Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights Therapeutics, 2018, 10, 1179559X1877135.	0.4	1
1388	Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial. Journal of Cardiovascular Pharmacology, 2018, 72, 112-116.	0.8	20
1389	Compartmentalized cyclic nucleotides have opposing effects on regulation of hypertrophic phospholipase Cβ signaling in cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2018, 121, 51-59.	0.9	21
1390	ACE Inhibitor-Induced Angioedema: a Review. Current Hypertension Reports, 2018, 20, 55.	1.5	78
1391	Translational Oral Health Research. , 2018, , .		2
1393	New Therapeutic Strategies in Heart Failure. , 2018, , 565-574.		0
1394	Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions. Acta Cardiologica, 2019, 74, 115-122.	0.3	20
1395	Cyclin dependent kinase inhibitor 1 C is a female-specific marker of left ventricular function after acute myocardial infarction. International Journal of Cardiology, 2019, 274, 319-325.	0.8	10
1396	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 2019, 281, 179-185.	0.8	9

#	Article	IF	Citations
1397	Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. International Journal of Cardiology, 2019, 281, 166-171.	0.8	29
1398	Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. American Journal of Cardiovascular Drugs, 2019, 19, 21-36.	1.0	3
1399	The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series. Journal of Oncology Pharmacy Practice, 2019, 25, 1231-1234.	0.5	25
1400	Clinical outcomes of Î²-blocker therapy in cocaine-associated heart failure. International Journal of Cardiology, 2019, 277, 153-158.	0.8	11
1401	Type 2 diabetes increases the risk of hospital admission for heart failure and reduces the risk of in hospital mortality in Spain (2001â€“2015). European Journal of Internal Medicine, 2019, 59, 53-59.	1.0	10
1402	Pharmacological therapy in adult congenital heart disease: growing need, yet limited evidence. European Heart Journal, 2019, 40, 1049-1056.	1.0	23
1403	Benefitâ€“risk review of different drug classes used in chronic heart failure. Expert Opinion on Drug Safety, 2019, 18, 37-49.	1.0	10
1404	Metabolic effects of cardiovascular drugs. Trends in Cardiovascular Medicine, 2019, 29, 176-187.	2.3	9
1405	HF progression among outpatients with HF in a community setting. International Journal of Cardiology, 2019, 277, 140-146.	0.8	9
1406	Angiotensin receptor neprilysin inhibitors in older patients with heart failure. BMJ Evidence-Based Medicine, 2019, 24, 5-7.	1.7	2
1407	Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients. Clinical Nutrition, 2019, 38, 1188-1197.	2.3	34
1408	Why Clinicians Should Care About theÂCardiac Interstitium. JACC: Cardiovascular Imaging, 2019, 12, 2305-2318.	2.3	20
1409	August 2019 at a glance: arrhythmogenic cardiomyopathy, biomarkers of inflammation, insulin treatment, initiation of sacubitril/valsartan, and pharmacyâ€based intervention to increase medication adherence. European Journal of Heart Failure, 2019, 21, 951-952.	2.9	0
1410	Renal Clearance of N-Terminal pro-Brain Natriuretic Peptide Is Markedly Decreased in Chronic Kidney Disease. Circulation Reports, 2019, 1, 326-332.	0.4	7
1411	Evolution of mitral regurgitation in patients with heart failure referred to a tertiary heart failure clinic. ESC Heart Failure, 2019, 6, 936-943.	1.4	4
1412	Heart Failure with Reduced Ejection Fraction. , 2019, , 383-395.		0
1413	Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application ofÂthe Efficiency Frontier. Value in Health, 2019, 22, 1119-1127.	0.1	13
1414	Neprilysin inhibitors and chest pain perception in acute myocardial infarction. Geriatrics and Gerontology International, 2019, 19, 840-841.	0.7	1

#	Article	IF	Citations
1415	The effects of sodiumâ€glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Failure, 2019, 6, 927-935.	1.4	64
1416	Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 195.	1.7	7
1417	Cardiovascular Pleiotropic Effects of Natriuretic Peptides. International Journal of Molecular Sciences, 2019, 20, 3874.	1.8	57
1418	Sacubitril/valsartan: A practical guide. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 309-313.	0.2	2
1419	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. Drugs, 2019, 79, 1543-1556.	4.9	11
1420	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	2.9	79
1421	The place of ARBs in heart failure therapy: is aldosterone suppression the key?. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471986813.	1.0	21
1422	Heart failure around the world. European Journal of Heart Failure, 2019, 21, 1187-1196.	2.9	56
1423	Potential benefits of yoga in patients with heart failure: A meta-analysis of controlled trials. European Journal of Integrative Medicine, 2019, 31, 100948.	0.8	0
1424	Genetic Ablation and Guanylyl Cyclase/Natriuretic Peptide Receptor-A: Impact on the Pathophysiology of Cardiovascular Dysfunction. International Journal of Molecular Sciences, 2019, 20, 3946.	1.8	18
1425	Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. Journal of the American Heart Association, 2019, 8, e012514.	1.6	39
1427	For Whom the Bell Tolls. Current Cardiology Reports, 2019, 21, 106.	1.3	5
1428	Aldehyde Dehydrogenase 2 and Heart Failure. Advances in Experimental Medicine and Biology, 2019, 1193, 89-106.	0.8	4
1429	Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. JAMA Cardiology, 2019, 4, 828.	3.0	40
1430	Hypertensive Heart Failure in the Very Old. Heart Failure Clinics, 2019, 15, 477-485.	1.0	11
1431	Heart Failure in Women Due to Hypertensive Heart Disease. Heart Failure Clinics, 2019, 15, 497-507.	1.0	4
1432	Hypertension and Heart Failure. Heart Failure Clinics, 2019, 15, 531-541.	1.0	124
1433	Combination of Peak Exercise Systolic Blood Pressure and Left Atrial Diameter as a Novel Non-Spirometry Prognostic Predictor Comparable to Peak Oxygen Uptake for Heart Failure With Reduced Ejection Fraction. Circulation Journal, 2019, 83, 1528-1537.	0.7	7

#	Article	IF	Citations
1434	Relationship between invasive hemodynamics and liver function in advanced heart failure. Scandinavian Cardiovascular Journal, 2019, 53, 235-246.	0.4	4
1435	Evolution of functional class,Âbiochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice. Journal of Comparative Effectiveness Research, 2019, 8, 685-697.	0.6	10
1436	New Insights Into Mechanisms of Acute Kidney Injury in Heart Disease. Canadian Journal of Cardiology, 2019, 35, 1158-1169.	0.8	12
1437	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. Korean Circulation Journal, 2019, 49, 469.	0.7	18
1438	Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 245-250.	0.2	0
1440	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. Circulation Research, 2019, 125, 265-281.	2.0	54
1441	LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model. Cardiovascular Therapeutics, 2019, 2019, 1-9.	1.1	26
1442	Prognostic Stratification and Importance of Follow-Up. , 2019, , 187-198.		0
1443	A defined, plant-based diet as a potential therapeutic approach in the treatment of heart failure: A clinical case series. Complementary Therapies in Medicine, 2019, 45, 211-214.	1.3	14
1444	Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H617-H626.	1.5	22
1445	Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure. Clinical Chemistry, 2019, 65, 1239-1247.	1.5	10
1446	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	2.9	159
1447	The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting. Internal and Emergency Medicine, 2019, 14, 1205-1208.	1.0	1
1448	Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation. Scientific Reports, 2019, 9, 9762.	1.6	8
1449	Ventricular Stability with Sacubitril-Valsartan: For the Many, Not the Few. Cardiology, 2019, 143, 36-36.	0.6	0
1450	Association between the activities of daily living and clinical outcomes in patients with heart failure. Journal of Cardiology, 2019, 74, 473.	0.8	0
1451	Association between reduced left ventricular ejection fraction following non-ST-segment elevation myocardial infarction and long-term mortality in patients of advanced age. International Journal of Cardiology, 2019, 296, 15-20.	0.8	6
1452	Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2019, 7, 862-874.	1.9	77

#	Article	IF	Citations
1453	Risk stratification in acute heart failure: We need a new agenda for clinical research. International Journal of Cardiology, 2019, 293, 179-180.	0.8	0
1454	Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?. European Journal of Heart Failure, 2019, 21, 1398-1401.	2.9	3
1455	Can Sacubitril/Valsartan Have a Proarrhythmic Effect in Some High-Risk Patients?. Cardiology, 2019, 143, 34-35.	0.6	0
1456	Clinical aspects of heart failure in individuals with diabetes. Diabetologia, 2019, 62, 1529-1538.	2.9	14
1457	Effects of Adipocyte Expansion on Cardiovascular System and Ongoing Debate over Obesity Paradox. International Heart Journal, 2019, 60, 499-502.	0.5	3
1458	Background pharmacological therapy in the ANTHEMâ€HF: comparison to contemporary trials of novel heart failure therapies. ESC Heart Failure, 2019, 6, 1052-1056.	1.4	6
1459	CRT Optimization: What Is New? What Is Necessary?. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 45.	0.4	8
1460	Renal denervation ameliorates post-infarction cardiac remodeling in rats through dual regulation of oxidative stress in the heart and brain. Biomedicine and Pharmacotherapy, 2019, 118, 109243.	2.5	4
1461	Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. Journal of the American Heart Association, 2019, 8, e012943.	1.6	15
1462	BNP as a Major Player in the Heart-Kidney Connection. International Journal of Molecular Sciences, 2019, 20, 3581.	1.8	57
1464	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and HeartÂFailure (Part 2/5). Journal of the American College of Cardiology, 2019, 74, 683-698.	1.2	22
1465	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. European Journal of Heart Failure, 2019, 21, 1259-1266.	2.9	46
1467	Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure. Clinical Chemistry, 2019, 65, 1187-1189.	1.5	2
1468	Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure. International Journal of Cardiology, 2019, 293, 203-210.	0.8	18
1469	The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Annals of the New York Academy of Sciences, 2019, 1455, 12-33.	1.8	46
1470	Defining the role of peritoneal dialysis in management of congestive heart failure. Expert Review of Cardiovascular Therapy, 2019, 17, 533-543.	0.6	14
1471	Cathepsin A Inhibitors to Treat Heart Disease. JACC Basic To Translational Science, 2019, 4, 345-347.	1.9	2
1472	Sacubitril/valsartan in patients with symptomatic chronic heart failure with reduced ejection fraction. Journal of Prescribing Practice, 2019, 1, 182-192.	0.1	4

#	Article	IF	Citations
1473	Clinical and Physiologic Implications of Negative Cardiopulmonary Interactions in Coexisting Chronic Obstructive Pulmonary Disease-Heart Failure. Clinics in Chest Medicine, 2019, 40, 421-438.	0.8	20
1474	Implication of Acute Kidney Injury in Heart Failure. Heart Failure Clinics, 2019, 15, 463-476.	1.0	15
1475	Left Ventricular Ejection Fraction Improvement Post Commencement of Sacubitril/Valsartan in Heart Failure Patients. Heart Lung and Circulation, 2019, 28, S179.	0.2	0
1476	Saudi Heart Association (SHA) guidelines for the management of heart failure. Journal of the Saudi Heart Association, 2019, 31, 204-253.	0.2	9
1477	2017 Guidelines for the management of heart failure by pharmacists. Canadian Pharmacists Journal, 2019, 152, 301-316.	0.4	1
1478	Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease. International Journal of Molecular Sciences, 2019, 20, 3265.	1.8	54
1479	Lumpers and splitters: the bumpy road to precision medicine. European Heart Journal, 2019, 40, 3292-3296.	1.0	15
1480	Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. European Heart Journal, 2020, 41, 882-889.	1.0	25
1481	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacological Reviews, 2019, 71, 539-570.	7.1	235
1482	Left Ventricular Systolic Dysfunction and Cardiovascular Outcomes in Tetralogy of Fallot: Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 1784-1790.	0.8	16
1483	Race, Natriuretic Peptides, and High-Carbohydrate Challenge. Circulation Research, 2019, 125, 957-968.	2.0	34
1484	Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System. Pharmacotherapy, 2019, 39, 1053-1059.	1.2	8
1485	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. Peritoneal Dialysis International, 2019, 39, 486-489.	1.1	12
1486	Sacubitril/valsartan: A practical guide revisited. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 527-529.	0.2	0
1487	Heart failure as a substrate and trigger for ventricular tachycardia. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 229-247.	0.6	38
1488	Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?. Current Hypertension Reports, 2019, 21, 86.	1.5	17
1489	SGLTâ€2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. Journal of the American Heart Association, 2019, 8, e013389.	1.6	119
1490	PARAGON-HF â€" Why We Do Randomized, Controlled Clinical Trials. New England Journal of Medicine, 2019, 381, 1675-1676.	13.9	12

#	Article	IF	Citations
1491	Transcatheter edge-to-edge mitral valve repair in functional mitral regurgitation: patient selection according to MITRA-FR and COAPT. Journal of Thoracic Disease, 2019, 11, S1966-S1968.	0.6	0
1492	Sacubitril/valsartan in heart failure and endâ€stage renal insufficiency. ESC Heart Failure, 2019, 6, 1331-1333.	1.4	20
1493	FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons. Communications Biology, 2019, 2, 394.	2.0	31
1494	The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Systematic Reviews, 2019, 8, 251.	2.5	3
1495	The Risk for Sudden Cardiac Death and Effect of Treatment With Sacubitril/Valsartan inÂHeartÂFailure. JACC: Heart Failure, 2019, 7, 999.	1.9	10
1496	Pharmacological Heart Failure Therapy in Children: Focus on Inotropic Support. Handbook of Experimental Pharmacology, 2019, 261, 177-192.	0.9	1
1497	Safety of sacubitril/valsartan initiated during hospitalization: data from a nonâ€selected cohort. ESC Heart Failure, 2019, 6, 1161-1166.	1.4	22
1498	Myocardial Strain for Identification of Î²-Blocker Responders in Heart Failure with Preserved Ejection Fraction. Journal of the American Society of Echocardiography, 2019, 32, 1462-1469.e8.	1.2	22
1499	Discovery of Novel Multi-target Inhibitor of angiotensin type 1 receptor and neprilysin inhibitors from Traditional Chinese Medicine. Scientific Reports, 2019, 9, 16205.	1.6	4
1500	Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan. Circulation: Heart Failure, 2019, 12, e005819.	1.6	57
1501	GDMT for heart failure and the clinician's conundrum. Clinical Cardiology, 2019, 42, 1155-1161.	0.7	7
1502	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. ESC Heart Failure, 2019, 6, 1199-1207.	1.4	11
1503	Initiation of Angiotensin Receptor-Neprilysin Inhibitor in HeartÂFailure With Low Cardiac Output. Journal of the American College of Cardiology, 2019, 74, 2326-2327.	1.2	9
1504	Heart failure with preserved ejection fraction: towards an understanding of an enigma. European Heart Journal, 2019, 40, 3277-3280.	1.0	2
1505	Relief and Prevention of Congestion in Heart Failure Enhance Quality and Length of Life. Circulation, 2019, 140, 1380-1382.	1.6	11
1506	Blood Pressure-Associated Genetic Variants in the Natriuretic Peptide Receptor 1 Gene Modulate Guanylate Cyclase Activity. Circulation Genomic and Precision Medicine, 2019, 12, e002472.	1.6	10
1507	Joint Shock/Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005675.	0.9	13
1508	Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors. Cardiovascular Therapeutics, 2019, 2019, 1-6.	1.1	5

#	Article	IF	Citations
1509	Association of Change in N-Terminal Proâ€“B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1085.	3.8	403
1510	Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1077.	3.8	220
1511	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	13.9	1,485
1512	Angiotensin Receptorâ€“Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1051.	3.8	8
1514	Temporal Trends and Patterns in Mortality After Incident Heart Failure. JAMA Cardiology, 2019, 4, 1102.	3.0	107
1515	Sacubitril/valsartan: A practical guide revisited. Revista Portuguesa De Cardiologia, 2019, 38, 527-529.	0.2	0
1516	Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension, 2019, 74, 1075-1083.	1.3	46
1517	Evaluation of Drug-Related Receptors in Children With Dilated Cardiomyopathy. Frontiers in Pediatrics, 2019, 7, 387.	0.9	3
1518	Lebetin 2, a Snake Venom-Derived B-Type Natriuretic Peptide, Provides Immediate and Prolonged Protection against Myocardial Ischemia-Reperfusion Injury via Modulation of Post-Ischemic Inflammatory Response. Toxins, 2019, 11, 524.	1.5	12
1519	New Molecules for Treating Resistant Hypertension: a Clinical Perspective. Current Hypertension Reports, 2019, 21, 80.	1.5	5
1520	Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. IJC Heart and Vasculature, 2019, 25, 100418.	0.6	27
1521	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes inÂHeartÂFailure With Reduced EjectionÂFraction. JACC: Heart Failure, 2019, 7, 933-941.	1.9	31
1522	Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue. Scientific Reports, 2019, 9, 11494.	1.6	7
1523	Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. Cardiac Failure Review, 2019, 5, 78-82.	1.2	3
1524	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379.	1.6	74
1525	2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 1966-2011.	1.2	222
1526	Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 986-1003.	0.7	37
1527	Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats. Journal of Cardiac Failure, 2019, 25, 921-931.	0.7	5

#	Article	IF	Citations
1528	238th ENMC International Workshop: Updating management recommendations of cardiac dystrophinopathyHoofddorp, The Netherlands, 30 November - 2 December 2018. Neuromuscular Disorders, 2019, 29, 634-643.	0.3	6
1529	An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure. Expert Review of Molecular Diagnostics, 2019, 19, 1019-1029.	1.5	6
1530	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. Physiological Genomics, 2019, 51, 506-515.	1.0	4
1531	Heart-Failure Therapy â€" New Drugs but Old Habits?. New England Journal of Medicine, 2019, 381, 2063-2064.	13.9	9
1532	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	13.9	4,108
1533	A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart FunctionÂClinics. CJC Open, 2019, 1, 173-181.	0.7	2
1534	Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension. Cardiology, 2019, 143, 124-133.	0.6	20
1535	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
1536	Looking back and thinking forwards â€" 15 years of cardiology and cardiovascular research. Nature Reviews Cardiology, 2019, 16, 651-660.	6.1	10
1537	Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. Frontiers in Physiology, 2019, 10, 1108.	1.3	49
1538	Prevention of Heart Failure. , 2019, , .		0
1540	Diabetes, heart failure, and renal dysfunction: The vicious circles. Progress in Cardiovascular Diseases, 2019, 62, 298-302.	1.6	151
1541	NT-proBNP, race and endothelial function in the Multi-Ethnic Study of Atherosclerosis. Heart, 2019, 105, 1590-1596.	1.2	3
1542	Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. European Journal of Preventive Cardiology, 2021, 28, 966-972.	0.8	16
1543	Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients. Journal of Clinical Medicine, 2019, 8, 1582.	1.0	33
1544	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. JACC: Heart Failure, 2019, 7, 878-887.	1.9	37
1545	The PARAGON-Heart failure trial â€" another disappointment for heart failure patients with hypertension and preserved ejection fraction. Blood Pressure, 2019, 28, 276-278.	0.7	0
1546	PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 2019, 115, e136-e139.	1.8	2

#	Article	IF	Citations
1547	Sacubitril/valsartan: A practical guide. Revista Portuguesa De Cardiologia, 2019, 38, 309-313.	0.2	6
1548	Soluble neprilysin does not correlate with prognosis in pulmonary hypertension. ESC Heart Failure, 2019, 6, 291-296.	1.4	6
1549	The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial. European Journal of Heart Failure, 2019, 21, 334-336.	2.9	1
1550	Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 122-123.	1.4	2
1551	Long term prognostic importance of late gadolinium enhancement in first-presentation non-ischaemic dilated cardiomyopathy. International Journal of Cardiology, 2019, 280, 124-129.	0.8	10
1552	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure â€“ A multicenter propensity score matched analysis. International Journal of Cardiology, 2019, 289, 83-90.	0.8	10
1553	Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. British Journal of Pharmacology, 2019, 176, 3447-3463.	2.7	115
1554	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. Hospital Practice (1995), 2019, 47, 67-72.	0.5	7
1555	Relationship Between Hospital Characteristics and Early Adoption of Angiotensinâ€Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. Journal of the American Heart Association, 2019, 8, e010484.	1.6	13
1556	Increasing Complexity of Heart Failure Therapy Requires Earlier and More Frequent Referral. Journal of Cardiac Failure, 2019, 25, 317-318.	0.7	4
1557	Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the reninâ€“angiotensin system in chronic heart failure? The culmination of a 20-year journey. European Heart Journal, 2019, 40, 3353-3355.	1.0	1
1558	Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. Circulation Research, 2019, 124, 1536-1550.	2.0	47
1559	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. Circulation Research, 2019, 124, 1618-1632.	2.0	39
1560	Inâ€hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. European Journal of Heart Failure, 2019, 21, 1008-1011.	2.9	1
1561	Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 175-185.	0.2	0
1562	Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?. Journal of Clinical Medicine, 2019, 8, 869.	1.0	23
1563	A practical guide to chronic heart failure management. The Prescriber, 2019, 30, 25-32.	0.1	0
1564	Effects of the Angiotensinâ€Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Metaâ€Analysis. Journal of the American Heart Association, 2019, 8, e012272.	1.6	137

#	Article	IF	Citations
1565	Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials. Cureus, 2019, 11, e3913.	0.2	5
1566	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 2019, 140, e294-e324.	1.6	342
1567	Treatment of Cardiorenal Syndrome. Cardiology Clinics, 2019, 37, 267-273.	0.9	15
1568	Association of Changes in HeartÂFailure Treatment With Patientsâ€™ Health Status. JACC: Heart Failure, 2019, 7, 615-625.	1.9	20
1569	Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006951.	2.1	13
1570	Heart failure guideline update: a guide for general practice. British Journal of General Practice, 2019, 69, 313-314.	0.7	0
1571	Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. European Journal of Heart Failure, 2019, 21, 998-1007.	2.9	233
1572	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	2.9	35
1573	Cardiorenal syndrome in heart failure with preserved ejection fractionâ€”an under-recognized clinical entity. Heart Failure Reviews, 2019, 24, 421-437.	1.7	26
1574	The renin-angiotensin-aldosterone system and its therapeutic targets. Experimental Eye Research, 2019, 186, 107680.	1.2	115
1575	Dilated cardiomyopathy: from epidemiologic to genetic phenotypes. Journal of Internal Medicine, 2019, 286, 362-372.	2.7	113
1576	Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Internal and Emergency Medicine, 2019, 14, 1287-1297.	1.0	45
1577	Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy. Journal of Cardiac Failure, 2019, 25, 686-689.	0.7	1
1578	Ethnic differences in acute heart failure outcomes in Ontario. International Journal of Cardiology, 2019, 291, 177-182.	0.8	9
1579	Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 2629.	1.8	44
1580	Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations. Revista Portuguesa De Cardiologia, 2019, 38, 245-250.	0.2	7
1581	Soluble Neprilysinã€€â€• Cardiac Function and Outcome in Hypertrophic Cardiomyopathy â€•. Circulation Reports, 2019, 1, 261-267.	0.4	3
1582	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure, 2019, 25, 584-619.	0.7	56

#	Article	IF	Citations
1583	CPAP Treatment and Cardiovascular Prevention. Chest, 2019, 156, 431-437.	0.4	48
1585	Early Unplanned Readmissions After Admission to Hospital With Heart Failure. American Journal of Cardiology, 2019, 124, 736-745.	0.7	16
1586	Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. Journal of Biological Chemistry, 2019, 294, 12567-12578.	1.6	42
1587	The PARAGON Heart Failure trial â€“ ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Blood Pressure, 2019, 28, 215-216.	0.7	3
1588	Primary Prevention of Sudden Cardiac Death. JAMA - Journal of the American Medical Association, 2019, 322, 161.	3.8	2
1589	Sex Differences in Heart Failureâ€"Female Representation in Heart Failure Studies. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	1
1590	Amino Acid-Based Metabolic Profile Provides Functional Assessment and Prognostic Value for Heart Failure Outpatients. Disease Markers, 2019, 2019, 1-10.	0.6	8
1591	Confirmatory Trials for Drugs Approved on a Single Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005494.	0.9	10
1592	New drugs: big changes in conservative heart failure therapy?. European Journal of Cardio-thoracic Surgery, 2019, 55, i3-i10.	0.6	10
1593	Does the heart transplant have a future?. European Journal of Cardio-thoracic Surgery, 2019, 55, i38-i48.	0.6	41
1594	Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2019, 32, 499-516.	0.9	63
1595	Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2019, 293, 159-164.	0.8	9
1596	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	2.0	115
1597	Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. Advances in Therapy, 2019, 36, 1549-1573.	1.3	3
1598	Overcoming Barriers to DevelopmentÂofÂNovel Therapies forÂCardiovascular Disease. JACC Basic To Translational Science, 2019, 4, 269-274.	1.9	12
1599	Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465.	1.9	94
1600	Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.	18.1	347
1601	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494

#	Article	IF	Citations
1602	A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471984019.	1.0	12
1603	Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clinical Therapeutics, 2019, 41, 1066-1079.	1.1	23
1604	New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failureâ€"Targeting the Sympathetic Nervous System. International Journal of Molecular Sciences, 2019, 20, 2430.	1.8	24
1605	The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet. Biomedicine and Pharmacotherapy, 2019, 116, 108954.	2.5	29
1607	Neprilysin inhibition: a new therapeutic option for type 2 diabetes?. Diabetologia, 2019, 62, 1113-1122.	2.9	41
1608	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 73, 2365-2383.	1.2	327
1609	Percutaneous Repair for Secondary Mitral Regurgitation. New England Journal of Medicine, 2019, 380, 1975-1978.	13.9	2
1610	A perâ€protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region. ESC Heart Failure, 2019, 6, 758-763.	1.4	10
1611	C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. International Journal of Molecular Sciences, 2019, 20, 2281.	1.8	93
1612	Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. JACC: Heart Failure, 2019, 7, 371-382.	1.9	36
1613	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. International Journal of Molecular Sciences, 2019, 20, 2092.	1.8	25
1614	Strainâ€selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains. British Journal of Pharmacology, 2019, 176, 2795-2807.	2.7	4
1615	Prognostic impact of MitraClip in patients with left ventricular dysfunction and functional mitral valve regurgitation: A comprehensive meta-analysis of RCTs and adjusted observational studies. International Journal of Cardiology, 2019, 290, 70-76.	0.8	11
1616	Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease. World Journal for Pediatric & Congenital Heart Surgery, 2019, 10, 292-295.	0.3	33
1617	Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. European Heart Journal, 2019, 40, 3345-3352.	1.0	59
1618	Potential Drug Interactions in Critically Ill Patients: Sacubitril/Valsartan and Mexiletine. Cardiology, 2019, 142, 81-82.	0.6	0
1621	Implications of Perceived Dyspnea and Global Well-Being Measured by Visual Assessment Scales During Treatment for Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 402-408.	0.7	3
1622	Natriuretic Peptides in Chronic Heart Failure. Cardiac Failure Review, 2019, 5, 44-49.	1.2	55

#	Article	IF	Citations
1623	Novel potassium binders as enabling therapy in heart failure. European Journal of Heart Failure, 2019, 21, 550-552.	2.9	7
1624	Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan. Cardiology, 2019, 142, 73-78.	0.6	22
1625	Biomarker of Collagen Turnover (Câ€Terminal Telopeptide) andÂPrognosis in Patients With Nonâ€STâ€Elevation Acute CoronaryÂSyndromes. Journal of the American Heart Association, 2019, 8, e011444.	1.6	11
1627	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
1628	Empowering patients to make informed choices. BMJ: British Medical Journal, 2019, 365, l1456.	2.4	0
1629	Anti-fibrotic Effects of Cardiac Progenitor Cells in a 3D-Model of Human Cardiac Fibrosis. Frontiers in Cardiovascular Medicine, 2019, 6, 52.	1.1	27
1630	Experiencia clÃ¬nica con sacubitrilo/valsartÃ¡n en pacientes con insuficiencia renal: la visiÃ³n del nefrÃ³logo. Nefrologia, 2019, 39, 646-652.	0.2	10
1631	Neprilysin Inhibitorâ€“Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice. Scientific Reports, 2019, 9, 6509.	1.6	25
1632	Clinical profiles in acute heart failure: an urgent need for a new approach. ESC Heart Failure, 2019, 6, 464-474.	1.4	42
1633	Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure. Revista Portuguesa De Cardiologia, 2019, 38, 175-185.	0.2	5
1634	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	2.9	264
1635	Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction â‰¤35%. Current Medical Research and Opinion, 2019, 35, 13-18.	0.9	6
1636	Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan. Current Medical Research and Opinion, 2019, 35, 19-22.	0.9	5
1637	Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder. Current Medical Research and Opinion, 2019, 35, 3-6.	0.9	2
1638	Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series. Current Medical Research and Opinion, 2019, 35, 7-11.	0.9	2
1639	Management of patient with heart failure: Italian â€œfield practiceâ€•experience of sacubitril/valsartan. Current Medical Research and Opinion, 2019, 35, 1-2.	0.9	0
1640	Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2019, 17, 319-330.	0.6	9
1641	Cardiac Remodeling: The Course Towards Heart Failure-II. Diagnostic and Therapeutic Approaches. , 2019, , 247-280.		0

#	Article	IF	Citations
1642	â€œReal Worldâ€•Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry. Cardiovascular Drugs and Therapy, 2019, 33, 315-322.	1.3	19
1643	Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Journal of Cardiology, 2019, 74, 49-52.	0.8	13
1644	How does neprilysin inhibition in heart failure work?. European Journal of Heart Failure, 2019, 21, 606-608.	2.9	0
1645	Effect of Neprilysin Inhibition on VariousÂNatriuretic Peptide Assays. Journal of the American College of Cardiology, 2019, 73, 1273-1284.	1.2	98
1646	What Explains the Benefits of ARNIÂTherapy in Heart Failure?. Journal of the American College of Cardiology, 2019, 73, 1285-1287.	1.2	1
1647	Sacubitril/valsartan can improve exercise performance in systolic chronic heart failure patients: a case report. Current Medical Research and Opinion, 2019, 35, 3-5.	0.9	8
1648	Management of a patient with heart failure by sacubitril/valsartan: improvement of functional capacity. Current Medical Research and Opinion, 2019, 35, 7-8.	0.9	2
1649	Rationale and design of the DIGITâ€HF trial (DIGitoxin to Improve ouTcomes in patients with advanced) Tj ETQq1 1 0.784314 rgBT /O Heart Failure, 2019, 21, 676-684.	2.9	51
1650	Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure. Journal of Cardiac Failure, 2019, 25, 412-413.	0.7	2
1651	Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. Internal and Emergency Medicine, 2019, 14, 1083-1090.	1.0	5
1652	Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure. European Journal of Heart Failure, 2019, 21, 537-539.	2.9	4
1653	New treatments for hyperkalaemia: clinical use in cardiology. European Heart Journal Supplements, 2019, 21, A41-A47.	0.0	6
1654	Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. European Heart Journal Supplements, 2019, 21, A55-A60.	0.0	17
1655	Emerging Therapy in Hypertension. Current Hypertension Reports, 2019, 21, 23.	1.5	10
1656	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. Journal of the American College of Cardiology, 2019, 73, 1264-1272.	1.2	139
1657	Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas Ã cause du BNP?. European Journal of Heart Failure, 2019, 21, 609-612.	2.9	3
1658	Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction â€“ A report from FAR NHL prospective registry. PLoS ONE, 2019, 14, e0214363.	1.1	23
1659	Relation between therapyâ€induced changes in natriuretic peptide levels and longâ€term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2019, 21, 613-620.	2.9	9

#	Article	IF	Citations
1660	Natriuretic peptides as a surrogate endpoint in clinical trialsâ€‰â€”â€‰a riddle wrapped in an enigma. European Journal of Heart Failure, 2019, 21, 621-623.	2.9	2
1661	Nine contemporary therapeutic directions in heart failure. Heart Asia, 2019, 11, e011150.	1.1	2
1662	Sacubitril/Valsartan and Mexiletine: A Proarrhythmic Combination?. Cardiology, 2019, 142, 4-6.	0.6	7
1663	When Payment Models Distort Perceptions and Care Delivery forPatients With Heart Failure. Journal of Cardiac Failure, 2019, 25, 227-229.	0.7	2
1664	Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation. Circulation, 2019, 139, 1366-1370.	1.6	26
1665	Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction. Journal of the American Heart Association, 2019, 8, e011077.	1.6	61
1667	Increasing the Adoption and Diffusion of a Novel Pharmacological Therapy That Is Both Mortality Reducing and Costâ€Effective. Journal of the American Heart Association, 2019, 8, e011783.	1.6	7
1668	Clinical practice with sacubitril/valsartan: more on the Italian experience. Current Medical Research and Opinion, 2019, 35, 1-2.	0.9	0
1669	Barriers to guideline mandated reninâ€“angiotensin inhibitor use: focus on hyperkalaemia. European Heart Journal Supplements, 2019, 21, A20-A27.	0.0	13
1670	Electrical Storm after Initiating Sacubitril/Valsartan: Arrhythmic Paradox. Cardiology, 2019, 142, 24-25.	0.6	9
1671	Clinical Profile and Ventricular Arrhythmias after Sacubitril/Valsartan Initiation. Cardiology, 2019, 142, 26-27.	0.6	8
1672	Update on heart failure management and future directions. Korean Journal of Internal Medicine, 2019, 34, 11-43.	0.7	84
1673	Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Current Medical Research and Opinion, 2019, 35, 9-12.	0.9	17
1674	Sacubitril/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure. Current Medical Research and Opinion, 2019, 35, 17-20.	0.9	5
1675	Interference With the Reninâ€“Angiotensin System (RAS): Classical Inhibitors and Novel Approaches. , 2019, , 523-530.		5
1676	Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure. Scientific Reports, 2019, 9, 5791.	1.6	43
1677	Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts. Circulation: Heart Failure, 2019, 12, e005565.	1.6	92
1678	Realâ€world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. European Journal of Heart Failure, 2019, 21, 588-597.	2.9	49

#	Article	IF	Citations
1679	Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. Journal of Cardiology, 2019, 74, 372-380.	0.8	56
1680	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation, 2019, 139, 2285-2288.	1.6	129
1681	Cross-Talk between Neurohormonal Pathways and the Immune System in Heart Failure: A Review of the Literature. International Journal of Molecular Sciences, 2019, 20, 1698.	1.8	38
1682	Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit. Clinical Research in Cardiology, 2019, 108, 1276-1286.	1.5	7
1683	Hypertension and Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2019, , .	0.1	0
1684	New Drugs for theÂHypertensive Failing Heart. Updates in Hypertension and Cardiovascular Protection, 2019, , 313-334.	0.1	0
1685	Renal Nerve Ablation. Updates in Hypertension and Cardiovascular Protection, 2019, , 377-389.	0.1	0
1686	Prevention and Treatment of Heart Failure in Hypertension Guidelines. Updates in Hypertension and Cardiovascular Protection, 2019, , 393-402.	0.1	0
1687	Natriuretic Peptides. Updates in Hypertension and Cardiovascular Protection, 2019, , 87-100.	0.1	1
1688	Placental Syncytiotrophoblast-Derived Extracellular Vesicles Carry Active NEP (Neprilysin) and Are Increased in Preeclampsia. Hypertension, 2019, 73, 1112-1119.	1.3	84
1689	Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure. Cardiology Clinics, 2019, 37, 139-146.	0.9	3
1690	Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 1074-1082.	1.5	108
1691	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naÃ¯ve cancer patients. Scientific Reports, 2019, 9, 2554.	1.6	18
1692	Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine, 2019, 8, 262.	1.0	43
1693	Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities. Irish Journal of Medical Science, 2019, 188, 1169-1174.	0.8	2
1694	Tolvaptan for Volume Management in Heart Failure. Pharmacotherapy, 2019, 39, 473-485.	1.2	11
1695	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. Cardiovascular Medicine, 2019, , 105-120.	0.0	0
1696	PIONEERing the In-Hospital Initiation of Sacubitrilâ€“Valsartan. New England Journal of Medicine, 2019, 380, 590-591.	13.9	12

#	Article	IF	Citations
1697	Applying data science approaches to identify frequent flyers in heart failure: rise of the machines. European Journal of Heart Failure, 2019, 21, 319-321.	2.9	1
1698	Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry. Journal of Cardiovascular Pharmacology, 2019, 73, 118-124.	0.8	28
1699	Dancing Cats, Heart Failure, and Circulating Troponin. Journal of Cardiac Failure, 2019, 25, 238-239.	0.7	2
1700	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in PatientsÂWith HFrEF. Journal of the American College of Cardiology, 2019, 73, 795-806.	1.2	173
1701	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	1.9	63
1702	A mouse model of heart failure exhibiting pulmonary edema and pleural effusion: Useful for testing new drugs. Journal of Pharmacological and Toxicological Methods, 2019, 96, 78-86.	0.3	4
1703	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2019, 21, 337-341.	2.9	129
1704	Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry. IJC Heart and Vasculature, 2019, 22, 102-104.	0.6	12
1705	Reframing Global Variation in HeartÂFailure Trials. JACC: Heart Failure, 2019, 7, 347-349.	1.9	1
1706	The reninâ€angiotensinâ€aldosterone system and its suppression. Journal of Veterinary Internal Medicine, 2019, 33, 363-382.	0.6	251
1707	In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitorsâ€”The Time Is Now. JAMA Cardiology, 2019, 4, 195.	3.0	5
1708	Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?. Blood Pressure, 2019, 28, 75-76.	0.7	5
1709	Hyperkalaemia: aetiology, epidemiology, and clinical significance. European Heart Journal Supplements, 2019, 21, A6-A11.	0.0	23
1710	An update on the CardioMEMS pulmonary artery pressure sensor. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471982682.	1.0	22
1711	Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review. Cardiovascular Drugs and Therapy, 2019, 33, 307-314.	1.3	26
1712	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	1.0	32
1714	Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovascular Research, 2019, 115, 922-934.	1.8	77
1715	Neprilysin inhibition for pulmonary arterial hypertension: a randomized, doubleâ€blind, placeboâ€controlled, proofâ€ofâ€concept trial. British Journal of Pharmacology, 2019, 176, 1251-1267.	2.7	20

#	Article	IF	Citations
1717	Current Pathophysiological and Genetic Aspects of Dilated Cardiomyopathy. , 2019, , .		0
1718	DespuÃ©s del DANISH, Â¿a quÃ© pacientes indicar un desfibrilador implantable?. Revista Espanola De Cardiologia Suplementos, 2019, 18, 40-45.	0.2	0
1719	HospitalizaciÃ³n: el momento mÃ¡s vulnerable. Revista Espanola De Cardiologia Suplementos, 2019, 18, 17-23.	0.2	0
1721	A translational approach to the renin-angiotensin-aldosterone system in heart failure. Annals of Research Hospitals, 0, 3, 11-11.	0.0	8
1722	Inicio del sacubitrilo-valsartÃ¡n en pacientes hospitalizados frente a ambulatorios en la vida real. REC: CardioClinics, 2019, 54, 205-208.	0.1	0
1723	Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view. Nefrologia, 2019, 39, 646-652.	0.2	7
1724	Effects of optimized heart failure medication on central sleep apnea with Cheyne-Stokes respiration pattern in chronic heart failure with reduced left-ventricular ejection fraction. , 2019, 2019, 5723-5726.		2
1725	Highlights in heart failure. ESC Heart Failure, 2019, 6, 1105-1127.	1.4	109
1726	The potential antiarrhythmic properties of sacubitril/valsartan. Journal of Cardiovascular Medicine, 2019, 20, 780-782.	0.6	2
1727	B-Type Natriuretic Peptides (BNP) and Tissue Doppler E/eÂ´ Before and After 4 Weeks Standard Treatment of African Heart Failure Subjects: The ABU-BNP Longitudinal Survey . Vascular Health and Risk Management, 2019, Volume 15, 559-569.	1.0	1
1728	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. Italian Journal of Medicine, 2019, 13, 205-224.	0.2	0
1729	Clinical Significance and Therapeutic Implication of Nocturnal Hypertension: Relationship between Nighttime Blood Pressure and Quality of Sleep. Korean Circulation Journal, 2019, 49, 818.	0.7	16
1730	Protocol-based follow-up program for heart failure patients: Impact on prognosis and quality of life. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 755-764.	0.2	2
1731	The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 883-895.	0.2	5
1732	Opportunities for practice nurses when managing heart failure. Practice Nursing, 2019, 30, 424-429.	0.1	0
1733	A evoluÃ§Ã£o histÃ³rica do envolvimento dos sistemas neuroâ€humorais no conhecimento da fisiopatologia e do tratamento da insuficiÃªncia cardÃaca. Revista Portuguesa De Cardiologia, 2019, 38, 883-895.	0.2	2
1734	Protocol-based follow-up program for heart failure patients: Impact on prognosis and quality of life. Revista Portuguesa De Cardiologia, 2019, 38, 755-764.	0.2	13
1736	Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does â€œXâ€•Really Mark the Spot?. Current Heart Failure Reports, 2019, 16, 250-256.	1.3	1

#	Article	IF	Citations
1737	Decelerating trends in heart failure survival. European Journal of Heart Failure, 2019, 21, 1326-1328.	2.9	1
1738	Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure. Cardiovascular Therapeutics, 2019, 2019, 1-10.	1.1	65
1739	Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. Circulation: Heart Failure, 2019, 12, e005691.	1.6	7
1740	Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 2019, 218, 66-74.	1.2	23
1741	Insuficiencia cardÃaca crÃ³nica. Medicine, 2019, 12, 5414-5426.	0.0	0
1743	Heart failure with preserved ejection fraction: present status and future directions. Experimental and Molecular Medicine, 2019, 51, 1-9.	3.2	46
1745	Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?. ESC Heart Failure, 2019, 6, 1334-1335.	1.4	5
1746	Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic To Translational Science, 2019, 4, 962-972.	1.9	3
1747	Sacubitril/valsartan in HFrEF â€“ Should the aces up our sleeves be played earlier?. IJC Heart and Vasculature, 2019, 25, 100428.	0.6	0
1748	cGMP manipulation in cardiometabolic disease. Current Opinion in Cardiology, 2019, 34, 376-383.	0.8	2
1749	Managing hypertension in patients with heart failure. Current Opinion in Cardiology, 2019, 34, 359-366.	0.8	6
1750	Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2019, 73, 301-306.	0.8	4
1751	Dementia and the heart failure patient. European Heart Journal Supplements, 2019, 21, L28-L31.	0.0	16
1752	Heart failure and its complications in patients with diabetes: Mounting evidence for a growing burden. European Journal of Preventive Cardiology, 2019, 26, 106-113.	0.8	17
1753	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	1.2	39
1754	Initiation, maintenance and withdrawal of disease-modifying treatment during an acute heart failure decompensation. Revista Clínica Espanõla, 2019, 219, 464-466.	0.3	0
1755	Heart Failure and Changes in Kidney Function. Heart Failure Clinics, 2019, 15, 455-461.	1.0	7
1756	Advances in MRI Applications to Diagnose and Manage Cardiomyopathies. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 74.	0.4	1

#	Article	IF	Citations
1757	MitraClip: How Do We Reconcile the Inconsistent Findings of MITRA-FR and COAPT?. Current Cardiology Reports, 2019, 21, 150.	1.3	8
1758	Skeletal muscle alterations in tachycardia-induced heart failure are linked to deficient natriuretic peptide signalling and are attenuated by RAS-/NEP-inhibition. PLoS ONE, 2019, 14, e0225937.	1.1	3
1759	Therapeutic Advances in Emergency Cardiology: A Focus on Acute Myocarditis. American Journal of Therapeutics, 2019, 26, e294-e300.	0.5	6
1760	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. American Journal of Therapeutics, 2019, 26, e671-e678.	0.5	6
1761	Arterial stiffness in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 527-536.	1.0	11
1762	Interest of albuminuria in nephrology, diabetology and as a marker of cardiovascular risk. Annales De Biologie Clinique, 2019, 77, 26-35.	0.2	7
1763	Sacubitril/valsartan improves medium-term reverse left ventricular remodeling. Journal of Cardiovascular Medicine, 2019, 20, 727-729.	0.6	8
1765	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failureâ€€â€• Digest Version â€•. Circulation Journal, 2019, 83, 2084-2184.	0.7	446
1766	Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2019, 322, 2292.	3.8	85
1767	Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. Scientific Reports, 2019, 9, 19178.	1.6	14
1768	Circulating proteomic signature of early death in heart failure patients with reduced ejection fraction. Scientific Reports, 2019, 9, 19202.	1.6	21
1769	Update on pediatric heart failure. Current Opinion in Pediatrics, 2019, 31, 598-603.	1.0	9
1770	In heart failure with reduced ejection fraction patientsâ€™ left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers. Journal of Cardiovascular Medicine, 2019, 20, 857-858.	0.6	2
1771	Effect and safety of LCZ696 in the treatment of hypertension. Medicine (United States), 2019, 98, e16093.	0.4	16
1772	The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The â€œHemodynamic Recoveryâ€• Journal of Clinical Medicine, 2019, 8, 2165.	1.0	24
1773	Effects of Low-Dose Sacubitril/Valsartan on Different Stages of Cardiac Hypertrophy in Salt-Loaded Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2019, 73, 282-289.	0.8	6
1774	Update in recent clinical trials in heart failure. Current Opinion in Cardiology, 2019, 34, 307-314.	0.8	2
1775	Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%: Retracted. Medicine (United States), 2019, 98, e17296.	0.4	3

#	Article	IF	Citations
1776	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. American Journal of Therapeutics, 2019, 26, e222-e233.	0.5	10
1777	Evolving Use of Biomarkers in the Management of Heart Failure. Cardiology in Review, 2019, 27, 153-159.	0.6	16
1778	In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?. Journal of Cardiovascular Pharmacology, 2019, 74, 1-3.	0.8	5
1779	Use of sacubitril/valsartan in Marfan syndromeâ€"related cardiomyopathy. Medicine (United States), 2019, 98, e17978.	0.4	3
1780	Increasing the heart failure nursing workforce: recommendations by the British Society for Heart Failure Nurse Forum. British Journal of Cardiac Nursing, 2019, 14, 1-12.	0.0	13
1781	Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy. International Journal of Molecular Sciences, 2019, 20, 6053.	1.8	14
1782	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502	2.9	65
1783	Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang. Biochemistry (Moscow), 2019, 84, 1346-1358.	0.7	17
1784	Efficacy of Sacubitril/Valsartan in Hypertension. American Journal of Therapeutics, 2022, 29, e322-e333.	0.5	11
1785	Updates in the management of heart failure for the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension, 2019, 28, 262-266.	1.0	6
1786	Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. Journal of Cardiovascular Pharmacology, 2019, 73, 149-154.	0.8	14
1787	Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988265.	1.0	2
1788	Etiology and Prognosis of Cardiogenic Shock in a Secondary Center without Surgical Back-Up. Cardiology Research and Practice, 2019, 2019, 1-7.	0.5	3
1789	Relationship between changing patientâ€reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HFâ€ACTION. European Journal of Heart Failure, 2019, 21, 63-70.	2.9	42
1790	A Drug Utilization Study of Sacubitril/Valsartan in Catalonia. Revista Espanola De Cardiologia (English Ed), 2019, 72, 593-595.	0.4	1
1791	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2019, 132, 16-24.	0.6	5
1792	Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Failure Reviews, 2019, 24, 167-176.	1.7	57
1793	TUSARC: Prognostic Value of High-Sensitivity Cardiac Troponin T Assay in Asymptomatic Patients with High Cardiovascular Risk. American Journal of Medicine, 2019, 132, 631-638.	0.6	7

#	Article	IF	Citations
1794	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0
1795	Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease. , 2019, , 171-177.		0
1796	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	1.8	78
1797	New drugs in preclinical and early stage clinical development in the treatment of heart failure. Expert Opinion on Investigational Drugs, 2019, 28, 51-71.	1.9	15
1798	Pharmacology of Cardiovascular Drugs. , 2019, , 192-212.e6.		4
1799	Natriuretic peptides in heart failure: Current achievements and future perspectives. International Journal of Cardiology, 2019, 281, 186-189.	0.8	23
1800	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, andÂReduced Ejection Fraction. JACC: Heart Failure, 2019, 7, 65-76.	1.9	62
1801	Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. American Journal of Transplantation, 2019, 19, 1518-1528.	2.6	11
1802	Contemporary Treatment of Heart Failure. Cardiac Electrophysiology Clinics, 2019, 11, 21-37.	0.7	3
1803	Contemporary Drug Treatment ofÂChronic Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2019, 7, 13-21.	1.9	122
1804	No longer failing to treat heart failure. JAAPA: Official Journal of the American Academy of Physician Assistants, 2019, 32, 11-15.	0.1	1
1805	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
1806	Discussing Outâ€ofâ€Pocket Costs With Patients: Shared Decision Making for Sacubitrilâ€Valsartan in Heart Failure. Journal of the American Heart Association, 2019, 8, e010635.	1.6	37
1807	Initiation, Continuation, Switching, and WithdrawalÂof Heart Failure Medical Therapies DuringÂHospitalization. JACC: Heart Failure, 2019, 7, 1-12.	1.9	109
1808	Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients. Acta Cardiologica, 2019, 74, 405-412.	0.3	20
1809	Treatment effect quantification for timeâ€toâ€event endpointsâ€“Estimands, analysis strategies, and beyond. Pharmaceutical Statistics, 2019, 18, 145-165.	0.7	38
1810	Lack of improvement in autonomic cardiac tone after sacubitril/valsartan at lower than target doses. Journal of Electrocardiology, 2019, 52, 99-100.	0.4	1
1811	Impact of Event Severity on Hospital Rankings Based on Heart Failure Readmission Rates. Population Health Management, 2019, 22, 243-247.	0.8	3

#	Article	IF	Citations
1812	Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. International Journal of Cardiology, 2019, 281, 158-165.	0.8	26
1813	Angiotensinâ€“Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine, 2019, 380, 539-548.	13.9	848
1814	Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. Heart Rhythm, 2019, 16, 733-740.	0.3	13
1815	Modes of death and prognostic outliers in chronic heart failure. American Heart Journal, 2019, 208, 100-109.	1.2	7
1816	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2018. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2-11.	0.6	5
1817	Management of Fluid Overload in Cardiorenal Patients. , 2019, , 825-835.e2.		0
1818	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarctionâ€"Results of the CHIARA MIA 1 Trial. Clinical Pharmacology in Drug Development, 2019, 8, 942-951.	0.8	17
1819	Heart Failure with Reduced Ejection Fraction in Women. Heart Failure Clinics, 2019, 15, 19-27.	1.0	46
1820	Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come. Chronic Diseases and Translational Medicine, 2019, 5, 75-88.	0.9	6
1821	Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H289-H297.	1.5	15
1822	Neutrophil-Initiated Myocardial Inflammation and Its Modulation by B-Type Natriuretic Peptide: A Potential Therapeutic Target. International Journal of Molecular Sciences, 2019, 20, 129.	1.8	6
1823	Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. JAMA Internal Medicine, 2019, 179, 224.	2.6	26
1824	Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40.	1.2	168
1825	Chronic Heart Failure: Impact of the Current Guidelines. Journal for Nurse Practitioners, 2019, 15, 125-131.e2.	0.4	0
1826	Critical Care Management of theÂACHD Patient with Heart Failure. Congenital Heart Disease in Adolescents and Adults, 2019, , 249-271.	0.2	0
1827	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	2.9	60
1828	Urinary Peptidomic Biomarker for Personalized Prevention and Treatment of Diastolic Left Ventricular Dysfunction. Proteomics - Clinical Applications, 2019, 13, 1800174.	0.8	17
1829	Student pharmacistsâ€™ performance and perceptions on an evidence-based medicine objective structured clinical examination. Currents in Pharmacy Teaching and Learning, 2019, 11, 302-308.	0.4	7

#	Article	IF	Citations
1830	Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. International Journal of Cardiology, 2019, 280, 184-189.	0.8	24
1831	Transient Receptor Potential Canonical 3 and Nuclear Factor of Activated T Cells C3 Signaling Pathway Critically Regulates Myocardial Fibrosis. Antioxidants and Redox Signaling, 2019, 30, 1851-1879.	2.5	12
1832	Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.	1.2	60
1833	Chronic heart failure: a disease of the brain. Heart Failure Reviews, 2019, 24, 301-307.	1.7	23
1834	Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety. American Journal of Cardiovascular Drugs, 2019, 19, 1-10.	1.0	2
1835	The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2019, 24, 109-114.	1.7	22
1836	Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Failure Reviews, 2019, 24, 245-254.	1.7	9
1837	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 112-120.	2.9	44
1838	Medication dosing for heart failure with reduced ejection fraction â€" opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	2.9	57
1839	Contemporary Management of Heart Failure in the Elderly. Drugs and Aging, 2019, 36, 137-146.	1.3	8
1840	Influenza Vaccine in Heart Failure. Circulation, 2019, 139, 575-586.	1.6	114
1841	Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. European Journal of Pharmaceutical Sciences, 2019, 128, 103-111.	1.9	18
1842	High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. Peptides, 2019, 112, 43-47.	1.2	6
1843	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	2.9	38
1844	The prognostic value of troponin T and Nâ€terminal pro Bâ€type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	2.9	54
1845	Synthesis, Isolation, and Analysis of Stereoisomers of Sacubitril. Organic Process Research and Development, 2019, 23, 102-107.	1.3	16
1846	Evidence-Based Management of the Patient with Congestive Heart Failure. Contemporary Cardiology, 2019, , 449-465.	0.0	0
1847	Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. European Journal of Heart Failure, 2019, 21, 598-605.	2.9	114

#	Article	IF	Citations
1848	Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation, 2019, 139, 1354-1365.	1.6	233
1849	Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. European Journal of Heart Failure, 2019, 21, 14-22.	2.9	71
1850	Updates in heart failure 30-day readmission prevention. Heart Failure Reviews, 2019, 24, 177-187.	1.7	37
1851	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. Annual Review of Pharmacology and Toxicology, 2019, 59, 41-63.	4.2	23
1852	Neprilysin levels at the acute phase of STâ€elevation myocardial infarction. Clinical Cardiology, 2019, 42, 32-38.	0.7	12
1853	B-type natriuretic peptide levels and benign adiposity in obese heart failure patients. Heart Failure Reviews, 2019, 24, 219-226.	1.7	4
1854	Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats. Clinical and Experimental Hypertension, 2019, 41, 62-69.	0.5	24
1855	Efecto inicial del sacubitrilo-valsartÃ¡n sobre la capacidad funcional en pacientes con insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n reducida: estudio piloto. Revista Espanola De Cardiologia, 2019, 72, 167-169.	0.6	4
1856	Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction. Herz, 2019, 44, 425-432.	0.4	24
1857	Cognitive performance of patients with chronic heart failure on sacubitril/valsartan. Herz, 2019, 44, 534-540.	0.4	16
1858	Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study. Revista Espanola De Cardiologia (English Ed), 2019, 72, 167-169.	0.4	6
1859	In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization. Herz, 2019, 44, 651-658.	0.4	7
1860	Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?. Nephrology Dialysis Transplantation, 2019, 34, 100-108.	0.4	16
1861	Telemonitoring in patients with heart failure: Is there a long-term effect?. Journal of Telemedicine and Telecare, 2019, 25, 158-166.	1.4	10
1862	Serum neprilysin and the risk of death in patients with out-of-hospital cardiac arrest of non-traumatic origin. European Heart Journal: Acute Cardiovascular Care, 2020, 9, S169-S174.	0.4	5
1863	Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial. Journal of Telemedicine and Telecare, 2020, 26, 64-72.	1.4	38
1864	Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure â" A Single Centre Case Series and Call for an International Registry. Heart Lung and Circulation, 2020, 29, 137-141.	0.2	31
1865	Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. Acta Cardiologica, 2020, 75, 10-19.	0.3	4

#	Article	IF	Citations
1866	Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction. Acta Cardiologica, 2020, 75, 20-25.	0.3	10
1867	Editorial commentary: The public physician in cardiology: The solution to information pollution. Trends in Cardiovascular Medicine, 2020, 30, 36-38.	2.3	3
1868	New insights in the assessment of left ventricular dyssynchrony: Laying the foundations for phase analysis by cardiac SPECT. Journal of Nuclear Cardiology, 2020, 27, 2280-2282.	1.4	0
1869	Sacubitril/Valsartan (EntrestoÂ®)-Induced Hyponatremia. Journal of Pharmacy Practice, 2020, 33, 696-699.	0.5	6
1870	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. European Heart Journal, 2020, 41, 1764-1774.	1.0	11
1871	Sacubitril/valsartan for heart failure in adults with complex congenital heart disease. International Journal of Cardiology, 2020, 300, 137-140.	0.8	35
1872	Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 199-205.	0.7	8
1873	Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation. Heart and Vessels, 2020, 35, 136-142.	0.5	10
1874	Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. Heart Lung and Circulation, 2020, 29, 1310-1317.	0.2	9
1875	Chronic kidney disease, heart failure and neprilysin inhibition. Nephrology Dialysis Transplantation, 2020, 35, 558-564.	0.4	39
1876	Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. Journal of Pharmacy Practice, 2020, 33, 553-557.	0.5	4
1877	C-type natriuretic peptide co-ordinates cardiac structure and function. European Heart Journal, 2020, 41, 1006-1020.	1.0	56
1880	Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 152-157.	1.0	19
1881	Inpatient management of acute decompensated heart failure. Postgraduate Medical Journal, 2020, 96, 33-42.	0.9	12
1882	ARNIs: balancing â€œthe good and the badâ€•of neuroendocrine response to HF. Clinical Research in Cardiology, 2020, 109, 599-610.	1.5	5
1883	Echocardiographic evaluation of the effects of sacubitrilâ€“valsartan on vascular properties in heart failure patients. International Journal of Cardiovascular Imaging, 2020, 36, 271-278.	0.7	4
1884	Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. American Journal of Medicine, 2020, 133, e25-e31.	0.6	29
1885	Streamlining drug discovery assays for cardiovascular disease using zebrafish. Expert Opinion on Drug Discovery, 2020, 15, 27-37.	2.5	13

#	Article	IF	Citations
1886	Declining clinical benefit of ICD in heart failure patients: Temporal trend of mortality outcomes from randomized controlled trials. Journal of Cardiology, 2020, 75, 148-154.	0.8	11
1887	Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiologica, 2020, 75, 732-736.	0.3	17
1888	Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 2020, 109, 638-645.	1.5	12
1889	Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. Journal of Cardiology, 2020, 75, 233-241.	0.8	26
1890	A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clinical Research in Cardiology, 2020, 109, 700-713.	1.5	13
1891	Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission. International Journal of Cardiology, 2020, 307, 109-113.	0.8	11
1892	Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. Heart Failure Reviews, 2020, 25, 295-303.	1.7	24
1893	The art of caring for adults with congenital heart disease in the face of imperfect data. International Journal of Cardiology, 2020, 300, 141-142.	0.8	3
1894	Angiotensin II and angiotensin 1â€“7: which is their role in atrial fibrillation?. Heart Failure Reviews, 2020, 25, 367-380.	1.7	37
1895	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
1896	Treatment of Heart Failure with Preserved Ejection Fraction. , 2020, , 568-585.		0
1897	Biomarkers and Precision Medicine in Heart Failure. , 2020, , 449-466.e3.		0
1898	Natriuretic Peptides in Heart Failure: Pathophysiologic and Therapeutic Implications. , 2020, , 127-135.e3.		0
1899	Alterations in Kidney Function Associated With Heart Failure. , 2020, , 214-221.e2.		0
1900	Management of Heart Failure in Special Populations. , 2020, , 586-598.e3.		0
1901	Reninâ€“Angiotensin Inhibition and Outcomes in Nursing Home Residents With Heart Failure. American Journal of Therapeutics, 2020, 27, e235-e242.	0.5	1
1902	New perspectives and future directions in the treatment of heart failure. Heart Failure Reviews, 2020, 25, 147-159.	1.7	37
1903	The reninâ€“angiotensinâ€“aldosterone system update: full-court press. Nephrology Dialysis Transplantation, 2020, 35, 1488-1490.	0.4	3

#	Article	IF	Citations
1904	Characteristics and outcomes of HFpEF with declining ejection fraction. Clinical Research in Cardiology, 2020, 109, 225-234.	1.5	20
1905	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Failure Reviews, 2020, 25, 31-42.	1.7	52
1906	Circulating Neprilysin in Patients WithÂHeartÂFailure and Preserved EjectionÂFraction. JACC: Heart Failure, 2020, 8, 70-80.	1.9	21
1907	Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2020, 73, 268-269.	0.4	9
1909	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
1910	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
1911	Risk assessment of post-discharge mortality among recently hospitalized Medicare heart failure patients with reduced or preserved ejection fraction. Current Medical Research and Opinion, 2020, 36, 179-188.	0.9	6
1912	Sex and Gender-Related Issues in Heart Failure. Heart Failure Clinics, 2020, 16, 121-130.	1.0	13
1913	Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiology, 2020, 5, 292.	3.0	28
1914	Angiotensin receptor/neprilysin inhibitorâ€"a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. Heart Failure Reviews, 2020, 25, 393-402.	1.7	17
1917	Chronic Kidney Disease and Heart Failureâ€"A Nephrologic Approach. , 2020, , 883-897.		0
1918	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. Revista Espanola De Cardiologia (English Ed), 2020, 73, 313-323.	0.4	10
1919	Kidney disease trials for the 21st century: innovations in design and conduct. Nature Reviews Nephrology, 2020, 16, 173-185.	4.1	14
1920	Role of endothelial dysfunction in heart failure. Heart Failure Reviews, 2020, 25, 21-30.	1.7	101
1921	Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind. International Journal of Cardiology, 2020, 300, 198-200.	0.8	0
1922	Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial. American Journal of Cardiovascular Drugs, 2020, 20, 283-293.	1.0	5
1923	Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Failure Reviews, 2020, 25, 685-701.	1.7	12
1924	The New Biology of Diabetic Kidney Diseaseâ€"Mechanisms and Therapeutic Implications. Endocrine Reviews, 2020, 41, 202-231.	8.9	77

#	Article	IF	Citations
1925	Hypertrophic cardiomyopathy: the future of treatment. European Journal of Heart Failure, 2020, 22, 228-240.	2.9	93
1926	The Association Between Secondhand Smoke Exposure and Survival for Patients With Heart Failure. Journal of Cardiac Failure, 2020, 26, 745-750.	0.7	4
1927	Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry. ESC Heart Failure, 2020, 7, 26-36.	1.4	8
1928	Recent advances in patient selection and devices for transcatheter edge-to-edge mitral valve repair in heart failure. Expert Review of Medical Devices, 2020, 17, 93-102.	1.4	6
1929	Sacubitrilâ€Valsartan in a routine community population: attention to volume status critical to achieving target dose. ESC Heart Failure, 2020, 7, 159-167.	1.4	22
1930	Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Expert Opinion on Therapeutic Targets, 2020, 24, 47-62.	1.5	25
1931	Angiotensin (1â€“12): New insights into heart failure pathogenesis. International Journal of Cardiology, 2020, 310, 118-119.	0.8	1
1932	Heart Failure With Mid-range Ejection Fraction. Current Heart Failure Reports, 2020, 17, 1-8.	1.3	24
1933	Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take?. Clinical Cardiology, 2020, 43, 137-144.	0.7	16
1934	Heart failure with reduced and preserved ejection fraction in adult congenital heart disease. Heart Failure Reviews, 2020, 25, 569-581.	1.7	16
1935	Cyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans. Biomedicine and Pharmacotherapy, 2020, 123, 109797.	2.5	7
1936	LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress. Biomedicine and Pharmacotherapy, 2020, 123, 109803.	2.5	31
1937	Short-term effects of angiotensin receptor-neprilysin inhibitors on diastolic strain and tissue doppler parameters in heart failure patients with reduced ejection fraction: A pilot trial. Hellenic Journal of Cardiology, 2020, 61, 415-418.	0.4	5
1938	Sudden Cardiac Death in Ischemic HeartÂDisease. JACC: Cardiovascular Imaging, 2020, 13, 2223-2238.	2.3	20
1939	A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. Journal of Cardiology, 2020, 75, 454-461.	0.8	13
1940	Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. Journal of Pain and Symptom Management, 2020, 59, 1127-1146.e1.	0.6	5
1941	Antihypertensive agents in Alzheimerâ€™s disease: beyond vascular protection. Expert Review of Neurotherapeutics, 2020, 20, 175-187.	1.4	26
1942	Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry. European Heart Journal, 2020, 41, 958-969.	1.0	28

#	Article	IF	Citations
1943	Is the glass half full or half empty after PARAGON-HF?. Cardiovascular Research, 2020, 116, e5-e7.	1.8	2
1944	cGMP: a unique 2nd messenger molecule â€“ recent developments in cGMP research and development. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 287-302.	1.4	82
1945	Cardiovascular Risk Assessment for Noncardiac Surgery: Are We Ready for Biomarkers?. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1914-1924.	0.6	5
1946	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
1947	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
1948	Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. Circulation, 2020, 141, 112-114.	1.6	11
1949	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361.	1.6	335
1950	Rationale and design of a navigatorâ€driven remote optimization of guidelineâ€directed medical therapy in patients with heart failure with reduced ejection fraction. Clinical Cardiology, 2020, 43, 4-13.	0.7	17
1951	Transforming the interpretation of significance in heart failure trials. European Journal of Heart Failure, 2020, 22, 177-180.	2.9	2
1952	A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years. European Journal of Medicinal Chemistry, 2020, 186, 111852.	2.6	5
1953	Hyperuricemia: a novel old disorderâ€"relationship and potential mechanisms in heart failure. Heart Failure Reviews, 2020, 25, 43-51.	1.7	28
1954	Prognostic Implications of Left Ventricular Cardiomyopathy in Adults With Tetralogy of Fallot. CJC Open, 2020, 2, 1-7.	0.7	4
1955	Stabilization of Perivascular Mast Cells by Endothelial CNP (C-Type Natriuretic Peptide). Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 682-696.	1.1	6
1956	The year in cardiology: heart failure. European Heart Journal, 2020, 41, 1232-1248.	1.0	11
1957	The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats. Journal of Pharmacological Sciences, 2020, 142, 124-126.	1.1	10
1958	Angiotensinâ€"neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. Journal of Hypertension, 2020, 38, 755-764.	0.3	27
1959	Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome. Diabetes and Vascular Disease Research, 2020, 17, 147916411989213.	0.9	14
1960	Angiotensinâ€"neprilysin inhibition in de novo heart failure â€“ starting off strong. European Journal of Heart Failure, 2020, 22, 313-314.	2.9	2

#	Article	IF	Citations
1961	Volume disorders and fluid resuscitation. , 2020, , 45-52.e1.		0
1962	Sacubitrilâ€“Valsartan for the Treatment of Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 105-107.	0.8	4
1963	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.	2.9	28
1964	Will the new decade bring home remote monitoring of heart failure patients?. Netherlands Heart Journal, 2020, 28, 1-2.	0.3	0
1965	Comparative Effectiveness of Sacubitril-ValsartanÂVersus ACE/ARB Therapy in Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2020, 8, 43-54.	1.9	40
1966	Left Ventricular Post-Infarct Remodeling. JACC: Heart Failure, 2020, 8, 131-140.	1.9	80
1967	From Theory to Practice. JACC: Heart Failure, 2020, 8, 55-56.	1.9	1
1968	Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology, 2020, 5, 202.	3.0	57
1969	Early Implementation of Sacubitril/Valsartan for Patients With Heart Failure. JAMA Cardiology, 2020, 5, 207.	3.0	1
1970	Hyperkalemia in heart failure. Current Opinion in Cardiology, 2020, 35, 150-155.	0.8	17
1971	The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016. Journal of Cardiovascular Medicine, 2020, 21, 6-12.	0.6	7
1972	Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. European Journal of Heart Failure, 2020, 22, 303-312.	2.9	52
1973	Sudden death in heart failure: do we understand what we observe?. European Heart Journal, 2020, 41, 1985-1987.	1.0	3
1974	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	1.3	61
1975	Chronic heart failure. , 2020, , 153-168.		0
1976	Therapies for Advanced Heart Failure Patients Ineligible for Heart Transplantation: Beyond Pharmacotherapy. Canadian Journal of Cardiology, 2020, 36, 234-243.	0.8	6
1977	Precision medicine in heart failure no longer a visual theory but a realistic opportunity. European Journal of Internal Medicine, 2020, 71, 20-22.	1.0	0
1978	Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?. Current Cardiology Reviews, 2020, 16, 25-35.	0.6	22

#	Article	IF	Citations
1979	Cardiac remodelling patterns and proteomics: the keys to move beyond ejection fraction in heart failure?. European Journal of Heart Failure, 2020, 22, 1156-1159.	2.9	3
1980	Understanding the dual mechanism of bioactive peptides targeting the enzymes involved in Renin Angiotensin System (RAS): An in-silico approach. Journal of Biomolecular Structure and Dynamics, 2020, 38, 5044-5061.	2.0	8
1981	The cGMP system: components and function. Biological Chemistry, 2020, 401, 447-469.	1.2	43
1982	Left ventricular hypertrophy and hypertension. Progress in Cardiovascular Diseases, 2020, 63, 10-21.	1.6	184
1983	It is time for consistency in the use of biomarkers in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 90-91.	2.9	2
1984	Contemporary approach to treating heart failure. Trends in Cardiovascular Medicine, 2020, 30, 507-518.	2.3	9
1985	The risk and prevention of sudden death in patients with heart failure with reduced ejection fraction. Current Opinion in Cardiology, 2020, 35, 138-144.	0.8	5
1986	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 370-384.	0.8	16
1987	cGMP Signaling and Modulation in Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 385-398.	0.8	27
1988	Tolerability of Sacubitril/Valsartan in Patients With Durable Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, e44-e45.	0.9	3
1989	Heart Failure with Preserved Ejection Fraction in Older Adults. Journal of the American Geriatrics Society, 2020, 68, 664-665.	1.3	1
1990	First Letâ€™s Try â€¦ Will the Success of New Therapies Paradoxically Challenge Outcomes in Advanced Heart Failure?. Circulation: Heart Failure, 2020, 13, e006610.	1.6	1
1991	The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure. International Heart Journal, 2020, 61, 1-6.	0.5	15
1992	Differences in medical treatment and clinical characteristics between men and women with heart failure â€“ a single-centre multivariable analysis. European Journal of Clinical Pharmacology, 2020, 76, 539-546.	0.8	11
1993	Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. Journal of the Chinese Medical Association, 2020, 83, 900-905.	0.6	4
1994	Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart, 2020, 7, e001305.	0.9	11
1995	LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-15.	1.9	27
1996	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e007829.	1.6	18

#	Article	IF	Citations
1997	Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 3159.	1.0	17
1998	Utility of Restricted Mean Survival Time Analysis for HeartÂFailure Clinical Trial Evaluation and Interpretation. JACC: Heart Failure, 2020, 8, 973-983.	1.9	28
1999	Vericiguat in Heart Failure with Reduced Ejection Fraction. New England Journal of Medicine, 2020, 383, 1496-1498.	13.9	7
2000	Effects of Angiotensin-Neprilysin Inhibition in Canines with Experimentally Induced Cardiorenal Syndrome. Journal of Cardiac Failure, 2020, 26, 987-997.	0.7	10
2001	Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population. Journal of Cardiovascular Pharmacology, 2020, 76, 445-451.	0.8	14
2002	The atrial flow regulator: current overview on technique and first experience. Therapeutic Advances in Cardiovascular Disease, 2020, 14, 175394472091957.	1.0	7
2003	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	1.3	40
2004	The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction. Cells, 2020, 9, 2134.	1.8	11
2005	Efficacy and safety of sacubitrilâ€valsartan in heart failure: a metaâ€analysis of randomized controlled trials. ESC Heart Failure, 2020, 7, 3841-3850.	1.4	26
2006	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	2.9	47
2007	Angiotensin Receptor-Neprilysin Inhibition Based on History of HeartÂFailure and Use of Renin-Angiotensin System Antagonists. Journal of the American College of Cardiology, 2020, 76, 1034-1048.	1.2	32
2008	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and HeartÂFailure Cause. JACC: Heart Failure, 2020, 8, 844-855.	1.9	56
2009	Heart Failure Trial Updateâ€"Analysis of Recent Data. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 2792-2800.	0.6	5
2011	Biomechanical and neuroautonomic adaptation to acute blood volume displacement in ischemic dilated cardiomyopathy: the predictive value of the CD25 test. Journal of Applied Physiology, 2020, 129, 1173-1182.	1.2	3
2012	Angiotensin-Neprilysin Inhibition in Black Americans. JACC: Heart Failure, 2020, 8, 859-866.	1.9	11
2013	Targeting Cyclic Guanosine Monophosphate to Treat HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	1.2	71
2014	Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 800-810.	1.9	64
2015	Real-World Epidemiology of Potassium Derangements Among Chronic Cardiovascular, Metabolic and Renal Conditions: A Population-Based Analysis . Clinical Epidemiology, 2020, Volume 12, 941-952.	1.5	8

#	Article	IF	Citations
2016	Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. Cardiovascular Research, 2020, 116, e152-e155.	1.8	8
2017	Â¿Hay evidencia para el bloqueo neurohormonal en pacientes con insuficiencia cardiaca y fracciÃ³n de eyecciÃ³n conservada?. REC: CardioClinics, 2020, 55, 128-130.	0.1	0
2018	Hiperpotasemia en pacientes con insuficiencia cardiaca en EspaÃ±a y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term. Revista Espanola De Cardiologia, 2020, 73, 313-323.	0.6	16
2019	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGMâ€HF. ESC Heart Failure, 2020, 7, 3355-3364.	1.4	9
2020	Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. Journal of Cardiovascular Medicine, 2020, 21, 882-888.	0.6	11
2021	The role of renin-angiotensin system in patients with left ventricular assist devices. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032096644.	1.0	4
2022	The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings. Biomedicine and Pharmacotherapy, 2020, 130, 110596.	2.5	15
2023	Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy. ESC Heart Failure, 2020, 7, 4172-4181.	1.4	12
2024	Indispensable but deceptive evidence-based medicine. Diabetes and Metabolism, 2020, 46, 415-422.	1.4	3
2025	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	2.9	23
2026	PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. American Heart Journal, 2020, 230, 35-43.	1.2	8
2027	Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease. JACC Basic To Translational Science, 2020, 5, 916-927.	1.9	17
2028	Update of Pediatric Heart Failure. Pediatric Clinics of North America, 2020, 67, 889-901.	0.9	9
2029	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Revista Portuguesa De Cardiologia, 2020, 39, 517-541.	0.2	8
2030	Letter to the Editor - New Pharmacotherapy for Heart Failure with Reduced Ejection Fraction. Expert Review of Cardiovascular Therapy, 2020, 18, 651-652.	0.6	0
2031	It is easy to see, but it is better to foresee: a case report on the favourable alliance between CardioMEMS and levosimendan. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.3	8
2032	Advanced heart failure with reduced ejection fraction. Baylor University Medical Center Proceedings, 2020, 33, 350-356.	0.2	0
2033	Twentyâ€year time trends in use of evidenceâ€based heart failure drug therapy in Denmark. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 30-38.	1.2	3

#	Article	IF	Citations
2034	Bias and Loss to Followâ€Up in Cardiovascular Randomized Trials: A Systematic Review. Journal of the American Heart Association, 2020, 9, e015361.	1.6	7
2035	Oneâ€Year Mortality After Intensification of Outpatient Diuretic Therapy. Journal of the American Heart Association, 2020, 9, e016010.	1.6	25
2036	Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. CJC Open, 2020, 2, 321-327.	0.7	8
2037	Insufficient Calorie Intake Worsens Post-Discharge Quality of Life and Increases Readmission Burden in HeartÂFailure. JACC: Heart Failure, 2020, 8, 756-764.	1.9	20
2038	Author's Reply. Value in Health, 2020, 23, 675-676.	0.1	0
2039	Benefits of Optimizing Heart Failure Medication Dosage. Journal for Nurse Practitioners, 2020, 16, 498-503.	0.4	0
2040	SacubitrilÂ/ValsartanÂ: suivi dâ€™une cohorte de patients insuffisants cardiaques en vie rÃ©elle. Pharmacien Hospitalier Et Clinicien, 2020, 55, 42-47.	0.3	0
2041	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128
2042	Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes. Diabetes Care, 2020, 43, 2248-2256.	4.3	25
2044	Management of patients with heart failure treated in cardiology consultations: IC-BERG Study. Revista Clínica Espanõla, 2020, 220, 339-349.	0.3	0
2045	Targets of cGMP/cGKI in Cardiac Myocytes. Journal of Cardiovascular Pharmacology, 2020, 75, 494-507.	0.8	11
2046	Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardio-Oncology, 2020, 6, 24.	0.8	30
2047	In Â®Entresto we trust. Cardio-Oncology, 2020, 6, 25.	0.8	3
2048	Resveratrol Improves Heart Function by Moderating Inflammatory Processes in Patients with Systolic Heart Failure. Antioxidants, 2020, 9, 1108.	2.2	20
2049	The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. International Journal of Molecular Sciences, 2020, 21, 8612.	1.8	19
2050	When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?. JACC: Heart Failure, 2020, 8, 1056.	1.9	0
2051	Standardized Definitions for EvaluationÂofÂHeart Failure Therapies: Scientific Expert Panel From the HeartÂFailure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	1.9	15
2052	Contemporary Management of Heart Failure in Patients With Diabetes. Diabetes Care, 2020, 43, 2895-2903.	4.3	20

#	Article	IF	Citations
2053	IGF1â€“PI3K-inducedÂphysiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity. Journal of Sport and Health Science, 2021, 10, 637-647.	3.3	24
2054	Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart, 2020, 7, e001294.	0.9	23
2055	The secret of success of heart failure therapy: A lesson for ACHD?. International Journal of Cardiology Congenital Heart Disease, 2020, 1, 100003.	0.2	0
2056	Annals for Hospitalists Inpatient Notes - Novel and Advanced Therapies for Heart Failureâ€”What a Hospitalist Needs to Know. Annals of Internal Medicine, 2020, 173, HO2-HO3.	2.0	0
2057	Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530.	1.4	52
2058	Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shockâ€“ a case report. European Heart Journal - Case Reports, 2020, 4, 1-4.	0.3	3
2059	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e007814.	1.6	9
2060	Prioritizing symptom management in the treatment of chronic heart failure. ESC Heart Failure, 2020, 7, 2193-2207.	1.4	32
2061	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. JACC Basic To Translational Science, 2020, 5, 715-726.	1.9	9
2062	Heart failure in congenital heart disease: management options and clinical challenges. Expert Review of Cardiovascular Therapy, 2020, 18, 503-516.	0.6	5
2063	Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?. Journal of Cardiovascular Medicine, 2020, 21, 682-687.	0.6	10
2064	Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China. Frontiers in Pharmacology, 2020, 11, 1101.	1.6	14
2065	NT-proBNP Response to Sacubitril/Valsartan in Hospitalized HeartÂFailure Patients With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 822-833.	1.9	21
2066	Sodium glucose cotransporter 2 inhibitors for all HFrEF patients: can we afford it? A cost-effectiveness analysis of dapagliflozin. European Journal of Preventive Cardiology, 2021, 28, 973-974.	0.8	1
2067	Sacubitrilat reduces proâ€arrhythmogenic sarcoplasmic reticulum Ca²⁺ leak in human ventricular cardiomyocytes of patients with endâ€stage heart failure. ESC Heart Failure, 2020, 7, 2992-3002.	1.4	16
2068	Targeting Protein Kinase G to Treat Cardiac Proteotoxicity. Frontiers in Physiology, 2020, 11, 858.	1.3	12
2069	Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension. Journal of Clinical Medicine, 2020, 9, 2265.	1.0	7
2070	Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a realâ€world study in Taiwan. ESC Heart Failure, 2020, 7, 3003-3012.	1.4	11

#	Article	IF	Citations
2071	Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	2.9	14
2072	Long-term outcomes of non-ischemic dilated cardiomyopathy patients with left ventricular ejection fraction â‰19% on medical therapy. Indian Heart Journal, 2020, 72, 557-562.	0.2	4
2073	The Journal of Cardiopulmonary Rehabilitation and Prevention at 40 yr and Its Role in Promoting Preventive Cardiology: Part 2. Journal of Cardiopulmonary Rehabilitation and Prevention, 2020, 40, 209-214.	1.2	11
2074	Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials. Cardiology, 2020, 145, 589-598.	0.6	18
2075	Empowering People Living with Heart Failure. Heart Failure Clinics, 2020, 16, 409-420.	1.0	4
2076	Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 488.	3.8	391
2077	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 318, 94-100.	0.8	15
2078	Long-Term Effects of Angiotensin Receptorâ€“Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction. Diagnostics, 2020, 10, 522.	1.3	4
2079	Angiotensin receptorâ€“neprilysin inhibition in heart failure with preserved ejection fraction: lessons from <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2020, 22, 1525-1530.	2.9	3
2080	Sympathetic activation and outcomes in chronic heart failure: Does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients?. European Journal of Internal Medicine, 2020, 81, 60-66.	1.0	14
2081	Renal safety and efficacy of angiotensin receptorâ€neprilysin inhibitor: A metaâ€analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1235-1243.	0.7	14
2082	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2020, 5, 1236.	3.0	46
2083	Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care. Netherlands Heart Journal, 2020, 28, 31-38.	0.3	5
2084	Care Gaps in Adherence to HeartÂFailure Guidelines. JACC: Heart Failure, 2020, 8, 725-738.	1.9	55
2085	Quadruple Therapy Is the New Standard of Care for HFrEF. JACC: Heart Failure, 2020, 8, 819-821.	1.9	13
2086	The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor. Annales D'Endocrinologie, 2020, 81, 476-481.	0.6	5
2087	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e000099.	0.9	45
2088	Role of Kinins in Hypertension and Heart Failure. Pharmaceuticals, 2020, 13, 347.	1.7	25

#	Article	IF	Citations
2089	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	2.9	101
2090	Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Services Research, 2020, 20, 964.	0.9	42
2091	A Stepwise Approach to the Management of Heart Failure and its Comorbidities. Journal of Osteopathic Medicine, 2020, 120, 90-99.	0.4	1
2093	Consensus and development of document for management of stabilized acute decompensated heart failure with reduced ejection fraction in India. Indian Heart Journal, 2020, 72, 477-481.	0.2	2
2094	Management of chronic heart failure. Clinics in Integrated Care, 2020, 2, 100016.	0.3	0
2095	Costâ€effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Failure, 2020, 7, 3582-3592.	1.4	31
2097	Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices. American Journal of Cardiovascular Drugs, 2020, 21, 383-393.	1.0	3
2098	Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 118-129.	1.4	20
2099	Optimizing the Profile of [99mTc]Tcâ€“NT(7â€“13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7926.	1.8	7
2100	CHIP phosphorylation by protein kinase G enhances protein quality control and attenuates cardiac ischemic injury. Nature Communications, 2020, 11, 5237.	5.8	24
2101	Angiotensin converting enzyme inhibitors and angiotensin receptor blockers. BJA Education, 2020, 20, 362-367.	0.6	0
2102	Sex-specific differences in access and response to medical and device therapies in heart failure: State of the art. Progress in Cardiovascular Diseases, 2020, 63, 640-648.	1.6	5
2103	Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 360.	0.7	1
2104	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e016309.	1.6	23
2105	Heart failure hospitalizations and costs in ICD/CRTâ€Ð recipients following replacement or upgrade: the DECODE registry. ESC Heart Failure, 2020, 7, 4377-4383.	1.4	2
2106	Amelioration of ischemic cardiomyopathy in patients using physiological ischemic training. Herz, 2020, 46, 173-179.	0.4	0
2107	A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy. Current Hypertension Reports, 2020, 22, 85.	1.5	13
2108	Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. ESC Heart Failure, 2020, 7, 3633-3643.	1.4	19

#	Article	IF	Citations
2109	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
2110	Effect of sacubitril/valsartan on renal function: a systematic review and metaâ€analysis of randomized controlled trials. ESC Heart Failure, 2020, 7, 3487-3496.	1.4	44
2111	BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era. Current Cardiology Reports, 2020, 22, 150.	1.3	7
2112	Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure. Journal of Medical Economics, 2020, 23, 1450-1460.	1.0	0
2113	Victims of Success in Failure. Circulation, 2020, 142, 1129-1131.	1.6	12
2114	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Molecular Medicine, 2020, 12, e10865.	3.3	104
2115	Letter by Krisai et al Regarding Article, â€œPreventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trialâ€. Circulation, 2020, 142, e184-e185.	1.6	0
2116	Beating the bushes for biomarkers. European Journal of Heart Failure, 2020, 22, 2075-2077.	2.9	0
2117	Use of sacubitril-valsartan in blood pressure control with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2020, 39, 1499-1501.	0.3	7
2118	Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany. ESC Heart Failure, 2020, 7, 2318-2330.	1.4	4
2119	Sexâ€based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. European Journal of Heart Failure, 2020, 22, 2018-2025.	2.9	21
2120	Ten lessons from the <scp>EMPERORâ€Reduced</scp> trial. European Journal of Heart Failure, 2020, 22, 1991-1993.	2.9	6
2121	Holding all the ACEs. The Prescriber, 2020, 31, 34-35.	0.1	0
2122	Glyphozines and treatment of cardiac disease. Geriatric Care, 2020, 6, .	0.2	0
2123	Combining health technology assessment and health technology management to deliver cost-effective prescribing and cost containment â€“ the Irish experience. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 431-436.	0.7	2
2124	Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort. Europace, 2020, 22, 1463-1469.	0.7	14
2125	33-Year-Old Woman With Postpartum Acute Shortness of Breath. Mayo Clinic Proceedings, 2020, 95, 2000-2004.	1.4	0
2126	Utilization of Sacubitril/Valsartan in Real-World Settings. American Journal of Cardiovascular Drugs, 2020, 20, 619-623.	1.0	0

#	Article	IF	Citations
2127	New and emerging cardiovascular and antihypertensive drugs. Expert Opinion on Drug Safety, 2020, 19, 1315-1327.	1.0	5
2128	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	1.0	101
2129	Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data . Therapeutics and Clinical Risk Management, 2020, Volume 16, 715-726.	0.9	10
2130	Bias Implications of Outcome Misclassification in Observational Studies Evaluating Association Between Treatments and Allâ€Cause or Cardiovascular Mortality Using Administrative Claims. Journal of the American Heart Association, 2020, 9, e016906.	1.6	12
2131	Efficacy and Safety Outcome of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Patients with Heart Failure and Preserved Ejection Fraction (HFpEF): Preliminary Results . Research Reports in Clinical Cardiology, 0, Volume 11, 39-47.	0.2	1
2132	<scp>DAPAâ€HF</scp>: does dapagliflozin provide â€˜bang for your buckâ€™ as a treatment for <scp>heart failure with reduced ejection fraction</scp>?. European Journal of Heart Failure, 2020, 22, 2157-2159.	2.9	1
2133	Neurohormonal Blockade During Left Ventricular Assist Device Support. ASAIO Journal, 2020, 66, 881-885.	0.9	4
2134	Targeting Cardiac Myocyte Na ⁺ -K ⁺ Pump Function With Î²3 Adrenergic Agonist in Rabbit Model of Severe Congestive Heart Failure. Circulation: Heart Failure, 2020, 13, e006753.	1.6	8
2135	The role of sacubitril/valsartan in the management of cardiac resynchronization therapy nonâ€responders: a retrospective analysis. ESC Heart Failure, 2020, 7, 4404-4407.	1.4	16
2136	Advances and New Insights in Post-Transplant Care: From Sequencing to Imaging. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	1
2137	Diversity and Inclusion. Journal of the American College of Cardiology, 2020, 76, 1494-1497.	1.2	11
2138	COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?. Pain Medicine, 2020, 21, 3246-3247.	0.9	3
2139	Safety, Pharmacokinetics, and Pharmacodynamics of TDâ€0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects. Clinical and Translational Science, 2020, 13, 1307-1315.	1.5	0
2140	Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	6
2141	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
2142	Serum potassium in the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2020, 22, 2056-2064.	2.9	34
2143	Impact of Î²â€blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation. Echocardiography, 2020, 37, 1392-1398.	0.3	3
2144	Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date . Therapeutics and Clinical Risk Management, 2020, Volume 16, 681-688.	0.9	5

#	Article	IF	Citations
2145	Comparison of effectiveness and survival after the MitraClip or Carillon procedure for severe functional mitral regurgitation: a single-center retrospective analysis. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 171-177.	0.5	1
2146	Significance of the Renin-Angiotensin System in Clinical Conditions. , 0, , .		6
2147	Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006255.	0.9	14
2148	Challenges and Potential Improvements to Patient Access to Pharmaceuticals. Circulation, 2020, 142, 790-798.	1.6	7
2149	Sacubitril/Valsartan: Potential Impact of ARNi â€œBeyond the Wallâ€•of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. Frontiers in Cardiovascular Medicine, 2020, 7, 616564.	1.1	4
2150	Show Me the Money. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007070.	0.9	13
2151	The many-faced hurdle of cardiac involvement in diabetes: where to focus?. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882097044.	1.4	0
2152	One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto. Pharmaceutics, 2020, 12, 1145.	2.0	9
2153	Mapping the Kansas City Cardiomyopathy Questionnaire (KCCQ) Onto EQ-5D-3L in Heart Failure Patients: Results for the Japanese and UK Value Sets. MDM Policy and Practice, 2020, 5, 238146832097160.	0.5	1
2154	Autonomic Modulation for Cardiovascular Disease. Frontiers in Physiology, 2020, 11, 617459.	1.3	65
2155	Relationship between Soluble (Pro)Renin Receptor and Renin Activity in Patients with Severe Heart Failure. Journal of Clinical Medicine, 2020, 9, 4110.	1.0	5
2156	Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II. Heart, 2021, 107, 1487-1492.	1.2	8
2158	Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction. CJC Open, 2020, 2, 447-453.	0.7	11
2159	Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study. Indian Heart Journal, 2020, 72, 535-540.	0.2	2
2160	When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 177-178.	0.2	0
2161	Heart failure units: State of the art in disease management. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 341-350.	0.2	1
2162	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. Journal of the American College of Cardiology, 2020, 76, 2527-2564.	1.2	41
2163	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proofâ€ofâ€concept study. ESC Heart Failure, 2020, 7, 4267-4276.	1.4	3

#	Article	IF	Citations
2164	Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction. IJC Heart and Vasculature, 2020, 31, 100656.	0.6	15
2165	PronÃ³stico actual de la insuficiencia cardiaca en EspaÃ±a y Europa. Una llamada de atenciÃ³n. REC: CardioClinics, 2020, 55, 201-203.	0.1	0
2166	<scp>VICTORIA</scp> in context. European Journal of Heart Failure, 2020, 22, 1747-1751.	2.9	2
2167	Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. Advances in Therapy, 2020, 37, 2620-2645.	1.3	5
2168	Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study. CJC Open, 2020, 2, 344-353.	0.7	9
2169	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International Journal of Cardiology, 2020, 313, 76-82.	0.8	30
2170	Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. Journal of Affective Disorders, 2020, 272, 132-137.	2.0	13
2172	Ejection fraction in heart failure revisited-Âwhere does the evidence start?. European Heart Journal, 2020, 41, 2363-2365.	1.0	20
2173	A Modern Integration of Palliative Care Into the Management of Heart Failure. Canadian Journal of Cardiology, 2020, 36, 1050-1060.	0.8	11
2174	Association between inflammation and skeletal muscle proteolysis, skeletal mass and strength in elderly heart failure patients and their prognostic implications. BMC Cardiovascular Disorders, 2020, 20, 228.	0.7	27
2175	ARNI in cardiovascular disease: current evidence and future perspectives. Future Cardiology, 2020, 16, 505-515.	0.5	18
2176	Phosphodiesterase 9 Inhibition in Models of Heart Failure With Preserved Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007107.	1.6	1
2177	Soluble ST2 and Soluble Markers of Fibrosis: Emerging Roles for Prognosis and Guiding Therapy. Current Cardiology Reports, 2020, 22, 41.	1.3	15
2178	Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover. Scientific Reports, 2020, 10, 8284.	1.6	11
2179	Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. Journal of the American Heart Association, 2020, 9, e015071.	1.6	5
2180	Guidelineâ€directed medical therapy for heart failure does not exist: a nonâ€judgmental framework for describing the level of adherence to evidenceâ€based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1759-1767.	2.9	41
2181	[6]â€Gingerol Ameliorates ISOâ€Induced Myocardial Fibrosis by Reducing Oxidative Stress, Inflammation, and Apoptosis through Inhibition of TLR4/MAPKs/NFâ€ºB Pathway. Molecular Nutrition and Food Research, 2020, 64, e2000003.	1.5	31
2182	Management of heart failure: an Italian national survey on fellows/specialists in geriatrics. Aging Clinical and Experimental Research, 2020, 32, 2049-2055.	1.4	1

#	Article	IF	Citations
2183	Introduction of sacubitril/valsartan in primary care followâ€up of heart failure: a prospective observational study (THESEUS). ESC Heart Failure, 2020, 7, 1626-1634.	1.4	3
2184	Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door. Heart Failure Reviews, 2022, 27, 767-778.	1.7	6
2185	Angiotensin Receptorâ€“Neprilysin Inhibitors and the Natriuretic Peptide Axis. Current Heart Failure Reports, 2020, 17, 67-76.	1.3	12
2186	Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovascular Diabetology, 2020, 19, 55.	2.7	27
2187	Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations. ESC Heart Failure, 2020, 7, 1477-1487.	1.4	6
2188	Cost-effectiveness analyses of sacubitril-valsartan for heart failure. Heart Failure Reviews, 2021, 26, 1119-1130.	1.7	13
2190	Vericiguat â€" Another Victory for Targeting Cyclic GMP in Heart Failure. New England Journal of Medicine, 2020, 382, 1952-1953.	13.9	17
2191	Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism. Annals of Medicine, 2020, 52, 178-190.	1.5	1
2192	Epidemiology of heart failure. European Journal of Heart Failure, 2020, 22, 1342-1356.	2.9	948
2193	Impact of Sacubitril-Valsartan on Markers of Glomerular Function. Current Heart Failure Reports, 2020, 17, 145-152.	1.3	14
2194	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	1.4	16
2195	Secondary prevention and outcomes in outpatients with coronary artery disease, atrial fibrillation or heart failure: a focus on disease overlap. Open Heart, 2020, 7, e001165.	0.9	8
2196	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1662-1671.	2.9	33
2197	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases, 2020, 63, 570-584.	1.6	53
2198	Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696. Journal of Organic Chemistry, 2020, 85, 6844-6853.	1.7	25
2199	Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway. Prostaglandins and Other Lipid Mediators, 2020, 150, 106454.	1.0	10
2200	Rationale and study design of <scp>OUTSTEPâ€HF</scp>: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1724-1733.	2.9	8
2201	Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. Biochemical Pharmacology, 2020, 178, 114057.	2.0	33

#	Article	IF	Citations
2202	Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling. Journal of Cardiac Failure, 2020, 26, 769-775.	0.7	9
2203	Long-term use of neprilysin inhibitor: Should we fear development of neurological diseases?. Revue Neurologique, 2020, 176, 529-530.	0.6	1
2204	The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358.	1.7	15
2205	Incidence of vasoplegic syndrome after cardiac transplantation in patients treated with sacubitril/valsartan. Clinical Transplantation, 2020, 34, e13994.	0.8	3
2206	Sacubitril/Valsartan in Advanced HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	1.9	39
2207	Efficacy and safety of sodiumâ€“glucose coâ€transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	2.9	29
2208	The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1483-1485.	2.9	3
2209	The Importance of Natriuretic Peptides in Cardiometabolic Diseases. Journal of the Endocrine Society, 2020, 4, bvaa052.	0.1	31
2210	New pharmacotherapy for heart failure with reduced ejection fraction. Expert Review of Cardiovascular Therapy, 2020, 18, 405-414.	0.6	4
2211	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. Cardiovascular Drugs and Therapy, 2020, 34, 723-735.	1.3	11
2212	The role of diabetes in cardiomyopathies of different etiologiesâ€"Characteristics and 1-year follow-up results of the EVITA-HF registry. PLoS ONE, 2020, 15, e0234260.	1.1	2
2213	Consenso de expertos sobre la insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n reducida: mÃ¡s allÃ¡ de las guÃas. Revista Espanola De Cardiologia Suplementos, 2020, 20, 1-46.	0.2	2
2214	Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor. Biomedicine and Pharmacotherapy, 2020, 129, 110410.	2.5	5
2215	Machine Learning in Cardiologyâ€"Ensuring Clinical Impact Lives Up to the Hype. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 379-390.	1.0	11
2216	Cardiac cGMP Signaling in Health and Disease. Journal of Cardiovascular Pharmacology, 2020, 75, 399-409.	0.8	11
2217	Advances in the Management of Acute Decompensated Heart Failure. Medical Clinics of North America, 2020, 104, 601-614.	1.1	7
2218	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics, 2020, 9, 265-278.	0.2	2
2219	Angiotensinâ€“ neprilysin inhibitors: should we initiate them in hospital for patients with acute decompensated heart failure?. BMJ Evidence-Based Medicine, 2020, 25, 151-152.	1.7	0

#	Article	IF	Citations
2220	Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovascular Endocrinology and Metabolism, 2020, 9, 17-23.	0.5	16
2221	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials, 2020, 21, 528.	0.7	10
2222	Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. Heart Failure Reviews, 2020, , 1.	1.7	9
2223	Angiotensin Receptorâ€Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension. Journal of the American Heart Association, 2020, 9, e015708.	1.6	49
2224	<scp>Sacubitril/valsartan</scp> in patients <scp>postâ€left</scp> ventricular assist device implant: a <scp>singleâ€centre</scp> case series. European Journal of Heart Failure, 2020, 22, 1490-1492.	2.9	6
2225	Management of neurogenic orthostatic hypotension in the heart failure patient. Autonomic Neuroscience: Basic and Clinical, 2020, 227, 102691.	1.4	5
2226	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine, 2020, 288, 491-506.	2.7	20
2227	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ, The, 2020, 369, m115.	3.0	57
2228	The year in cardiology: heart failure. The year in cardiology 2019.. SA Heart Journal, 2020, 17, .	0.0	0
2229	Inflammation and Circulating Natriuretic Peptide Levels. Circulation: Heart Failure, 2020, 13, e006570.	1.6	47
2230	The Globalisation of Cardiology and Cardiovascular Diseases in the Worldâ€“Societyâ€”A Case Study with a Special Focus on Heart Failure. International Journal of Environmental Research and Public Health, 2020, 17, 3150.	1.2	1
2231	Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report. Clinical Case Reports (discontinued), 2020, 8, 1349-1352.	0.2	2
2232	Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) Study. Canadian Journal of Cardiology, 2020, 36, 1269-1277.	0.8	5
2233	Improving physical activity and exercise capacity in heart failure. Taking the first step isÂalways the hardest. European Journal of Heart Failure, 2020, 22, 1734-1736.	2.9	0
2234	Abnormalities of Potassium in HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 2836-2850.	1.2	94
2235	Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 1897.	1.0	14
2236	Metodologia clinica oggi nel paziente internistico complesso. Italian Journal of Medicine, 2020, , 1-135.	0.2	0
2237	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. JACC: Heart Failure, 2020, 8, 347-358.	1.9	53

#	Article	IF	Citations
2238	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2020, 382, 1180-1183.	13.9	21
2239	Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction. Acta Cardiologica, 2020, 75, 774-782.	0.3	12
2240	Diagnosis and management of the adult patient with a failing Fontan circulation. Heart Failure Reviews, 2020, 25, 633-646.	1.7	17
2241	Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis. Clinical Drug Investigation, 2020, 40, 493-501.	1.1	13
2242	Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case Report. CJC Open, 2020, 2, 176-178.	0.7	6
2243	Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with endâ€stage of renal disease. ESC Heart Failure, 2020, 7, 1125-1129.	1.4	46
2244	Pumps and The New Pills. ASAIO Journal, 2020, 66, 258-260.	0.9	1
2245	Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e750-e772.	1.6	237
2246	Approach to a Child with Congestive Heart Failure. Indian Journal of Pediatrics, 2020, 87, 312-320.	0.3	1
2247	Age and Heart Failure Trials â€“ Lessons from DAPA-HF. Journal of Cardiac Failure, 2020, 26, 191-192.	0.7	1
2248	Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. IJC Heart and Vasculature, 2020, 27, 100486.	0.6	33
2249	Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2020, 8, 245.	1.9	0
2250	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiology, 2020, 16, 227-236.	0.5	16
2251	Long-term outcomes following percutaneous coronary intervention to an unprotected left main coronary artery in cardiogenic shock. International Journal of Cardiology, 2020, 308, 20-25.	0.8	3
2252	Understanding the results of the PARAGONâ€HF trial. European Journal of Heart Failure, 2020, 22, 1531-1535.	2.9	7
2253	Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model. Journal of Cardiac Failure, 2020, 26, 527-537.	0.7	27
2254	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	13.9	753
2255	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	1.0	151

#	Article	IF	Citations
2256	Comparing the Benefit of Novel Therapies Across Clinical Trials. Circulation, 2020, 142, 717-719.	1.6	46
2257	A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs. Cardiovascular Drugs and Therapy, 2020, 34, 215-221.	1.3	6
2258	Effect of Sacubitril/Valsartan on circulating catecholamine levels during a 6-month follow-up in heart failure patients. Timeo Danaos et dona ferentes?. Acta Cardiologica, 2020, 76, 1-6.	0.3	2
2259	Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4
2260	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. Diabetes, Obesity and Metabolism, 2020, 22, 1243-1262.	2.2	13
2262	The Emulation and Adaptation of a Global Model of Clinical Practice Guidelines on Chronic Heart Failure in BRICS Countries: A Comparative Study. International Journal of Environmental Research and Public Health, 2020, 17, 1735.	1.2	3
2263	Eligibility for sacubitrilâ€“valsartan in patients with acute decompensated heart failure. ESC Heart Failure, 2020, 7, 1282-1290.	1.4	9
2264	Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. Trends in Molecular Medicine, 2020, 26, 583-596.	3.5	33
2265	Can HFpEF and HFrEF Coexist?. Circulation, 2020, 141, 709-711.	1.6	11
2266	Myocardial work improvement after sacubitrilâ€“valsartan therapy: a new echocardiographic parameter for a new treatment. Journal of Cardiovascular Medicine, 2020, 21, 223-230.	0.6	20
2267	Personalized Approach to Cancer Treatmentâ€“Related Cardiomyopathy. Current Heart Failure Reports, 2020, 17, 43-55.	1.3	3
2268	Acute heart failure. Nature Reviews Disease Primers, 2020, 6, 16.	18.1	237
2269	Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 2020, 43, 430-440.	0.7	15
2270	Toward Improved Understanding of Potential Harm in HeartÂFailure. JACC: Heart Failure, 2020, 8, 246-247.	1.9	0
2271	Reply. JACC: Heart Failure, 2020, 8, 245-246.	1.9	0
2272	Baroreflex Activation Therapy in Patients With HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 1-13.	1.2	121
2273	How to slice the pie: heart failure subgroups and their clinical meaning. European Heart Journal, 2020, 41, 2339-2343.	1.0	0
2274	Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. Peptides, 2020, 132, 170352.	1.2	10

#	Article	IF	Citations
2275	Unidades de insuficiÃªncia cardÃaca: estado da arte na abordagem da insuficiÃªncia cardÃaca. Revista Portuguesa De Cardiologia, 2020, 39, 341-350.	0.2	2
2276	Explaining Heart Failure Hyper-mortality in Sub Saharan Africa: Global Genomic and Environmental Contribution Review. Journal of the National Medical Association, 2020, 112, 141-157.	0.6	7
2277	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L325-L336.	1.3	69
2278	Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy. Cardiovascular Drugs and Therapy, 2020, 34, 755-762.	1.3	7
2279	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	1.9	87
2280	Response to beta-blockers and natriuretic peptide level in acute heart failure: analysis of data from the Korean acute heart failure registry. Clinical Research in Cardiology, 2020, 110, 1392-1403.	1.5	1
2281	Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction. PLoS ONE, 2020, 15, e0233161.	1.1	0
2282	Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study. Heart Lung and Circulation, 2020, 29, 1782-1789.	0.2	4
2283	Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction. BMC Cardiovascular Disorders, 2020, 20, 316.	0.7	2
2284	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Failure, 2020, 7, 727-736.	1.4	7
2285	Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan . Vascular Health and Risk Management, 2020, Volume 16, 41-51.	1.0	15
2286	Mineralocorticoid receptor antagonist use following heart failure hospitalization. ESC Heart Failure, 2020, 7, 482-492.	1.4	10
2287	Early experience of Sacubitrilâ€“Valsartan in heart failure with reduced ejection fraction in realâ€world clinical setting. ESC Heart Failure, 2020, 7, 1049-1055.	1.4	14
2288	Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin indb/dbdiabetic mice. Physiological Reports, 2020, 8, e14364.	0.7	10
2289	Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Failure, 2020, 7, 559-566.	1.4	15
2290	Racial/ethnic differences in circulating natriuretic peptide levels: The Diabetes Prevention Program. PLoS ONE, 2020, 15, e0229280.	1.1	8
2291	Healthâ€related quality of life in patients with heart failure eligible for treatment with sacubitrilâ€“valsartan. Nursing Open, 2020, 7, 556-562.	1.1	1
2292	The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Applied Health Economics and Health Policy, 2020, 18, 669-677.	1.0	4

#	Article	IF	Citations
2293	Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital. Journal of Community Hospital Internal Medicine Perspectives, 2020, 10, 38-44.	0.4	4
2294	Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466.	1.5	7
2295	Sexâ€related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence. European Journal of Heart Failure, 2020, 22, 845-847.	2.9	0
2296	Acute Decompensated Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction. Heart Failure Clinics, 2020, 16, 187-200.	1.0	3
2297	Ambulatory levosimendan infusions. Effective and efficient in advanced heart failure?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 345-347.	0.4	0
2298	Randomized trial of a left ventricular assist device as destination therapy versus guidelineâ€directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. European Journal of Heart Failure, 2020, 22, 739-750.	2.9	17
2299	PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. American Heart Journal, 2020, 223, 98-105.	1.2	12
2300	Venom natriuretic peptides guide the design of heart failure therapeutics. Pharmacological Research, 2020, 155, 104687.	3.1	12
2301	Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients. European Journal of Health Economics, 2020, 21, 557-572.	1.4	13
2302	ABCs of Heart Failure Management: A Guide for Nurse Practitioners. Journal for Nurse Practitioners, 2020, 16, 243-248.	0.4	0
2303	Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. CardioRenal Medicine, 2020, 10, 69-84.	0.7	23
2304	Adoption of sacubitril-valsartan in the Medicare population. American Heart Journal, 2020, 223, 81-83.	1.2	1
2305	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.	1.6	96
2306	Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty. ESC Heart Failure, 2020, 7, 757-762.	1.4	28
2307	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure, 2020, 22, 834-844.	2.9	36
2308	Sodiumâ€“glucose coâ€transporter 2 inhibitors and acute heart failure. European Journal of Heart Failure, 2020, 22, 723-725.	2.9	6
2309	The therapeutic effect of Bâ€type natriuretic peptides in acute decompensated heart failure. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1120-1133.	0.9	4
2310	Time-based clinical and functional achievements in real-life HF patients on ARNI treatment. European Journal of Internal Medicine, 2020, 76, 115-117.	1.0	7

#	Article	IF	Citations
2311	Heart failure in the Veneto region of Italy: analysis of therapeutic pathways and the utilization of healthcare resources. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 499-505.	0.7	2
2312	Insulin-like growth factor-II overexpression accelerates parthenogenetic stem cell differentiation into cardiomyocytes and improves cardiac function after acute myocardial infarction in mice. Stem Cell Research and Therapy, 2020, 11, 86.	2.4	10
2313	Vericiguat for heart failure and the VICTORIA trial â€“ the dog that didn't bark?. European Journal of Heart Failure, 2020, 22, 576-577.	2.9	5
2314	Traditional and Novel Imaging of Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. Current Heart Failure Reports, 2020, 17, 28-33.	1.3	21
2315	Heart Failure and Comorbiditiesâ€”Part 2. Current Emergency and Hospital Medicine Reports, 2020, 8, 69-75.	0.6	0
2317	Manejo de los pacientes con insuficiencia cardiaca atendidos en la consulta de cardiologÃa: Estudio IC-BERG. Revista Clinica Espanola, 2020, 220, 339-349.	0.2	5
2318	In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan. PLoS ONE, 2020, 15, e0228926.	1.1	38
2319	Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. American Journal of Medicine, 2020, 133, 525-527.	0.6	6
2320	Bradykininâ€”from snake poison to therapeutic options. Acta Physiologica, 2020, 228, e13445.	1.8	5
2321	Sympathetic Activation in Hypertensive Chronic Kidney Disease â€“ A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?. Frontiers in Physiology, 2019, 10, 1546.	1.3	18
2322	Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity. International Journal of Cardiology, 2020, 305, 106-112.	0.8	6
2323	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 348-357.	0.4	39
2324	Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan. Cardiology, 2020, 145, 275-282.	0.6	19
2325	Second Hits in Dilated Cardiomyopathy. Current Cardiology Reports, 2020, 22, 8.	1.3	15
2326	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432.	3.0	59
2327	Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 188-194.	1.3	5
2328	CTâ€‹GFBPâ€4 as a novel prognostic biomarker in acute heart failure. ESC Heart Failure, 2020, 7, 434-444.	1.4	14
2329	CARDIOPATÃA EN EL PACIENTE ANCIANO. Revista MÃ©dica ClÃnica Las Condes, 2020, 31, 21-27.	0.2	0

#	Article	IF	Citations
2330	HeartÂFailure With PreservedÂEjectionÂFraction. Journal of the American College of Cardiology, 2020, 75, 255-257.	1.2	4
2331	Viral Myocarditisâ€"Incidence, Diagnosis and Management. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1591-1601.	0.6	81
2332	LCZ696 (sacubitril/valsartan) for patients with heart failure. The Cochrane Library, 0, , .	1.5	0
2333	Radiosynthesis of the ¹¹Câ€methyl derivative of LBQ657 for PET investigation of the neprilysin inhibitor sacubitril. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 65-71.	0.5	1
2334	Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD). Clinical Research in Cardiology, 2020, 109, 1035-1047.	1.5	14
2335	Substance and Substrate. Circulation, 2020, 141, 362-366.	1.6	16
2336	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
2337	Effectiveness of sacubitrilâ€"valsartan in cancer patients with heart failure. ESC Heart Failure, 2020, 7, 763-767.	1.4	47
2338	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 159-169.	0.8	89
2339	Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. PLoS ONE, 2020, 15, e0232280.	1.1	28
2340	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure, 2020, 22, 1357-1365.	2.9	66
2341	The prevalence and importance of frailty in heart failure with reduced ejection fractionÂâ€"Âan analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2020, 22, 2123-2133.	2.9	85
2342	Managing heart failure with preserved ejection fraction. Annals of Translational Medicine, 2020, 8, 395-395.	0.7	7
2343	Diabetic Agents, From Metformin toÂSGLT2 Inhibitors and GLP1ÂReceptorÂAgonists. Journal of the American College of Cardiology, 2020, 75, 1956-1974.	1.2	48
2344	Atrial fibrillation in patients with heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2020, 35, 260-270.	0.8	1
2345	Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting. JAMA Cardiology, 2020, 5, 631.	3.0	100
2346	Shortâ€term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan. ESC Heart Failure, 2020, 7, 964-972.	1.4	23
2347	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36

#	Article	IF	Citations
2348	Readmission and death in patients admitted with newâ€onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 2020, 22, 1777-1785.	2.9	53
2350	Chagas disease: still a neglected emergency?. Lancet, The, 2020, 395, 1113-1114.	6.3	5
2351	Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience. Heart Lung and Circulation, 2020, 29, 1688-1695.	0.2	5
2352	The Challenges of NT-proBNP Testing inÂHFpEF. JACC: Heart Failure, 2020, 8, 382-385.	1.9	12
2353	The importance of developing hyperkalaemia in heart failure during long-term follow-up. Acta Cardiologica, 2020, 76, 1-9.	0.3	3
2354	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362.	1.0	38
2355	Minimal Invasive Pericardial Perfusion Model in Swine: A Translational Model for Cardiac Remodeling After Ischemia/Reperfusion Injury. Frontiers in Physiology, 2020, 11, 346.	1.3	0
2356	The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator. Journal of Clinical Medicine, 2020, 9, 1111.	1.0	26
2357	Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls. Journal of Clinical Medicine, 2020, 9, 1130.	1.0	17
2358	Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 1199.	1.0	37
2359	Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan. American Journal of Cardiology, 2020, 125, 1856-1862.	0.7	33
2360	Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. European Journal of Pharmacology, 2020, 881, 173120.	1.7	37
2361	CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations. Human Pathology, 2020, 99, 98-106.	1.1	2
2362	Guideline-concordant-phenotyping: Identifying patient indications for implantable cardioverter defibrillators from electronic health records. International Journal of Medical Informatics, 2020, 138, 104138.	1.6	3
2363	When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry. Revista Portuguesa De Cardiologia, 2020, 39, 177-178.	0.2	0
2364	Heart failure management in dialysis patients: Many treatment options with no clear evidence. Seminars in Dialysis, 2020, 33, 198-208.	0.7	20
2365	Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. Circulation, 2020, 141, 1235-1237.	1.6	14
2367	Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure, 2020, 7, 856-864.	1.4	33

#	Article	IF	Citations
2368	Use of sacubitril/valsartan in nonâ€compaction cardiomyopathy: a case report. ESC Heart Failure, 2020, 7, 1186-1189.	1.4	4
2369	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 2020, 22, 898-901.	2.9	59
2370	Megaâ€trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	2.9	11
2371	Age and biomarkers in heart failure: challenging the current model to select patients for clinical trials. European Journal of Heart Failure, 2020, 22, 2089-2092.	2.9	1
2372	Healthâ€related quality of life scores: ending the minimum 5â€point difference as the clinically meaningful threshold. European Journal of Heart Failure, 2020, 22, 1006-1008.	2.9	4
2373	From <scp>PARADIGM</scp> to <scp>PARAGON</scp> further evidence supporting continuous heart failure spectrum. European Journal of Heart Failure, 2020, 22, 1536-1539.	2.9	5
2374	Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complicationsâ€"A systematic review. Indian Heart Journal, 2020, 72, 14-19.	0.2	6
2375	Device-based therapies for arterial hypertension. Nature Reviews Cardiology, 2020, 17, 614-628.	6.1	77
2376	Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction. Scientific Reports, 2020, 10, 6665.	1.6	26
2377	Second revolution in cardiovascular prevention. Journal of the Chinese Medical Association, 2020, 83, 327-336.	0.6	6
2378	Sacubitril-Valsartan, a New Opportunity for Heart Failure with Recovered Ejection Fraction?. Cardiology, 2020, 145, 283-284.	0.6	0
2379	Implantable Cardioverterâ€"Defibrillators in Trials of Drug Therapy for Heart Failure: AÂSystematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e015177.	1.6	9
2380	Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. European Journal of Preventive Cardiology, 2021, 28, 983-989.	0.8	29
2381	Reverse Remodeling and Current Medical Therapy in Heart Failure with Reduced Ejection Fraction. International Heart Journal, 2020, 61, 197-198.	0.5	2
2382	Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices. Current Topics in Medicinal Chemistry, 2020, 20, 266-271.	1.0	0
2383	Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences. Journal of Clinical Medicine, 2020, 9, 906.	1.0	30
2384	Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats. Pharmaceutics, 2020, 12, 320.	2.0	8
2385	Myocardial strain in nonischemic dilated cardiomyopathy with feature tracking. Feasibility and prognostic implications. Revista Espanola De Cardiologia (English Ed), 2021, 74, 159-166.	0.4	4

#	Article	IF	Citations
2386	Heart failure treatment upâ€titration and outcome and age: an analysis of BIOSTATâ€CHF. European Journal of Heart Failure, 2021, 23, 436-444.	2.9	20
2387	Improving exercise capacity and quality of life using nonâ€invasive heart failure treatments: evidence from clinical trials. European Journal of Heart Failure, 2021, 23, 92-113.	2.9	67
2388	Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system. British Journal of Clinical Pharmacology, 2021, 87, 406-413.	1.1	3
2389	Left-Ventricular Function After 3ÂMonths of Sacubitril-Valsartan in Acute Decompensated Heart Failure. Journal of Cardiovascular Translational Research, 2021, 14, 290-298.	1.1	5
2390	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. Trends in Cardiovascular Medicine, 2021, 31, 111-116.	2.3	4
2391	High-density lipoprotein-mediated cardioprotection in heart failure. Heart Failure Reviews, 2021, 26, 767-780.	1.7	7
2392	Increased concentrations of bioactive adrenomedullin subsequently to angiotensinâ€receptor/neprilysinâ€inhibitor treatment in chronic systolic heart failure. British Journal of Clinical Pharmacology, 2021, 87, 916-924.	1.1	13
2393	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1839-1859.	0.6	30
2394	Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 6-30.	2.7	104
2395	Cardiac sympathetic imaging in heart failure: Is revival possible?. Journal of Nuclear Cardiology, 2021, 28, 86-89.	1.4	1
2396	Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic. Metabolic Syndrome and Related Disorders, 2021, 19, 115-118.	0.5	3
2397	Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: realâ€world data from the Swedish Heart Failure Registry. Journal of Internal Medicine, 2021, 289, 369-384.	2.7	13
2398	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 322, 183-190.	0.8	31
2399	B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trial. Heart, 2021, 107, 396-402.	1.2	6
2400	Inpatient Initiation of Sacubitril/Valsartan. Annals of Pharmacotherapy, 2021, 55, 480-495.	0.9	2
2401	Three cases of psychosis after use of sacubitril/valsartan. Revista Espanola De Cardiologia (English Ed) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	0
2402	A Systematic Review on the Use of Sacubitril/Valsartan Initiated Prior to Discharge in Hospitalized Patients With Heart Failure. Annals of Pharmacotherapy, 2021, 55, 378-389.	0.9	0
2403	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401.	1.8	23

#	Article	IF	Citations
2404	The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 241-254.	1.0	13
2405	Renal Denervation to Treat Heart Failure. Annual Review of Physiology, 2021, 83, 39-58.	5.6	28
2406	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 Ã— 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). American Heart Journal, 2021, 231, 137-146.	1.2	21
2407	Safety and Tolerability of Sacubitril/Valsartan Initiation in Inpatient Versus Outpatient Setting: A Retrospective Real World Study. Heart Lung and Circulation, 2021, 30, 674-682.	0.2	8
2408	How Diabetes and Heart Failure Modulate Each Other and Condition Management. Canadian Journal of Cardiology, 2021, 37, 595-608.	0.8	10
2409	Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on Nâ€terminal pro Bâ€type natriuretic peptide levels. Clinical Cardiology, 2021, 44, 85-90.	0.7	15
2410	Directly Measured Adherence to Treatment in Chronic Heart Failure: LEVEL-CHF Registry. American Journal of the Medical Sciences, 2021, 361, 491-498.	0.4	4
2411	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. International Journal of Cardiology, 2021, 327, 138-145.	0.8	19
2412	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. JAMA Cardiology, 2021, 6, 200.	3.0	18
2413	Machine learning and statistical methods for predicting mortality in heart failure. Heart Failure Reviews, 2021, 26, 545-552.	1.7	16
2414	The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. Heart Lung and Circulation, 2021, 30, 683-691.	0.2	18
2415	Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMPâ€HF registry. ESC Heart Failure, 2021, 8, 710-713.	1.4	3
2416	Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. Journal of Applied Physiology, 2021, 130, 256-268.	1.2	13
2417	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in HeartÂFailure and Reduced EjectionÂFraction. JACC: Heart Failure, 2021, 9, 42-51.	1.9	20
2418	Appropriateness rating for the application of optimal medical therapy and multidisciplinary care among heart failure patients. ESC Heart Failure, 2021, 8, 300-308.	1.4	5
2419	Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction. Cardiology and Therapy, 2021, 10, 9-25.	1.1	1
2420	Is Exercise Helpful or Harmful in Dealing With Specific Arrhythmia. Current Problems in Cardiology, 2021, 46, 100740.	1.1	2
2421	Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC Heart Failure, 2021, 8, 719-724.	1.4	3

#	Article	IF	Citations
2422	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	1.4	9
2423	Updated Review of Nuclear Molecular Imaging of Thyroid Cancers. Endocrine Practice, 2021, 27, 494-502.	1.1	5
2424	Treatment of HF in an Era of MultipleÂTherapies. JACC: Heart Failure, 2021, 9, 1-12.	1.9	26
2425	Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism. Life Sciences, 2021, 266, 118877.	2.0	12
2426	Dilated cardiomyopathy: room for (cautious) optimism?. Paediatrics and Child Health (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582	0.2	0
2427	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe. Journal of Clinical Hypertension, 2021, 23, 556-567.	1.0	16
2428	OUTSTEPâ€HF: randomised controlled trial comparing shortâ€term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 127-135.	2.9	50
2429	TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 123-130.	1.0	9
2430	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	1.9	27
2431	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2021, 44, 595-603.	4.3	5
2432	Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice. Biomedicine and Pharmacotherapy, 2021, 133, 110824.	2.5	15
2433	Cardiac contractility modulation for the treatment of moderate to severe HF. Expert Review of Medical Devices, 2021, 18, 15-21.	1.4	19
2434	How to <scp>ATTRâ€ACT</scp> the perfect match?. European Journal of Heart Failure, 2021, 23, 275-276.	2.9	2
2435	Possible Association Between Body Temperature and B-Type Natriuretic Peptide in Patients With Cardiovascular Diseases. Journal of Cardiac Failure, 2021, 27, 75-82.	0.7	14
2436	The Predicament of Large Numbers of Observations and How We Got There: Critical Review. journal of applied laboratory medicine, The, 2021, 6, 496-509.	0.6	1
2437	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. Journal of Cardiac Failure, 2021, 27, 2-19.	0.7	16
2438	Concentration-Dependent Renin-Angiotensin System Inhibition Effects After Transcatheter Aortic Valve Replacement: Important Evidence, but More Data Are Needed. Canadian Journal of Cardiology, 2021, 37, 370-371.	0.8	1
2439	Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. Annals of Pharmacotherapy, 2021, 55, 805-813.	0.9	1

#	Article	IF	Citations
2440	A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. European Journal of Heart Failure, 2021, 23, 175-185.	2.9	30
2441	Serum potassium and heart failure: association, causation, and clinical implications. Heart Failure Reviews, 2021, 26, 479-486.	1.7	10
2442	Reorganization of heart failure management and improved outcome â€“ the 4D HF Project. Scandinavian Cardiovascular Journal, 2021, 55, 1-8.	0.4	6
2443	A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study. European Journal of Clinical Pharmacology, 2021, 77, 125-131.	0.8	6
2444	Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 165-173.	0.7	12
2445	Cardiac contractility modulation for patient with refractory heart failure: an updated evidence-based review. Heart Failure Reviews, 2021, 26, 227-235.	1.7	10
2446	Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2021, 55, 197-211.	0.8	2
2447	Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, 26, 217-226.	1.7	10
2448	Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation. Journal of Pharmacy Practice, 2021, 34, 454-458.	0.5	8
2449	Determinants of maximal dose titration of sacubitril/valsartan in clinical practice. Acta Cardiologica, 2021, 76, 20-29.	0.3	9
2450	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 2021, 42, 1199-1202.	1.0	24
2451	Sympathetic activation in congestive heart failure: an updated overview. Heart Failure Reviews, 2021, 26, 173-182.	1.7	30
2452	Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction. Herz, 2021, 46, 69-74.	0.4	5
2453	Tolerability and efficacy of sacubitril/valsartan in clinical practice. Internal Medicine Journal, 2021, 51, 87-92.	0.5	6
2454	Chagas Disease: Chronic Chagas Cardiomyopathy. Current Problems in Cardiology, 2021, 46, 100507.	1.1	59
2456	Heart Failure With Reduced Ejection Fraction. , 2021, , 185-200.		0
2457	Cardiovascular Medications. , 2021, , 597-642.		1
2458	Cardiovascular Complications. , 2021, , 557-578.		0

#	Article	IF	Citations
2459	Tres casos de psicosis tras la toma de sacubitrilo-valsartÃ¡n. Revista Espanola De Cardiologia, 2021, 74, 103-105.	0.6	2
2460	Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and anÂICD: A Longitudinal Study. Clinical Drug Investigation, 2021, 41, 169-176.	1.1	17
2461	Novel approaches to management of hypertension. Current Opinion in Nephrology and Hypertension, 2021, 30, 54-62.	1.0	5
2462	Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure. Theranostics, 2021, 11, 7995-8007.	4.6	26
2463	Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. International Journal of Heart Failure, 2021, 3, 205.	0.9	4
2464	Perioperative management of patients with heart failure. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2021, , 6.	0.2	8
2465	Reverse Cardiac Remodeling and ARNI Therapy. Current Heart Failure Reports, 2021, 18, 71-83.	1.3	19
2466	Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 2021, 18, 400-423.	6.1	198
2467	Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart, 2021, 107, 1725-1730.	1.2	35
2468	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. Annals of Pharmacotherapy, 2021, 55, 1267-1275.	0.9	3
2469	Neprilysin Inhibitors. , 2021, , 1-8.		0
2470	The Metabolic Role of GRK2 in Insulin Resistance and Associated Conditions. Cells, 2021, 10, 167.	1.8	14
2471	Sacubitril/valsartan reduces levels of procollagen types I and III and correlates with reverse cardiac remodeling. REC: CardioClinics, 2021, 56, 14-21.	0.1	5
2472	Pharmacotherapy: Sex and gender evidence in medication safety and efficacy. , 2021, , 259-275.		0
2473	Molecular, Gene, and Cellular Mechanism. , 2021, , 1-10.		0
2474	Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098023.	1.4	6
2475	Commentary: Coronary artery bypass grafting in midrange ejection fraction: Charting unknown waters. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	0
2476	Neurological complications of cardiovascular drugs. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 177, 319-344.	1.0	1

#	Article	IF	Citations
2477	Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure. British Journal of Cardiology, 2021, , .	0.7	1
2479	Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management. Cureus, 2021, 13, e12419.	0.2	9
2480	Atrial fibrillation and chronic heart failure: interrelationship and approaches to treatment. Kardiologicheskii Vestnik, 2021, 16, 5.	0.1	5
2481	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. Frontiers in Physiology, 2020, 11, 612722.	1.3	11
2482	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 671-680.	1.0	96
2483	Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Therapeutic Advances in Cardiovascular Disease, 2021, 15, 175394472097774.	1.0	16
2484	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. European Heart Journal, 2022, 43, 1428-1431.	1.0	10
2485	Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 1304-1313.	1.4	19
2486	Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Failure, 2021, 8, 1706-1710.	1.4	23
2488	Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report. Clinical Medicine Insights: Cardiology, 2021, 15, 117954682110107.	0.6	3
2489	Receptors | Angiotensin Receptors. , 2021, , 110-121.		0
2491	Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study. Cardiology, 2021, 146, 335-344.	0.6	3
2492	Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study. Frontiers in Cardiovascular Medicine, 2020, 7, 602363.	1.1	14
2493	Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. ESC Heart Failure, 2021, 8, 918-927.	1.4	17
2494	Realâ€world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMARTâ€•Registry. ESC Heart Failure, 2021, 8, 1675-1680.	1.4	7
2495	Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats. Frontiers in Pharmacology, 2020, 11, 600953.	1.6	9
2496	Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2021, 20, 577-588.	1.0	5
2497	Implications for Clinical Practice from a Multicenter Survey of Heart Failure Management Centers. Clinics, 2021, 76, e1991.	0.6	0

#	Article	IF	Citations
2498	Angiotensin receptor neprilysin inhibitor use in patients with left ventricular assist devices: A single-center experience. International Journal of Artificial Organs, 2022, 45, 118-120.	0.7	2
2499	Kardiomyopathien. , 2021, , 110-118.		0
2500	Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension. Frontiers in Pharmacology, 2020, 11, 602985.	1.6	7
2501	Perspectives of bilateral thoracic sympathectomy for treatment of heart failure. Clinics, 2021, 76, e3248.	0.6	0
2503	Device-based treatment options for heart failure with preserved ejection fraction. Heart Failure Reviews, 2021, 26, 749-762.	1.7	16
2504	Ambulatory Management of Worsening Heart Failure: Current Strategies and Future Directions. Heart International, 2021, 15, 49.	0.4	3
2505	Heart Failure in African Americans and Hispanic Americans: A Persistent and Disproportionate Burden in Underrepresented Minorities. Contemporary Cardiology, 2021, , 55-74.	0.0	1
2506	Remote Patient Monitoring in Heart Failure: Factors for Clinical Efficacy. International Journal of Heart Failure, 2021, 3, 31.	0.9	20
2507	Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1131-1139.	2.2	36
2508	Randomized Controlled Trials 2: Analysis. Methods in Molecular Biology, 2021, 2249, 213-227.	0.4	0
2509	The Effect of Sacubitril/Valsartan in a Dialysis Patient with Severe Heart Failure. Case Reports in Clinical Medicine, 2021, 10, 197-202.	0.1	1
2510	Empagliflozin in Heart Failure. New England Journal of Medicine, 2021, 384, 384-388.	13.9	3
2511	Considering dose in pharmacological therapies for heart failure. Lancet, The, 2021, 397, 274-275.	6.3	0
2512	Pharmacotherapeutic principles of fluid management in heart failure. Expert Opinion on Pharmacotherapy, 2021, 22, 595-610.	0.9	2
2513	Heart failure: From novel pharmaceutical therapies to circulation support systems. Hellenic Journal of Cardiology, 2021, 62, 452-454.	0.4	0
2514	Acute heart failure treatment: a light at the end of the tunnel?. European Journal of Heart Failure, 2021, 23, 698-702.	2.9	5
2515	Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic HeartÂFailure. JACC: Heart Failure, 2021, 9, 85-95.	1.9	12
2516	DeformaciÃ³n miocÃ¡rdica en miocardiopatÃa dilatada no isquÃ©mica mediante feature tracking. Factibilidad e implicaciones pronÃ³sticas. Revista Espanola De Cardiologia, 2021, 74, 159-166.	0.6	2

#	Article	IF	Citations
2517	Renal protective effect of sacubitril/valsartan in patients with heart failure. Scientific Reports, 2021, 11, 4593.	1.6	5
2518	Time to Revisit a Voluntary FDA Comparative Effectiveness Pathway. Therapeutic Innovation and Regulatory Science, 2021, 55, 643-645.	0.8	0
2519	Re: Implication of lowâ€dose sacubitril/valsartan. Clinical Cardiology, 2021, 44, 290-290.	0.7	0
2520	Early Detection of Fluid Retention in Patients with Advanced Heart Failure: A Review of a Novel Multisensory Algorithm, HeartLogicTM. Sensors, 2021, 21, 1361.	2.1	6
2521	Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?. Cells, 2021, 10, 457.	1.8	14
2522	Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?. Cardiac Failure Review, 2020, 7, e02.	1.2	11
2523	Hospital readmissions of patients with heart failure from real world: timing and associated risk factors. ESC Heart Failure, 2021, 8, 1388-1397.	1.4	45
2524	Neprilysin and Corin. JACC: Heart Failure, 2021, 9, 96-99.	1.9	1
2525	Lowâ€fat hypocaloric diet reduces neprilysin in overweight and obese human subjects. ESC Heart Failure, 2021, 8, 938-942.	1.4	7
2526	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Failure, 2021, 8, 861-871.	1.4	20
2527	Overview of the 84th Annual Scientific Meeting of the Japanese Circulation Societyã€€â€• Change Practice! â€•. Circulation Journal, 2021, 85, 323-329.	0.7	0
2528	Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2020, 11, 626375.	1.6	11
2529	Implication of low dose sacubitril/valsartan. Clinical Cardiology, 2021, 44, 289-289.	0.7	1
2531	Personalizing heart failure management in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2022, 37, 2055-2062.	0.4	11
2532	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€HF. Journal of the American Heart Association, 2021, 10, e019238.	1.6	20
2533	Meet Me in the Middle. JACC: Heart Failure, 2021, 9, 161-163.	1.9	4
2534	Heart failure or heart success?. Cardiovascular Research, 2021, 117, e29-e34.	1.8	4
2535	Heart failure in advanced chronic kidney disease: treatment rationale. Herz, 2021, 46, 217-220.	0.4	2

#	Article	IF	Citations
2536	Gliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes. Deutsches Ärzteblatt International, 2021, 118, .	0.6	5
2537	Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3398-3412.	1.8	3
2538	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 546-556.	1.3	26
2539	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	1.2	612
2541	A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure. Frontiers in Physiology, 2021, 12, 642117.	1.3	2
2542	Novel Implantable Cardioverter Defibrillator Programming With High Rate Cut-Off, Long Detection Intervals and Multiple Anti-Tachycardia Pacing Reduces Mortality. Circulation Journal, 2021, 85, 291-299.	0.7	2
2543	A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovascular Drugs and Therapy, 2022, 36, 309-322.	1.3	12
2544	Impact of Sacubitrilâ€"Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 167-175.	1.0	8
2545	Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy. Frontiers in Pediatrics, 2021, 9, 639551.	0.9	2
2546	A New Requirement for Publication: Access to Effective Drugs for Ethical Reasons, The Example of Heart Failure. ESC Heart Failure, 2021, 8, 799-801.	1.4	1
2547	Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!. European Journal of Pharmacology, 2021, 894, 173851.	1.7	17
2548	Analysis of causes of death in patients with implanted defibrillators. Clinical Research in Cardiology, 2021, 110, 895-904.	1.5	3
2549	The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?. Cells, 2021, 10, 650.	1.8	31
2550	The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in longâ€term studies. ESC Heart Failure, 2021, 8, 2345-2348.	1.4	4
2551	Antiarrhythmic effect of sacubitril/valsartan in high arrhythmic risk inherited cardiomyopathies. REC: CardioClinics, 2021, , .	0.1	0
2552	A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension. Cardiology Research and Practice, 2021, 2021, 1-10.	0.5	4
2553	Narrative review in the current role of angiotensin receptor-neprilysin inhibitors. Annals of Translational Medicine, 2021, 9, 518-518.	0.7	3
2554	Sacubitril/valsartan: from the PARADIGM-HF trial results to heart failure patients in internal medicine. A narrative review. Italian Journal of Medicine, 2021, 15, .	0.2	0

#	Article	IF	Citations
2555	Diabetes Management in Patients with Heart Failure. Diabetes and Metabolism Journal, 2021, 45, 158-172.	1.8	9
2556	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. Expert Review of Medical Devices, 2021, 18, 261-272.	1.4	1
2557	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784.	2.9	12
2558	Novel Trial Design: CHIEF-HF. Circulation: Heart Failure, 2021, 14, e007767.	1.6	23
2559	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1029-1040.	1.2	113
2560	Engineering an Amine Transaminase for the Efficient Production of a Chiral Sacubitril Precursor. ACS Catalysis, 2021, 11, 3762-3770.	5.5	32
2561	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	0
2563	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	1.9	6
2564	NTâ€proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure. Clinical Pharmacology and Therapeutics, 2021, 110, 498-507.	2.3	18
2565	Hearts and Minds: an Exercise in Clinical Reasoning. Journal of General Internal Medicine, 2021, 36, 1778-1783.	1.3	2
2566	Diretrizes Brasileiras de HipertensÃ£o Arterial â€“ 2020. Arquivos Brasileiros De Cardiologia, 2021, 116, 516-658.	0.3	340
2567	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study. Circulation: Heart Failure, 2021, 14, e007891.	1.6	6
2568	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	1.5	5
2569	Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2058-2069.	1.4	25
2570	Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?. Cells, 2021, 10, 641.	1.8	20
2571	Racial and ethnic disparities in heart failure: current state and future directions. Current Opinion in Cardiology, 2021, 36, 320-328.	0.8	57
2572	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	1.6	13
2573	Myocardial stress perfusion scintigraphy for outcome prediction in patients with severe left ventricular systolic dysfunction. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3502-3511.	3.3	1

#	Article	IF	Citations
2574	Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients. Journal of Cardiovascular Pharmacology, 2021, 77, 343-348.	0.8	0
2575	Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 469-477.	1.8	9
2576	Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes and Metabolism Journal, 2021, 45, 146-157.	1.8	56
2577	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. Scientific Reports, 2021, 11, 5940.	1.6	2
2578	Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?. Egyptian Heart Journal, 2021, 73, 26.	0.4	3
2579	The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications. , 0, , .		0
2580	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958.	1.6	15
2581	Cardiovascular Disease in Chronic Kidney Disease. Circulation, 2021, 143, 1157-1172.	1.6	680
2582	Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 388-396.	1.8	13
2583	SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2210-2219.	1.4	26
2584	Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacological Reviews, 2021, 73, 730-762.	7.1	80
2585	Differences in risk profiles and long-term outcomes in acute heart failure patients with preserved and reduced left ventricular ejection fraction in the Czech Republic: The AHEAD registry sub-analysis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, 165, 34-42.	0.2	0
2586	Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy. Cardio-Oncology, 2021, 7, 12.	0.8	1
2588	Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 143, 7-13.	0.7	29
2589	Updates in pharmacotherapy of heart failure with reduced ejection fraction. Annals of Translational Medicine, 2021, 9, 516-516.	0.7	5
2590	Sex Differences in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e018574.	1.6	85
2591	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
2592	Kinins and Kinin Receptors in Cardiovascular and Renal Diseases. Pharmaceuticals, 2021, 14, 240.	1.7	13

#	Article	IF	Citations
2594	Atrial fibrosis and substrate based characterization in atrial fibrillation: Time to move forwards. Journal of Cardiovascular Electrophysiology, 2021, 32, 1147-1160.	0.8	11
2595	Neprilysin inhibition does not alter dynamic of proenkephalinâ€A 119â€159 and proâ€substance P in heart failure. ESC Heart Failure, 2021, 8, 2016-2024.	1.4	3
2596	1 year follow Up results of â€œARTIM HF TRIALâ€•(angiotensin receptor neprilysin inhibitor effect on TEI) Tj ETQq0 0 0 rgBT /Overlock 10	0.2	3
2597	Commentary on: Reninâ€“angiotensin system overactivation in perivascular adipose tissue contributes to vascular dysfunction in heart failure. Clinical Science, 2021, 135, 683-686.	1.8	0
2598	Cardiac medication management in Duchenne muscular dystrophy. Pediatric Pulmonology, 2021, 56, 747-752.	1.0	4
2599	Patient Education and Sacubitril/Valsartan: A Randomized Comparative Trial. Hospital Pharmacy, 2022, 57, 001857872199980.	0.4	0
2600	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	2.9	11
2601	Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA). Biomarkers, 2021, 26, 309-317.	0.9	3
2602	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart, 2021, 8, e001585.	0.9	30
2603	Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic lowâ€dose loop diuretic therapy. European Journal of Heart Failure, 2021, 23, 1110-1119.	2.9	9
2604	Medical Therapy of Heart Failure with Reduced Ejection Fractionâ€”A Call for Comparative Research. Journal of Clinical Medicine, 2021, 10, 1803.	1.0	1
2605	Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. HRB Open Research, 2020, 3, 5.	0.3	3
2606	Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review, 0, 15, .	0.5	12
2607	Novelties in Therapy of Chronic Heart Failure. Heart Failure Clinics, 2021, 17, 255-262.	1.0	3
2608	Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 2021, 41, 526-536.	1.2	5
2609	Evolving Cardiac Electrical Therapies for Advanced Heart Failure Patients. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009668.	2.1	4
2610	The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. Expert Opinion on Pharmacotherapy, 2021, 22, 1319-1341.	0.9	0
2611	A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 632-643.	0.8	31

#	Article	IF	Citations
2612	Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISEâ€MI): design and baseline characteristics. European Journal of Heart Failure, 2021, 23, 1040-1048.	2.9	70
2613	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 531-546.	0.8	170
2614	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. Current Pharmaceutical Design, 2021, 27, 1289-1297.	0.9	8
2615	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 447-455.	1.2	7
2616	LCZ696 ameliorates lipopolysaccharide-induced endothelial injury. Aging, 2021, 13, 9582-9591.	1.4	12
2617	The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 613295.	1.1	9
2618	LCZ696 Attenuated Doxorubicin-Induced Chronic Cardiomyopathy Through the TLR2-MyD88 Complex Formation. Frontiers in Cell and Developmental Biology, 2021, 9, 654051.	1.8	19
2619	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 560-571.	0.8	40
2620	Renal protection in chronic heart failure: focus on sacubitril/valsartan. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 445-452.	1.4	20
2622	Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 331-332.	1.0	0
2623	Incidence and Outcomes of Pneumonia in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1961-1973.	1.2	35
2624	Sacubitrilâ€Based Urea and Thiourea Derivatives as Novel Inhibitors for Antiâ€Tubercular against Dormant Tuberculosis. ChemistrySelect, 2021, 6, 3869-3874.	0.7	16
2625	Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. Children, 2021, 8, 322.	0.6	9
2626	Impact of Pneumonia in HeartÂFailureÂPatients. Journal of the American College of Cardiology, 2021, 77, 1974-1976.	1.2	3
2627	News on angiotensin II and atrial fibrillation : from the molecular to the pathophysiological.. Revista Ciencias BiomÃ‰dicas (cartagena), 2021, 10, 109-119.	0.0	0
2628	Angiotensin Receptor-Neprilysin Inhibition Improves Blood Pressure and Heart Failure Control in Left Ventricular Assist Device Patients. ASAIO Journal, 2021, 67, e207-e210.	0.9	3
2629	Sacubitril/valsartan use in combination with inotropic support. An option for patients with acute heart failure. REC: CardioClinics, 2021, , .	0.1	0
2630	Actual state of â€œtriple therapyâ€•for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database. PLoS ONE, 2021, 16, e0249711.	1.1	1

#	Article	IF	Citations
2631	Positive Recommendation for Angiotensin Receptorâ€“Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 528-530.	0.8	0
2632	Heart Failure: One, None, and a Hundred Thousand. Heart Failure Clinics, 2021, 17, xiii-xv.	1.0	0
2633	Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition. European Journal of Pharmaceutical Sciences, 2021, 159, 105731.	1.9	3
2634	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. Current Heart Failure Reports, 2021, 18, 132-143.	1.3	1
2635	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
2636	The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape. Canadian Journal of Cardiology, 2021, 37, 644-654.	0.8	7
2637	Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system. European Journal of Pharmacology, 2021, 897, 173961.	1.7	6
2638	Looking forward and backward for sudden death risk: competing risk is everywhere. European Journal of Heart Failure, 2021, 23, 1357-1360.	2.9	0
2639	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. European Heart Journal, 2021, 42, 1825-1857.	1.0	342
2640	Rationale for and Practical Use of Sacubitril/Valsartan in the Patientâ€™s Journey with Heart Failure and Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e06.	1.2	1
2641	Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors. Pflugers Archiv European Journal of Physiology, 2021, 473, 595-610.	1.3	8
2642	Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy. Medicina (Lithuania), 2021, 57, 416.	0.8	3
2643	Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. Journal of Pharmacy Practice, 2022, 35, 859-863.	0.5	3
2644	Initiation and titration of sacubitril/valsartan in different types of centers. REC: CardioClinics, 2021, 56, 92-97.	0.1	2
2645	Assessing the facilities and healthcare services for heart failure: Taiwan versus European countries. Journal of the Formosan Medical Association, 2022, 121, 258-268.	0.8	2
2646	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. American Heart Journal, 2021, 234, 90-100.	1.2	20
2647	Tailoring the management of hypertension to comorbidities. Current Opinion in Cardiology, 2021, 36, 405-412.	0.8	1
2648	Impact of Cardiovascular Hemodynamics on Cognitive Aging. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1255-1264.	1.1	16

#	Article	IF	Citations
2649	Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fractionâ€€â€• Results From the PARALLEL-HF Study â€•. Circulation Journal, 2021, 85, 584-594.	0.7	37
2650	Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 286-297.	1.2	3
2651	Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience. Minerva Cardiology and Angiology, 2022, 70, .	0.4	2
2653	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	0.7	18
2654	Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodiumâ€“glucose co-transporter 2 inhibitors?. Future Cardiology, 2021, 17, 497-506.	0.5	2
2655	Chronobiology of Natriuretic PeptidesÂand Blood Pressure in LeanÂandÂObese Individuals. Journal of the American College of Cardiology, 2021, 77, 2291-2303.	1.2	15
2656	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 539-546.	1.4	22
2657	Effective influence of sacubutril/valsartan on systolic function of left ventricle in patients with heart failure and a reduced ejÐµction fraction. Society and Innovations, 2021, 2, 746-752.	0.0	0
2658	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. International Journal of Cardiology, 2021, 330, 91-97.	0.8	10
2659	Insuffisance cardiaque et diabÃ¨teÂ: donnÃ©es Ã©pidÃ©miologiques, phÃ©notype et impact sur le pronostic. Medecine Des Maladies Metaboliques, 2021, 15, 246-251.	0.1	1
2660	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21.	1.2	7
2661	Consensus on basic conduct during the hospital admission of patients with acute heart failure. Revista Clínica Espanõla, 2021, 221, 283-296.	0.3	0
2662	Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-Î²1/Smads Pathway. Frontiers in Pharmacology, 2021, 12, 696472.	1.6	9
2663	Progress in Heart Failure Treatment. Japanese Journal of Cardiovascular Surgery, 2021, 50, 217-219.	0.0	0
2664	Rapid evidenceâ€based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 882-894.	2.9	88
2665	Differences in NTâ€proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019712.	1.6	6
2666	Sex and Heart Failure Treatment Prescription and Adherence. Frontiers in Cardiovascular Medicine, 2021, 8, 630141.	1.1	5
2667	Mechanisms and Models in Heart Failure. Circulation Research, 2021, 128, 1435-1450.	2.0	24

#	Article	IF	Citations
2668	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
2669	Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2021, 77, 650-659.	0.8	3
2670	Hyperkalaemia in Heart Failure. Cardiac Failure Review, 2021, 7, e10.	1.2	4
2671	Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. CJC Open, 2021, 3, 646-657.	0.7	2
2672	Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. Frontiers in Cardiovascular Medicine, 2021, 8, 678121.	1.1	6
2673	Representation of Black patients in heart failure clinical trials. Current Opinion in Cardiology, 2021, 36, 329-334.	0.8	5
2674	Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 2021, 28, e292-e298.	0.5	4
2675	Consenso de actuaciÃ³n bÃ¡sica durante el ingreso hospitalario por insuficiencia cardiaca aguda. Revista Clinica Espanola, 2021, 221, 283-296.	0.2	5
2676	Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. International Journal of Cardiology, 2021, 331, 164-171.	0.8	32
2677	Primary Prevention Implantable Cardioverter-Defibrillator Therapy in Heart Failure with Recovered Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 585-596.	0.7	1
2678	2021 ACC update of the heart failure guidelines. Cor Et Vasa, 2021, 63, 264-270.	0.1	5
2679	Revisiting the Role of Guideline-Directed Medical Therapy for Patients with Heart Failure and Severe Functional Mitral Regurgitation. Cardiology Clinics, 2021, 39, 255-265.	0.9	1
2680	Cellular Mechanisms of the Anti-Arrhythmic Effect of Cardiac PDE2 Overexpression. International Journal of Molecular Sciences, 2021, 22, 4816.	1.8	12
2681	Association between sacubitril/valsartan initiation and realâ€world health status trajectories over 18Âmonths in heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2670-2678.	1.4	7
2682	Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?. Journal of Cardiovascular Development and Disease, 2021, 8, 57.	0.8	7
2683	Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?. PLoS ONE, 2021, 16, e0249674.	1.1	1
2684	Visualising and understanding cGMP signals in the cardiovascular system. British Journal of Pharmacology, 2021, , .	2.7	16
2685	Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Failure Reviews, 2021, , 1.	1.7	9

#	Article	IF	Citations
2686	Hypertension: Current trends and future perspectives. British Journal of Clinical Pharmacology, 2021, 87, 3721-3736.	1.1	18
2687	NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction. Lancet Diabetes and Endocrinology,the, 2021, 9, 261-263.	5.5	0
2688	Protective Renal Effects of Atrial Natriuretic Peptide: Where Are We Now?. Frontiers in Physiology, 2021, 12, 680213.	1.3	11
2689	Is there a role for reninâ€“angiotensinâ€“aldosterone system and neprilysin inhibition in the failing systemic right ventricle?. International Journal of Cardiology Congenital Heart Disease, 2021, 3, 100119.	0.2	1
2690	CNP regulates cardiac contractility and increases cGMP near both SERCA and TnI: difference from BNP visualized by targeted cGMP biosensors. Cardiovascular Research, 2022, 118, 1506-1519.	1.8	13
2691	Exploring the Food and Drug Administrationâ€™s review and approval of Entresto (sacubitril/valsartan). Pharmacology Research and Perspectives, 2021, 9, e00794.	1.1	8
2692	Copeptin as a predictive marker of incident heart failure. ESC Heart Failure, 2021, 8, 3180-3188.	1.4	22
2693	Where are we in 2021 with heart failure with reduced ejection fraction?â€”current outlook and expectations from new promising clinical trials. Heart Failure Reviews, 2021, , 1.	1.7	8
2694	Sacubitrilâ€“valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 330, 112-119.	0.8	14
2695	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.2	9
2696	Left atrial assist device for heart failure with preserved ejection fraction: initial results with torque control mode in diastolic heart failure model. Heart Failure Reviews, 2021, , 1.	1.7	8
2697	Sex-related differences in the pharmacological treatment of heart failure. , 2022, 229, 107891.		14
2698	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2021, 2021, CD012721.	1.5	19
2699	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for HeartÂFailure. JACC: Heart Failure, 2021, 9, 336-345.	1.9	23
2700	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.3	47
2701	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. American Journal of Preventive Cardiology, 2021, 6, 100183.	1.3	4
2702	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational costâ€effectiveness analysis utilising <scp>AFFIRMâ€AHF</scp>. European Journal of Heart Failure, 2021, 23, 1687-1697.	2.9	23
2703	The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2021, 10, 2824.	1.0	14

#	Article	IF	Citations
2704	What can heart failure trialists learn from oncology trialists?. European Heart Journal, 2021, 42, 2373-2383.	1.0	9
2705	Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a realâ€world study. ESC Heart Failure, 2021, 8, 3783-3790.	1.4	10
2706	Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARSâ€CoVâ€2 infection. ESC Heart Failure, 2021, 8, 4026-4036.	1.4	5
2707	Nonâ€invasive home telemonitoring in patients with decompensated heart failure: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 3696-3708.	1.4	20
2708	Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis. Circulation: Heart Failure, 2021, 14, e007909.	1.6	14
2709	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> (<scp>Vericiguat</scp> Global Study in) Tj ETQq1 1 0.784314 rgBT /Overlock	2.9	58
2710	Association Between Angiotensin Receptorâ€“Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008410.	1.6	27
2712	Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic HeartÂFailure. JACC: Heart Failure, 2021, 9, 430-438.	1.9	10
2713	Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedemaâ€”Prevalence and Relevance. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2160-2168.	2.0	11
2714	Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic. Biomedical Papers of the Medical Faculty of the University Palacký. Olomouc, Czechoslovakia, 2022, 166, 322-327.	0.2	2
2715	Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 684297.	1.1	6
2716	Comparing the Modified Frailty Index with conventional scores for prediction of cardiac resynchronization therapy response in patients with heart failure. Journal of Frailty, Sarcopenia and Falls, 2021, 06, 79-85.	0.4	2
2717	Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure. Heart, 2021, 107, 1364-1366.	1.2	2
2718	Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clinical Pharmacokinetics, 2021, 60, 1407-1421.	1.6	14
2719	Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options. Frontiers in Medicine, 2021, 8, 653634.	1.2	14
2720	An Hypothesis: Disproportion Between Cardiac Troponin and B-Type Natriuretic Peptide Levelsâ€”A High Risk and Poor Prognostic Biomarker in Patients With Fulminant Myocarditis?. Heart Lung and Circulation, 2021, 30, 837-842.	0.2	8
2721	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	1.0	38
2722	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<scp>US</scp>, <scp>UK</scp> and Sweden). European Journal of Heart Failure, 2021, 23, 1499-1511.	2.9	80

#	Article	IF	Citations
2723	Concentrationâ€dependent clinical and prognostic importance of highâ€sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <scp>EMPEROR</scp>â€Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	2.9	30
2724	Declining Rates of ICD Therapies in a Secondary Prevention Population. JACC: Clinical Electrophysiology, 2021, 7, 793-795.	1.3	0
2725	Expert consensus on acute management of ventricular arrhythmias â€“ VT network Austria. IJC Heart and Vasculature, 2021, 34, 100760.	0.6	1
2726	Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.4	1
2727	Current Modulation of Guanylate Cyclase Pathway Activityâ€"Mechanism and Clinical Implications. Molecules, 2021, 26, 3418.	1.7	16
2729	Preclinical models of myocardial infarction: from mechanism to translation. British Journal of Pharmacology, 2022, 179, 770-791.	2.7	16
2730	Towards precision medicine in heart failure. Nature Reviews Cardiology, 2021, 18, 745-762.	6.1	34
2731	Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. Journal of Cardiac Failure, 2021, 27, 1231-1239.	0.7	8
2732	Bioengineering Technologies for Cardiac Regenerative Medicine. Frontiers in Bioengineering and Biotechnology, 2021, 9, 681705.	2.0	15
2733	Five Years of Sacubitril/Valsartanâ€"a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovascular Drugs and Therapy, 2022, 36, 915-924.	1.3	4
2734	Cardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression. Frontiers in Physiology, 2021, 12, 679930.	1.3	6
2735	Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment. Vnitrni Lekarstvi, 2021, 67, 212-117.	0.1	0
2736	Valve Academic Research Consortium 3: Updated Endpoint Definitions for AorticÂValve Clinical Research. Journal of the American College of Cardiology, 2021, 77, 2717-2746.	1.2	416
2737	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opinion on Pharmacotherapy, 2021, 22, 1847-1855.	0.9	18
2738	Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis. Frontiers in Medicine, 2021, 8, 657067.	1.2	9
2739	Epitranscriptomics of Ischemic Heart Diseaseâ€"The IHD-EPITRAN Study Design and Objectives. International Journal of Molecular Sciences, 2021, 22, 6630.	1.8	10
2740	From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin. International Journal of Molecular Sciences, 2021, 22, 6617.	1.8	6
2741	Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways. Journal of Cardiovascular Translational Research, 2022, 15, 131-142.	1.1	25

#	Article	IF	Citations
2742	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	4.9	2
2743	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 678.	3.0	26
2744	Local Action of Neprilysin Exacerbates Pressure Overload Induced Cardiac Remodeling. Hypertension, 2021, 77, 1931-1939.	1.3	5
2745	Treatment for hyperkalaemia in heart failure: a network meta-analysis. The Cochrane Library, 2021, 2021, .	1.5	0
2746	Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment. American Journal of Physiology - Renal Physiology, 2021, 320, F1133-F1151.	1.3	20
2748	Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights. Expert Review of Cardiovascular Therapy, 2021, 19, 1-10.	0.6	6
2749	Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624.	1.7	19
2750	Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?. European Journal of Heart Failure, 2021, 23, 1437-1444.	2.9	9
2751	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 1518-1524.	2.9	20
2752	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart, 2021, 107, 1407-1416.	1.2	16
2753	Effects of angiotensin receptor neprilysin inhibitor on renal function in patients with heart failure: a systematic review and meta-analysis. Postgraduate Medical Journal, 2021, , postgradmedj-2021-140132.	0.9	1
2754	The real-life heart failure patient: importance of guideline-directed medical therapy. Netherlands Heart Journal, 2021, 29, 368-369.	0.3	0
2755	Prognostic relevance of elevated plasma osmolality on admission in acute decompensated heart failure with preserved ejection fraction: insights from PURSUIT-HFpEF registry. BMC Cardiovascular Disorders, 2021, 21, 281.	0.7	3
2756	Sacubitrilâ€valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTOâ€SAS study. ESC Heart Failure, 2021, 8, 2513-2526.	1.4	15
2757	Patient-Reported Outcomes in Patients with Cardiomyopathy. Current Cardiology Reports, 2021, 23, 91.	1.3	3
2758	Rapid Repurposing of Novel Combination Drugs for the Treatment of Heart Failure via a Computationally Guided Network Screening Approach. Journal of Chemical Information and Modeling, 2022, 62, 5223-5232.	2.5	6
2759	Acute on chronic heart failureâ€"Which variations on Bâ€type natriuretic peptide levels?. Journal of the American College of Emergency Physicians Open, 2021, 2, e12448.	0.4	3
2760	Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices. Journal of Cardiac Failure, 2021, 27, 1328-1336.	0.7	7

#	Article	IF	Citations
2761	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "heart and vessels failure". Minerva Cardiology and Angiology, 2022, 70, .	0.4	8
2762	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 2021, 110, 1334-1349.	1.5	4
2763	Cardiac natriuretic peptide deficiency sensitizes the heart to stress-induced ventricular arrhythmias via impaired CREB signalling. Cardiovascular Research, 2022, 118, 2124-2138.	1.8	8
2764	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. Pharmacotherapy, 2021, 41, 710-721.	1.2	1
2765	Reninâ€“Angiotensinâ€“Aldosterone System and Immunomodulation: A State-of-the-Art Review. Cells, 2021, 10, 1767.	1.8	41
2766	Review of the top 5 cardiology studies of 2019-20. Canadian Pharmacists Journal, 2021, 154, 388-393.	0.4	0
2767	Effect of sacubitrilâ€“valsartan on cardiac function in hemodialysis patients. Therapeutic Apheresis and Dialysis, 2022, 26, 244-245.	0.4	3
2768	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 144, 199-209.	1.6	40
2769	Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. Journal of Cardiovascular Medicine, 2021, 22, 848-856.	0.6	6
2770	Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials. Pharmacological Research, 2021, 169, 105573.	3.1	22
2771	Implicaciones pronÃ³sticas de la hipo e hiperpotasemia en la insuficiencia cardÃaca aguda con fracciÃ³n de eyecciÃ³n reducida. AnÃ¡lisis de la mortalidad cardiovascular y reingresos hospitalarios. Medicina ClÃnica, 2021, , .	0.3	1
2772	Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions. Heart Failure Reviews, 2022, 27, 1201-1210.	1.7	18
2773	Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study. Patient Preference and Adherence, 2021, Volume 15, 1693-1706.	0.8	8
2774	Atrial Natriuretic Peptide31â€“67: A Novel Therapeutic Factor for Cardiovascular Diseases. Frontiers in Physiology, 2021, 12, 691407.	1.3	6
2775	Diarrhoea with the Angiotensin Receptor Neprilysin Inhibitor sacubitril+valsartan: a pharmacovigilance study. Fundamental and Clinical Pharmacology, 2021, , .	1.0	3
2776	Imaging of Cardiac Transplantation: An Overview. Seminars in Nuclear Medicine, 2021, 51, 335-348.	2.5	5
2777	Clinical inertia and medical therapy for heart failure: the unintended harms of â€˜first, doÂnoÂharmâ€™. European Journal of Heart Failure, 2021, 23, 1343-1345.	2.9	19
2778	Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis. Heart Failure Reviews, 2022, 27, 645-654.	1.7	19

#	Article	IF	Citations
2779	Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort. Singapore Medical Journal, 2021, 62, 359-361.	0.3	0
2780	Impact of Sacubitril/Valsartan on Right Heart Failure. International Heart Journal, 2021, 62, 932-934.	0.5	1
2781	Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Failure Reviews, 2022, 27, 465-492.	1.7	44
2782	Genetic Determinant of Familial Dilated Cardiomyopathy and Genotype-Targeted Therapeutic Strategy. , 0, , .		1
2783	Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. Hypertension Research, 2021, 44, 1239-1250.	1.5	19
2784	Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 691907.	1.1	26
2785	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. Current Heart Failure Reports, 2021, 18, 284-289.	1.3	10
2786	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. European Journal of Heart Failure, 2021, 23, 1250-1255.	2.9	17
2787	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182.	1.6	28
2788	Chegou a Hora de uma Nova Terapia PadrÃ£o para a InsuficiÃªncia CardÃaca com FraÃ§Ã£o de EjeÃ§Ã£o Reduzida?. Arquivos Brasileiros De Cardiologia, 2021, 117, 149-152.	0.3	0
2789	Optimizer Smart System for the treatment of chronic heart failure: Overview of its safety and efficacy. Expert Review of Medical Devices, 2021, 18, 505-512.	1.4	0
2790	Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease â€“ A case series. British Journal of Clinical Pharmacology, 2021, , .	1.1	3
2791	Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Current Cardiology Reports, 2021, 23, 117.	1.3	12
2793	Implantable cardioverter defibrillator shocks from ventricular tachyarrhythmias in patients with ischemic heart disease: Preventative measures, shortcomings, costâ€effectiveness, and global practice perspectives. Journal of Cardiovascular Electrophysiology, 2021, 32, 2558-2566.	0.8	1
2794	Central and peripheral sympathetic activation in heart failure. Cardiovascular Research, 2022, 118, 1857-1871.	1.8	20
2795	Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	2
2796	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovascular Research, 2022, 118, 2085-2102.	1.8	23
2797	Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study. European Journal of Clinical Pharmacology, 2021, 77, 1835-1842.	0.8	17

#	Article	IF	Citations
2798	Pharmacological secondary prevention of MI. The Prescriber, 2021, 32, 13-20.	0.1	0
2799	CuantificaciÃ³n y tratamiento de la congestiÃ³n en insuficiencia cardÃaca: una visiÃ³n clÃnica y fisiopatolÃ³gica. Nefrologia, 2022, 42, 145-162.	0.2	11
2800	Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure. World Journal of Cardiology, 2021, 13, 183-203.	0.5	11
2801	ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial). Indian Heart Journal, 2021, 73, 605-611.	0.2	6
2802	cGMP and mitochondrial K⁺ channelsâ€"Compartmentalized but closely connected in cardioprotection. British Journal of Pharmacology, 2022, 179, 2344-2360.	2.7	10
2803	Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. Frontiers in Cardiovascular Medicine, 2021, 8, 683418.	1.1	6
2804	Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease. Frontiers in Veterinary Science, 2021, 8, 700230.	0.9	5
2806	Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart, 2021, 107, 1748-1755.	1.2	20
2807	The challenges of an aging tetralogy of Fallot population. Expert Review of Cardiovascular Therapy, 2021, 19, 581-593.	0.6	6
2808	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	2.8	49
2809	Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure. Cureus, 2021, 13, e16332.	0.2	2
2810	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. Frontiers in Physiology, 2021, 12, 643721.	1.3	8
2811	Sacubitril/valsartan in real-life clinical practice. Turk Kardiyoloji Dernegi Arsivi, 2021, 49, 353-356.	0.6	0
2812	Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis. BMC Cardiovascular Disorders, 2021, 21, 324.	0.7	5
2813	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 530-545.	2.7	9
2814	Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target?. OMICS A Journal of Integrative Biology, 2021, 25, 408-416.	1.0	5
2815	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 463-482.	1.0	4
2816	Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. Diabetes Research and Clinical Practice, 2021, 177, 108822.	1.1	4

#	Article	IF	Citations
2817	Kidney Function and Outcomes in Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 330-343.	1.2	90
2818	Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study. Journal of the Chinese Medical Association, 2021, 84, 833-841.	0.6	8
2819	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	1.7	22
2820	Modern trends in pharmacological treatment heart failure. Klinicka Farmakologie A Farmacie, 2021, 35, 54-59.	0.1	1
2821	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. American Heart Journal, 2021, 237, 45-53.	1.2	3
2822	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	9
2823	Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake. Frontiers in Pharmacology, 2021, 12, 709467.	1.6	9
2824	A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials. Statistics in Medicine, 2021, 40, 5702-5724.	0.8	2
2825	Shared Care to Destination Therapy Left Ventricular Assist Device Site: a Novel Strategy to Start a Successful Mechanical Circulatory Support Program. Current Cardiology Reports, 2021, 23, 112.	1.3	2
2826	Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption. Medicine (United States), 2021, 100, e26809.	0.4	2
2827	Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction. Molecular Therapy, 2021, 29, 2499-2513.	3.7	3
2828	Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure. ADCES in Practice, 0, , 2633559X2110344.	0.2	0
2829	Incidence and Predictors of Progression in Asymptomatic Patients With Stable Heart Failure. American Journal of Cardiology, 2021, 152, 88-93.	0.7	1
2830	Sacubitril/valsartan decreases mortality in the rat model of the isoprenalineâ€induced takotsuboâ€like syndrome. ESC Heart Failure, 2021, 8, 4130-4138.	1.4	3
2831	Mortality and <scp>guidelineâ€directed</scp> medical therapy in <scp>realâ€world</scp> heart failure patients with reduced ejection fraction. Clinical Cardiology, 2021, 44, 1192-1198.	0.7	19
2832	ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure. European Heart Journal Supplements, 2021, 23, C176-C183.	0.0	2
2833	Novel Non-pharmaceutical Advancements in Heart Failure Management: The Emerging Role of Technology. Current Cardiology Reviews, 2022, 18, .	0.6	1
2834	Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of â€˜too little, too lateâ€™. European Journal of Heart Failure, 2021, 23, 1514-1517.	2.9	9

#	Article	IF	Citations
2835	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
2837	Moderate potassium lowering effect of exogenous atrial natriuretic peptide in patients with acute heart failure. Journal of Cardiology, 2021, 78, 558-563.	0.8	0
2838	Advanced HeartÂFailure and Angiotensin System Fascinating Complexities. Journal of the American College of Cardiology, 2021, 78, 541-542.	1.2	0
2839	Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. Cancer, 2021, 127, 4646-4655.	2.0	10
2840	Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study. Frontiers in Pharmacology, 2021, 12, 733475.	1.6	13
2841	National Trends in the Use of Sacubitril/Valsartan. Journal of Cardiac Failure, 2021, 27, 839-847.	0.7	9
2842	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	1.0	899
2843	Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan. Acta Cardiologica, 2021, , 1-6.	0.3	7
2844	Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients. Cureus, 2021, 13, e17118.	0.2	2
2845	Implementing a PARADIGM Shift. Journal of Cardiac Failure, 2021, 27, 837-838.	0.7	0
2846	Cardiac complications associated with hematopoietic stem-cell transplantation. Bone Marrow Transplantation, 2021, 56, 2637-2643.	1.3	11
2847	Sacubitril/valsartan in realâ€life European patients with heart failure and reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 3547-3556.	1.4	29
2848	Survival Association of Angiotensin Inhibitors in Heart Failure With Reduced Ejection Fraction: Comparisons Using Self-Identified Race and Genomic Ancestry. Journal of Cardiac Failure, 2022, 28, 215-225.	0.7	0
2849	Determinants of worse prognosis in patients with cardiac resynchronization therapy defibrillators. Are ventricular arrhythmias an adjunctive risk factor?. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 42-48.	0.6	0
2850	Problems with the outcome measures in randomized controlled trials of traditional Chinese medicine in treating chronic heart failure caused by coronary heart disease: a systematic review. BMC Complementary Medicine and Therapies, 2021, 21, 217.	1.2	7
2852	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia, 2021, 40, 975-983.	0.2	6
2853	Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Eventsâ€"Application to Clinical Trials in Chronic Heart Failure. Statistics in Biopharmaceutical Research, 2023, 15, 268-279.	0.6	9
2854	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	0.7	30

#	Article	IF	Citations
2855	Reply. Journal of the American College of Cardiology, 2021, 78, 760-761.	1.2	0
2856	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 926.	3.0	65
2857	Angiotensin receptor blocker neprilysin inhibitors. World Journal of Cardiology, 2021, 13, 325-339.	0.5	3
2858	Diabetes mellitus and acute coronary syndromes. MÃ¬Å¾narodnij EndokrinologÃ¬Ënij Å½urnal, 2021, 17, 346-360.	0.1	0
2859	ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. European Heart Journal Supplements, 2021, 23, C184-C195.	0.0	5
2860	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	0.4	89
2861	What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. Clinical Oncology, 2021, 33, 483-493.	0.6	5
2862	Stem cell therapy in the heart: Biomaterials as a key route. Tissue and Cell, 2021, 71, 101504.	1.0	37
2863	What Is the Status of Regenerative Therapy in Heart Failure?. Current Cardiology Reports, 2021, 23, 146.	1.3	4
2864	Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts. Scientific Reports, 2021, 11, 16542.	1.6	13
2865	Cost-effectiveness analysis of screening for first-degree relatives of patients with bicuspid aortic valve. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 447-457.	1.8	15
2866	Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review. Current Cardiology Reviews, 2022, 18, .	0.6	1
2867	New Drugs for Heart Failure: What is the Evidence in Older Patients?. Journal of Cardiac Failure, 2022, 28, 316-329.	0.7	1
2868	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	0.7	370
2869	Angiotensin receptor blocker neprilysin inhibitors. World Journal of Cardiology, 2021, 13, 326-340.	0.5	0
2870	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs, 2021, 81, 1491-1511.	4.9	18
2871	Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice. Annals of Pharmacotherapy, 2021, , 106002802110361.	0.9	2
2872	Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 90-102.	0.4	3

#	Article	IF	Citations
2873	Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper. Journal of Clinical Medicine, 2021, 10, 3519.	1.0	6
2874	Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias. International Journal of Molecular Sciences, 2021, 22, 8994.	1.8	22
2875	Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2021, 78, 202-210.	0.8	8
2876	Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2021, 153, 150-152.	0.7	0
2877	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021459.	1.6	10
2878	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
2879	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. Circulation Reports, 2021, 3, 440-448.	0.4	18
2880	Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury. International Journal of Molecular Sciences, 2021, 22, 8598.	1.8	2
2881	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. European Journal of Internal Medicine, 2021, 90, 10-15.	1.0	6
2882	Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study. Implementation Science, 2021, 16, 84.	2.5	5
2883	Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 2021, 1-11.	1.0	2
2884	Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up. IJC Heart and Vasculature, 2021, 35, 100821.	0.6	9
2885	Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria. ESC Heart Failure, 2021, 8, 3656-3662.	1.4	4
2886	The effects of sacubitril/valsartan on heart failure with preserved ejection fraction: a meta-analysis. Acta Cardiologica, 2022, 77, 471-479.	0.3	3
2887	Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Scientific Reports, 2021, 11, 16335.	1.6	12
2888	Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. Molecules, 2021, 26, 5006.	1.7	11
2889	Proteomics of Mouse Heart Ventricles Reveals Mitochondria and Metabolism as Major Targets of a Post-Infarction Short-Acting GLP1Ra-Therapy. International Journal of Molecular Sciences, 2021, 22, 8711.	1.8	4
2890	Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis. Frontiers in Physiology, 2021, 12, 693099.	1.3	17

#	Article	IF	Citations
2891	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. Frontiers in Physiology, 2021, 12, 652163.	1.3	14
2892	Financial burden, distress, and toxicity in cardiovascular disease. American Heart Journal, 2021, 238, 75-84.	1.2	28
2893	Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A metaâ€analysis. Clinical Cardiology, 2021, 44, 1354-1359.	0.7	13
2894	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
2896	Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension. Hypertension, 2021, 78, 604-616.	1.3	7
2897	Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure. Circulation Reports, 2021, 3, 589-593.	0.4	4
2898	Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. European Journal of Pharmacology, 2021, 907, 174288.	1.7	7
2899	Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Revista Clínica Espanõla, 2022, 222, 195-204.	0.3	6
2900	The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 593-600.	1.0	12
2901	Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007665.	0.9	9
2902	Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?. Journal of Cardiovascular Pharmacology, 2021, 78, 331-333.	0.8	1
2903	Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: AÂMeta-analysis. CJC Open, 2021, 3, S202-S208.	0.7	8
2904	Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway. Frontiers in Pharmacology, 2021, 12, 727838.	1.6	12
2905	Understanding the pharmacology of heart failure. Practice Nursing, 2021, 32, 363-368.	0.1	0
2906	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASISâ€HF</scp> and <scp>RALES</scp>. European Journal of Heart Failure, 2022, 24, 529-538.	2.9	7
2907	Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 629-634.	0.4	2
2908	Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome. Life Sciences, 2021, 280, 119692.	2.0	8
2909	Prevalence of Chronic Heart Failure, Associated Factors, and Therapeutic Management in Primary Care Patients in Spain, IBERICAN Study. Journal of Clinical Medicine, 2021, 10, 4036.	1.0	5

#	Article	IF	Citations
2910	Early treatment with combination of SS31 and entresto effectively preserved the heart function in doxorubicin-induced dilated cardiomyopathic rat. Biomedicine and Pharmacotherapy, 2021, 141, 111886.	2.5	5
2911	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. Cardiology, 2021, , .	0.6	2
2912	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	2.9	69
2913	Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology. Annual Review of Pharmacology and Toxicology, 2022, 62, 551-571.	4.2	8
2914	Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction. Angiology, 2021, , 000331972110473.	0.8	10
2915	Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardio-Oncology, 2021, 7, 33.	0.8	11
2916	A randomized clinical trial on the shortâ€term effects of 12â€week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the <scp>ACTIVITYâ€HF</scp> study. European Journal of Heart Failure, 2021, 23, 2073-2082.	2.9	20
2917	Enantioselective Total Synthesis of Sacubitril. ChemistrySelect, 2021, 6, 8928-8930.	0.7	0
2918	Mackay Heart Failure Study: Examining the Root Causes, Compliance With Guideline-Based Therapy and Prognosis. Heart Lung and Circulation, 2021, 30, 1302-1308.	0.2	2
2919	Similarities and Differences Between HFmrEF and HFpEF. Frontiers in Cardiovascular Medicine, 2021, 8, 678614.	1.1	14
2920	Prognostic Importance of NT-proBNP andÂEffect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	1.2	55
2921	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 876-886.	1.9	19
2922	Prognostic predictors and echocardiographic time course after device replacement in patients treated chronically with cardiac resynchronization therapy devices. Heart and Vessels, 2021, , 1.	0.5	1
2923	Point of care with serial NT-proBNP measurement in patients with acute decompensated heart failure as a therapy-monitoring during hospitalization (POCâ€“HF): Study protocol of a prospective, unblinded, randomized, controlled pilot trial. Contemporary Clinical Trials Communications, 2021, 23, 100825.	0.5	2
2924	Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study. American Heart Journal, 2021, 239, 1-10.	1.2	15
2925	Novel Strategies Reflect the Paradigm Shift in the Treatment of Heart Failure with Reduced Ejection Fraction. Internal Medicine, 2021, 60, 2709-2710.	0.3	0
2926	Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments. Hypertension, 2021, 78, 564-577.	1.3	35
2927	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 829-850.e1.	0.4	34

#	Article	IF	Citations
2929	Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. Drugs, 2021, 81, 1599-1604.	4.9	6
2930	Tissue Inhibitor of Metalloproteinase-1 Is Increased in Chagasic Cardiomyopathy. American Journal of Tropical Medicine and Hygiene, 2021, 105, 638-642.	0.6	1
2931	Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, , .	1.4	9
2932	An Expanded Heart Failure Indication for Sacubitril/Valsartan. JAMA Cardiology, 2021, 6, 1357.	3.0	3
2933	Effects of angiotensin-receptor neprilysin inhibitor on exercise capacity, quality of life, and cardiac function in heart failure with preserved ejection fraction. Medicine, Case Reports and Study Protocols, 2021, 2, e0160.	0.0	0
2934	Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Advanced Drug Delivery Reviews, 2021, 176, 113904.	6.6	49
2935	Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand. Clinical Drug Investigation, 2021, 41, 907-915.	1.1	13
2936	Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age. Future Cardiology, 2021, 17, 1131-1142.	0.5	9
2937	The systemic right ventricle in adult congenital heart disease: why is it still such a challenge and is there any hope on the horizon?. Current Opinion in Cardiology, 2022, 37, 123-129.	0.8	2
2938	Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan. Internal Medicine, 2021, 60, 2807-2809.	0.3	4
2939	Comparative efficacy of medication and cardiac resynchronization therapy in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2021, 26, 4491.	0.4	0
2940	MLK3 mediates impact of PKG1Î± on cardiac function and controls blood pressure through separate mechanisms. JCI Insight, 2021, 6, .	2.3	3
2941	Incremental Value of Global Longitudinal Strain in the Long-Term Prediction of Heart Failure among Patients with Coronary Artery Disease. Journal of the American Society of Echocardiography, 2022, 35, 187-195.	1.2	12
2942	Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. Journal of Clinical Medicine, 2021, 10, 4409.	1.0	5
2943	Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?. Journal of Clinical Medicine, 2021, 10, 4325.	1.0	3
2944	Reninâ€“angiotensin system inhibitors and clinical outcomes in patients with atrial fibrillation and heart failure: a propensity score-matched study from the Chinese Atrial Fibrillation Registry. Journal of International Medical Research, 2021, 49, 030006052110414.	0.4	0
2945	Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System. Frontiers in Physiology, 2021, 12, 738218.	1.3	26
2946	Hyperkalemia in Patients With Left Ventricular Assist Devices. Circulation Reports, 2021, 3, 647-653.	0.4	0

#	Article	IF	Citations
2947	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444.	0.7	60
2948	Ischemic mitral regurgitation. Current Opinion in Cardiology, 2021, Publish Ahead of Print, 755-763.	0.8	0
2950	Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 180.	2.7	13
2952	Vericiguat, organic nitrates, and heart failure in African Americans. International Journal of Cardiology, 2021, 338, 136-137.	0.8	1
2953	Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan. Journal of Cardiovascular Pharmacology, 2021, 78, 403-406.	0.8	2
2954	Importance of Optimized Guideline-Based Therapy for Preventing Rehospitalization of Chronic Heart Failure Patientsã€€â€• From the KUNIUMI Acute Cohort â€•. Circulation Reports, 2021, 3, 511-519.	0.4	0
2955	Assessment of Physical Activity Using Waist-Worn Accelerometers in Hospitalized Heart Failure Patients and Its Relationship with Kansas City Cardiomyopathy Questionnaire. Journal of Clinical Medicine, 2021, 10, 4103.	1.0	1
2956	Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology, 2022, 19, 100-116.	6.1	156
2957	Left Ventricular Reverse Remodeling in Heart Failure: Remission to Recovery. Structural Heart, 2021, 5, 466-481.	0.2	19
2958	Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. European Journal of Clinical Pharmacology, 2022, 78, 19-25.	0.8	10
2960	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circulation Journal, 2021, 85, 2252-2291.	0.7	80
2961	Predictors of right ventricular function improvement with sacubitril/valsartan in a realâ€•life population of patients with chronic heart failure. Clinical Physiology and Functional Imaging, 2021, 41, 505-513.	0.5	7
2962	Clinical Trials of Heart Failure: Is There a Question of Sex?. Canadian Journal of Cardiology, 2021, 37, 1303-1309.	0.8	3
2963	Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review. Canadian Journal of Cardiology, 2021, 37, 1438-1449.	0.8	15
2964	The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. Viruses, 2021, 13, 1904.	1.5	24
2965	The Effect of Angiotensin Receptor Inhibitors and Neprilysin on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 298-306.	0.2	0
2966	Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/Î²-Catenin Signaling Pathway. Frontiers in Pharmacology, 2021, 12, 724147.	1.6	19
2967	Methodological challenges in the analysis of recurrent events for randomised controlled trials with application to cardiovascular events in<scp>LEADER</scp>. Pharmaceutical Statistics, 2022, 21, 241-267.	0.7	9

#	Article	IF	Citations
2968	Soluble Guanylate Cyclase Stimulators in Heart Failure. Cureus, 2021, 13, e17781.	0.2	6
2969	Impact of Sacubitril/valsartan on Clinical Outcomes During Left Ventricular Assist Device Supports. ASAIO Journal, 2021, Publish Ahead of Print, .	0.9	1
2970	Functional Mitral Regurgitation in Heart Failure: Analysis of the ESC Multidisciplinary Heart-Team Position Statement and Review of Current Guidelines. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	0.6	0
2971	Potential pitfalls when interpreting plasma BNP levels in heart failure practice. Journal of Cardiology, 2021, 78, 269-274.	0.8	19
2972	Pathophysiology of Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 519-531.	1.0	9
2973	Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1H)-one APJ receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2021, 50, 128325.	1.0	7
2974	Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia. Journal of Cardiology, 2021, 78, 275-284.	0.8	5
2975	Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG. Journal of Cardiology, 2021, 78, 261-268.	0.8	14
2976	The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. Current Cardiology Reports, 2021, 23, 163.	1.3	6
2977	Angiotensin II receptor type 1 â€“ An update on structure, expression and pathology. Biochemical Pharmacology, 2021, 192, 114673.	2.0	23
2978	Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction. Journal of Comparative Effectiveness Research, 2021, 10, 1055-1063.	0.6	1
2979	Effects of enalapril folic acid combined with levamlodipine on incidence of cardiovascular and cerebrovascular events in patients with essential hypertension. Materials Express, 2021, 11, 1739-1745.	0.2	0
2980	Disease-modifier Drugs in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 561-573.	1.0	2
2981	Novel O-[11C]-methylated derivatives of the neprilysin inhibitor sacubitril: Radiosynthesis, autoradiography and plasma stability evaluation. Nuclear Medicine and Biology, 2021, 102-103, 34-44.	0.3	1
2982	Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials. American Heart Journal, 2021, 241, 108-119.	1.2	10
2983	Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102834.	1.4	7
2984	The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. , 2021, 227, 107863.		59
2985	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. American Journal of Preventive Cardiology, 2021, 8, 100250.	1.3	51

#	Article	IF	Citations
2986	Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. , 2021, 228, 107920.		20
2987	Entresto protected the cardiomyocytes and preserved heart function in cardiorenal syndrome rat fed with high-protein diet through regulating the oxidative stress and Mfn2-mediated mitochondrial functional integrity. Biomedicine and Pharmacotherapy, 2021, 144, 112244.	2.5	15
2988	Group 2 Pulmonary Hypertension: Clinical Features and Treatment. , 2022, , 665-677.		0
2989	Heart Failure and Pulmonary Hypertension. , 2022, , 217-255.		0
2990	Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial. Frontiers in Pharmacology, 2020, 11, 571106.	1.6	2
2991	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. Scientific Reports, 2021, 11, 732.	1.6	14
2992	General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. , 2021, , 463-472.		0
2993	Chronische Herzinsuffizienz. , 2021, , 92-109.		0
2994	Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary. Journal of Clinical Hypertension, 2021, 23, 692-695.	1.0	4
2995	Ambient Temperature and Cardiorenal Connection in Elderly Patients with Stable Heart Failure. Tohoku Journal of Experimental Medicine, 2021, 254, 81-87.	0.5	0
2996	Predicting Sudden Cardiac Death After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009422.	2.1	4
2997	Cardiac Myosin Activation for the Treatment of Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 77, 4-10.	0.8	5
2998	Venous Thromboembolism in Heart Failure Patients: Building Evidence towards Better Care and the Need for Precision. Korean Circulation Journal, 2021, 51, 781.	0.7	0
2999	Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives. International Journal of Molecular Sciences, 2021, 22, 775.	1.8	25
3000	Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction. ESC Heart Failure, 2021, 8, 1204-1215.	1.4	12
3001	Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients. Yonsei Medical Journal, 2021, 62, 391.	0.9	0
3002	Reninâ€“Angiotensinâ€“Aldosterone System. , 2021, , 1-6.		0
3003	AtualizaÃ§Ã£o de TÃ³picos Emergentes da Diretriz Brasileira de InsuficiÃªncia CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 116, 1174-1212.	0.3	13

#	Article	IF	Citations
3004	Commentary: A stitch in time saves nine, but medical therapy makes that stitch shine. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1900-1901.	0.4	0
3005	Myocardial protective effect of sacubitril-valsartan on rats with acute myocardial infarction. Perfusion (United Kingdom), 2021, , 026765912199057.	0.5	1
3007	Sacubitrilo-valsartÃ¡n: correlaciÃ³n entre biomarcadores y remodelado en la IC con FEVI reducida. REC: CardioClinics, 2021, 56, 4-6.	0.1	0
3008	Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?. International Journal of Heart Failure, 2021, 3, 106.	0.9	3
3009	The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Therapeutic Advances in Cardiovascular Disease, 2021, 15, 175394472110026.	1.0	10
3010	Sodiumâ€“glucose Cotransporter 2 Inhibitorsâ€™ Rise to the Backbone of Heart Failure Management: A Clinical Review. Heart International, 2021, 15, 42.	0.4	0
3011	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. International Journal of Cardiology, 2021, 323, 188-191.	0.8	7
3012	Using Patient-Reported Outcomes to Assess Healthcare Quality: Toward Better Measurement of Patient-Centered Care in Cardiovascular Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 1.	0.5	5
3013	Osteocrin, a bone-derived humoral factor, exerts a renoprotective role in ischemiaâ€“reperfusion injury in mice. Nephrology Dialysis Transplantation, 2022, 37, 444-453.	0.4	3
3014	Hyperkalemia in heart failure: Foe or friend?. Clinical Cardiology, 2020, 43, 666-675.	0.7	17
3016	Cardiac PET Imaging: Principles and New Developments. , 2017, , 451-483.		1
3017	Compartmentation of Natriuretic Peptide Signalling in Cardiac Myocytes: Effects on Cardiac Contractility and Hypertrophy. Cardiac and Vascular Biology, 2017, , 245-271.	0.2	2
3018	Hormonal Systems. Updates in Hypertension and Cardiovascular Protection, 2018, , 81-106.	0.1	1
3019	Pharmaceutical Treatment for Heart Failure. Advances in Experimental Medicine and Biology, 2020, 1177, 269-295.	0.8	7
3020	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2020, 109, 1048-1059.	1.5	20
3021	Management and Care of Older Cardiac Patients. , 2018, , 245-265.		6
3023	Heart failure: From novel pharmaceutical therapies to circulation support systems. Hellenic Journal of Cardiology, 2020, 61, 359-361.	0.4	2
3024	Cardiac Endocrinology. JACC Basic To Translational Science, 2020, 5, 949-960.	1.9	17

#	Article	IF	Citations
3025	Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity. JACC: CardioOncology, 2020, 2, 774-787.	1.7	30
3026	Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy. , 2020, 213, 107584.		22
3027	Remodelado ventricular tras el uso de sacubitrilo-valsartÃ¡n en la miocardiopatÃa tÃ³xica del paciente con cÃ¡ncer. Revista Espanola De Cardiologia, 2020, 73, 268-269.	0.6	9
3028	Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Revista Espanola De Geriatria Y Gerontologia, 2020, 55, 65-69.	0.2	18
3029	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.	6.3	376
3030	Assessing the lifetime benefit of heart failure therapies. Lancet, The, 2020, 396, 75-77.	6.3	2
3031	Una historia resumida. Impacto de los avances en cardiopatÃa isquÃ©mica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 2-6.	0.2	1
3032	Cardiac natriuretic peptides. Nature Reviews Cardiology, 2020, 17, 698-717.	6.1	262
3033	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	1.0	117
3034	EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 2021, 42, 711-714.	1.0	8
3035	Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. European Journal of Preventive Cardiology, 2021, 28, 110-123.	0.8	20
3036	Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis. European Journal of Preventive Cardiology, 2021, 28, 1665-1669.	0.8	9
3037	Nonpharmacologic Treatment for Heart Failure. Cardiology in Review, 2021, 29, 48-53.	0.6	6
3038	The Role of Testosterone in Patients With Heart Failure: A Systematic Review. Cardiology in Review, 2021, 29, 156-161.	0.6	6
3039	Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coronary Artery Disease, 2021, 32, 418-426.	0.3	17
3040	Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coronary Artery Disease, 2021, 32, 427-431.	0.3	14
3041	New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF). Medicine (United States), 2020, 99, e18341.	0.4	9
3043	Systematic synthesis of a 6-component organic-salt alloy of naftopidil, and pentanary, quaternary and ternary multicomponent crystals. IUCrJ, 2018, 5, 816-822.	1.0	16

#	Article	IF	Citations
3044	Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan. Acta Crystallographica Section F, Structural Biology Communications, 2019, 75, 405-411.	0.4	4
3045	COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure. MBio, 2020, 11, .	1.8	2
3046	Functional Screening Identifies MicroRNA Regulators of Corin Activity and Atrial Natriuretic Peptide Biogenesis. Molecular and Cellular Biology, 2019, 39, .	1.1	13
3047	Change in renal function associated with drug treatment in heart failure: national guidance. Heart, 2019, 105, 904-910.	1.2	62
3048	Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial. American Journal of Physiology - Renal Physiology, 2020, 318, G635-G645.	1.6	8
3049	Oxidative Stress in Ischemic Heart Disease. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-30.	1.9	63
3050	Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions. Circulation: Heart Failure, 2020, 13, e007094.	1.6	22
3051	Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Medical Journal, 2020, 61, 320-326.	0.3	5
3052	Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS. JCI Insight, 2019, 4, .	2.3	12
3053	Antisense regulation of atrial natriuretic peptide expression. JCI Insight, 2019, 4, .	2.3	14
3054	C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness. JCI Insight, 2020, 5, .	2.3	25
3055	Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 217-231.	1.0	21
3056	Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882097044.	1.4	26
3057	Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination. Journal of Geriatric Cardiology, 2016, 13, 914-923.	0.2	2
3058	Prediction of sudden death in elderly patients with heart failure. Journal of Geriatric Cardiology, 2018, 15, 185-192.	0.2	11
3059	Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report. American Journal of Case Reports, 2017, 18, 576-579.	0.3	16
3060	Recent advances in the treatment of chronic heart failure. F1000Research, 2019, 8, 2134.	0.8	7
3061	Improved Cardiovascular Disease Outcomes in Older Adults. F1000Research, 2016, 5, 112.	0.8	21

#	Article	IF	Citations
3062	The cardiac enigma: current conundrums in heart failure research. F1000Research, 2016, 5, 72.	0.8	9
3063	Cardio-renal syndrome. F1000Research, 2016, 5, 2123.	0.8	14
3064	Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. HRB Open Research, 2020, 3, 5.	0.3	3
3065	Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report. World Journal of Clinical Cases, 2019, 7, 4098-4105.	0.3	9
3066	Predictive model identifies key network regulators of cardiomyocyte mechano-signaling. PLoS Computational Biology, 2017, 13, e1005854.	1.5	53
3067	Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen. PLoS ONE, 2016, 11, e0158114.	1.1	4
3068	Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure. PLoS ONE, 2017, 12, e0169743.	1.1	25
3069	Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. Cardiology Research, 2020, 11, 376-385.	0.5	11
3070	Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials. Cardiology Research, 2019, 10, 24-33.	0.5	16
3071	Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study. Cardiology Research, 2019, 10, 293-302.	0.5	13
3072	Utilization of Ultrasound to Assess Volume Status in Heart Failure. Journal of Clinical Medicine Research, 2020, 12, 230-232.	0.6	2
3073	Heart Failure in Women. Methodist DeBakey Cardiovascular Journal, 2021, 13, 216.	0.5	76
3074	The particulars of certain drugsâ€™ effect on the endogenous coenzyme Q10 plasma level in patients with cardiovascular diseases. Drug Metabolism and Personalized Therapy, 2020, 35, .	0.3	2
3075	Effect of angiotensin/neprilysin inhibition on ventricular repolarization and clinical arrhythmogenesis. Cardio-IT, 2020, 7, .	0.3	2
3076	Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. Endocrine Connections, 2020, 9, 438-444.	0.8	6
3077	Normal Reference Intervals for Cardiac Dimensions and Function for Use in Echocardiographic Practice: A Guideline from the British Society of Echocardiography. Echo Research and Practice, 2020, 7, G1-G18.	0.6	89
3078	Gaps in the Heart Failure Guidelines. Cardiac Failure Review, 2015, 1, 50.	1.2	1
3079	What the General Practitioner Needs to Know About Their Chronic Heart Failure Patientt. Cardiac Failure Review, 2016, 2, 79-84.	1.2	12

#	Article	IF	Citations
3080	Current Understanding Of The Compensatory Actions Of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective. Cardiac Failure Review, 2016, 2, 14.	1.2	15
3081	Calming the Nervous Heart: Autonomic Therapies in Heart Failure. Cardiac Failure Review, 2018, 4, 92.	1.2	47
3082	The Limitations of Symptom-based Heart Failure Management. Cardiac Failure Review, 2019, 5, 74-77.	1.2	10
3083	Sodiumâ€“Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. Cardiac Failure Review, 2020, 6, e31.	1.2	17
3084	Gaps in the Heart Failure Guidelines. European Cardiology Review, 2014, 9, 104.	0.7	2
3085	Highlights of the 2016 European Society of Cardiology Guidelines on Heart Failure. European Cardiology Review, 2017, 12, 76.	0.7	3
3086	Hidden in Heart Failure. European Cardiology Review, 2019, 14, 89-96.	0.7	3
3087	Diagnosing and managing acute heart failure in the emergency department. Clinical and Experimental Emergency Medicine, 2015, 2, 141-149.	0.5	14
3088	Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure. Russian Journal of Cardiology, 2020, 25, 65-71.	0.4	2
3089	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	229
3090	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	32
3091	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology, 2020, 25, 4103.	0.4	132
3092	Combined RAAS and NEP Inhibition. International Cardiovascular Forum Journal, 0, 17, .	1.1	1
3094	Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696. Oncotarget, 2017, 8, 83323-83333.	0.8	15
3095	LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	8
3096	A review of racial disparities in transcatheter aortic valve replacement (TAVR): accessibility, referrals and implantation. Annals of Translational Medicine, 2018, 6, 10-10.	0.7	25
3097	Glycosylation of natriuretic peptides in obese heart failure: mechanistic insights. Annals of Translational Medicine, 2019, 7, 611-611.	0.7	8
3098	First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy. Meditsinskiy Sovet, 2019, , 42-48.	0.1	4

#	Article	IF	Citations
3099	Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options. Current Medicinal Chemistry, 2020, 27, 4522-4535.	1.2	2
3100	Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure. Current Topics in Medicinal Chemistry, 2019, 19, 1850-1866.	1.0	6
3101	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Current Topics in Medicinal Chemistry, 2019, 19, 1818-1849.	1.0	22
3102	Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease. Current Cardiology Reviews, 2018, 14, 60-66.	0.6	7
3103	Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure. Current Cardiology Reviews, 2020, 16, 202-211.	0.6	4
3104	Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review. Current Cardiology Reviews, 2020, 16, 55-64.	0.6	7
3105	Editorial Nutritional Modulators in Chronic Heart Failure. The Open Nutraceuticals Journal, 2015, 8, 1-4.	0.2	2
3107	Antihypertensive effect of sacubitril/valsartan: a meta-analysis. Minerva Cardioangiologica, 2019, 67, 214-222.	1.2	10
3108	Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction. Minerva Cardioangiologica, 2019, 67, 456-463.	1.2	11
3109	Interventional procedures versus medical therapy alone: outcome of cardiac patient management - a systematic review. Minerva Cardioangiologica, 2020, 68, 586-591.	1.2	1
3110	Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure. Journal of Cardiovascular Medicine, 2021, 22, 508-510.	0.6	2
3111	Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits. Acta Pharmaceutica, 2021, 71, 473-484.	0.9	6
3112	Editorial: Heart Failure in Type 2 Diabetes â€“ The â€œForgottenâ€•Complication. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2018, 25, 123-130.	0.3	4
3113	The Treatment of Heart Failure with Reduced Ejection Fraction. Deutsches Ärzteblatt International, 2020, 117, 376-386.	0.6	37
3114	Effect of Angiotensin-Converting Enzyme Blockade, Alone or Combined With Blockade of Soluble Epoxide Hydrolase, on the Course of Congestive Heart Failure and Occurrence of Renal Dysfunction in Ren-2 Transgenic Hypertensive Rats With Aorto-Caval Fistula. Physiological Research, 2017, 67, 401-415.	0.4	14
3115	Sacubitril/Valsartan and implantable cardioverter- -defibrillators: evolving therapeutic strategies. A case report. Cor Et Vasa, 2020, 62, 479-482.	0.1	5
3116	Small and Intermediate Calcium Activated Potassium Channels in the Heart: Role and Strategies in the Treatment of Cardiovascular Diseases. Frontiers in Physiology, 2020, 11, 590534.	1.3	14
3117	ANP and BNP Exert Anti-Inflammatory Action via NPR-1/cGMP Axis by Interfering with Canonical, Non-Canonical, and Alternative Routes of Inflammasome Activation in Human THP1 Cells. International Journal of Molecular Sciences, 2021, 22, 24.	1.8	21

#	Article	IF	Citations
3118	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 113.	0.0	12
3119	Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. International Journal of Heart Failure, 2019, 1, 4.	0.9	45
3120	Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry. International Journal of Heart Failure, 2019, 1, 57.	0.9	13
3121	Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure. International Journal of Heart Failure, 2020, 2, 73.	0.9	15
3122	Sex and Gender Differences in Heart Failure. International Journal of Heart Failure, 2020, 2, 157.	0.9	43
3123	Paradigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?. International Journal of Heart Failure, 2020, 2, 145.	0.9	20
3124	Heart failure with preserved ejection fraction: insights from recent clinical researches. Korean Journal of Internal Medicine, 2020, 35, 514-534.	0.7	10
3126	Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence. Korean Journal of Internal Medicine, 2020, 35, 498-513.	0.7	12
3127	Current status of heart failure: global and Korea. Korean Journal of Internal Medicine, 2020, 35, 487-497.	0.7	27
3128	2018 Korean Heart Rhythm Society Guidelines for Antiarrhythmic Drug Therapy in Non-valvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 140-152.	0.1	3
3129	The ABCs of managing systolic heart failure: Past, present, and future. Cleveland Clinic Journal of Medicine, 2016, 83, 753-765.	0.6	7
3130	Heart failure guidelines: What you need to know about the 2017 focused update. Cleveland Clinic Journal of Medicine, 2019, 86, 123-139.	0.6	5
3131	ACE inhibitor and ARB therapy: Practical recommendations. Cleveland Clinic Journal of Medicine, 2019, 86, 608-611.	0.6	6
3132	Endothelial glycocalyx: Role in body fluid homeostasis and fluid management. Indian Journal of Anaesthesia, 2019, 63, 6.	0.3	31
3133	Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. Journal of Family Medicine and Primary Care, 2019, 8, 1855.	0.3	21
3134	Eplerenone: The multifaceted drug in cardiovascular pharmacology. Journal of Pharmacy and Bioallied Sciences, 2020, 12, 381.	0.2	5
3135	Evaluating the Adherence to Guidelines for Management of Acute Heart Failure in the Gaza Strip Hospitals: A Medical Chartâ€“Based Review Study. Global Journal on Quality and Safety in Healthcare, 2019, 2, 21-29.	0.1	2
3136	Range of adiposity and cardiorenal syndrome. World Journal of Diabetes, 2020, 11, 322-350.	1.3	13

#	Article	IF	Citations
3137	Allogeneic cardiosphere-derived cells for the treatment of heart failure with reduced ejection fraction: the Dilated cardiomYopathy iNtervention with Allogeneic Myocardlally-regenerative Cells (DYNAMIC) trial. EuroIntervention, 2020, 16, e293-e300.	1.4	32
3138	Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. World Journal of Cardiology, 2020, 12, 501-511.	0.5	7
3139	Update of treatment of heart failure with reduction of left ventricular ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2016, 1, 106-116.	0.5	8
3140	State of the Art Review: Brachial-Ankle PWV. Journal of Atherosclerosis and Thrombosis, 2020, 27, 621-636.	0.9	51
3141	Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiology Journal, 2016, 23, 591-598.	0.5	10
3142	Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. Cardiology Journal, 2019, 26, 575-583.	0.5	16
3143	Teaching Student Pharmacists to Apply Drug Literature to Patient Cases. American Journal of Pharmaceutical Education, 2017, 81, 34.	0.7	10
3144	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.1	50
3145	Critical Questions about PARADIGM-HF and the Future. Acta Cardiologica Sinica, 2016, 32, 387-96.	0.1	17
3146	Drosophila neprilysins control insulin signaling and food intake via cleavage of regulatory peptides. ELife, 2016, 5, .	2.8	23
3147	Increasing heart vascularisation after myocardial infarction using brain natriuretic peptide stimulation of endothelial and WT1+ epicardial cells. ELife, 2020, 9, .	2.8	11
3148	DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs in Context, 2020, 9, 1-7.	1.0	20
3149	Role of reninâ€“angiotensinâ€“aldosterone system inhibitors in heart failure and chronic kidney disease. Drugs in Context, 2020, 9, 1-9.	1.0	7
3150	Heart failure and acute renal dysfunction in the cardiorenal syndrome. Clinical Medicine, 2020, 20, 146-150.	0.8	15
3151	Puesta al dÃa sobre el empleo de dapagliflozina en insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n reducida. Revista Espanola De Cardiologia Suplementos, 2021, 21, 1-9.	0.2	0
3152	Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure. MDM Policy and Practice, 2021, 6, 238146832110416.	0.5	1
3153	AsociaciÃ³n entre valsartÃ¡n e inhibidores de neprilisina en el manejo de la falla cardiaca.. Revista Ciencias BiomÃ‰dicas (cartagena), 2021, 10, 198-206.	0.0	0
3155	Understanding the pharmacology of heart failure. Journal of Prescribing Practice, 2021, 3, 404-410.	0.1	0

#	Article	IF	Citations
3156	Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and metaâ€•analysis. Pharmacology Research and Perspectives, 2021, 9, e00844.	1.1	11
3157	Does sacubitril/valsartan work in acute myocardial infarction? The PARADISE-AMI study. European Heart Journal Supplements, 2021, 23, E87-E90.	0.0	5
3158	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. European Cardiology Review, 2021, 16, e40.	0.7	9
3159	Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. Pharmacoeconomics, 2021, 39, 1343-1354.	1.7	20
3160	Effects of an outpatient intervention comprising nurseâ€•led nonâ€•invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<scp>AMULET</scp> study): a randomised controlled trial. European Journal of Heart Failure, 2022, 24, 565-577.	2.9	23
3161	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008072.	0.9	2
3162	Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan. Diagnostics, 2021, 11, 1845.	1.3	10
3163	Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 37-41.	0.6	3
3164	Changes over time in the association between type 2 diabetes and post-discharge outcomes in decompensated chronic heart failure patients: Findings from the RICA Registry. Revista Clínica Espanõla, 2022, 222, 63-72.	0.3	1
3165	Study protocol: Traditional Chinese Medicine (TCM) syndrome differentiation for heart failure patients and its implication for long-term therapeutic outcomes of the Qiliqiangxin capsules. Chinese Medicine, 2021, 16, 103.	1.6	9
3166	Nitric oxide â€” soluble guanylate cyclase â€” cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3035.	0.4	2
3167	Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment. Cardiovascular Diagnosis and Therapy, 2021, 11, 1093-1100.	0.7	5
3168	Rationale and design of a multiâ€•center, prospective randomized controlled trial on the effects of sacubitrilâ€“valsartan versus enalapril on left ventricular remodeling in <scp>ST</scp>â€•elevation myocardial infarction: The <scp>PERIâ€•STEMI</scp> study. Clinical Cardiology, 2021, 44, 1709-1717.	0.7	6
3169	Dapagliflozin Versus Sacubitrilâ€“Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2022, 22, 325-331.	1.0	4
3170	ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction. ESC Heart Failure, 2021, 8, 4607-4616.	1.4	14
3171	Hypertensive Heart Failure in Asia. Pulse, 2021, 9, 47-56.	0.9	5
3172	Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review. Current Cardiology Reviews, 2022, 18, .	0.6	2
3173	Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data. Cardio-Oncology, 2021, 7, 35.	0.8	9

#	Article	IF	Citations
3175	Properties of Two While-Alive Estimands for Recurrent Events and Their Potential Estimators. Statistics in Biopharmaceutical Research, 2023, 15, 257-267.	0.6	7
3176	The Role of Neurohormonal Systems, Inflammatory Mediators and Oxydative Stress in Cardiomyopathy. , 0, , .		1
3177	Endovascular renal sympathetic denervation to improve heart failure with reduced ejection fraction: the IMPROVE-HF-I study. Netherlands Heart Journal, 2022, 30, 149-159.	0.3	4
3178	Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart, 2021, 8, e001704.	0.9	3
3179	Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure. Frontiers in Physiology, 2021, 12, 650124.	1.3	5
3180	Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 863-872.	0.7	6
3181	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	1.9	32
3182	Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study. EClinicalMedicine, 2021, 41, 101149.	3.2	9
3184	Participant Adherence. , 2015, , 297-318.		0
3186	Re: Ny og bedre medisin mot hjertesvikt. Tidsskrift for Den Norske Laegeforening, 2015, 135, 830-831.	0.2	0
3187	Medicatie bij hartfalen. , 2015, , 53-83.		0
3191	Cardio Renal Syndromes 2015: Is there a Silver Lining to the Dark Clouds?. The Open Urology & Nephrology Journal, 2015, 8, 45-52.	0.2	0
3193	Novel Drugs in the Treatment of Hypertension. Updates in Hypertension and Cardiovascular Protection, 2016, , 157-178.	0.1	0
3194	Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertension Journal, 2016, 2, 145-152.	0.1	0
3195	Foreword. Cardiac Failure Review, 2016, 2, 6.	1.2	0
3197	Hemmstoffe des Renin-Angiotensin-Systems. , 2016, , 209-235.		0
3198	Novel Therapies for the Prevention and Management of Acute Decompensated Heart Failure. , 2016, , 29-71.		0
3199	Epigenetic and Nongenomic Roles for Histone Deacetylases in Heart Failure. Cardiac and Vascular Biology, 2016, , 209-229.	0.2	0

#	Article	IF	Citations
3200	Inhibitoren des Renin-Angiotensin-Aldosteron-Systems. Springer-Lehrbuch, 2016, , 373-389.	0.1	0
3201	Natriuretic Peptides: Physiology for the Clinician. , 2016, , 161-172.		0
3204	The PARADIGM-HF trial (October 2015). Cleveland Clinic Journal of Medicine, 2016, 83, 167.1-167.	0.6	1
3205	In reply: The PARADIGM-HF trial (October 2015). Cleveland Clinic Journal of Medicine, 2016, 83, 167.2-168.	0.6	1
3206	Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Medical Weekly, 2016, 146, w14295.	0.8	7
3207	NEW HORIZONS IN THE MANAGEMENT OF HEART FAILURE. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 1604-1607.	0.0	1
3209	ÐÐµÐºÐ¾Ð¼Ð¼ÐµÐ½Ð´Ð°Ñ†Ð¸Ð¸ 2016 Ð•Ð²Ñ€Ð¾Ð¿ÐµÐ¹ÑÐºÐ¾Ð³Ð¾ Ð¾Ð±Ñ‰ÐµÑÑ‚Ð²Ð° ÐºÐ°Ñ€Ð´Ð¸Ð¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¿Ð¾		
3212	Heart failure in patients with type 2 diabetes mellitus: pathogenesis and treatment. LÃ¬ki UkraÃ¯ni, 2016, .	0.0	0
3214	Herztherapeutika. , 2017, , 491-503.		0
3215	Leitsymptom Dyspnoe, LeistungsschwÃche. , 2017, , 115-226.		0
3216	Outpatient Medication Titration in Acute Heart Failure. Contemporary Cardiology, 2017, , 243-258.	0.0	0
3217	Report from the Japanese Society of Pediatric Cardiology and Cardiac Surgery Research Committee on Cardio-Vascular Function in Adult Patients with Congenital Heart Disease: Treatment Strategy for Hypoplastic Left Heart Syndrome Based on the Cardiovascular Pathophysiology. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2017, 33, 269-280.	0.0	0
3218	Hemmstoffe des Renin-Angiotensin-Systems. , 2017, , 211-236.		0
3220	Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). , 2017, , 273-339.		0
3221	1. The Latest Clinical Findings and Treatments for Heart Failure. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 510-515.	0.0	0
3222	Neue Arzneimittel 2016. , 2017, , 55-135.		0
3223	B-Type Natriuretic Peptide as a Predictor of Short-Term Mortality in On-Pump Coronary Artery Bypass Grafting. Brazilian Journal of Cardiovascular Surgery, 2017, 32, 462-467.	0.2	0
3224	Heart Failure with Preserved Ejection Fraction (HFpEF). , 2017, , 197-209.		0

#	Article	IF	Citations
3225	Contemporary versus tradition: Implantable cardioverter defibrillator use in nonischemic dilated cardiomyopathy. International Journal of Heart Rhythm, 2017, 2, 53.	0.0	0
3226	Kardiologie. , 2017, , 61-143.		0
3227	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2017, , 85-96.		0
3228	The Role of Natriuretic Peptides in the Pathophysiology and Treatment of Heart Failure. Advances in Medical Diagnosis, Treatment, and Care, 2017, , 1-16.	0.1	1
3229	Does Angiotensin Receptor Neprilysin Inhibitor (ARNI) Improve Functional Capacity Assessed by 6 Minutes Walking Test?. European Cardiology Review, 2017, 12, 100.	0.7	0
3230	Cyclic GMP/Protein Kinase Localized Signaling and Disease Implications. Cardiac and Vascular Biology, 2017, , 273-290.	0.2	0
3231	Neurohormonal Activation and the Management of Heart Failure. , 2017, , 239-246.		0
3232	Dual inhibition in the treatment of heart failure. Interni Medicina Pro Praxi, 2017, 19, 29-32.	0.0	0
3235	Novinky v lieÄbe srdcovÃ©ho zlyhÃ¡vania - editorial. Vnitrni Lekarstvi, 2017, 63, 234-235.	0.1	0
3236	Novelties in the treatment of heart failure. Vnitrni Lekarstvi, 2017, 63, 255-264.	0.1	2
3237	Chronic Heart Failure. , 2017, , .		0
3238	Other Devices for Heart Failure â€“ Cardiac Contractility Modulation (CCM). International Cardiovascular Forum Journal, 0, 10, .	1.1	0
3239	Herzinsuffizienz und Diabetes. Klinikarzt, 2017, 46, 318-323.	0.0	0
3240	Diagnosis, prevention and treatment of chronic heart failure: what the therapist of the outpatient health care unit should know (according to the recommendations of the European Society of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Cardiosomatics, 2017, 8, 29-38.	0.2	0
3244	Tropical Coronary Artery Disease and Arrhythmogenic Potentialsâ€"The Changing Pattern towards Endomyocardial Fibrosisâ€"An Analysis. Case Reports in Clinical Medicine, 2018, 07, 397-429.	0.1	1
3245	Kardiomyopathien. , 2018, , 94-101.		0
3246	Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies. , 2018, , 259-317.		0
3247	Management of Advanced Heart Failure: An Overview. , 2018, , 1-14.		0

#	Article	IF	Citations
3248	Hemmstoffe des Renin-Angiotensin-Systems. , 2018, , 263-288.		0
3249	Herztherapeutika. , 2018, , 539-552.		0
3250	Traitement de l'insuffisance cardiaque. , 2018, , 141-166.e2.		0
3251	Acute and Chronic Heart Failure. , 2018, , 237-252.		0
3252	OBSOLETE: Echocardiography in Heart Failure. , 2018, , .		0
3253	Drug Therapy in Adult Congenital Heart Disease Heart Failure. Congenital Heart Disease in Adolescents and Adults, 2018, , 187-200.	0.2	1
3254	Chronische Herzinsuffizienz. , 2018, , 80-93.		0
3255	Sex-Based Differences in Risk Determinants and Management of Heart Failure. , 2018, , 49-61.		0
3256	Cardiac Disease in Older Adults. , 2018, , 1-21.		0
3257	Future Research. Congenital Heart Disease in Adolescents and Adults, 2018, , 251-263.	0.2	0
3258	Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?. International Cardiovascular Forum Journal, 0, 12, .	1.1	2
3259	Chronische Herzinsuffizienz: Strukturierte Versorgung auf verschiedenen Stufen. Deutsches Ärzteblatt International, 0, , .	0.6	0
3260	New dual inhibitor of AT1 receptors and vasopeptidase (LCZ 696) anf the PARADIGM HF study. Intervencni A Akutni Kardiologie, 2018, 17, 36-38.	0.0	1
3262	Should ablation of atrial fibrillation be proposed to all patients with symptomatic heart failure? â€“ CASTLE-AF randomized controlled trial. In A Good Rythm, 2018, 2, 36-38.	0.0	0
3263	L'insuffisance cardiaque aiguÃ« aux urgences : prÃ©sentations cliniques, diagnostic et prise en charge thÃ©rapeutique. Medecine Intensive Reanimation, 2018, 27, 428-442.	0.1	0
3264	New Trend of Heart Failure Treatment. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1115-1122.	0.0	0
3265	2018 Korean Heart Rhythm Society Guidelines for Detection and Management of Risk Factors and Concomitant Cardiovascular Diseases in Korean Patients with Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 324-335.	0.1	2
3266	Pharmacological therapy for chronic heart failure. Vnitrni Lekarstvi, 2018, 64, 853-859.	0.1	1

#	Article	IF	Citations
3267	2. Advances and Limitations of Pharmacological and Nonpharmacological Treatment of Heart Failure. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1794-1799.	0.0	0
3270	Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial. Journal of Cardiovascular Medicine and Cardiology, 0, , 046-047.	0.1	0
3271	Sacubitril/valsartan in patient with dominant right-sided heart failure. Cardiologia Croatica, 2018, 13, 368-368.	0.0	0
3272	The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. Drugs in Context, 2018, 7, 1-11.	1.0	0
3273	Inhibition of Renal Fibrosis and Glomerular Injury by Sacubitril/Valsartan, a Combination Angiotensin Receptor Blocker and Neprilysin Inhibitor, in a Salt-Sensitive Hypertensive Model Using Angiotensin 1 Receptor Knockout Mice: The Contribution of Non-Angiotensin Blocking Effects to Renal Protection. Open Medicine Journal, 2018, 5, 108-118.	0.5	0
3274	How does the Extracellular Matrix Change in the Setting of Heart Failure?. International Journal of Medical Students, 2018, 6, 102-109.	0.2	0
3275	Key Considerations For Integrating Sacubitril/Valsartan Into Chronic Heart Failure Management. Journal of the Minneapolis Heart Institute Foundation, 2018, 2, 34-43.	0.0	0
3277	Normalised Heart Rate Variability After Sacubitril/Valsartan. European Journal of Arrhythmia & Electrophysiology, 2019, 5, 60.	0.2	0
3278	Navigating the Major Adverse Cardiovascular Event (MACE)-atherosclerotic Cardiovascular Disease versus Heart Failure. US Endocrinology, 2019, 15, 24.	0.3	0
3279	Herztherapeutika. , 2019, , 701-717.		0
3280	Pharmacological Targets of Hypertension. Learning Materials in Biosciences, 2019, , 179-191.	0.2	0
3281	HEART FAILURE - MEDICAL, ECONOMIC AND SOCIAL PROBLEM. WiadomoÅ›ci Lekarskie, 2019, 72, 284-290.	0.1	0
3282	Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabÃ©tique. , 2019, , 377-390.		0
3283	Unresolved Issues and Future Perspectives. , 2019, , 217-227.		0
3285	Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 112, 649-705.	0.3	12
3286	Current Management and Treatment. , 2019, , 199-215.		1
3287	Eligibility and Usage of Sacubitril/Valsartan in Korea. International Journal of Heart Failure, 2019, 1, 69.	0.9	4
3289	Perioperative management of patients with chronic heart failure. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2019, , 5.	0.2	6

#	Article	IF	Citations
3290	Oxidative Stress and Heart Failure. , 2019, , 257-311.		1
3291	Challenges and Future in Precision Cardiovascular Medicine. Cardiovascular Prevention and Pharmacotherapy, 2019, 1, 10.	0.0	2
3292	Heart Failure in Older Patients. , 2019, , .		0
3293	The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros De Cardiologia, 2019, 112, 791-792.	0.3	0
3294	Hemmstoffe des Renin-Angiotensin-Systems. , 2019, , 359-388.		0
3296	Paciente Â«estableÂ» con insuficiencia cardiaca: el momento oportuno. Revista Espanola De Cardiologia Suplementos, 2019, 18, 11-16.	0.2	0
3297	HEART FAILURE IN OPOLE VOIVODESHIP â€“ EPIDEMIOLOGY AND FUTURE PERSPECTIVES. WiadomoÅ›ci Lekarskie, 2019, 72, 112-119.	0.1	2
3298	Cardiogenic shock as consequence of chemotherapy-related dilated cardiomyopathy: a case report. Pharmacy & Pharmacology International Journal, 2019, 7, .	0.1	0
3299	7. Diabetes and Heart Failure: How to Treat Doubles Dangers. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 147a-147a.	0.0	0
3301	4. Current Status and Future Perspectives of Heart Failure Treatment. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 527-534.	0.0	0
3302	Therapie der chronischen Herzinsuffizienz. Pharma-Kritik (discontinued), 2019, 40, .	0.0	0
3303	A review of interventions to improve clinical outcomes following hospitalisation for heart failure. Kardiologia Polska, 2019, 77, 341-346.	0.3	0
3305	1. Pharmacotherapy for Cardiovascular Disease: current status. Japanese Journal of Clinical Pharmacology and Therapeutics, 2019, 50, 99-106.	0.1	0
3306	Dual inhibition of at1 receptor for angiotensin ii and neprilysin or sacibtrilâ€‘valsartan. Interni Medicina Pro Praxi, 2019, 21, 118-124.	0.0	0
3307	Introductory Chapter: Heart Failure - A Multifaceted Syndrome. , 0, , .		0
3308	UtilizaciÃ³n de sacubitrilo-valsartÃ¡n en CataluÃ±a. Revista Espanola De Cardiologia, 2019, 72, 593-595.	0.6	0
3309	Navigating Your Acute Heart Failure Patient in Emergency and Pre-Discharge Phase. ACI (Acta) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	0.0	0
3311	Diuretic Therapy Complicated by Hyponatremia. , 2020, , 175-189.		0

#	Article	IF	Citations
3312	7. Diabetes and Heart Failure: How to Treat Doubles Dangers. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1902-1911.	0.0	0
3314	Inicio, mantenimiento y retirada del tratamiento modificador de la enfermedad durante una descompensaciÃ³n por insuficiencia cardiaca aguda. Revista Clinica Espanola, 2019, 219, 464-466.	0.2	0
3315	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology, 2019, , 98-111.	0.4	6
3316	Cardiovascular Disease in Chronic Kidney Disease. , 2020, , 111-121.		0
3317	Sacubitril / valsartÃ¡n: nueva opciÃ³n terapeÃºtica en insuficiencia cardÃaca. Revista Medica Sinergia, 2019, 4, e297.	0.0	0
3318	Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure. PatologÃ¤, 2019, .	0.1	0
3319	Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 318-323.	0.2	2
3323	Leitsymptom Dyspnoe, LeistungsschwÃche. , 2020, , 117-229.		0
3324	Hemmstoffe des Renin-Angiotensin-Systems. , 2020, , 231-259.		0
3325	Effects of highest dose of sacubitril/valsartan association compared to lower doses on mortality and ventricular arrhythmias. Journal of Cardiology and Cardiovascular Medicine, 2020, 5, 089-094.	0.1	1
3326	The management of worsening heart failure. South African General Practitioner, 2020, 1, 65-68.	0.0	0
3327	Dilated cardiomyopathy in an adolescent â€“ a diagnostic challenge. Pediatru Ro, 2020, 3, 22.	0.0	0
3329	Triple neurohormonal blockade in de novo heart failure with reduced ejection fraction during index hospitalization. REC: CardioClinics, 2020, 55, 79-85.	0.1	0
3330	MANAGEMENT OF HEART FAILURE PATIENTS (UPDATE 2019) â€“ PHARMACOLOGICAL THERAPY. In A Good Rythm, 2020, 1, 30-32.	0.0	0
3331	Resection of the Atrial Appendages and its Impact in the Natriuretic Homeostasis: Development and Validation of an Animal Model in an Academic Medical Center. Revista De Investigacion Clinica, 2020, 72, 103-109.	0.2	1
3332	Infusiones ambulatorias de levosimendÃ¡n: Â¿eficaces y eficientes en la insuficiencia cardiaca avanzada?. Revista Espanola De Cardiologia, 2020, 73, 345-347.	0.6	1
3333	Management of the heart failure patient in the primary care setting. Singapore Medical Journal, 2020, 61, 225-229.	0.3	5
3334	Enâ€teresting case of acute kidney injury. Internal Medicine Journal, 2020, 50, 640-641.	0.5	1

#	Article	IF	Citations
3335	Erythropoietin role in the therapeutic management of heart failure patients with anemia. Journal of Cardiology & Current Research, 2020, 13, 77-79.	0.1	0
3336	Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data. Russian Journal of Cardiology, 2020, 25, 3870.	0.4	6
3337	A relaÃ§Ã£o direta entre vitamina D e insuficiÃªncia cardÃaca: Uma revisÃ£o sistemÃ¡tica.. Brazilian Journal of Implantology and Health Sciences, 2020, 2, 34-51.	0.0	0
3338	Pharmacist- or Nurse Practitionerâ€"Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	2
3341	The year in cardiology: heart failureâ€The year in cardiology 2019. Cardiologia Croatica, 2020, 15, 167-188.	0.0	1
3342	Why We Fail at Heart Failure: Lymphatic Insufficiency Is Disregarded. Cureus, 2020, 12, e8930.	0.2	4
3343	Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure. Cardiology Journal, 2020, 27, 625-632.	0.5	2
3344	Pharmacological Treatment of Chronic Heart Failure. Journal of the Nihon University Medical Association, 2020, 79, 209-215.	0.0	0
3345	Estabilidad clÃnica en la insuficiencia cardiaca. Mito o realidad. Revista Clinica Espanola, 2020, 220, 356-358.	0.2	0
3346	Cost to Save a Life in Heart Failure: Health Disparity Costs Lives. Cureus, 2020, 12, e10081.	0.2	1
3348	Central directions for reducing cardiovascular mortality: what can be changed today?. Russian Journal of Cardiology, 2020, 25, 3983.	0.4	12
3349	Neprilysin as a Biomarker: Challenges and Opportunities. Cardiac Failure Review, 2020, 6, e23.	1.2	6
3350	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
3351	The Association Between Pneumonia and Heart failure. Clinical Pulmonary Medicine, 2020, 27, 125-130.	0.3	3
3352	ICD in primary prevention: the ugly duckling of Spain. Revista Espanola De Cardiologia (English Ed), 2021, 75, 2-2.	0.4	0
3353	Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study. ESC Heart Failure, 2021, 8, 4497-4505.	1.4	13
3354	Endocrine system dysfunction and chronic heart failure: a clinical perspective. Endocrine, 2021, , 1.	1.1	9
3355	Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy. Journal of Clinical Medicine, 2021, 10, 4989.	1.0	10

#	Article	IF	Citations
3356	Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel. Frontiers in Cell and Developmental Biology, 2021, 9, 760035.	1.8	9
3357	Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients. Minerva Cardiology and Angiology, 2022, 70, .	0.4	3
3358	Relevance of Neutrophil Neprilysin in Heart Failure. Cells, 2021, 10, 2922.	1.8	5
3359	Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. Joint Commission Journal on Quality and Patient Safety, 2022, 48, 25-32.	0.4	1
3360	Reverse remodeling in diabetic cardiomyopathy: the role of extracellular matrix. Minerva Cardiology and Angiology, 2022, 70, .	0.4	3
3361	The benefits of sacubitrilâ€“valsartan in patients with acute myocardial infarction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 4852-4862.	1.4	15
3362	Sacubitril/valsartan in the treatment of right ventricular dysfunction in patients with heart failure with reduced ejection fraction. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	2
3363	Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study. Hypertension, 2021, 78, 1781-1790.	1.3	21
3364	Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease â€“ Experience from a tertiary centre in Singapore. International Journal of Cardiology Congenital Heart Disease, 2021, 6, 100268.	0.2	3
3365	Immunologische NotfÃlle. , 2020, , 166-173.		0
3366	Heart is the Target Organ of Endogenous Cardiac Natriuretic Peptides. International Heart Journal, 2020, 61, 77-82.	0.5	0
3368	Pharmacologic Support of theÂFailing Heart. , 2020, , 597-605.		0
3369	Turkish Society of Cardiology Consensus Paper on Evaluation and Treatment of Resistant Hypertension. Anatolian Journal of Cardiology, 2020, 24, 137-152.	0.5	2
3370	Atrial and Brain Natriuretic Peptides. , 2020, , 1-6.		0
3371	Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention. American Journal of Cardiovascular Drugs, 2021, 21, 487-497.	1.0	2
3373	The renal patient seen by non-renal physicians: the kidney embedded in the â€˜milieu intÃ©rieurâ€™. CKJ: Clinical Kidney Journal, 2021, 14, 1077-1087.	1.4	1
3374	Prevention of Heart Failure. Contemporary Cardiology, 2021, , 489-512.	0.0	1
3375	Angiotensin Receptor-Neprilysin Inhibition for Doxorubicin-Mediated Cardiotoxicity. JACC: CardioOncology, 2020, 2, 788-790.	1.7	0

#	Article	IF	Citations
3376	The Results of the Use of Angiotensin Receptor Inhibitors and Neprilisin in Secondary Functional Mitral Regurgitation in Outpatient Practice. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2020, 75, 514-522.	0.2	2
3377	Care bundle to reduce readmission in patients with heart failure: a modified Delphi consensus panel in Argentina. BMJ Open, 2020, 10, e040028.	0.8	1
3378	Progress in drug treatment of older patients with chronic heart failure. Aging Pathobiology and Therapeutics, 2020, 2, 176-179.	0.3	0
3379	The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!. ESC Heart Failure, 2020, 7, 3274-3277.	1.4	1
3380	Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Annals of Pharmacotherapy, 2021, 55, 1069-1075.	0.9	8
3381	The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report. European Heart Journal - Case Reports, 2021, 5, ytaa530.	0.3	2
3382	Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Contemporary Cardiology, 2021, , 611-651.	0.0	0
3383	Heart Failure in Diabetes Mellitus: An Updated Review. Current Pharmaceutical Design, 2020, 26, 5933-5952.	0.9	3
3385	Guanylyl Cyclase. , 2021, , 1-7.		0
3386	Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?. Current Opinion in Cardiology, 2021, 36, 211-218.	0.8	0
3387	The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction. Kardiologiya, 2020, 60, 117-127.	0.3	3
3388	Acute Tubular Necrosis Associated with Angiotensin Receptor-Neprilysin Inhibitor. Internal Medicine, 2022, , .	0.3	1
3389	Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium. Annals of Pediatric Cardiology, 2020, 13, 334.	0.2	1
3390	Classification of Heart Failure: A Farewell to Ejection Fraction?. Anatolian Journal of Cardiology, 2020, 25, 2-6.	0.5	0
3391	Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitrilâ€“valsartan in Heart Failure with Reduced Ejection Fraction. Journal of Cardiovascular Imaging, 2020, 28, 244.	0.2	4
3392	Novel pharmacotherapies for heart failure. , 2020, , 359-380.		0
3393	Cardiac Disease in Older Adults. , 2020, , 229-249.		0
3394	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents. Diabetes Mellitus, 2019, 22, 467-472.	0.5	0

#	Article	IF	Citations
3395	Innovations in pharmacological treatment of heart failure. Vnitrni Lekarstvi, 2019, 65, 611-619.	0.1	0
3396	Efficacy and Safety of Sacubitril-Valsartan in the Treatment of Heart Failure with Preserved Ejection Fraction. Advances in Clinical Medicine, 2020, 10, 1353-1359.	0.0	0
3397	Novel treatments for diastolic heart failure. , 2020, , 95-127.		0
3399	Acute Decompensated Heart Failure. , 2020, , 119-136.		0
3400	Management of Acute Heart Failure. , 2020, , 95-100.		0
3401	Atrial Natriuretic Peptide. , 2020, , 1-8.		0
3403	Chronic Heart Failure. , 2020, , 137-154.		0
3404	Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days versus â‰¥90 Wear Days. In Vivo, 2020, 34, 3601-3610.	0.6	4
3405	Herztherapeutika. , 2020, , 555-570.		0
3406	Contemporary therapies for chronic heart failure with reduced ejection fraction. South African General Practitioner, 2020, 1, 146-150.	0.0	0
3407	ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS. , 2020, , D-1-D17-4.		0
3408	Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: ATA study. Anatolian Journal of Cardiology, 2020, 24, 32-40.	0.5	7
3410	Inhibitoren des Renin-Angiotensin-Aldosteron-Systems. , 2020, , 393-411.		0
3411	Heart Failure â€“ Pathophysiology and Current Therapeutic Implications. International Journal of Cardiovascular Sciences, 2020, 33, 439-446.	0.0	0
3412	The Impact of Discontinuation of Sacubitril-Valsartan and Shifting to Angiotensin-Converting Enzyme inhibitor or Angiotensin Receptor Blocker in Patients with Heart Failure with Reduced Ejection Fraction. Anatolian Journal of Cardiology, 2020, 25, 163-169.	0.5	1
3413	Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure. Circulation, 2020, 141, 589-591.	1.6	0
3414	Ventricular Tachycardia and Heart Failure. , 0, , .		0
3415	III. Treatment of Heart Failure; 3. Novel Topics of Pharmacological Therapy for Chronic Heart Failure. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 215-223.	0.0	0

#	Article	IF	Citations
3418	Victoria Trial: Vericiguat Joins the Big League, or Does it?. International Cardiovascular Forum Journal, 0, 19, .	1.1	0
3419	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers, 2021, 13, 5527.	1.7	4
3420	Managing Cancer Patients and Survivors With Advanced Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	0
3421	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. ESC Heart Failure, 2021, , .	1.4	4
3422	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	2.7	38
3423	Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	3
3424	Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 541-545.	1.0	3
3425	Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 712-720.	1.4	6
3426	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors forÂHeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012.	1.2	48
3427	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. International Journal of General Medicine, 2021, Volume 14, 7797-7805.	0.8	2
3428	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2022, 7, 17.	3.0	77
3429	Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway. , 2021, 25, 821-828.		13
3430	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. Journal of the American Heart Association, 2021, 10, e021094.	1.6	23
3431	Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia. Redox Biology, 2021, 48, 102179.	3.9	10
3432	Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology. Journal of Cardiovascular Medicine, 2020, 21, 927-943.	0.6	5
3433	Effectiveness of angiotensin receptor inhibitors and non-lysine in functional mitral regurgitation. Klinicheskaia Meditsina, 2020, 98, 106-114.	0.2	0
3435	Neonatal enteroviral myocarditis: a potentially devastating disease. , 2020, , 57-72.		0
3436	Advanced Heart Failure Management and Selection for Advanced Therapies. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 216-235.	0.3	0

#	Article	IF	Citations
3437	Sacubitril/valsartan versus candesartan in women with heart failure receiving adjuvant therapy for breast cancer - is there any antiarrhythmic effect?. Journal of Arrhythmology, 2020, 27, 34-41.	0.1	2
3439	Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2020, 25, 4049.	0.4	1
3440	Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure. Meditsinskiy Sovet, 2020, , 34-39.	0.1	2
3441	Chronic and End-Stage Heart Failure. , 2021, , 517-533.		0
3443	Anticoagulation in Patients with Heart Failure and Sinus Rhythm. International Heart Journal, 2020, 61, 1204-1211.	0.5	1
3444	The Evolution and Future Direction of The Cardiac Biomarker. EMJ Cardiology, 0, , .	0.0	2
3445	Melhora no Consumo MÃ¡ximo de OxigÃªnio e na VentilaÃ§Ã£o apÃ³s Tratamento com Sacubitril-Valsartana. Arquivos Brasileiros De Cardiologia, 2020, 115, 821-827.	0.3	2
3446	Terapia com o Inibidor da Neprilisina e do Receptor de Angiotensina e Melhora de ParÂ¢metros de ExercÃcio na InsuficiÃªncia CardÃaca com FraÃ§Ã£o de EjeÃ§Ã£o Reduzida. Arquivos Brasileiros De Cardiologia, 2020, 115, 828-829.	0.3	0
3447	TÃ³picos Emergentes em InsuficiÃªncia CardÃaca: Nova Era do Tratamento FarmacolÃ³gico. Arquivos Brasileiros De Cardiologia, 2020, 115, 956-960.	0.3	1
3448	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 517-541.	0.2	0
3449	Heart failure features and sacubitril/valsartan effects. Journal of Cardiovascular Medicine, 2021, 22, 234-235.	0.6	0
3450	Angiotensin receptor-neprilisyn inhibitors: Are their beneficial effects mediated through diastolic or systolic function improvement?. Hellenic Journal of Cardiology, 2020, 61, 419-420.	0.4	1
3451	Prolonged First-Dose Hypotension Induced by Sacubitril/Valsartan. Acta Cardiologica Sinica, 2018, 34, 96-98.	0.1	1
3452	PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?. Journal of Geriatric Cardiology, 2015, 12, 470-3.	0.2	3
3453	Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. American Health and Drug Benefits, 2015, 8, 330-4.	0.5	37
3454	Analytical Issues with Natriuretic Peptides - has this been Overly Simplified?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 189-207.	0.7	25
3455	Can Natriuretic Peptides be Used to Guide Therapy?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 208-16.	0.7	9
3456	Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. American Health and Drug Benefits, 2016, 9, 78-82.	0.5	3

#	Article	IF	Citations
3457	One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry. Acta Cardiologica Sinica, 2017, 33, 127-138.	0.1	33
3458	Heart Failure: A Class Review of Pharmacotherapy. P and T, 2017, 42, 464-472.	1.0	7
3459	Sacubitril-valsartan: novel therapy for heart failure. Canadian Family Physician, 2017, 63, 697.	0.1	3
3460	LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. American Journal of Translational Research (discontinued), 2017, 9, 5473-5484.	0.0	49
3461	Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. American Journal of Cardiovascular Disease, 2017, 7, 108-113.	0.5	55
3463	Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat. American Journal of Translational Research (discontinued), 2018, 10, 2290-2305.	0.0	6
3465	Heart Failure in Older Adults: A Geriatrician Call for Action. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S23-S29.	0.6	0
3466	Improved outcome with standardized plan for clinical management of acute decompensated chronic heart failure. Journal of Geriatric Cardiology, 2019, 16, 12-18.	0.2	6
3467	After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan?. Journal of Geriatric Cardiology, 2019, 16, 151-155.	0.2	1
3468	Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction. Acta Cardiologica Sinica, 2020, 36, 125-132.	0.1	4
3469	Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-90.	3.0	1
3470	Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Canadian Journal of Hospital Pharmacy, 2020, 73, 186-192.	0.1	3
3471	C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. American Journal of Cardiovascular Disease, 2020, 10, 174-181.	0.5	1
3472	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. Echo Research and Practice, 2020, 7, L1-L4.	0.6	3
3473	Reply to Letter to the Editor regarding reference limits for echocardiography. Echo Research and Practice, 2020, , .	0.6	0
3475	Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?. Journal of Geriatric Cardiology, 2020, 17, 782-786.	0.2	1
3476	Recent advances in managing primary hypertension. Faculty Reviews, 2020, 9, 4.	1.7	1
3477	Heart failure in the elderly. Journal of Geriatric Cardiology, 2021, 18, 219-232.	0.2	3

#	Article	IF	Citations
3478	The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications. Acta Cardiologica Sinica, 2021, 37, 394-403.	0.1	0
3479	The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, e176-e181.	0.5	0
3481	Successful treatment of severe heart failure in advanced diabetic kidney disease using angiotensinâ€“neprilysin inhibitors (sacubitril/valsartan) â€“ report of two cases with review of options in literature. Indian Journal of Nephrology, 2021, 31, 587.	0.2	2
3482	Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists. Peptides, 2022, 147, 170697.	1.2	18
3483	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy. Biomedicine and Pharmacotherapy, 2022, 145, 112463.	2.5	16
3484	Safety and Efficacy of Sacubitril/Valsartan Early Initiation in Hospitalized Patients with Heart Failure and Reduced Ejection Fraction. Medical Journal of the University of Cairo Faculty of Medicine, 2021, 89, 2143-2149.	0.0	0
3485	Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). Experimental and Therapeutic Medicine, 2021, 22, 1463.	0.8	1
3486	Representation of Chronic Kidney Disease in Randomized Controlled Trials Among Patients With Heart failure With Reduced Ejection Fraction: A Systematic Review. Current Problems in Cardiology, 2023, 48, 101047.	1.1	5
3487	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Frontiers in Cardiovascular Medicine, 2021, 8, 754499.	1.1	30
3488	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	3.8	72
3489	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. American Journal of Cardiovascular Drugs, 2022, 22, 263-270.	1.0	7
3490	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
3491	Radiolabeled Bombesin Analogs. Cancers, 2021, 13, 5766.	1.7	34
3492	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Journal of Cardiac Failure, 2022, 28, 370-384.	0.7	16
3494	Very Long-Term Follow-Up in Cardiac Resynchronization Therapy: Wider Paced QRS Equals Worse Prognosis. Journal of Personalized Medicine, 2021, 11, 1176.	1.1	1
3495	The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e18.	1.2	22
3496	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 513-525.	2.9	33
3497	Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. Blood Purification, 2022, 51, 270-279.	0.9	7

#	Article	IF	Citations
3498	The mitochondrial regulator PGC1Î± is induced by cGMPâ€“PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure. FEBS Letters, 2021, 596, 17.	1.3	9
3499	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Statistics in Medicine, 2021, 40, 6235-6242.	0.8	5
3500	Transcatheter mitral valve interventions. Progress in Cardiovascular Diseases, 2021, 69, 84-88.	1.6	1
3501	Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Research and Clinical Practice, 2021, 40, 555-565.	0.9	8
3502	Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China. Frontiers in Pharmacology, 2021, 12, 733681.	1.6	22
3503	Angiotensin Receptorâ€“Neprilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine, 2021, 385, 1845-1855.	13.9	130
3504	Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russian Journal of Cardiology, 2021, 26, 4699.	0.4	1
3505	Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review. Pathogens, 2021, 10, 1493.	1.2	12
3506	Sex Differences in Heart Failure. Journal of Cardiac Failure, 2022, 28, 477-498.	0.7	62
3507	Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. Scientific Reports, 2021, 11, 22342.	1.6	12
3508	Obstructive sleep apnea and stroke: The mechanisms, the randomized trials, and the road ahead. Sleep Medicine Reviews, 2022, 61, 101568.	3.8	21
3509	Sudden cardiac death - a known unknown?. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, 166, 258-266.	0.2	1
3510	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical Drug Investigation, 2022, 42, 1-16.	1.1	4
3511	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGONâ€HF trial. ESC Heart Failure, 2022, 9, 164-177.	1.4	5
3512	Drawing Boundaries around PARADISE. New England Journal of Medicine, 2021, 385, 1906-1907.	13.9	4
3513	Effect of Angiotensinâ€“Neprilysin Versus Reninâ€“Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 604017.	1.6	5
3514	Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders. American Journal of Cardiology, 2021, 161, 120-122.	0.7	0
3515	Diabetes and treatment of chronic heart failure in a large realâ€world heart failure population. ESC Heart Failure, 2022, 9, 353-362.	1.4	13

#	Article	IF	Citations
3517	Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial. Cardiovascular Diagnosis and Therapy, 2022, 12, 42-54.	0.7	7
3518	Neprilysin Inhibitors. , 2021, , 1075-1082.		0
3520	Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era. Electrolyte and Blood Pressure, 2021, 19, 19.	0.6	4
3521	The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 176-181.	0.5	3
3522	Guanylyl Cyclase. , 2021, , 755-761.		0
3523	Mortality and Heart Failure Risk Reductions in Patients Treated with Sacubitril-Valsartan in Clinical Trials. SSRN Electronic Journal, 0, , .	0.4	0
3524	Herztherapeutika. , 2021, , 461-476.		0
3525	Atrial and Brain Natriuretic Peptides. , 2021, , 269-275.		0
3526	Antihypertensive Drugs. , 2021, , 165-174.		2
3527	Reninâ€“Angiotensinâ€“Aldosterone System. , 2021, , 1353-1358.		0
3528	Atrial Natriuretic Peptide. , 2021, , 544-551.		0
3529	C-Type Natriuretic Peptide and Its Receptors. , 2021, , 499-504.		1
3530	Hemmstoffe des Renin-Angiotensin-Systems. , 2021, , 131-161.		0
3531	Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis. Journal of Healthcare Engineering, 2022, 2022, 1-8.	1.1	3
3532	Current and future therapeutic perspective in chronic heart failure. Pharmacological Research, 2022, 175, 106035.	3.1	31
3533	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	1.6	7
3534	Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases. Hypertension Research, 2022, 45, 389-400.	1.5	15
3537	Screeningâ€guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in atâ€risk patients. European Journal of Heart Failure, 2022, 24, 620-630.	2.9	7

#	Article	IF	Citations
3538	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. International Journal of Cardiology, 2022, 350, 62-68.	0.8	13
3539	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. American Heart Journal, 2022, 245, 110-116.	1.2	3
3540	LCZ696 Effect on Improving Quality of Life and Ejection Fraction of Palestinian Patients with Heart Failure and Reduced Ejection Fraction. Journal of the Royal Medical Services, 2019, 26, 73-78.	0.0	1
3541	Studien auf dem EuropÃischen Kardiologenkongress: Unerwartete Ergebnisse. , 0, , .		0
3542	Pharmacologic heart failure treatment: A case-based review of current guidelines. Journal of the American Association of Nurse Practitioners, 2021, 33, 1042-1049.	0.5	0
3544	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. Echo Research and Practice, 2020, 7, L1-L4.	0.6	4
3545	Response to Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. Echo Research and Practice, 2020, 7, L5-L7.	0.6	0
3546	ACEi to ARNi: â€œThe Switchâ€•An Evidence Based Review. Journal of Cardiovascular Medicine and Cardiology, 2020, , 288-292.	0.1	0
3547	Recent advances in managing primary hypertension. Faculty Reviews, 2020, 9, 4.	1.7	4
3548	Diuretics and Clinical Management of Congestion in Heart Failure: A Review. , 2021, 1, 55-62.		1
3549	The Novel Data Collection and Analytics Tools for Remote Patient Monitoring in Heart Failure (Nov-RPM-HF) Trial: Protocol for a Single-Center Prospective Trial. JMIR Research Protocols, 2022, 11, e32873.	0.5	2
3550	Checklist para A PrÃ©-Alta de Internamento por InsuficiÃªncia CardÃaca. Revista De MedicinÄƒ InternÄƒ, Neurologe, Psihiatrie, Neurochirurgie, Dermato-venerologie MedicinÄƒ InternÄƒ, 2021, 28, 76-81.	0.0	0
3551	Prevention and management of hyperkalemia in patients treated with reninâ€“angiotensinâ€“aldosterone system inhibitors. Cmaj, 2021, 193, E1836-E1841.	0.9	6
3552	Endpoints in Heart Failure Drug Development. Cardiac Failure Review, 2022, 8, e01.	1.2	10
3553	Sacubitril/Valsartan, left ventricular reverse remodeling and advanced echocardiographic imaging: is it a resolved conundrum?. Minerva Cardiology and Angiology, 2022, , .	0.4	0
3555	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation. Health Technology Assessment, 2022, 26, 1-128.	1.3	5
3556	Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, e007993.	0.9	1
3557	Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. International Journal of Heart Failure, 2022, 4, 75.	0.9	10

#	Article	IF	Citations
3558	Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future. Journal of Human Hypertension, 2022, 36, 695-704.	1.0	2
3559	Key Points for Pharmacists From the ACC Expert Consensus Decision Pathway for Patients Hospitalized With Heart Failure. Journal of Pharmacy Practice, 2022, , 089719002110647.	0.5	0
3560	Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10.	0.5	3
3561	Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 787810.	1.1	6
3562	The Evolving Evidence Base of Implantable Cardiac defribrillators: Past, Present, and Future. European Medical Journal Innovations, 0, , 33-39.	2.0	1
3563	Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction. Journal of International Medical Research, 2022, 50, 030006052110679.	0.4	5
3564	LCZ696 Protects against Diabetic Cardiomyopathy-Induced Myocardial Inflammation, ER Stress, and Apoptosis through Inhibiting AGEs/NF-ÎºB and PERK/CHOP Signaling Pathways. International Journal of Molecular Sciences, 2022, 23, 1288.	1.8	15
3565	Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients. Journal of Clinical Hypertension, 2022, 24, 300-308.	1.0	17
3566	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	0.8	8
3567	Myocardial strain to identify benefit from betaâ€blockers in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2022, , .	1.4	3
3568	Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study. Journal of Racial and Ethnic Health Disparities, 2023, 10, 118-129.	1.8	5
3569	Targeting mitochondrial dysfunction with elamipretide. Heart Failure Reviews, 2022, 27, 1925-1932.	1.7	9
3570	Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 551-561.	2.9	20
3571	Vascular Endothelial Cell Dysfunction in Preeclampsia. , 2022, , 187-218.		0
3572	Susceptibility to infections and adaptive immunity in adults with heart failure. ESC Heart Failure, 2022, 9, 1195-1205.	1.4	3
3573	Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy. Frontiers in Physiology, 2021, 12, 813012.	1.3	6
3574	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. Cardiovascular Drugs and Therapy, 2022, , 1.	1.3	5
3575	Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men. Clinical Chemistry, 2022, 68, 713-720.	1.5	5

#	Article	IF	Citations
3576	A new lead: Sacubitril-valsartan's unique benefit in HFrEF could lie with sympathoinhibition. Autonomic Neuroscience: Basic and Clinical, 2022, , 102949.	1.4	0
3577	Is it time to revisit ICD indications?. Heart Failure Reviews, 2022, , 1.	1.7	2
3578	Nudging within learning health systems: next generation decision support to improve cardiovascular care. European Heart Journal, 2022, 43, 1296-1306.	1.0	16
3579	Characterizing a Clinical Trial â€“ Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction. Clinical Epidemiology, 2022, Volume 14, 39-49.	1.5	1
3580	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 348.	1.0	5
3582	Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study. Cardiology and Therapy, 2022, 11, 113-127.	1.1	5
3583	<scp>Angiotensinâ€“neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	2.9	14
3584	Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study. Frontiers in Pharmacology, 2021, 12, 769896.	1.6	2
3585	Vericiguat. Cardiology in Review, 2022, Publish Ahead of Print, .	0.6	3
3586	Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertension Research, 2022, 45, 824-833.	1.5	32
3587	Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 2418-2428.	0.4	6
3588	Management of Atrial Fibrillation in Patients 75 Years and Older. Journal of the American College of Cardiology, 2022, 79, 166-179.	1.2	34
3589	Impact of sacubitril/valsartan on the indication for defibrillator and left ventricular remodeling: real life data. REC: CardioClinics, 2022, 57, 172-181.	0.1	1
3590	Treatment of heart failure with reduced ejection fraction. Journal of the Korean Medical Association, 2022, 65, 9-17.	0.1	0
3591	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert Opinion on Pharmacotherapy, 2022, 23, 303-320.	0.9	1
3592	Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project. European Heart Journal, 2022, 43, 2591-2599.	1.0	27
3593	El DAI en la prevenciÃ³n primaria: el patito feo de nuestro paÃs. Revista Espanola De Cardiologia, 2022, 75, 2-4.	0.6	0
3594	The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842110586.	1.0	7

#	Article	IF	Citations
3595	Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure. Journal of Clinical Medicine, 2022, 11, 539.	1.0	1
3596	Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study. Cardiovascular Drugs and Therapy, 2022, , 1.	1.3	0
3598	Optimizing individual heart failure treatment. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	0
3599	Implementation of the Mental Capacity Act: a national observational study comparing resultant trends in place of death for older heart failure decedents with or without comorbid dementia. BMC Medicine, 2022, 20, 30.	2.3	1
3601	Sample size formula for a win ratio endpoint. Statistics in Medicine, 2022, 41, 950-963.	0.8	7
3602	Drug Treatment of Heart Failure in Children: Gaps and Opportunities. Paediatric Drugs, 2022, 24, 121-136.	1.3	3
3603	Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2022, 17, e0263131.	1.1	15
3604	Heart failure: a 70 year Odyssey. European Heart Journal, 2022, 43, 1697-1699.	1.0	3
3605	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
3606	Reverse re-modelling chronic heart failure by reinstating heart rate variability. Basic Research in Cardiology, 2022, 117, 4.	2.5	23
3607	Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2022, 10, 119-128.	1.9	15
3608	Cardiovascular Events and Longâ€Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€IT. Journal of the American Heart Association, 2022, 11, e022733.	1.6	4
3609	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	1.2	23
3611	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405.	4.9	7
3612	An assessment of thermoneutral housing conditions on murine cardiometabolic function. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H234-H245.	1.5	5
3613	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2022, 10, 73-84.	1.9	115
3614	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	1.2	21
3615	New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure. Advances in Medical Sciences, 2022, 67, 95-102.	0.9	3

#	Article	IF	Citations
3616	OUP accepted manuscript. European Heart Journal, 2022, , .	1.0	3
3617	Sacubitril-Valsartan in Patients with Ischemic Cardiomyopathy Undergoing Off-Pump Coronary Artery Bypass Graftingâ€"Is It Safe?. Thoracic and Cardiovascular Surgeon, 2022, 70, 575-578.	0.4	1
3618	Risk of outcomes in a Spanish population with heart failure. REC: CardioClinics, 2022, 57, 85-96.	0.1	1
3619	Sacubitril/valsartan, sodiumâ€glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438.	1.2	5
3620	Impact of Initial Therapy on Readmissions in Minority Versus White Populations With Heart Failure. Journal of Pharmacy Practice, 2023, 36, 594-599.	0.5	0
3622	The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensinâ€converting enzyme inhibitor in dilated cardiomyopathy. ESC Heart Failure, 2022, 9, 1175-1185.	1.4	4
3623	Treating Patients with Heart Failure and Mild Symptoms: Stay Awake at the Wheel. Journal of Cardiac Failure, 2022, 28, 349-350.	0.7	1
3624	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. ESC Heart Failure, 2022, 9, 1107-1117.	1.4	12
3625	Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article â€˜Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISEâ€MI): design and baseline characteristicsâ€™. European Journal of Heart Failure, 2022, 24, 1324-1324.	2.9	3
3626	Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension. Frontiers in Physiology, 2021, 12, 815796.	1.3	6
3627	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. Heart Failure Reviews, 2022, 27, 1761-1777.	1.7	3
3628	What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies. Journal of Cardiovascular Development and Disease, 2022, 9, 54.	0.8	1
3629	Drug therapy for heart failure with reduced ejection fraction: what is the â€˜rightâ€™ dose?. European Journal of Heart Failure, 2022, 24, 421-430.	2.9	9
3630	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 794-803.	2.9	15
3631	Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity. Archives of Toxicology, 2022, 96, 1065-1074.	1.9	19
3633	Off-Label Use of Cardiovascular Drugs in the Home Therapy of Children With Congenital or Acquired Heart Disease. American Journal of Cardiology, 2022, 166, 131-137.	0.7	3
3634	Management of ventricular arrhythmias in heart failure: Current perspectives. Heart Rhythm O2, 2021, 2, 796-806.	0.6	3
3635	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424.	1.0	144

#	Article	IF	Citations
3636	Perioperative management of emergent cesarean section in a patient with peripartum cardiomyopathy and orthopnea: a case report. Journal of International Medical Research, 2021, 49, 030006052110630.	0.4	2
3637	Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. Journal of Cardiovascular Medicine, 2022, 23, 149-156.	0.6	23
3638	Clinical Experience of Use of Sacubitril/Valsartan in a Patient with Dilated Cardiomyopathy, Chronic Heart Failure with Reduced Ejection Fraction and Ventricular Arrhythmias. , 2021, 1, 39-48.		1
3639	Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Advances in Pharmacology, 2022, , .	1.2	5
3640	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	0.7	9
3641	Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current Hypertension Reports, 2022, 24, 1-20.	1.5	5
3642	Capillaries as a Therapeutic Target for Heart Failure. Journal of Atherosclerosis and Thrombosis, 2022, 29, 971-988.	0.9	4
3643	Effects of Sacubitril/Valsartan on Cardiac Structure and Cardiac Function of Patients with Heart Failure and Reduced Ejection Fraction. Advances in Clinical Medicine, 2022, 12, 1959-1968.	0.0	1
3646	Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2022, 76, 17.	0.4	2
3647	Leitsymptom Dyspnoe, LeistungsschwÃche. , 2022, , 121-242.		0
3648	Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study. American Heart Journal Plus, 2022, 13, 100118.	0.3	0
3649	New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?. Journal of Cardiology, 2023, 81, 26-32.	0.8	3
3650	ARNI in HFrEFâ€"One-Centre Experience in the Era before the 2021 ESC HF Recommendations. International Journal of Environmental Research and Public Health, 2022, 19, 2089.	1.2	0
3651	Cardiac Peptidesâ€"Current Physiology, Pathophysiology, Biochemistry, Molecular Biology, and Clinical Application. Biology, 2022, 11, 330.	1.3	3
3652	Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts. International Journal of Molecular Sciences, 2022, 23, 2145.	1.8	17
3653	Characterization of heart failure patients with reverse left ventricular remodelling postâ€angiotensin receptor blockers/neprilysin inhibitors therapy. ESC Heart Failure, 2022, 9, 1682-1688.	1.4	6
3654	High-Dose Thiamine Supplementation in Older Patients With Heart Failure: A Pilot Randomized Controlled Crossover Trial (THIAMINE-HF). CJC Open, 2022, 4, 532-539.	0.7	2
3656	Diagnosis and Treatment of Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2022, 327, 662.	3.8	219

#	Article	IF	Citations
3658	Out with the Old and In with the New: Primary Care Management of Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 2022, 8, e04.	1.2	1
3659	Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril/valsartan: a case report. European Heart Journal - Case Reports, 2022, 6, ytac091.	0.3	1
3660	Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation. Journal of the American College of Cardiology, 2022, 79, 665-678.	1.2	30
3661	Management of heart failure in older people. Journal of Pharmacy Practice and Research, 2022, 52, 72-79.	0.5	2
3662	(Pharmacotherapy of chronic heart failure from the viewpoint of the new ESC 2021 guidelines). Cor Et Vasa, 2022, 64, 61-65.	0.1	0
3663	Mechanisms and Efficacy of Traditional Chinese Medicine in Heart Failure. Frontiers in Pharmacology, 2022, 13, 810587.	1.6	6
3664	Telemedical Monitoring Based on Implantable Devicesâ€"the Evolution Beyond the CardioMEMSâ„¢ Technology. Current Heart Failure Reports, 2022, 19, 7-14.	1.3	2
3665	Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients. JACC Basic To Translational Science, 2022, 7, 116-127.	1.9	20
3668	Heart Failure Subtypes and Cardiomyopathies in Women. Circulation Research, 2022, 130, 436-454.	2.0	28
3669	Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies. Biomedicines, 2022, 10, 602.	1.4	21
3670	Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology. Frontiers in Cardiovascular Medicine, 2022, 9, 801143.	1.1	4
3671	Impact of angiotensin receptorâ€"neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study. Physiological Reports, 2022, 10, e15209.	0.7	5
3672	First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure. Journal of Medical Science, 2022, 91, e606.	0.2	0
3673	Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism. Cureus, 2022, 14, e22762.	0.2	2
3674	Cardiovascular Disease in DuchenneÂMuscular Dystrophy. JACC Basic To Translational Science, 2022, 7, 608-625.	1.9	16
3675	Subjective and Objective Impact of Angiotensin Receptorâ€"Neprilysin Inhibitors on Systemic Right Ventricle Patients. Heart Lung and Circulation, 2022, 31, 964-973.	0.2	6
3676	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
3677	Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study. American Journal of Cardiovascular Drugs, 2022, 22, 535-544.	1.0	9

#	Article	IF	Citations
3678	Opportunistic screening for asymptomatic left ventricular dysfunction in type 2 diabetes mellitus. Postgraduate Medical Journal, 2023, 99, 476-483.	0.9	3
3679	Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 794707.	1.1	9
3680	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
3681	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153.	2.9	11
3682	Prognostic Significance of a Combination of Cardiogenic Shock and the Critical Culprit Lesion Location in ST-Elevation Myocardial Infarctions. International Heart Journal, 2022, 63, 191-201.	0.5	3
3683	Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the <scp>S</scp>wedish Heart Failure Registry. European Journal of Heart Failure, 2022, 24, 871-884.	2.9	33
3684	Diabetes mellitus and congestive heart failure. MÃ¬Å¾narodnij EndokrinologÃ¬Ânij Å½urnal, 2022, 18, 57-69.	0.1	1
3685	Management of a Patient with Severe Hypotension and Advanced Heart Failure with Reduced Left Ventricular Ejection Fraction. Russian Archives of Internal Medicine, 2022, 12, 143-155.	0.0	0
3686	Advances in the Treatment Strategies in Hypertension: Present and Future. Journal of Cardiovascular Development and Disease, 2022, 9, 72.	0.8	12
3687	The First Year of Noninvasive Remote Telemonitoring in Chronic Heart Failure Is not Cost Saving but Improves Quality of Life: The Randomized Controlled CardioBBEAT Trial. Telemedicine Journal and E-Health, 2022, 28, 1613-1622.	1.6	5
3688	Recent developments in cGMP research: From mechanisms to medicines and back. British Journal of Pharmacology, 2022, 179, 2321-2327.	2.7	2
3689	Therapeutic targets for cardiac fibrosis: from old school to next-gen. Journal of Clinical Investigation, 2022, 132, .	3.9	53
3690	Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiology and Therapy, 2022, 11, 203-230.	1.1	4
3691	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	1
3692	Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations. Therapeutics and Clinical Risk Management, 2022, Volume 18, 315-322.	0.9	13
3693	Sex Differences in Therapies for Heart Failure. Current Pharmaceutical Design, 2022, 28, 1295-1303.	0.9	1
3694	Role of new drug therapies and innovative procedures in older patients with heart failure: from trials to clinical practice. Minerva Medica, 2022, , .	0.3	2
3695	Optimizing Foundational Therapies in Patients With HFrEF. JACC Basic To Translational Science, 2022, 7, 504-517.	1.9	47

#	Article	IF	Citations
3696	Citri Reticulatae Pericarpium alleviates postmyocardial infarction heart failure by upregulating <scp>PPARÎ³</scp> expression. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 661-673.	0.9	5
3697	Advanced heart failure: guidelineâ€directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Failure, 2022, 9, 1507-1523.	1.4	26
3698	Network metaâ€analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction. Journal of Internal Medicine, 2022, 292, 333-349.	2.7	10
3699	Heart Failure and Drug Therapies: A Metabolic Review. International Journal of Molecular Sciences, 2022, 23, 2960.	1.8	7
3700	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 782-790.	2.9	16
3701	Effects of mokuboito, a Japanese Kampo medicine, on longâ€term clinical outcomes in patients with heart failure. Traditional & Kampo Medicine, 2022, 9, 49-56.	0.2	0
3702	Atrial fibrillation in old age: current treatment options. Ã›Å¾no-Rossijskij Å¾urnal TerapevtiÄeskoj Praktiki, 2022, 3, 7-14.	0.1	1
3703	INDY as a Therapeutic Target for Cardio-Metabolic Disease. Metabolites, 2022, 12, 244.	1.3	1
3704	Prognostic implications of hypo and hyperkalaemia in acute heart failure with reduced ejection fraction. Analysis of cardiovascular mortality and hospital readmissions. Medicina ClÃnica (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	0
3705	Heart failure in adults with congenital heart disease. International Journal of Cardiology, 2022, 357, 39-45.	0.8	17
3706	The Role of Cardioprotection in CancerÂTherapy Cardiotoxicity. JACC: CardioOncology, 2022, 4, 19-37.	1.7	47
3708	Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiologyâ€”A PROLONG-II Substudy. Sensors, 2022, 22, 2037.	2.1	3
3709	Temporal trend and potential impact of angiotensin receptorÂneprilysin inhibitors on transcatheter edge-to-edge mitral valve repair. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.4	0
3710	Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. Journal of Pharmacy Practice, 2023, 36, 905-914.	0.5	4
3711	Baseline characteristics of outpatients with heart failure according to phenotype: preliminary analysis from SMYRNA-HF registry. The European Research Journal, 2022, 8, 266-274.	0.1	1
3713	The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up. Frontiers in Medicine, 2022, 9, 817833.	1.2	4
3715	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Expert Opinion on Pharmacotherapy, 2022, 23, 673-680.	0.9	3
3718	Summary of updates to the 2021 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology, 2022, 27, 4820.	0.4	6

#	Article	IF	Citations
3719	Biomarker changes as surrogate endpoints in earlyâ€phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118.	1.4	4
3720	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	0.7	42
3721	A Retrospective Cohort Evaluation of a Pharmacist-Led Approach for Transitioning Patients to an Angiotensin Receptorâ€"Neprilysin Inhibitor. Journal of Pharmacy Practice, 2023, 36, 1061-1067.	0.5	0
3722	Prevalence and Prognostic Implications of Left Ventricular Systolic Dysfunction in Adults With Congenital Heart Disease. Journal of the American College of Cardiology, 2022, 79, 1356-1365.	1.2	17
3723	Sacubitril/Valsartan Off-Label Uses for Heart Failure. Journal of Cardiac Failure, 2022, , .	0.7	0
3724	Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients. Journal of Cardiovascular Pharmacology, 2022, 79, 472-478.	0.8	4
3725	Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat. Biomedicine and Pharmacotherapy, 2022, 148, 112745.	2.5	2
3726	Prognostic Value of Time in Blood Pressure Target Range Among Patients With HeartÂFailure. JACC: Heart Failure, 2022, 10, 369-379.	1.9	8
3727	Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011â€“2015: Insights from the National Cardiovascular Data Registry. Heart Rhythm O2, 2022, 3, 405-414.	0.6	1
3728	Contribution of cyclooxygenase-1-dependent prostacyclin synthesis to bradykinin-induced dermal extravasation. Biomedicine and Pharmacotherapy, 2022, 148, 112786.	2.5	4
3729	Sudden cardiac death in heart failure with preserved ejection fraction: an updated review. International Journal of Arrhythmia, 2022, 23, .	0.3	2
3730	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet, The, 2022, 399, 1391-1400.	6.3	67
3731	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	1.2	314
3732	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
3733	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001062.	1.6	133
3734	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC: Heart Failure, 2022, 10, 415-427.	1.9	4
3735	Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea. Frontiers in Cardiovascular Medicine, 2022, 9, 861663.	1.1	8
3736	Bacterial Cellulose and ECM Hydrogels: An Innovative Approach for Cardiovascular Regenerative Medicine. International Journal of Molecular Sciences, 2022, 23, 3955.	1.8	17

#	Article	IF	Citations
3737	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
3738	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. , 2022, 238, 108185.		16
3740	Heart failure and its treatment from the perspective of sympathetic nerve activity. Journal of Cardiology, 2022, 79, 691-697.	0.8	14
3741	Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	2
3742	Arrhythmias in heart failureâ€"Where the past meets the future. Heart Rhythm O2, 2021, 2, 669-670.	0.6	0
3743	Medical management of acute heart failure. Faculty Reviews, 2021, 10, 82.	1.7	6
3744	Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials. Medicine (United States), 2021, 100, e28231.	0.4	4
3745	Bortezomib-Induced Reversible Cardiomyopathy: Recovered with Guideline-Directed Medical Therapy. Cureus, 2021, 13, e20295.	0.2	1
3746	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030.	0.7	5
3747	Life-threatening ventricular arrhythmia and left ventricular dysfunction associated with anti-mitochondrial antibody-positive myositis: a case report. European Heart Journal - Case Reports, 2021, 5, ytab469.	0.3	3
3748	Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 2021, 1-6.	1.0	0
3749	Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement. Heart Rhythm O2, 2021, 2, 698-709.	0.6	4
3750	Sacubitril/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic. Cardiovascular Diagnosis and Therapy, 2021, 11, 1217-1227.	0.7	4
3751	PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction. European Heart Journal, 2022, 43, 559-560.	1.0	4
3752	Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenterÂItalian register. European Heart Journal Open, 2022, 2, .	0.9	11
3753	New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction. Journal of Cardiovascular Emergencies, 2021, 7, 88-99.	0.1	0
3754	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 975-983.	0.2	0
3755	Managing the economic challenges in the treatment of heart failure. BMC Cardiovascular Disorders, 2021, 21, 612.	0.7	4

#	Article	IF	Citations
3756	ARNI Pre-Operative Use and Vasoplegic Syndrome in Patients Undergoing Heart Transplantation or Left Ventricular Assist Device Surgery. Medical Sciences (Basel, Switzerland), 2022, 10, 2.	1.3	3
3757	Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction. Heart Rhythm O2, 2021, 2, 724-732.	0.6	6
3758	Improvement of left ventricular function with surgical revascularization in patients eligible for implantable cardioverterâ€defibrillator. Journal of Cardiovascular Electrophysiology, 2022, 33, 244-251.	0.8	3
3759	Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry. Journal of Cardiac Failure, 2022, 28, 765-774.	0.7	5
3760	Hospitalisations in HFpEF: More than just a matter of the heart. European Journal of Clinical Investigation, 2022, 52, e13739.	1.7	0
3761	Role of Diabetes Mellitus in Acute Coronary Syndrome Patients with Heart Failure and Midrange Ejection Fraction Who Have Undergone Percutaneous Coronary Intervention: A 3-Year Case-Series Follow-Up Retrospective Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 4931-4944.	1.1	2
3762	Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks. JAMA Cardiology, 2022, 7, 450.	3.0	17
3763	Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. Children, 2021, 8, 1200.	0.6	2
3764	Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 768-776.	1.4	8
3765	Nâ€terminal proâ€Bâ€type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 87-99.	1.4	3
3767	Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 803984.	1.1	4
3768	What can machines learn about heart failure? A systematic literature review. International Journal of Data Science and Analytics, 2022, 13, 163-183.	2.4	3
3769	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	1.0	8
3772	Pharmacological Treatment in Patients with Advanced Heart Failure: Recommendations and Challenges. , 2022, 2, 109-115.		0
3773	Arterial stiffness and pulsatile hemodynamics in heart failure. , 2022, , 565-589.		4
3774	Rethinking the Definition of Heart Failure Based on Ejection Fraction: Reflections with Impact on Therapy. , 2022, 2, 76-79.		1
3775	Treatment of Heart Failure with reduced Ejection Fraction in 2022: The Essential Pillars. , 2022, 2, 15-23.		0
3776	Pharmacological Treatment Sequencing for Heart Failure with Reduced Ejection Fraction. , 2022, 2, 31-35.		0

#	Article	IF	Citations
3777	Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2573-2587.	1.0	41
3778	SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. , 2022, 2, 67-71.		0
3779	Sequencing of Pharmacotherapy for Heart Failure with Reduced Ejection Fraction: A Clinical Profile-Based Approach. , 2022, 2, 36-40.		0
3780	Therapeutic approaches to improve pulmonary arterial load and right ventricularâ€“pulmonary arterial coupling. , 2022, , 935-958.		0
3781	Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. European Heart Journal, 2022, 43, 2549-2561.	1.0	136
3782	Pharmacokinetics, Mechanism of Action, and Adverse Effects of the Main Drugs Used to Treat Heart Failure: A Practical Overview for the Clinical Cardiologist. , 2022, 2, 4-11.		0
3783	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. JAMA Cardiology, 2022, 7, 540.	3.0	20
3784	LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats. Scientific Reports, 2022, 12, 4930.	1.6	10
3785	Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. ESC Heart Failure, 2022, 9, 2428-2434.	1.4	13
3786	Cost-Effectiveness of Sacubitrilâ€“Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. Journal of Pharmacy Practice, 2023, 36, 915-924.	0.5	1
3787	Sex-Based Differences in HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 1530-1541.	1.2	22
3788	Cyclic GMP and PKG Signaling in Heart Failure. Frontiers in Pharmacology, 2022, 13, 792798.	1.6	19
3789	Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling. Current Problems in Cardiology, 2023, 48, 101215.	1.1	17
3790	Effects of Sacubitril/Valsartan Versus Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: The Rationale and Design of A Randomized Clinical Trial. Cardiovascular & Hematological Disorders Drug Targets, 2022, 22, .	0.2	0
3791	Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. International Journal of Cardiology, 2022, 359, 76-83.	0.8	2
3792	GuÃa ESC 2021 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
3793	GuÃa ESC 2021 sobre la prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃ¬nica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	0.6	27
3794	Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate. European Journal of Heart Failure, 2022, 24, 867-870.	2.9	3

#	Article	IF	Citations
3795	Sex and Gender-Related Issues in Heart Failure. Cardiology Clinics, 2022, 40, 259-268.	0.9	3
3818	Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index. ESC Heart Failure, 2022, 9, 2037-2043.	1.4	1
3819	Gender difference in heart failure with preserved ejection fraction: clinical profiles, examinations, and prognosis. Heart and Vessels, 2022, 37, 1710-1718.	0.5	4
3820	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. European Journal of Internal Medicine, 2022, 102, 8-16.	1.0	10
3821	Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduction and Targeted Therapy, 2022, 7, 134.	7.1	18
3822	History and evolution of pacing and devices. Heart, 2022, 108, 794-799.	1.2	6
3823	Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Metaâ€Analysis of Observational Studies. Journal of the American Heart Association, 2022, 11, e024449.	1.6	11
3828	Medication management for heart failure with reduced ejection fraction. Canadian Family Physician, 2021, 67, 915-922.	0.1	1
3832	The efficacy and safety of Sacubitril/Valsartan in the treatment of chronic heart failure: a meta-analysis.. American Journal of Translational Research (discontinued), 2021, 13, 12114-12128.	0.0	1
3838	proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action. Circulation Research, 2022, 130, 101161CIRCRESAHA122320882.	2.0	5
3840	Heart Failure Relapses in Response to Acute Stresses â€“ Role of Immunological and Inflammatory Pathways. Frontiers in Cardiovascular Medicine, 2022, 9, 809935.	1.1	3
3841	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Translation of the document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2022, 64, 7-86.	0.1	1
3842	Guideline-directed device therapies in heart failure: A clinical practice-based analysis using electronic health record data. American Heart Journal Plus, 2022, 16, 100139.	0.3	0
3843	The Canadian Heart Failure (CAN-HF) Registry: A Canadian multi-centre, retrospective study of inpatients with heart failure.. CJC Open, 2022, , .	0.7	3
3844	Twenty-year trends in heart failure among U.S. adults, 1999â€“2018: The growing impact of obesity and diabetes. International Journal of Cardiology, 2022, 362, 104-109.	0.8	7
3845	The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients. ESC Heart Failure, 2022, 9, 2435-2444.	1.4	8
3846	Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction. Sleep and Breathing, 2023, 27, 283-289.	0.9	2
3847	Vericiguat in heart failure: From scientific evidence to clinical practice. Revista Clínica Espanõla, 2022, 222, 359-369.	0.3	5

#	Article	IF	Citations
3848	Frontier and Hotspot Evolution in Cardiorenal Syndrome: A Bibliometric Analysis From 2003 to 2022. Current Problems in Cardiology, 2023, 48, 101238.	1.1	11
3849	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e16.	1.2	6
3850	Angiotensin receptorâ€“neprilysin inhibitors for hypertensionâ€”hemodynamic effects and relevance to hypertensive heart disease. Hypertension Research, 2022, 45, 1097-1110.	1.5	14
3851	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Cardiac Failure Review, 0, 8, .	1.2	1
3852	Angiotensin Receptor and Neprilysin Inhibitors for COVID-19 Treatment and Personalized Medicine?. OMICS A Journal of Integrative Biology, 2022, 26, 318-319.	1.0	0
3853	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. Journal of Cardiovascular Development and Disease, 2022, 9, 149.	0.8	7
3854	Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovascular Disorders, 2022, 22, 217.	0.7	9
3855	Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy. Scientific Reports, 2022, 12, 7730.	1.6	4
3856	Improving clinical trial efficiency using a machine learningâ€based risk score to enrich study populations. European Journal of Heart Failure, 2022, 24, 1418-1426.	2.9	10
3858	Arterial hypertension - clinical trials update 2022. Hypertension Research, 2022, , .	1.5	3
3859	Multimorbidity, guidelineâ€directed medical therapies, and associated outcomes among hospitalized heart failure patients. ESC Heart Failure, 2022, 9, 2500-2510.	1.4	12
3860	Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?. JAMA Cardiology, 2022, , .	3.0	1
3861	Sacubitril/Valsartan vs. ACEi/ARB at Hospital Discharge and 5-Year Survival in Older Patients with Heart Failure with Reduced Ejection Fraction: A Decision Analysis Approach. American Heart Journal, 2022, 250, 23-23.	1.2	6
3862	Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay. Diagnostics, 2022, 12, 1172.	1.3	6
3863	Murine models of radiation cardiotoxicity: A systematic review and recommendations for future studies. Radiotherapy and Oncology, 2022, 173, 19-31.	0.3	15
3864	Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: <scp>the EVALUATEâ€HF trial</scp>. European Journal of Heart Failure, 2022, 24, 1200-1208.	2.9	10
3865	Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	7
3866	Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF). Journal of Cardiovascular Translational Research, 2022, 15, 1424-1435.	1.1	4

#	Article	IF	Citations
3867	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Failure Reviews, 2023, 28, 585-596.	1.7	11
3868	Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure. Biology, 2022, 11, 717.	1.3	8
3869	Albuminuria, estimated glomerular filtration rate, and traditional predictors for composite cardiovascular and kidney outcome: a population-based cohort study in Korea. Kidney Research and Clinical Practice, 2022, 41, 567-579.	0.9	3
3870	New therapies for the treatment of heart failure with preserved ejection fraction. American Journal of Health-System Pharmacy, 2022, 79, 1424-1430.	0.5	4
3871	Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients. Journal of Cardiovascular Translational Research, 2022, 15, 1192-1202.	1.1	4
3872	Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction: assessment with 3.0ÂT MRI feature tracking. Cardiovascular Diabetology, 2022, 21, 69.	2.7	8
3873	Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. European Heart Journal Digital Health, 2022, 3, 284-295.	0.7	5
3874	Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview. Nefrologia, 2022, 42, 145-162.	0.2	2
3876	Effect of pulmonary artery pressureâ€guided therapy on heart failure readmission in a nationally representative cohort. ESC Heart Failure, 2022, 9, 2511-2517.	1.4	5
3877	Using routine healthcare data to evaluate the impact of the Medicines at Transitions Intervention (MaTI) on clinical outcomes of patients hospitalised with heart failure: protocol for the Improving the Safety and Continuity Of Medicines management at Transitions of care (ISCOMAT) cluster randomised controlled trial with embedded process evaluation, health economics evaluation and internal pilot. BMJ Open, 2022, 12, e054274.	0.8	2
3878	Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat. Journal of Cardiac Failure, 2022, 28, 1298-1308.	0.7	8
3879	Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitrilâ€“valsartan. Scientific Reports, 2022, 12, 8186.	1.6	2
3880	Headâ€toâ€head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	2.9	18
3882	Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD. Cells, 2022, 11, 1657.	1.8	7
3883	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98.	1.2	48
3884	The need for increased pragmatism in cardiovascular clinical trials. Nature Reviews Cardiology, 2022, 19, 737-750.	6.1	22
3886	Empagliflozin as a part of optimal medical therapy for chronic heart failure. Kardiologicheskii Vestnik, 2022, 17, 16.	0.1	0
3887	Valsartan and sacubitril combination treatment enhances collagen production in older adult human skin cells. Experimental Gerontology, 2022, 165, 111835.	1.2	2

#	Article	IF	Citations
3888	The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	2
3890	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a metaâ€analysis. ESC Heart Failure, 2022, 9, 2753-2761.	1.4	7
3891	Impact of Bâ€linesâ€guided intensive heart failure management on outcome of discharged heart failure patients with residual Bâ€lines. ESC Heart Failure, 2022, 9, 2713-2718.	1.4	4
3892	Pulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapyâ€“Observations from an Advanced Elderly German Heart Failure Cohort. Life, 2022, 12, 766.	1.1	0
3893	The PONTE (<u>P</u>DTA FOR INTEGRATED F<u>O</u>LLOW-UP TERRITORY HOSPITAL OF THE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 increased adherence to guideline-recommended therapies through web-based shared clinical database. European Heart Journal Supplements, 2022, 24, C221-C224.	0.0	0
3894	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2022, 15, 2186-2199.	1.4	9
3895	Paradigm change in the treatment of chronic heart failure according to ESC Guide 2021: New innovative drugs in focus. Timocki Medicinski Glasnik, 2022, 47, 40-47.	0.0	1
3896	Angiotensin <scp>Receptorâ€Neprilysin</scp> Inhibitor Attenuates Cardiac Hypertrophy and Improves Diastolic Dysfunction in A Mouse Model of Heart Failure with Preserved Ejection Fraction. Clinical and Experimental Pharmacology and Physiology, 0, , .	0.9	3
3897	Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study. Frontiers in Physiology, 2022, 13, .	1.3	12
3898	Editorial: Myocardial Remodeling: Mechanisms and Translational Implications. Frontiers in Pharmacology, 2022, 13, .	1.6	0
3899	Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	9
3900	Disease-Modifying Therapy of Chronic Heart Failure on the Background of Heart Rhythm and Conductivity Disorders (Clinical Case). , 2022, 2, 31-40.		0
3902	Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction. Clinical Drug Investigation, 2022, 42, 533-540.	1.1	2
3903	Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	6
3904	Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. American Heart Journal, 2022, 251, 127-136.	1.2	5
3905	Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?. Journal of Clinical Medicine, 2022, 11, 3081.	1.0	2
3906	SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. Current Atherosclerosis Reports, 2022, 24, 627-634.	2.0	8
3907	Sacubitril-Valsartan Increases Ultrafiltration in Patients Undergoing Peritoneal Dialysis: A Short-Term Retrospective Self-Controlled Study. Frontiers in Medicine, 2022, 9, .	1.2	2

#	Article	IF	Citations
3908	Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States. Biology, 2022, 11, 859.	1.3	5
3909	Multidimensional Approach of Heart Failure Diagnosis and Prognostication Utilizing Cardiac Imaging with Biomarkers. Diagnostics, 2022, 12, 1366.	1.3	1
3910	PATHOPHYSIOLOGICAL PRINCIPLES UNDERLYING THE EFFECT OF SACUBITRIL-VALSARTAN ON HYPERTENSION-INDUCED CARDIOVASCULAR REMODELING. Ek'sperimentuli Da Klinikuri Medic'ina, 0, , .	0.0	0
3911	Apparent Treatment-Resistant Hypertension Across the Spectrum of HeartÂFailure Phenotypes in the SwedishÂHF Registry. JACC: Heart Failure, 2022, 10, 380-392.	1.9	5
3912	Kardiorenales Syndrom: Herz- und Niereninsuffizienz gleichzeitig im Fokus. , 0, , .		1
3913	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	4.3	109
3914	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. Journal of Clinical Medicine, 2022, 11, 3192.	1.0	10
3915	Ischemic Mitral Regurgitation. Journal of Coronary Artery Disease, 2022, 28, 24-31.	0.1	0
3916	Prevention of complications in the treatment of chronic heart failure in 2022: results of a survey of specialists. Profilakticheskaya Meditsina, 2022, 25, 33.	0.2	0
3918	Angiotensin Receptor/Neprilysin Inhibitor Effects in CRTd Non-Responders: From Epigenetic to Clinical Beside. SSRN Electronic Journal, 0, , .	0.4	0
3919	Sacubitril-valsartan therapy in a patient with heart failure due to isolated left ventricular noncompaction: a case report and literature review. Cardiology Plus, 2022, 7, 56-59.	0.2	1
3920	Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction. Cardiology Plus, 2022, 7, 20-28.	0.2	1
3921	Diastolic left ventricular dysfunction and heart failure with preserved ejection fraction in elderly. Buletinul AÅžM: ÅžtiinÅ£e Medicale, 2022, 72, 123-129.	0.0	0
3922	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of the Nihon University Medical Association, 2022, 81, 73-76.	0.0	0
3923	Genotypes and Electrocardiographic Parameters for Predicting the Effect of Antiarrhythmic Drugs. Japanese Journal of Clinical Pharmacology and Therapeutics, 2022, 53, 75-80.	0.1	0
3924	Blood Pressure Assessment and Treatment in the Observation Unit. Current Hypertension Reports, 2022, 24, 311-323.	1.5	1
3926	Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. Cardiology Journal, 0, , .	0.5	3
3927	Effects of Gut Microbiota and Metabolites on Heart Failure and Its Risk Factors: A Two-Sample Mendelian Randomization Study. Frontiers in Nutrition, 0, 9, .	1.6	28

#	Article	IF	Citations
3928	Moving Beyond Selfâ€Reported Race in Our Understanding of Cardiovascular Medicine. Journal of the American Heart Association, 2022, 11, .	1.6	0
3929	Corin Missense Variants, Blood Pressure, and Hypertension in 11Â322 Black Individuals: Insights From REGARDS and the Jackson Heart Study. Journal of the American Heart Association, 2022, 11, .	1.6	3
3930	Value-Based Prices Could Establish Common Ground on HeartÂFailure Drug Pricing and Coverage. Journal of the American College of Cardiology, 2022, 79, 2526-2528.	1.2	1
3931	Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 2022, 21, .	2.7	14
3932	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	1.0	5
3933	Fluid REStriction in Heart Failure vs Liberal Fluid UPtake: Rationale and Design of the Randomized FRESH-UP Study. Journal of Cardiac Failure, 2022, 28, 1522-1530.	0.7	9
3934	A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. Hospital Practice (1995), 0, , .	0.5	0
3935	Angiotensin receptorâ€neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime. ESC Heart Failure, 0, , .	1.4	2
3936	Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. European Heart Journal, 2022, 43, 2994-2996.	1.0	6
3937	Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. Current Heart Failure Reports, 2022, 19, 191-199.	1.3	2
3938	Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015â€“2018: single-center prospective study. Heart and Vessels, 2022, 37, 2014-2028.	0.5	3
3939	Utilization of sacubitrilâ€“valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy. Future Cardiology, 0, , .	0.5	0
3940	Salivary potassium measured by genetically encoded potassium ion indicators as a surrogate for plasma potassium levels in hemodialysis patients â€“ a proof-of-concept study. Nephrology Dialysis Transplantation, 0, , .	0.4	0
3941	Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies. Cureus, 2022, , .	0.2	4
3942	Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction. Clinical Drug Investigation, 2022, 42, 567-579.	1.1	7
3943	New Advances in Cardiorenal Syndromeâ€”Ready for Prime Time?. Journal of Clinical Medicine, 2022, 11, 3460.	1.0	0
3944	Adequate enrollment of women in cardiovascular drug trials and the need for sex-specific assessment and reporting. American Heart Journal Plus, 2022, , 100155.	0.3	0
3945	Combined therapy with dapagliflozin and entresto offers an additional benefit on improving the heart function in rat after ischemia-reperfusion injury. Biomedical Journal, 2023, 46, 100546.	1.4	4

#	Article	IF	Citations
3946	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 2017-2026.	2.2	9
3947	Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. Current Heart Failure Reports, 2022, 19, 290-302.	1.3	11
3948	Contemporary Trends in the Use of and Expenditures on Digoxin in the United States. American Journal of Cardiovascular Drugs, 2022, 22, 567-575.	1.0	3
3949	Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Failure, 2022, 9, 2909-2917.	1.4	10
3950	Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 2516-2525.	1.2	34
3951	Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure. Journal of the American Heart Association, 2022, 11, .	1.6	6
3952	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€HF. Journal of the American Heart Association, 2022, 11, .	1.6	3
3953	Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting. Pharmacological Reviews, 2022, 74, 462-505.	7.1	18
3954	Application and evaluation of sacubitril/valsartan in patients with cardiac insufficiency during perioperative period of cardiac surgery. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	1
3955	Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: From epigenetic to clinical beside. Pharmacological Research, 2022, 182, 106303.	3.1	12
3956	Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study. European Journal of Pharmacology, 2022, 928, 175053.	1.7	10
3957	Association of Age with Optimal Medical Therapy in Patients with Chronic Heart Failure. , 2022, 2, 138-145.		0
3958	LCZ696 Protects Against Doxorubicin-Induced Cardiotoxicity by Inhibiting Ferroptosis Via AKT/SIRT3/SOD2 Signaling Pathway Activation. SSRN Electronic Journal, 0, , .	0.4	0
3959	Effects of Sacubitril/Valsartan on the Right Ventricular-Pulmonary Arterial Coupling in Patients with Heart Failure Complicated with Pulmonary Hypertension. Advances in Clinical Medicine, 2022, 12, 6075-6082.	0.0	0
3960	Clinical Course and Therapy Optimization of Patients after Discharge from Heart Failure Clinic - An 'Interventional' Quality Control Study. SSRN Electronic Journal, 0, , .	0.4	0
3961	Profile of nonischemic dilated cardiomyopathy patients with long-term survival â‰¥10 years on medical therapy alone. Journal of Family Medicine and Primary Care, 2022, 11, 2389.	0.3	0
3962	Is There Room for Sacubitril-Valsartan in the Treatment of Advanced Heart Failure?. , 2022, 2, 192-194.		0
3964	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 5006-5016.	1.0	15

#	Article	IF	Citations
3965	Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review. CJC Open, 2022, 4, 802-809.	0.7	2
3966	Improving implementation of evidenceâ€based therapies for heart failure. Clinical Cardiology, 2022, 45, .	0.7	2
3967	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clinical Cardiology, 2022, 45, .	0.7	8
3968	Effects of Sacubitril/Valsartan on the Renal Resistance Index. Journal of Clinical Medicine, 2022, 11, 3683.	1.0	3
3969	The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review. Drugs and Aging, 2022, 39, 631-643.	1.3	5
3970	In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 0, 8, .	1.2	9
3971	Atrial fibrillation in heart failure patients: An update on reninâ€“angiotensinâ€“aldosterone system pathway blockade as a therapeutic and prevention target. Cardiology Journal, 2023, 30, 312-326.	0.5	3
3972	Drugs for heart failure and arrhythmias. Medicine, 2022, , .	0.2	0
3973	Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?. Current Protein and Peptide Science, 2022, 23, 321-334.	0.7	4
3974	Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction. Clinical Cardiology, 2022, 45, .	0.7	2
3975	Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 2022, 45, .	0.7	7
3976	Prevention of sudden death in heart failure with reduced ejection fraction: do we still needÂan implantable cardioverterâ€defibrillator for primary prevention?. European Journal of Heart Failure, 2022, 24, 1460-1466.	2.9	12
3977	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
3978	Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	3
3979	Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. Clinical Research in Cardiology, 2023, 112, 111-122.	1.5	8
3980	ARNI or ARB Treats Residual Left Ventricular Remodelling after Surgery for Valvular Regurgitation: ReReRe study protocol. ESC Heart Failure, 0, , .	1.4	1
3981	Benefits of Interventional Telemonitoring on Survival and Unplanned Hospitalization in Patients With Chronic Heart Failure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
3982	B-Type Natriuretic Peptide (BNP) Revisitedâ€”Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?. Biology, 2022, 11, 1034.	1.3	10

#	Article	IF	Citations
3984	The HOPE Clinic â€“ More Than Just a Name Change. Journal of Cardiac Failure, 2022, , .	0.7	0
3985	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. European Journal of Heart Failure, 2022, 24, 1614-1622.	2.9	15
3986	Application of Angiotensin Receptorâ€“Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus. Frontiers in Medicine, 0, 9, .	1.2	7
3987	Chronic heart failure: epidemiology, investigation and management. Medicine, 2022, , .	0.2	0
3988	Renin-angiotensin-aldosterone inhibition in chronic heart failure: From theory into practice. European Journal of Internal Medicine, 2022, , .	1.0	0
3989	Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review. European Journal of Health Economics, 2023, 24, 453-467.	1.4	5
3990	Tolerability of Sacubitril/Valsartan in Patients With Advanced HeartÂFailure. JACC: Heart Failure, 2022, 10, 449-456.	1.9	9
3991	Sacubitril/Valsartan in Advanced HeartÂFailure. JACC: Heart Failure, 2022, 10, 457-458.	1.9	1
3993	Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
3994	Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
3995	Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases. Biology, 2022, 11, 1017.	1.3	4
3996	Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. Frontiers in Physiology, 0, 13, .	1.3	7
3997	A narrative review on sacubitril/valsartan and ventricular arrhythmias. Medicine (United States), 2022, 101, e29456.	0.4	3
3999	Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. Journal of Cardiovascular Development and Disease, 2022, 9, 225.	0.8	3
4000	Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation. Clinical Cardiology, 2022, 45, 839-849.	0.7	5
4001	Current status of hypertension and treatment in Asia. Hypertension Research, 2022, 45, 1095-1096.	1.5	1
4002	Optimizing Therapies in Heart Failure: The Role of Potassium Binders. Biomedicines, 2022, 10, 1721.	1.4	4
4003	Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. Expert Review of Cardiovascular Therapy, 2022, 20, 529-541.	0.6	3

#	Article	IF	Citations
4005	The Potential Role of Renal Denervation in the Management of Heart Failure. Journal of Clinical Medicine, 2022, 11, 4147.	1.0	4
4006	Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverterâ€Ðefibrillator Generator Changes. Journal of the American Heart Association, 2022, 11, .	1.6	2
4007	Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy. Biomedicine and Pharmacotherapy, 2022, 153, 113382.	2.5	4
4009	Angiotensin 2 Type 1 Receptor Blockade with Neprilysin Inhibition for Chronic Heart Failure: A New Paradigm?. Annals of the Academy of Medicine, Singapore, 2015, 44, 272-273.	0.2	1
4010	Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment. Life, 2022, 12, 1111.	1.1	22
4012	Breaking the Bank: The Financial Burden of Living With Heart Failure. Journal of Cardiac Failure, 2022, 28, 1434-1436.	0.7	1
4013	Levosimendan as a â€œBridge to Optimizationâ€•in Patients with Advanced Heart Failure with Reduced Ejectionâ€”A Single-Center Study. Journal of Clinical Medicine, 2022, 11, 4227.	1.0	5
4014	A cardiac-null mutation of Prdm16 causes hypotension in mice with cardiac hypertrophy via increased nitric oxide synthase 1. PLoS ONE, 2022, 17, e0267938.	1.1	2
4015	Use of guidelineâ€•recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. European Journal of Heart Failure, 2022, 24, 2185-2195.	2.9	23
4016	Efficacy of three novel drugs in the treatment of heart failure: A network meta-analysis. Medicine (United States), 2022, 101, e29415.	0.4	0
4017	Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through Î²3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. Circulation: Heart Failure, 2022, 15, .	1.6	13
4018	Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community. Journal of Cardiac Failure, 2022, 28, 1500-1508.	0.7	5
4019	Impact analysis of heart failure across European countries: an ESCâ€HFA position paper. ESC Heart Failure, 2022, 9, 2767-2778.	1.4	17
4020	Vericiguat and NTâ€proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Failure, 2022, 9, 3791-3803.	1.4	14
4021	Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction. Life, 2022, 12, 1112.	1.1	0
4022	Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature. Expert Opinion on Drug Discovery, 2022, 17, 1111-1129.	2.5	2
4023	Risk Factors, Outcomes and Healthcare Utilisation in Individuals with Multimorbidity Including Heart Failure, Chronic Kidney Disease and Type 2 Diabetes Mellitus - a National Electronic Health Record Study. SSRN Electronic Journal, 0, , .	0.4	0
4024	Effects of Sacubitril/Valsartan on the Expression of CaMKII/Cav1.2 in Atrial Fibrillation Stimulation Rabbit Model. BioMed Research International, 2022, 2022, 1-8.	0.9	1

#	Article	IF	Citations
4025	Is Sacubitril/Valsartan a Safe and Effective Option in Real World Patients with Mild to Severe Chronic Kidney Disease?. Hearts, 2022, 3, 81-87.	0.4	1
4026	Consensus statement on the current pharmacological prevention and management of heart failure. Medical Journal of Australia, 2022, 217, 212-217.	0.8	14
4027	Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2022, 146, 339-357.	1.6	21
4029	Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4030	Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
4031	Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy. Science Translational Medicine, 2022, 14, .	5.8	13
4032	New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review. Pharmaceutics, 2022, 14, 1569.	2.0	0
4033	Effects of guideline-directed medical therapy in patients with left bundle branch block-induced cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.4	0
4034	Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes. Kardiologiya, 2022, 62, 44-53.	0.3	6
4035	Management of Heart Failure in Patients with Chronic Kidney Disease. European Cardiology Review, 0, 17, .	0.7	5
4036	Predictors and outcomes of quality of life in elderly patients with heart failure. American Heart Journal Plus, 2022, 19, 100188.	0.3	0
4037	Clinically unrecognized plasma volume expansion predicts longâ€term allâ€cause mortality in chronic heart failure. Clinical Cardiology, 0, , .	0.7	2
4038	Use of Guideline-Directed Medical Therapy in Patients Aged â‰¥ 65 Years After the Diagnosis of Heart Failure: A Canadian Population-Based Study. CJC Open, 2022, 4, 1015-1023.	0.7	11
4039	The importance of randomization in clinical research. Indian Journal of Thoracic and Cardiovascular Surgery, 0, , .	0.2	0
4040	Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice. BMC Nephrology, 2022, 23, .	0.8	1
4041	Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. Expert Opinion on Pharmacotherapy, 2022, 23, 1589-1599.	0.9	5
4042	2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European Heart Journal, 2022, 43, 3826-3924.	1.0	298
4043	Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Failure, 2022, 9, 3737-3750.	1.4	12

#	Article	IF	Citations
4045	Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovascular Research, 2023, 118, 3416-3433.	1.8	24
4046	Therapeutic advances in guidelineâ€directed medical therapy for heart failure: the idealistic versus the pragmatic truth for vulnerable patients. Postgraduate Medicine, 2022, 134, 641-643.	0.9	1
4047	The Association between Marital Status and Outcomes of Patients Hospitalized with Heart Failure. International Journal of Behavioral Medicine, 0, , .	0.8	0
4048	Use and Outâ€ofâ€Pocket Cost of Sacubitrilâ€Valsartan in Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, .	1.6	4
4049	Thoughts on the usefulness of aÂnew scoring system for heart failure. Netherlands Heart Journal, 2022, 30, 400-401.	0.3	1
4050	Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 2022, 43, 4469-4479.	1.0	16
4051	A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates. Pharmacoeconomics, 0, , .	1.7	0
4052	Ten year ageâ€and sexâ€specific temporal trends in incidence and prevalence of heart failure in VÃstra GÃ¶taland, Sweden. ESC Heart Failure, 2022, 9, 3931-3941.	1.4	2
4053	Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995â€“2021. Medicine (United States), 2022, 101, e29398.	0.4	2
4054	Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathy. European Heart Journal, 0, , .	1.0	1
4055	Management of heart failure with reduced ejection fraction. Heart, 0, , heartjnl-2020-318811.	1.2	4
4056	Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4057	Evaluating Guideline Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction Post-coronary Artery Bypass Grafting. Journal of Pharmacy Practice, 0, , 089719002211181.	0.5	0
4058	Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction. Frontiers in Endocrinology, 0, 13, .	1.5	3
4059	Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials. Frontiers in Public Health, 0, 10, .	1.3	3
4061	Characteristics and Outcomes of Heart Failure Patients from a Middle-Income Country: The RECOLFACA Registry. Global Heart, 2022, 17, 57.	0.9	2
4062	Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target. Frontiers in Physiology, 0, 13, .	1.3	2
4064	Establishing a Cardiac ICU Recovery Clinic: Characterizing a Model for Continuity of Cardiac Critical Care. Critical Pathways in Cardiology, 2022, 21, 135-140.	0.2	0

#	Article	IF	Citations
4065	Decongestion Models and Metrics in Acute Heart Failure: ESCAPE Data in the Age of the Implantable Cardiac Pressure Monitor. Texas Heart Institute Journal, 2022, 49, .	0.1	0
4066	Multimorbidity and combined interventions for patients with coronary heart disease in Chinese population: Latent class analysis of a multi-center study. International Journal of Cardiology, 2022, , .	0.8	1
4067	2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 2022, 43, 3997-4126.	1.0	733
4068	Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Frontiers in Pharmacology, 0, 13, .	1.6	12
4069	Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management. Current Heart Failure Reports, 2022, 19, 303-315.	1.3	3
4070	Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control. International Journal of Cardiology, 2022, 367, 81-89.	0.8	3
4071	Oxidative stress regulates cardiomyocyte energy metabolism through the IGF2BP2-dynamin2 signaling pathway. Biochemical and Biophysical Research Communications, 2022, 624, 134-140.	1.0	1
4072	Water, acid-base, buffers, and homeostatic control systems of body fluids. , 2023, , 15-38.		0
4073	Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a <scp>populationâ€based</scp> cohort study of >25â€‰000 Medicare beneficiaries. European Journal of Heart Failure, 2022, 24, 1506-1515.	2.9	11
4074	Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study. BMJ Open, 2022, 12, e059905.	0.8	3
4075	Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1673-1682.	0.7	1
4076	Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. JACC: Cardiovascular Interventions, 2022, 15, 1711-1722.	1.1	17
4077	Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry. ESC Heart Failure, 2022, 9, 4209-4218.	1.4	5
4078	Telomere Shortening in Hypertensive Heart Disease Depends on Oxidative DNA Damage and Predicts Impaired Recovery of Cardiac Function in Heart Failure. Hypertension, 2022, 79, 2173-2184.	1.3	16
4079	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. Biomedicine and Pharmacotherapy, 2022, 155, 113701.	2.5	3
4080	The role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy: HF-optimize. Heart and Lung: Journal of Acute and Critical Care, 2023, 57, 95-101.	0.8	5
4081	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. , 2022, , 133-198.		0
4082	Biomarkers of Cardiac Stretch in Critical Illness: A Narrative Review. Biomarkers in Disease, 2022, , 1-17.	0.0	0

#	Article	IF	Citations
4083	Cardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. , 2022, , 579-614.		0
4084	Cardiorenal Syndrome. Nephrology Self-assessment Program: NephSAP, 2022, 21, 29-40.	3.0	0
4086	Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure. ESC Heart Failure, 2022, 9, 4077-4087.	1.4	2
4087	Empagliflozin in acute myocardial infarction: the EMMY trial. European Heart Journal, 2022, 43, 4421-4432.	1.0	93
4088	Cardioncology of childrenâ€™s patients: an interdisciplinary approach to treatment and supportive therapy. , 2022, , 54-57.		0
4089	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. , 0, , .		0
4090	Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?. Hearts, 2022, 3, 88-95.	0.4	0
4092	Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status. JACC: Heart Failure, 2022, 10, 976-988.	1.9	3
4093	Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study. Expert Opinion on Drug Safety, 2023, 22, 259-266.	1.0	1
4094	Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitrilâ€“Valsartan in Clinical Trials. American Journal of Therapeutics, 2022, 29, e572-e575.	0.5	0
4095	Edema formation in congestive heart failure and the underlying mechanisms. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	11
4096	Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology, 0, 13, .	1.6	8
4097	Impact of Worsening Heart Failure on Long-Term Prognosis in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2022, 184, 63-71.	0.7	2
4098	Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	1.9	4
4099	New Strategies to Prevent Rehospitalizations for Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 199-212.	0.4	2
4100	Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure. American Journal of Cardiovascular Drugs, 0, , .	1.0	1
4101	Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide. Biology, 2022, 11, 1351.	1.3	4
4102	Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fractionâ€”A New Endpoint from Old Clinical Trials. Journal of Clinical Medicine, 2022, 11, 5518.	1.0	0

#	Article	IF	Citations
4104	Validation of the Implantable Cardioverter-Defibrillators Indication Criteria for Nonischemic Cardiomyopathyã€€â€• Why? When? How? â€•. Circulation Journal, 2022, , .	0.7	0
4105	â€˜Acute Heart Failureâ€™: Should We Abandon the Term Altogether?. Current Heart Failure Reports, 2022, 19, 425-434.	1.3	3
4106	Rapid recommendations. Canadian Family Physician, 2022, 68, 664-666.	0.1	1
4107	(Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into) Tj ETQq1 1 0.784314 rgBT /Ov 2022, 64, 441-454.	0.1	0
4108	HeartÂFailure Drug Treatmentâ€”Inertia,ÂTitration, and Discontinuation. JACC: Heart Failure, 2023, 11, 1-14.	1.9	51
4109	Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF). Journal of Education, Health and Sport, 2022, 12, 583-588.	0.0	0
4110	Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nature Reviews Cardiology, 2023, 20, 90-108.	6.1	24
4111	Real-World Experience of Angiotensin Receptorâ€“Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease. Mayo Clinic Proceedings, 2023, 98, 88-99.	1.4	1
4112	Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure. ESC Heart Failure, 0, , .	1.4	1
4113	How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?. , 2022, 1, .		0
4114	Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure. ESC Heart Failure, 2023, 10, 66-79.	1.4	6
4115	Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation. Therapeutic Innovation and Regulatory Science, 2023, 57, 109-120.	0.8	5
4116	Neprilysin Inhibitors in HeartÂFailure. JACC Basic To Translational Science, 2023, 8, 88-105.	1.9	22
4117	Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. Journal of Human Hypertension, 2023, 37, 1-19.	1.0	19
4118	Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. Cureus, 2022, , .	0.2	1
4119	Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy. Netherlands Heart Journal, 2023, 31, 89-99.	0.3	2
4120	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0
4121	Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction: The ARIC Study. Journal of the American Heart Association, 2022, 11, .	1.6	10

#	Article	IF	Citations
4122	Coronary Artery Bypass Graft Surgery Brings Better Benefits to Heart Failure Hospitalization for Patients with Severe Coronary Artery Disease and Reduced Ejection Fraction. Diagnostics, 2022, 12, 2233.	1.3	3
4123	The mortality for the implantable cardiac defibrillator in nonischemic cardiomyopathy: An updated systematic review and metaâ€analysis. Clinical Cardiology, 0, , .	0.7	1
4124	Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. Clinical Chemistry, 2022, 68, 1391-1398.	1.5	3
4125	Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study. International Journal of Cardiology, 2023, 371, 244-251.	0.8	4
4126	Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base. International Journal of Cardiology, 2023, 371, 273-277.	0.8	2
4127	Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
4128	Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. Journal of Clinical Medicine, 2022, 11, 5199.	1.0	12
4129	Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis. Current Problems in Cardiology, 2023, 48, 101412.	1.1	2
4130	Sacubitril/Valsartan in Patients With Heart Failure and Concomitant Endâ€Stage Kidney Disease. Journal of the American Heart Association, 2022, 11, .	1.6	14
4131	Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. Pharmaceutics, 2022, 14, 1964.	2.0	0
4132	Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1767-1777.	2.9	14
4133	Vericiguatâ€"Filling the Gaps in Heart Failure Management. Indian Journal of Clinical Cardiology, 2022, 3, 133-134.	0.3	0
4134	Roles of autophagy in angiotensin <scp>II</scp>â€induced cardiomyocyte apoptosis. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 1342-1351.	0.9	2
4135	Cold shock domainâ€"containing protein E1 is a posttranscriptional regulator of the LDL receptor. Science Translational Medicine, 2022, 14, .	5.8	8
4136	Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without TypeÂ2 Diabetes. Advances in Therapy, 2022, 39, 4837-4846.	1.3	5
4137	Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: winâ€ratio analysis of the PARADISEâ€MI trial. European Journal of Heart Failure, 2022, 24, 1918-1927.	2.9	12
4138	Accuracy of the Number Needed to Treat Compared With Diagnostic Testing. Archives of Pathology and Laboratory Medicine, 2022, , .	1.2	0
4139	Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes. International Journal of Cardiology, 2023, 370, 300-308.	0.8	3

#	Article	IF	Citations
4140	Novel antihypertensive agents for resistant hypertension: what does the future hold?. Hypertension Research, 2022, 45, 1918-1928.	1.5	6
4141	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. International Journal of Molecular Sciences, 2022, 23, 11336.	1.8	3
4142	Risk of Acute Kidney Injury Among Older Adults With Heart Failure and With Reduced Ejection Fraction Treated With Angiotensin-Neprilysin Inhibitor vs Renin-Angiotensin System Inhibitor in Routine Clinical Care. Journal of Cardiac Failure, 2023, 29, 138-146.	0.7	5
4143	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. Journal of Clinical Hypertension, 2022, 24, 1218-1225.	1.0	1
4146	Antagonistic Atrial Natriuretic Peptide with the Renin-Angiotensin-Aldosterone System and Effects on Systemic Blood Pressure Regulation. Journal of Modern Medicinal Chemistry, 0, 10, 13-22.	0.8	0
4147	Dynamic but discordant alterations in zDHHC5 expression and palmitoylation of its substrates in cardiac pathologies. Frontiers in Physiology, 0, 13, .	1.3	5
4148	Frailty interferes with the guidelineâ€directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Failure, 2023, 10, 223-233.	1.4	6
4149	Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of <scp>EMPERORâ€Reduced</scp>. European Journal of Heart Failure, 2022, 24, 2297-2304.	2.9	13
4150	Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation. BMC Medicine, 2022, 20, .	2.3	5
4151	Prorenin: What are its functions?. Hypertension Research, 0, , .	1.5	0
4152	Effect of sacubitril/valsartan on cognitive impairment in colchicineâ€induced Alzheimer's model in rats. Fundamental and Clinical Pharmacology, 2023, 37, 275-286.	1.0	6
4153	Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials. Heart Failure Reviews, 2023, 28, 905-923.	1.7	1
4154	Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction. Scientific Reports, 2022, 12, .	1.6	0
4155	The MAGGIC risk score in the prediction of death or hospitalization in patients with heart failure: Comparison with natriuretic peptides. Revista Portuguesa De Cardiologia, 2022, 41, 941-947.	0.2	1
4156	Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation, 2022, 146, 1067-1081.	1.6	15
4158	Management of Heart Failure. JAMA - Journal of the American Medical Association, 2022, 328, 1346.	3.8	11
4159	Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. Heart Failure Reviews, 2023, 28, 949-959.	1.7	7
4160	Sacubitril/valsartan: An antiarrhythmic drug?. Journal of Cardiovascular Electrophysiology, 2022, 33, 2375-2381.	0.8	2

#	Article	IF	Citations
4161	Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry. International Journal of Cardiology, 2023, 370, 279-286.	0.8	3
4162	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. Current Heart Failure Reports, 2022, 19, 467-475.	1.3	2
4163	Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure. Pharmacotherapy, 0, , .	1.2	0
4164	Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3Î²/NF-ÎºB pathway in cardiomyocytes. Archives of Biochemistry and Biophysics, 2022, 730, 109415.	1.4	3
4165	Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction. Current Problems in Cardiology, 2022, 47, 101385.	1.1	4
4166	EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. Eurasian Heart Journal, 2019, , 4-85.	0.2	13
4167	Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study. International Journal of Heart Failure, 2022, 4, 193.	0.9	8
4168	Drug Titration for Patients With Heart Failure With Reduced Ejection Fraction Is a Challenge for Physicians in the Era of Four Pillar Drugs. International Journal of Heart Failure, 2022, 4, 180.	0.9	0
4169	Behavioral Medicine Treatments for Heart Failure. , 2022, , 1171-1205.		0
4170	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). Eurasian Heart Journal, 2022, , 6-56.	0.2	0
4171	Cardiovascular diseases guideline-directed medical therapy in low- and middle-income countries: A call for action. , 2022, 1, 67.		2
4172	Heart Failure and Diabetes Mellitus: Dangerous Liaisons. International Journal of Heart Failure, 2022, 4, 163.	0.9	7
4173	<i>In silico</i> study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor. RSC Advances, 2022, 12, 29719-29726.	1.7	2
4174	ÕŠÕ¡Õ°ÕºÕ¡Õ¶Õ¾Õ¡Õ®, Õ´Õ«Õ»Õ«Õ¶ Ö‡ Õ«Õ»Õ¡Õ® Õ¡Ö€Õ¿Õ¡Õ´Õ²Õ´Õ¡Õ¶ Ö†Ö€Õ¡Õ¯ÖÕ«Õ¡ÕµÕ¸Õ¾ Ö„Ö€Õ¸Õ¶Õ«Õ¯Õ¡Õ¯Õ		
4175	Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	5
4176	Renin-Angiotensin System Inhibitors and Major Cardiovascular Events after Sepsis. Annals of the American Thoracic Society, 2023, 20, 414-423.	1.5	3
4177	Clinical outcomes in heart failure with reduced left ventricular ejection fraction and good functional capacity: The illusion of stability. Revista Portuguesa De Cardiologia, 2022, , .	0.2	2
4178	A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3

#	Article	IF	Citations
4180	Use of Sacubitril/Valsartan Prior to Primary Prevention Implantable Cardioverter Defibrillator Implantation.. CJC Open, 2022, , .	0.7	0
4182	Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. Journal of Cardiac Failure, 2023, 29, 87-107.	0.7	8
4183	New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. Meditsinskiy Sovet, 2022, , 44-51.	0.1	0
4184	The role of bioelectrical phase angle in patients with heart failure. Reviews in Endocrine and Metabolic Disorders, 2023, 24, 465-477.	2.6	8
4186	The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials. Medicine (United States), 2022, 101, e30904.	0.4	1
4187	Should we consider recombinant human brain natriuretic peptide to prevent post-operative atrial fibrillation?. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	0
4188	Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications. Biomedicines, 2022, 10, 2471.	1.4	9
4189	Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. BMC Health Services Research, 2022, 22, .	0.9	13
4190	High versus low dose losartan and serum potassium: an analysis from HEAAL. Journal of Cardiac Failure, 2022, , .	0.7	0
4191	SILICOFCM platform, multiscale modeling of left ventricle from echocardiographic images and drug influence for cardiomyopathy disease. Computer Methods and Programs in Biomedicine, 2022, 227, 107194.	2.6	6
4192	Metabolomics implicate eicosanoids in severe functional mitral regurgitation. ESC Heart Failure, 2023, 10, 311-321.	1.4	3
4193	Left Ventricular Remodeling and Heart Failure Predictors in Acute Myocardial Infarction Patients with Preserved Left Ventricular Ejection Fraction after Successful Percutaneous Intervention in Western Romania. Life, 2022, 12, 1636.	1.1	1
4194	Guideline-Directed Medical Therapy. Journal of the American College of Cardiology, 2022, 80, 1542-1544.	1.2	1
4195	Dose-Response to Sacubitril/Valsartan inÂPatients With HeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2022, 80, 1529-1541.	1.2	13
4196	A practical approach to the guidelineâ€directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Failure, 2023, 10, 24-31.	1.4	9
4197	The association between betaâ€blockers and outcomes in patients with heart failure and concurrent Alzheimer's disease and related dementias. Journal of the American Geriatrics Society, 0, , .	1.3	2
4198	Low blood pressure and guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2023, 370, 255-262.	0.8	3
4199	The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period. International Journal of Cardiology, 2023, 370, 412-418.	0.8	3

#	Article	IF	Citations
4200	Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart, 2022, 9, e001977.	0.9	4
4201	Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients. Frontiers in Drug Discovery, 0, 2, .	1.1	1
4203	Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. Structural Heart, 2022, , 100082.	0.2	0
4204	The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation, 2022, 146, 1749-1757.	1.6	6
4205	Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension. Clinical Research in Cardiology, 2023, 112, 855-867.	1.5	3
4206	Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4207	Myocardial Viability Testing in the Management of Ischemic Heart Failure. Life, 2022, 12, 1760.	1.1	6
4208	Sustained Reduction in Pulmonary Artery Pressures and Hospitalizations During 2 Years of Ambulatory Monitoring. Journal of Cardiac Failure, 2023, 29, 56-66.	0.7	12
4209	LCZ696 protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation. International Immunopharmacology, 2022, 113, 109379.	1.7	24
4210	Discovery of novel dihydropyrazole-stilbene derivatives for ameliorating heart failure through modulation of p38/NF-Î²B signaling pathway. Bioorganic Chemistry, 2022, 129, 106206.	2.0	2
4211	Advances in congestive heart failure biomarkers. Advances in Clinical Chemistry, 2023, , 205-248.	1.8	3
4212	New Paradigms in Heart Failure: RAAS Inhibition and the Management of Hyperkalaemia. EMJ Cardiology, 0, , 53-61.	0.0	0
4213	Optimising Renin-Angiotensin-Aldosterone System Inhibitor Therapy in Heart Failure and Resistant Hypertension: Challenges and Solutions. European Medical Journal (Chelmsford, England), 0, , 19-26.	3.0	0
4214	Protecting the Heart in Cancer Patients: The Role of Cardio-Oncology. EMJ Cardiology, 0, , 47-52.	0.0	1
4215	Outpatient treatment of worsening heart failure with intravenous diuretics: first results from a multicentre 2â€yyear experience. ESC Heart Failure, 2023, 10, 594-600.	1.4	3
4216	Hypertension management in patients with cardiovascular comorbidities. European Heart Journal, 2023, 44, 2066-2077.	1.0	24
4218	Sequencing of medical therapy in heart failure with a reduced ejection fraction. Heart, 0, , heartjnl-2022-321497.	1.2	1
4219	Pathophysiology and Management of Heart Failure in the Elderly. International Journal of Angiology, 0, , .	0.2	0

#	Article	IF	Citations
4220	Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2022, 15, .	1.6	6
4221	Does exercise training improve exercise tolerance, quality of life, and echocardiographic parameters in patients with heart failure with preserved ejection fraction? A systematic review and meta-analysis of randomized controlled trials. Heart Failure Reviews, 2023, 28, 795-806.	1.7	2
4222	Heart Failure with Improved Ejection Fraction: Insight into the Variable Nature of Left Ventricular Systolic Function. International Journal of Environmental Research and Public Health, 2022, 19, 14400.	1.2	9
4223	Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. JACC: Heart Failure, 2023, 11, 44-54.	1.9	1
4224	Endoplasmic reticulum stress-activated nuclear factor-kappa B signaling pathway induces the upregulation of cardiomyocyte dopamine D1 receptor in heart failure. Biochemical and Biophysical Research Communications, 2022, 637, 247-253.	1.0	5
4225	Sodiumâ€“glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome. European Heart Journal Supplements, 2022, 24, I68-I71.	0.0	3
4226	Hospitalizations and Mortality in PatientsÂWith Secondary Mitral Regurgitation and HeartÂFailure. Journal of the American College of Cardiology, 2022, 80, 1857-1868.	1.2	10
4227	Perioperative changes in left ventricular systolic function following surgical revascularization. PLoS ONE, 2022, 17, e0277454.	1.1	1
4228	Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 931-932.	0.4	5
4229	Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond â€“ major changes are coming. Journal of Cardiovascular Medicine, 2022, 23, 761-769.	0.6	4
4231	Trends in ACEi and ARB expenditure: Compelling case for competition in generic drug markets. International Journal of Cardiology, 2023, 370, 419-420.	0.8	0
4232	Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension. Circulation Reports, 2022, , .	0.4	0
4233	<scp>Healthâ€related</scp> quality of life outcomes in <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 2264-2274.	2.9	6
4234	Estimating the Time to Benefit for Therapies in Heart Failure with Reduced Ejection Fraction: A Case Study of Sacubitril-Valsartan Using Reconstructed Data from a Randomized Controlled Trial. Drugs and Aging, 2022, 39, 959-966.	1.3	1
4236	Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 187, 84-92.	0.7	1
4237	Heart Failure in Rheumatic Disease. Rheumatic Disease Clinics of North America, 2023, 49, 67-79.	0.8	1
4238	Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 188, 52-60.	0.7	1
4239	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). Eurasian Heart Journal, 2022, , 6-56.	0.2	0

#	Article	IF	Citations
4240	Effectiveness and Safety of Sacubitril/Valsartan for Heart Failure with Reduced Ejection Fraction Secondary to Duchenne Muscular Dystrophy-Associated Cardiomyopathy. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2022, .	0.0	0
4241	The Impact of Angiotensin Receptorâ€“Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis. Journal of Innovations in Cardiac Rhythm Management, 2022, 13, 5164-5175.	0.2	5
4242	The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder. IHJ Cardiovascular Case Reports (CVCR), 2022, 6, 158-162.	0.0	0
4243	Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction. Clinical Research in Cardiology, 2023, 112, 167-174.	1.5	1
4244	Hibernation or Transformation? Challenges in Cardiovascular Drug Development. Frontiers in Cardiovascular Drug Discovery, 2022, , 102-140.	0.0	0
4245	Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitrilâ€Valsartan: A Multicenter Echocardiographic Registry. ESC Heart Failure, 2023, 10, 846-857.	1.4	8
4246	Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report. Journal of Pharmacy Practice, 2024, 37, 495-499.	0.5	1
4247	Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimensâ€"From a Cardiologistâ€™s View. Journal of Clinical Medicine, 2022, 11, 7041.	1.0	7
4248	Early predicting improvement of severe systolic heart failure by left atrial volume. Heart and Vessels, 2023, 38, 523-534.	0.5	1
4249	HeartÂFailure Burden by Autopsy, Guideline-Directed Medical Therapy, and ICD Utilization Among Sudden Deaths. JACC: Clinical Electrophysiology, 2023, 9, 403-413.	1.3	0
4250	Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. American Journal of Cardiology, 2022, , .	0.7	0
4251	The Effect of Coenzyme Q10 as a Part of Standard Therapy on Plasma Concentrations of Ubiquinol, Ubiquinone, Total CoQ10 and its Redox State in Patients with Ischemic Heart Disease. Current Drug Metabolism, 2022, 23, 991-999.	0.7	1
4252	Management of ventricular arrhythmias in heart failure: current perspectives. Intervencni A Akutni Kardiologie, 2022, 21, 139-149.	0.0	0
4253	Combined Therapy of Low-Dose Angiotensin Receptorâ€“Neprilysin Inhibitor and Sodiumâ€“Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics, 2022, 14, 2629.	2.0	1
4254	Atrial fibrillation and heart failure: the â€˜Clash of the titansâ€™ webinar. British Journal of Cardiac Nursing, 2022, 17, 1-5.	0.0	0
4255	Effect of add-on sacubitril/valsartan on the left ventricular hypertrophy of a patient with hypertension. Journal of International Medical Research, 2022, 50, 030006052211384.	0.4	2
4256	Frequency and predictors of hyperkalemia in the heart failure outpatient clinic. Acta Medica Alanya, 0, , .	0.2	0
4257	Role of Cardiac Natriuretic Peptides in Heart Structure and Function. International Journal of Molecular Sciences, 2022, 23, 14415.	1.8	21

#	Article	IF	Citations
4258	How to Initiate and Uptitrate GDMT in HeartÂFailure. JACC: Heart Failure, 2022, 10, 992-995.	1.9	4
4259	Efficacy of guidelineâ€directed medical treatment in heart failure with mildly reduced ejection fraction. ESC Heart Failure, 2023, 10, 1035-1042.	1.4	3
4260	Getting Cost Discussions Right: Nudging Patients to Avoid Cognitive Pitfalls. Circulation: Cardiovascular Quality and Outcomes, 2023, 16, .	0.9	3
4261	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. Cardiovascular Research, 2023, 118, 3467-3481.	1.8	4
4262	A Critical Evaluation of Patient Pathways and Missed Opportunities in Treatment for Heart Failure. Journal of Cardiovascular Development and Disease, 2022, 9, 455.	0.8	1
4263	Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure. Circulation: Heart Failure, 0, , .	1.6	0
4264	Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4265	Development and Piloting of a Web-Based Tool to Teach Relative and Absolute Risk Reductions. International Journal of Environmental Research and Public Health, 2022, 19, 16086.	1.2	1
4266	Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure. Journal of Clinical Medicine, 2022, 11, 7262.	1.0	4
4267	Renal Safety of de Novo Angiotensin-Neprilysin Inhibition in Older Adults: Insights From a Population-Based Analysis. Journal of Cardiac Failure, 2023, 29, 147-149.	0.7	0
4268	Pharmacologic blockade of the natriuretic peptide clearance receptor promotes weight loss and enhances insulin sensitivity in type 2 diabetes. Translational Research, 2022, , .	2.2	1
4269	The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with endâ€stage renal disease and heart failure. European Journal of Heart Failure, 2023, 25, 98-107.	2.9	5
4270	Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, .	1.6	3
4271	Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial. Circulation: Cardiovascular Interventions, 2022, 15, .	1.4	4
4272	Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Congenital Heart Disease. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	4
4273	Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. Journal of the American Heart Association, 0, , .	1.6	1
4274	Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4275	Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come. European Heart Journal Supplements, 2022, 24, L2-L9.	0.0	0

#	Article	IF	Citations
4276	The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice. Cardiology, 2023, 148, 27-37.	0.6	3
4277	Getting ahead of the game: in-hospital initiation of HFrEF therapies. European Heart Journal Supplements, 2022, 24, L38-L44.	0.0	3
4278	Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?. European Journal of Heart Failure, 2023, 25, 95-97.	2.9	0
4279	ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Failure, 2023, 10, 1531-1544.	1.4	19
4280	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ESC Heart Failure, 2023, 10, 1555-1569.	1.4	3
4281	Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis. Annals of Pharmacotherapy, 2023, 57, 907-917.	0.9	1
4282	Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System. Journal of Cardiac Failure, 2023, 29, 258-268.	0.7	1
4283	Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure. JAMA Cardiology, 2023, 8, 150.	3.0	7
4284	The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus. ESC Heart Failure, 2023, 10, 943-954.	1.4	4
4285	Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4286	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. European Heart Journal Supplements, 2022, 24, L10-L19.	0.0	6
4287	Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials. BMC Medicine, 2022, 20, .	2.3	2
4288	Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis. Internal and Emergency Medicine, 0, , .	1.0	0
4289	Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 2023, 109, 823-831.	1.2	7
4290	Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. Journal of Cardiac Failure, 2023, 29, 389-402.	0.7	5
4291	Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Open Heart, 2022, 9, e002069.	0.9	0
4292	Targeting the â€˜vulnerableâ€™ periodÂâ€“Âfirst 3â€“6Âmonths after an acute heart failure admissionÂâ€“Âthe light gets brighter. European Journal of Heart Failure, 2023, 25, 30-34.	2.9	5
4293	Intervention of Compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome: A multi-center, randomized, double-blind, controlled trial. Medicine (United States), 2022, 101, e32311.	0.4	0

#	Article	IF	Citations
4294	The impact of catheter ablation in patientâ€™s heart failure and atrial fibrillation: a meta-analysis of randomized clinical trials. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 1487-1497.	0.6	1
4295	Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis. International Journal of Molecular Sciences, 2023, 24, 1756.	1.8	7
4296	Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest. Journal of Clinical Medicine, 2023, 12, 693.	1.0	4
4298	Use of Guideline-Directed Medical Therapy in Patients Aged 80 Years or Older with Heart Failure with Reduced Ejection Fraction. CJC Open, 2023, , .	0.7	0
4299	Your Career Path. , 2022, , 29-39.		0
4300	Preparing Unnatural Amino Acids. , 2022, , .		0
4301	Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology. Journal of Clinical Medicine, 2023, 12, 621.	1.0	0
4303	Augmentation of Natriuretic Peptide Bioactivity via Combined Inhibition of Neprilysin and Phosphodiesterase-9 in Heart Failure. JACC: Heart Failure, 2023, , .	1.9	0
4304	Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers, 2023, 15, 312.	1.7	8
4305	Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study). Journal of Clinical Medicine, 2023, 12, 699.	1.0	4
4306	Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial. Circulation: Heart Failure, 0, , .	1.6	2
4307	Acute heart failure after nonâ€cardiac surgery: incidence, phenotypes, determinants and outcomes. European Journal of Heart Failure, 2023, 25, 347-357.	2.9	7
4308	Renin Angiotensin System Inhibitors in Heart Failure with Reduced Ejection Fraction: Clinical Evidence and Considerations for Use. , 2023, , 331-347.		0
4309	Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. Cardiovascular Drugs and Therapy, 0, , .	1.3	0
4310	The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation. Rational Pharmacotherapy in Cardiology, 2023, 18, 662-668.	0.3	0
4311	Reninâ€“Angiotensinâ€“Aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330.		1
4312	Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction. Journal of Cardiovascular Pharmacology and Therapeutics, 2023, 28, 107424842211463.	1.0	0
4313	Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. Drugs in Context, 0, 12, 1-14.	1.0	1

#	Article	IF	Citations
4314	Emerging concepts in heart failure management and treatment: focus on vericiguat. Drugs in Context, 0, 12, 1-11.	1.0	1
4315	Blood pressure in heart failure management and prevention. Hypertension Research, 2023, 46, 817-833.	1.5	15
4316	Efficacy and safety of lowâ€dose sacubitril/valsartan in heart failure patients: A systematic review and metaâ€analysis. Clinical Cardiology, 2023, 46, 296-303.	0.7	2
4317	Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 1173-1179.	0.5	0
4318	Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	0
4319	Tafamidis Beyond the ATTR-ACT Trial. , 2022, 1, 100158.		0
4320	Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). BMJ Open, 2022, 12, e066252.	0.8	2
4321	The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure. AÄ°BÃœ Ä°zzet Baysal TÄ±p FakÃ¼ltesi Dergisi, 2022, 11, 337-336.	0.0	2
4322	Endocrine functions of the heart: from bench to bedside. European Heart Journal, 2023, 44, 643-655.	1.0	14
4323	Emerging molecular imaging targets and tools for myocardial fibrosis detection. European Heart Journal Cardiovascular Imaging, 2023, 24, 261-275.	0.5	12
4324	Arterielle Hypertonie. , 2022, , 155-204.		0
4325	Herzerkrankungen. , 2022, , 205-220.		0
4326	Effect of sacubitril/valsartan on natriuretic peptide in patients with compensated heart failure. Heart and Vessels, 2023, 38, 773-784.	0.5	1
4327	Personalizing Risk Assessment for Sudden Cardiac Death in HeartÂFailure. JACC: Heart Failure, 2023, 11, 55-57.	1.9	0
4328	Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis. Journal of Personalized Medicine, 2023, 13, 243.	1.1	2
4329	Comparative Risk of Angioedema WithÂSacubitril-Valsartan vs Renin-Angiotensin-AldosteroneÂInhibitors. Journal of the American College of Cardiology, 2023, 81, 321-331.	1.2	5
4330	Evaluation of the effectiveness of serelaxin in the treatment of patients with acute decompensation of heart failure: Five-year follow-up. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2023, 37, 129-138.	0.1	0
4331	Sakubitril valsartanâ€™Ä±n deneysel havyan modellerindeki yeri. , 0, , .		0

#	Article	IF	Citations
4332	Diretriz Brasileira de Dispositivos CardÃacos EletrÃ´nicos ImplantÃ¡veis â€“ 2023. Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.3	1
4333	Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVOâ€Ð registry. ESC Heart Failure, 2023, 10, 1193-1204.	1.4	9
4334	Medications for When the Heart Fails. Physician Assistant Clinics, 2023, , .	0.1	0
4336	The Real-World Price of Switching toÂanÂARNI. Journal of the American College of Cardiology, 2023, 81, 332-335.	1.2	0
4337	The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis. Current Problems in Cardiology, 2023, 48, 101602.	1.1	4
4338	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 10-26.	1.8	4
4340	Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circulation: Heart Failure, 0, , .	1.6	1
4341	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. Canadian Journal of Kidney Health and Disease, 2023, 10, 205435812211505.	0.6	3
4342	Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimerâ€™s disease. Frontiers in Physiology, 0, 14, .	1.3	9
4343	Management of Heart Failure With Reduced Ejection Fraction. Current Problems in Cardiology, 2023, 48, 101596.	1.1	5
4344	Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction. Marmara Medical Journal, 2023, 36, 99-104.	0.2	1
4345	Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction. BMC Cardiovascular Disorders, 2023, 23, .	0.7	1
4346	Comprehensive analysis of the RNA transcriptome expression profiles and construction of the ceRNA network in heart failure patients with sacubitril/valsartan therapeutic heterogeneity after acute myocardial infarction. European Journal of Pharmacology, 2023, 944, 175547.	1.7	3
4347	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
4348	CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2. Circulation Research, 2023, 132, 400-414.	2.0	5
4349	Prevalence and prognostic impact of left ventricular systolic dysfunction or pulmonary congestion after acute myocardial infarction. ESC Heart Failure, 2023, 10, 1347-1357.	1.4	6
4350	Biomarkers of Cardiac Stretch in Critical Illness: A Narrative Review. Biomarkers in Disease, 2023, , 1029-1045.	0.0	0
4351	Reninâ€“angiotensinâ€“aldosterone system inhibitors. New and old approaches. , 2023, , 317-334.		0

#	Article	IF	Citations
4353	Dosing of basic pharmacotherapy and its effect on the prognosis of patients hospitalized for heart failure. Vnitrni Lekarstvi, 2023, 69, 109-118.	0.1	0
4354	Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 2023, 25, 488-496.	2.9	4
4356	Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report. Russian Journal of Cardiology, 2023, 28, 5341.	0.4	0
4357	Ð¡ost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2023, 28, 5386.	0.4	4
4358	Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure. ESC Heart Failure, 2023, 10, 2042-2050.	1.4	4
4359	Sacubitril/Valsartan Improves Left Atrial and Ventricular Strain and Strain Rate in Patients with Heart Failure with Reduced Ejection Fraction. Life, 2023, 13, 995.	1.1	2
4360	Long-Term Effects of Sacubitril-Valsartan on Cardiac Remodeling: A Parallel Echocardiographic Study of Left and Right Heart Adaptive Response. Journal of Clinical Medicine, 2023, 12, 2659.	1.0	4
4361	GLUT4 mediates the protective function of gastrodin against pressure overload-induced cardiac hypertrophy. Biomedicine and Pharmacotherapy, 2023, 161, 114324.	2.5	1
4362	LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4. Biomedicine and Pharmacotherapy, 2023, 162, 114569.	2.5	2
4363	Regional management of worsening heart failure: rationale and design of the CHAINâ€HF registry. ESC Heart Failure, 2023, 10, 2074-2083.	1.4	2
4364	Updates for Cardioâ€Kidney Protective Effects by Angiotensin Receptorâ€Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection. Journal of the American Heart Association, 2023, 12, .	1.6	3
4365	Good Habits for a Lifetime. , 2022, , 89-96.		0
4366	Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore. Value in Health Regional Issues, 2023, 34, 108-117.	0.5	1
4367	Plasma renin activity variation following admission predicts patient outcome in acute decompensated heart failure with reduced and mildly reduced ejection fraction. Heliyon, 2023, 9, e13181.	1.4	0
4368	Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan. Journal of Clinical Medicine, 2023, 12, 1086.	1.0	3
4369	Omecamtiv Mecarbil in Black Patients With HeartÂFailure and Reduced EjectionÂFraction. JACC: Heart Failure, 2023, , .	1.9	0
4370	Characteristics of patients hospitalized for acute heart failure and discharged from an emergency medicine ward with sacubitril-valsartan: differences with patients in the PIONEER-HF and TRANSITION studies. Journal of Cardiovascular Medicine, 2023, 24, 203-205.	0.6	0
4371	The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. ESC Heart Failure, 2023, 10, 1314-1325.	1.4	3

#	Article	IF	Citations
4372	Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1. Cell Reports, 2023, 42, 112059.	2.9	5
4373	Comparison of Investigator-Reported and Centrally Adjudicated HeartÂFailureÂOutcomes in the EMPEROR-Reduced Trial. JACC: Heart Failure, 2023, 11, 407-417.	1.9	3
4374	Medication-Attributable Adverse EventsÂin HeartÂFailure Trials. JACC: Heart Failure, 2023, 11, 425-436.	1.9	1
4375	Effectiveness of sacubitril/valsartan for patients with cancer therapyâ€'related cardiac dysfunction: A systematic review of descriptive studies. Oncology Letters, 2023, 25, .	0.8	0
4376	Heart Failure With Stable Mildly-reduced Ejection Fraction: Prognosis and Predictors of Outcomes. Current Problems in Cardiology, 2023, 48, 101631.	1.1	3
4377	Advances in Heart Failure with Preserved Ejection Fraction Management - The Role of Sacubitril-Valsartan, Pirfenidone, Spironolactone and Empagliflozin: Is Success a Series of Small Victories?. Current Pharmaceutical Design, 2023, 29, 502-508.	0.9	3
4378	Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction. ESC Heart Failure, 2023, 10, 1358-1371.	1.4	3
4379	Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial. American Heart Journal Plus, 2023, 26, 100264.	0.3	0
4380	Vericiguat in HFrEF. JACC: Heart Failure, 2023, 11, 224-226.	1.9	1
4381	Treatment of Advanced (Stage D) HeartÂFailure in the New Era. JACC: Heart Failure, 2023, 11, 258-260.	1.9	0
4382	A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 0, , .	0.2	0
4383	Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Diseaseâ€"A Real-World Experience. Journal of Clinical Medicine, 2023, 12, 1334.	1.0	0
4384	Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles. Biomolecules, 2023, 13, 321.	1.8	2
4385	I. General: Read Treatment Algorism for Heart Failure in the Guideline Focused Update; 1. Heart Failure with Reduced Ejection Fraction (HFrEF). The Journal of the Japanese Society of Internal Medicine, 2022, 111, 206-212.	0.0	0
4386	II. Details: Therapeutic Agents for Chronic Heart Failure; 6. Vericiguat. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 255-262.	0.0	0
4387	II. Details: Therapeutic Agents for Chronic Heart Failure; 1. ARNI and ACE Inhibitorãƒ»ARB. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 221-227.	0.0	0
4389	Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment. Clinical Chemistry, 2023, 69, 350-362.	1.5	3
4390	Are patents important indicators of innovation for Chagas disease treatment?. Expert Opinion on Therapeutic Patents, 2023, 33, 193-209.	2.4	1

#	Article	IF	Citations
4391	Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. Journal of Cardiac Failure, 2023, 29, 922-930.	0.7	8
4392	Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart, 0, , heartjnl-2022-321702.	1.2	3
4393	Long-term outcome of cardiac resynchronization therapy patients in the elderly. GeroScience, 2023, 45, 2289-2301.	2.1	1
4394	Transcatheter interventions for heart failure. EuroIntervention, 2023, 18, 1135-1149.	1.4	3
4395	Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina. Health Economics Review, 2023, 13, .	0.8	0
4396	Spot Urinary Sodium Measurements: the Future Direction of the Treatment and Follow-up of Patients with Heart Failure. Current Heart Failure Reports, 2023, 20, 88-100.	1.3	1
4397	Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2023, 81, 1443-1455.	1.2	9
4398	Functional assessment based on cardiopulmonary exercise testing in mild heart failure: A multicentre study. ESC Heart Failure, 2023, 10, 1689-1697.	1.4	4
4399	Incidence, determinants, and outcomes of recovered left ventricular ejection fraction (LVEF) in patients with non-ischemic systolic heart failure; a hospital-based cohort study. Indian Heart Journal, 2023, 75, 128-132.	0.2	1
4400	zDHHC9 Regulates Cardiomyocyte Rab3a Activity and Atrial Natriuretic Peptide Secretion Through Palmitoylation of Rab3gap1. JACC Basic To Translational Science, 2023, 8, 518-542.	1.9	3
4402	Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation. Scientific Reports, 2023, 13, .	1.6	3
4403	Sudden cardiac death prevention in the era of novel heart failure medications. American Heart Journal Plus, 2023, 27, 100281.	0.3	0
4404	TRANSFORM-HF closes the loop on diuretic therapy in heart failure. European Heart Journal, 0, , .	1.0	0
4405	Assessing Correlation Between Thoracic Impedance and Remotely Monitored Pulmonary Artery Pressure in Chronic Systolic Heart Failure. Cardiology Research, 2023, 14, 32-37.	0.5	0
4406	Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?. Circulation, 2023, 147, 759-767.	1.6	4
4407	Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study. ESC Heart Failure, 2023, 10, 1745-1756.	1.4	5
4408	Age differences of patients treated with wearable cardioverter defibrillator: Data from a multicentre registry. European Journal of Clinical Investigation, 0, , .	1.7	0
4409	Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure. Heart and Vessels, 2023, 38, 1042-1048.	0.5	1

#	Article	IF	Citations
4410	Cost-Effectiveness of Comprehensive Quadruple Therapy for HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2023, 11, 541-551.	1.9	10
4411	â€œDeliveringâ€•Equitable Care for Patients With HeartÂFailure. JACC: Heart Failure, 2023, 11, 389-391.	1.9	0
4412	Sacubitrilâ€“valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis. Frontiers in Pharmacology, 0, 14, .	1.6	0
4413	Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. Current Heart Failure Reports, 2023, 20, 101-112.	1.3	0
4414	Sex and gender differences in myocarditis and dilated cardiomyopathy: An update. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	33
4415	A comparative study between angiotensin receptor neprilysin inhibitor (thiorphan/irbesartan) with each of nitrate and carvedilol in a rat model of myocardial ischemic reperfusion injury. Fundamental and Clinical Pharmacology, 0, , .	1.0	0
4416	Effect of sacubitrilâ€“valsartan on the incidence of atrial fibrillation: A metaâ€analysis. Journal of Cardiovascular Electrophysiology, 2023, 34, 1037-1042.	0.8	1
4417	Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. New England Journal of Medicine, 2023, 388, 2037-2048.	13.9	74
4418	Virtual Care Team Guided Management of Patients With Heart Failure DuringÂHospitalization. Journal of the American College of Cardiology, 2023, 81, 1680-1693.	1.2	17
4419	Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimerâ€™s disease model in rats. International Journal of Immunopathology and Pharmacology, 2023, 37, 039463202311614.	1.0	3
4420	Sacubitril/valsartan as a component of therapy for chronic heart failure. Reviews on Clinical Pharmacology and Drug Therapy, 2023, 20, 407-413.	0.2	0
4421	Implantable Cardioverter-Defibrillator forÂPrimary Prevention in Asia. JACC Asia, 2023, , .	0.5	0
4422	New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. International Journal of Molecular Sciences, 2023, 24, 5089.	1.8	8
4423	Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms. International Journal of Molecular Sciences, 2023, 24, 5131.	1.8	5
4424	Acute asymptomatic hyponatraemia following inpatient initiation of angiotensin receptorâ€“neprilysin inhibitor: a case report. European Heart Journal - Case Reports, 2023, 7, .	0.3	0
4425	The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network metaâ€analysis. ESC Heart Failure, 2023, 10, 1822-1834.	1.4	3
4426	Identifying the patient with heart failure to be treated with vericiguat. Current Medical Research and Opinion, 2023, 39, 661-669.	0.9	1
4428	Holistic approach to drug therapy in a patient with heart failure. Heart, 2023, 109, 1183-1191.	1.2	1

#	Article	IF	Citations
4429	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114.	0.8	0
4430	Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts. Revista Espanola De Cardiologia (English Ed), 2023, , .	0.4	1
4431	Leveraging Biomarkers for Precision Medicine in Heart Failure. Journal of Cardiac Failure, 2023, 29, 459-462.	0.7	2
4432	Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction. BMC Cardiovascular Disorders, 2023, 23, .	0.7	2
4433	Dramatic disease regression in a case of HFrEF with endâ€stage renal failure treated with sacubitril/valsartan and SGLT2i. ESC Heart Failure, 2023, 10, 2099-2106.	1.4	3
4435	Efficacy of sodiumâ€“glucose cotransporter 2 inhibitors and angiotensin <scp>receptorâ€“neprilysin</scp> inhibitors for heart failure in black patients: a systematic review and <scp>metaâ€analysis</scp> of randomized controlled trials. European Journal of Heart Failure, 2023, 25, 591-593.	2.9	0
4436	Diagnosis and Management of Pediatric Heart Failure. Indian Journal of Pediatrics, 2023, 90, 492-500.	0.3	3
4437	Heart failure with reduced ejection fraction and atrial fibrillation: a Subâ€Saharan African perspective. ESC Heart Failure, 2023, 10, 1580-1596.	1.4	3
4438	Urinary neprilysin â€“ Another marker to predict postoperative acute kidney injury. Journal of Anaesthesiology Clinical Pharmacology, 2023, 39, 143.	0.2	0
4439	Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis. Cureus, 2023, , .	0.2	0
4440	Effects of angiotensin receptorâ€neprilysin inhibitor on insulin resistance in patients with heart failure. ESC Heart Failure, 0, , .	1.4	1
4441	Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 2023, 44, 1136-1153.	1.0	32
4442	Beyond Stage C: Considerations in the Management of Patients With Heart Failure Progression and Gaps in Evidence. Journal of Cardiac Failure, 2023, 29, 818-831.	0.7	0
4443	Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?. European Heart Journal, 2023, 44, 1154-1156.	1.0	4
4444	Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
4445	Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat. Patient Preference and Adherence, 0, Volume 17, 839-849.	0.8	0
4446	Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization. Expert Opinion on Pharmacotherapy, 2023, 24, 705-713.	0.9	0
4447	The dual inhibitor Sacubitril-valsartan ameliorate high-fat high-fructose-induced metabolic disorders in rats superiorly compared to valsartan only. Journal of Pharmacy and Pharmacology, 0, , .	1.2	0

#	Article	IF	Citations
4448	Arterial stiffness and its associations with left ventricular diastolic function according to heart failure types. Clinical Hypertension, 2023, 29, .	0.7	0
4450	Acute Effects of Sacubitril/Valsartan with Initial Initiation in Pediatric Patients in the Cardiac Intensive Care Unit. Pediatric Cardiology, 0, , .	0.6	0
4451	Impact of Moderate Aortic Stenosis in Patients With HeartÂFailure With ReducedÂEjection Fraction. Journal of the American College of Cardiology, 2023, 81, 1235-1244.	1.2	7
4452	The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. European Journal of Internal Medicine, 2023, 112, 62-69.	1.0	0
4453	The history and mystery of sacubitril/valsartan: From clinical trial to the real world. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	1
4454	Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System. Clinical Drug Investigation, 2023, 43, 265-275.	1.1	3
4456	Multi-omic analysis of the cardiac cellulome defines a vascular contribution to cardiac diastolic dysfunction in obese female mice. Basic Research in Cardiology, 2023, 118, .	2.5	5
4457	Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. World Journal of Cardiovascular Diseases, 2023, 13, 138-169.	0.0	0
4458	Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a realâ€world study. ESC Heart Failure, 2023, 10, 1961-1971.	1.4	4
4459	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. Pharmaceutics, 2023, 15, 1092.	2.0	1
4460	Atrial Natriuretic Peptides as a Bridge between Atrial Fibrillation, Heart Failure, and Amyloidosis of the Atria. International Journal of Molecular Sciences, 2023, 24, 6470.	1.8	4
4461	Chronic Heart Failure in Children: State of the Art and New Perspectives. Journal of Clinical Medicine, 2023, 12, 2611.	1.0	2
4462	Heart failure: pathophysiology and the emergence of novel therapies. , 2023, , 441-458.		0
4463	Effects of sacubitril-valsartan in Patients with Various Types of Heart Failure: A Meta-Analysis. Journal of Cardiovascular Pharmacology, 2023, Publish Ahead of Print, .	0.8	2
4464	Clinical outcomes in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary interventions later than 48 h after symptom onset. European Heart Journal: Acute Cardiovascular Care, 2023, 12, 376-385.	0.4	1
4465	Myokine Musclin Is Critical for Exercise-Induced Cardiac Conditioning. International Journal of Molecular Sciences, 2023, 24, 6525.	1.8	2
4466	Multimorbidity and Heart Failure. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 71-94.	0.1	0
4467	New perspectives in the treatment of chronic heart failure. Vnitrni Lekarstvi, 2023, 69, 82-87.	0.1	0

#	Article	IF	Citations
4468	Up-regulated lncRNA SNHG9 mediates the pathogenesis of dilated cardiomyopathy via miR-326/EPHB3 axis. Journal of Thrombosis and Thrombolysis, 2023, 55, 634-648.	1.0	1
4469	Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	1
4470	Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease. American Journal of Medicine, 2023, 136, 677-686.	0.6	2
4471	Trends in heart failure prevalence in Japan 2014â€“2019: a report from healthcare administration databases. ESC Heart Failure, 2023, 10, 1996-2009.	1.4	5
4472	Validation of the Portuguese Version of the Kansas City Cardiomyopathy Questionnaire-12. Journal of Cardiovascular Development and Disease, 2023, 10, 162.	0.8	1
4473	Angiotensin receptor-neprilysin inhibitors and cardiac remodeling. Brazilian Journal of Medical and Biological Research, 0, 56, .	0.7	0
4474	Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial. Journal of Cardiac Failure, 2023, 29, 863-869.	0.7	2
4475	Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?. Cardiology, 2023, 148, 195-206.	0.6	2
4476	Sacubitril/valsartan in peritoneal dialysis â€“ lessons from a pharmacokinetic study. Nephrology Dialysis Transplantation, 0, , .	0.4	0
4477	Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Chronic Heart Failure. , 0, 2, .		4
4478	Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. JACC: Heart Failure, 2023, 11, 583-592.	1.9	1
4479	Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction. ESC Heart Failure, 2023, 10, 2010-2018.	1.4	2
4480	A review of current key guidelines for managing highâ€risk patients with diabetes and heart failure and future prospects. Diabetes, Obesity and Metabolism, 2023, 25, 33-47.	2.2	0
4481	Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan. JACC: Heart Failure, 2023, 11, 749-759.	1.9	3
4482	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. Korean Circulation Journal, 2023, 53, 217.	0.7	4
4483	Cardiac Regenerative Therapy Using Human Pluripotent Stem Cells for Heart Failure: A State-of-the-Art Review. Journal of Cardiac Failure, 2023, 29, 503-513.	0.7	0
4484	Effects of Sacubitril/Valsartan on cardiac function, blood biochemistry and clinical efficacy in early ventricular remodeling after acute myocardial infarction. Biotechnology and Genetic Engineering Reviews, 0, , 1-16.	2.4	1
4485	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. International Journal of Heart Failure, 2023, 5, 66.	0.9	9

#	Article	IF	Citations
4486	Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction. Life, 2023, 13, 1000.	1.1	1
4488	The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. Circulation Research, 2023, 132, 902-914.	2.0	11
4489	Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 2023, 44, 2202-2212.	1.0	5
4490	Correlation between the Six-Minute Walk Test and Subjective Functional Class in Patients with Heart Failure. World Journal of Cardiovascular Diseases, 2023, 13, 205-213.	0.0	0
4491	Updates in Cardiorenal Syndrome. Medical Clinics of North America, 2023, , .	1.1	1
4492	The First Dedicated Comprehensive Heart Failure Program in the United States: The Division of Circulatory Physiology at Columbia Presbyterian (1992â€“2004). Journal of Cardiac Failure, 2023, 29, 1078-1090.	0.7	0
4493	Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Leads to a Shorter Hospital Stay in Patients With Acute Decompensated Heart Failure. Circulation Reports, 2023, , .	0.4	0
4494	Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2023, 25, 687-697.	2.9	2
4495	Treatment of type 2 diabetes patients with heart conditions. Expert Review of Endocrinology and Metabolism, 2023, 18, 255-265.	1.2	9
4496	Long-term cardiac effect of sacubitril-valsartan in hemodialysis patients with a reduced ejection fraction after aortic valve replacement for aortic stenosis: a case report with literature review. Renal Replacement Therapy, 2023, 9, .	0.3	2
4497	Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. Cardiac and Vascular Biology, 2023, , 229-264.	0.2	0
4498	Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide. Current Cardiology Reports, 0, , .	1.3	0
4499	The Difference Between Cystatin Câ€“ and Creatinine-Based Estimated GFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF. American Journal of Kidney Diseases, 2023, 82, 521-533.	2.1	4
4500	Transcatheter left ventriculoplasty. EuroIntervention, 2023, 18, 1399-1407.	1.4	1
4501	Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena. Journal of Diabetes, 2023, 15, 397-408.	0.8	4
4503	Heart failure therapy: the fifth card. European Heart Journal Supplements, 2023, 25, B140-B143.	0.0	1
4504	The Present Clinical Treatment and Future Emerging Interdisciplinary for Heart Failure: Where we are and What we can do. Intensive Care Research, 2023, 3, 3-11.	0.2	3
4512	Hallmarks of cardiovascular ageing. Nature Reviews Cardiology, 2023, 20, 754-777.	6.1	28

#	Article	IF	Citations
4544	Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?. Hypertension Research, 0, , .	1.5	0
4580	Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. Contemporary Diabetes, 2023, , 779-819.	0.0	0
4602	Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists. Cardiology and Therapy, 0, , .	1.1	0
4626	Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781.	0.0	0
4629	Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives. Cardiovascular Drugs and Therapy, 0, , .	1.3	1
4655	Dilated Cardiomyopathy in Children. , 2023, , 1-24.		0
4664	Heart Failure Management in Developing Countries. , 2023, , 1-28.		0
4665	EMERGING SMALL-MOLECULE THERAPEUTICS FOR DILATED CARDIOMYOPATHY. Medicinal Chemistry Reviews, 0, , 143-163.	0.1	0
4692	Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure. American Journal of Cardiovascular Drugs, 0, , .	1.0	0
4694	Discontinuation of Loop Diuretics in Older Patients with Chronic Stable Heart Failure: A Narrative Review. Drugs and Aging, 2023, 40, 981-990.	1.3	1
4700	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. Cardiology and Therapy, 0, , .	1.1	0
4726	Recent successes in heart failure treatment. Nature Medicine, 2023, 29, 2424-2437.	15.2	4
4730	Gender Differences in Cardiovascular Health: Hormonal Effects on Cardiovascular Risk and Management. Handbook of Experimental Pharmacology, 2023, , 201-218.	0.9	0
4754	Neutral endopeptidase (neprilysin). , 2024, , 321-330.		0
4791	Renin Angiotensin Aldosterone System Blockers. , 2024, , 258-273.		0
4829	The GENTIL Method for Isolation of Human Adult Cardiomyocytes from Cryopreserved Tissue for Proteomic Analyses. Methods in Molecular Biology, 2024, , 145-167.	0.4	0
4855	What Interventions Are Effective for Managing Dyspnea in Heart Failure?. , 2023, , 138-146.		0
4874	Natriuretic peptide testing strategies in heart failure: A 2023 update. Advances in Clinical Chemistry, 2023, , .	1.8	0

#	Article	IF	Citations
4876	Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report. CEN Case Reports, 0, , .	0.5	0
4879	Management of Cardiovascular Disease in Chronic Kidney Disease. , 2023, , 171-197.		0
4912	The Additional Value of T1 Mapping in Cardiac Disease: State of the Art. Current Cardiovascular Imaging Reports, 0, , .	0.4	0
4916	Herz und Niere. Springer Reference Medizin, 2023, , 175-189.	0.0	0
4919	Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening, and Clinical Translation. , 2024, , 207-224.		0
4939	Antiarrhythmic Treatment in Heart Failure. Current Heart Failure Reports, 2024, 21, 22-32.	1.3	0
4948	Chronische Herzinsuffizienz. , 2024, , 98-117.		0
4949	Kardiomyopathien. , 2024, , 118-126.		0
4961	An Overview on Hypertension Mediated Organ Damage. , 2023, , 79-88.		0
4982	Cardiovascular Drugs in Left Ventricular Failure During Noninvasive Mechanical Ventilation: Summary of Pharmacological Strategies. , 2023, , 105-116.		0
4983	Advanced Treatment of Refractory Congestive Heart Failure by Peritoneal Ultrafiltration with Icodextrin in Patients without End-Stage Renal Disease. , 0, , .		0
4989	Kardiorenales Syndrom. Springer Reference Medizin, 2023, , 1-12.	0.0	0
4997	Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia, 2024, 67, 574-601.	2.9	0
5007	Arterielle Hypertonie. , 2023, , 177-226.		0
5009	Herzerkrankungen. , 2023, , 227-242.		0
5022	The Role of Uric Acid in Hypertension and Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 139-154.	0.1	0
5023	The Role of Drug Therapy in Lowering Mortality and Morbidity: From High-Risk Hypertension to Established Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 391-408.	0.1	0
5024	Reversibility of Cardiac Remodeling in Hypertensive Patients with Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 357-370.	0.1	0

#	Article	IF	Citations
5026	Unmet Needs in Drug Treatment of Heart Failure in Hypertension. Updates in Hypertension and Cardiovascular Protection, 2023, , 409-422.	0.1	0
5027	Treating Hypertension Complicated with Heart Failure: Going Beyond the Numbers. Updates in Hypertension and Cardiovascular Protection, 2023, , 339-355.	0.1	0